0001144204-12-029585.txt : 20120515 0001144204-12-029585.hdr.sgml : 20120515 20120515162257 ACCESSION NUMBER: 0001144204-12-029585 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120515 DATE AS OF CHANGE: 20120515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SKYSTAR BIO-PHARMACEUTICAL CO CENTRAL INDEX KEY: 0001076939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330901534 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34394 FILM NUMBER: 12845079 BUSINESS ADDRESS: STREET 1: RM 10601, JIEZUO PLAZA, NO. 4 STREET 2: FENGHUI ROAD SOUTH, GAOXIN DISTRICT CITY: XIAN PROVINCE STATE: F4 ZIP: 00000 BUSINESS PHONE: 407-645-4433 MAIL ADDRESS: STREET 1: RM 10601, JIEZUO PLAZA, NO. 4 STREET 2: FENGHUI ROAD SOUTH, GAOXIN DISTRICT CITY: XIAN PROVINCE STATE: F4 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: CYBER GROUP NETWORK CORP DATE OF NAME CHANGE: 20000711 10-Q 1 v312439_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

x	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the quarterly period ended March 31, 2012

	or

o	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

	For the transition period from ______ to ______.

Commission File Number 001-34394

SKYSTAR BIO-PHARMACEUTICAL COMPANY

(Exact name of small business issuer as specified in its charter)

Nevada	33-0901534
(State or other jurisdiction of	(I.R.S. employer
incorporation or organization)	identification number)

4/F Building B, Chuangye Square, No. 48 Keji Road,

Gaoxin District, Xi’an Province, P.R. China

(Address of principal executive offices and zip code)

(8629) 8819-3188

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

	Large Accelerated Filer o	Accelerated Filer o
	Non-accelerated filer o	Smaller Reporting Company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

As of May 10, 2012, the Registrant had 7,604,800 shares of common stock outstanding.

SKYSTAR BIO-PHARMACEUTICAL COMPANY

FORM 10-Q

INDEX

		Page No.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		3

PART I. FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements	4

	Condensed Consolidated Balance Sheets as of March 31, 2012 (unaudited) and December 31, 2011	4

	Condensed Consolidated Statements of Income and Comprehensive Income for the Three Months Ended March 31, 2012 and 2011 (unaudited)	5

	Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2012 and 2011 (unaudited)	6

	Condensed Consolidated Statements of Shareholders’ Equity as of March 31, 2012 (unaudited) and December 31, 2011	7

	Notes to the Condensed Consolidated Financial Statements (unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24

Item 4.	Controls and Procedures	30

PART II. OTHER INFORMATION

Item 6.	Exhibits	31

SIGNATURES		33

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Forward-looking statements usually contain the words “estimate,” “anticipate,” “believe,” “expect,” or similar expressions, and are subject to numerous known and unknown risks and uncertainties. In evaluating such statements, prospective investors should carefully review various risks and uncertainties identified in this Report, including the matters set forth under the captions “Risk Factors” and in our other SEC filings. These risks and uncertainties could cause our actual results to differ materially from those indicated in the forward-looking statements. We undertake no obligation to update or publicly announce revisions to any forward-looking statements to reflect future events or developments.

Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading “Risks Relating to Our Business” below, as well as those discussed elsewhere in this Quarterly Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. We file reports with the SEC. You can read and copy any materials we file with the SEC at the SEC’s Public Reference Room, 100 F. Street, NE, Washington, D.C. 20549 on official business days during the hours of 10 a.m. to 3 p.m. You can obtain additional information about the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including the Company.

We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made throughout the entirety of this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,		December 31,
	2012 (Unaudited)		2011
ASSETS
CURRENT ASSETS:
Cash	$	9,386,584	$	7,048,968
Accounts receivable, net of allowance for doubtful accounts of $480,237 (Unaudited) and $438,678 as of March 31, 2012 and December 31, 2011, respectively		5,783,831		3,391,493
Inventories		13,962,087		14,851,159
Deposits, prepaid expenses and other receivables		34,914,476		32,648,448
Loans receivable		981,699		964,088
Total current assets		65,028,677		58,904,156

PLANT AND EQUIPMENT, NET		28,273,028		28,376,559

CONSTRUCTION-IN-PROGRESS		9,434,227		8,839,055

OTHER ASSETS:
Long-term prepayments		1,189,788		1,512,817
Long-term prepayments for acquisitions		652,609		569,788
Intangible assets, net		5,610,135		5,674,206
Total other assets		7,452,532		7,756,811
Total assets	$	110,188,464	$	103,876,581

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable	$	2,046,341	$	1,047,067
Other payable and accrued expenses		6,059,237		5,274,598
Short-term loans		7,476,480		7,366,320
Deposits from customers		1,640,457		1,432,529
Taxes payable		1,585,156		160,081
Due to related parties		380,669		56,273
Total current liabilities		19,188,340		15,336,868

OTHER LIABILITIES:
Deferred government grant		396,000		393,500
Warrant/purchase option liability		37,800		43,400
Total other liabilities		433,800		436,900
Total liabilities		19,622,140		15,773,768

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY
Preferred stock, $0.001 par value, 50,000,000 shares authorized, No Series “A” shares authorized. 48,000,000 Series “B” shares authorized. No Series “B” shares issued and outstanding
Common stock, $0.001 par value, 40,000,000 shares authorized, 7,161,919 shares issued and outstanding as of March 31, 2012 (Unaudited) and December 31, 2011		7,162		7,162
Paid-in capital		35,784,378		35,784,378
Statutory reserves		5,708,135		5,708,135
Retained earnings		40,396,785		38,492,031
Accumulated other comprehensive income		8,669,864		8,111,107
Total shareholders’ equity		90,566,324		88,102,813
Total liabilities and shareholders’ equity	$	110,188,464	$	103,876,581

The accompanying notes are an integral part of these condensed consolidated financial statements.

SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011

(Unaudited)

	Three Months Ended March 31,
	2012			2011

REVENUE, net	$	7,926,337		$	7,086,954

COST OF REVENUE		3,643,658			3,491,346

GROSS PROFIT		4,282,679			3,595,608

OPERATING EXPENSES:
Research and development costs		3,654			287,472
Selling expenses		705,616			369,404
General and administrative expenses		1,105,435			1,294,798
Total operating expenses		1,814,705			1,951,674

INCOME FROM OPERATIONS		2,467,974			1,643,934

OTHER INCOME (EXPENSE):
Other income, net		53,760			182
Interest income (expense), net		(153,612	)		29,672
Change in fair value of warrant/purchase option liability		5,600			735,494
Total other income (expense), net		(94,252	)		765,348

INCOME BEFORE PROVISION FOR INCOME TAXES		2,373,722			2,409,282

PROVISION FOR INCOME TAXES		468,968			477,450

NET INCOME		1,904,754			1,931,832

OTHER COMPREHENSIVE INCOME:
Foreign currency translation adjustment		558,757			465,593

COMPREHENSIVE INCOME	$	2,463,511		$	2,397,425

EARNINGS PER SHARE:
Basic	$	0.26		$	0.27
Diluted	$	0.26		$	0.27

WEIGHTED AVERAGE NUMBER OF COMMON SHARES:
Basic		7,210,256			7,166,919
Diluted		7,210,256			7,179,309

The accompanying notes are an integral part of these condensed consolidated financial statements.

SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011
(Unaudited)

	Three months ended March 31,
	2012			2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	1,904,754		$	1,931,832

Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation		343,129			332,428
Amortization		100,373			230,922
Provision for doubtful accounts		38,869			-
Change in fair value of warrant/purchase option liability		(5,600	)		(735,494	)
Change in operating assets and liabilities
Accounts receivable		(2,415,647	)		(757,356	)
Inventories		985,908			(6,826,437	)
Deposits, prepaid expenses and other receivables		(2,144,356	)		(2,603,343	)
Accounts payable		980,926			197,277
Other payable and accrued expenses		606,331			360,449
Deposits from customers		199,329			14,989
Taxes payable		1,427,655			1,566,418

Net cash provided by (used in) operating activities		2,021,671			(6,288,315	)

CASH FLOWS FROM INVESTING ACTIVITIES:

Payments of long-term prepayments		-			(451,722	)
Loans receivables		(11,515	)		-
Collection of loans receivables		-			7,609,000
Purchases of plant and equipment		(54,965	)		(22,275	)
Purchases of intangible assets		-			(38,045	)
Payments on construction-in-progress		(44,940	)		(634,222	)

Net cash (used in) provided by investing activities		(111,420	)		6,462,736

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term loans		63,520			1,257,007
Due to related parties		326,061			62,834
Net cash provided by financing activities		389,581			1,319,841

EFFECT OF EXCHANGE RATE CHANGES ON CASH		37,784			21,296

INCREASE IN CASH		2,337,616			1,515,558

CASH, beginning of period		7,048,968			5,887,831

CASH, end of period	$	9,386,584		$	7,403,389

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	$	152,583		$	54,409
Non-cash investing and financing activities
Long-term prepayment transferred to construction-in-progress	$	333,480		$	421,843
Construction-in-progress transferred to property, plant and equipment	$	3,633		$	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

											Accumulated
							Retained earnings				other
	Common stock				Paid-in		Statutory				comprehensive
	Shares		Amount		capital		reserves		Unrestricted		income		Total
BALANCE, December 31, 2011		7,161,919	$	7,162	$	35,784,378	$	5,708,135	$	38,492,031	$	8,111,107	$	88,102,813

Foreign currency translation		-		-		-		-		-		558,757		558,757
Net income		-		-		-		-		1,904,754		-		1,904,754

BALANCE, March 31, 2012		7,161,919	$	7,162	$	35,784,378	$	5,708,135	$	40,396,785	$	8,669,864	$	90,566,324

The accompanying notes are an integral part of these condensed consolidated financial statements.

SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2012

(Unaudited)

Note 1 - ORGANIZATION

Organization and description of business

Skystar Bio-Pharmaceutical Company (“Skystar” or the “Company”) was incorporated in Nevada on September 24, 1998. Since its acquisition on November 7, 2005 of Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (“Skystar Cayman”), a Cayman Islands company, the Company has been engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the Company are in the People’s Republic of China (“China” or the “PRC”).

All of the Company’s operations are carried out by Xi’an Tianxing Bio-Pharmaceutical Co., Limited (“Xi’an Tianxing”), a PRC joint stock company that the Company controls through contractual arrangements originally between Skystar Cayman and Xi’an Tianxing. On March 10, 2008, the Company entered into a series of agreements transferring all of the rights and obligations of Skystar Cayman under the contractual arrangements to Sida Biotechnology (Xi’an) Co., Ltd. (“Sida”), a PRC company. Sida is the wholly owned subsidiary of Fortunate Time International Limited (“Fortunate Time”), a Hong Kong company and wholly owned subsidiary of Skystar Cayman. Xi’an Tianxing also has a wholly owned subsidiary, Shanghai Siqiang Biotechnological Co., Ltd. (“Shanghai Siqiang”), a PRC company.

As a result of these contractual arrangements, which obligate Sida to absorb all of the risk of loss from Xi’an Tianxing’s activities and enable Sida to receive all of its expected residual returns, the Company accounts for Xi’an Tianxing as a variable interest entity (“VIE”) under the Financial Accounting Standards Board’s (“FASB”) interpretation on consolidation of variable interest entities. Accordingly, the Company consolidates Xi’an Tianxing’s results, assets, and liabilities.

On September 18, 2009, Skystar Bio-Pharmaceutical Inc. (“Skystar California”) was incorporated in California and became a wholly owned subsidiary of Skystar. On December 20, 2010, we dissolved Skystar California.

On April 21, 2010, Kunshan Sikeda Biotechnology Co., Ltd. (“Kunshan Sikeda”) was incorporated in Kunshan, Jiangsu province, China with registered capital of RMB 500,000, of which Xi’an Tianxing and Sida each contributed RMB 250,000. Kunshan Sikeda is jointly owned by Xi’an Tianxing and Sida.

On May 7, 2010, Fortunate Time formed Skystar Biotechnology (Kunshan) Co., Limited (“Skystar Kunshan”) in Kunshan, Jiangsu province, China with registered capital of $15,000,000, of which $2,250,000 was paid by Fortunate Time in cash, and of which the remaining $12,750,000 is required to be invested in the future. Kunshan was formed in connection with an acquisition of assets to meet part of the registered capital requirements, and was intended to be a micro-organism manufacturing facility for the Company once the acquisition was complete. The asset acquisition was completed in September 2011, and the Company is in the process of transferring the assets acquired to meet part of the registered capital requirements.

On August 11, 2010, Sida became the parent company of Skystar Biotechnology (Jingzhou) Co., Limited (“Skystar Jingzhou”), a company established in Jingzhou, Hubei Province, China on February 5, 2010, with registered capital of approximately $4.1 million (RMB 26,000,000), of which approximately $3.7 million (RMB 23,480,000) has been paid. The remaining approximately $399,168 (RMB 2,520,000) is required to be invested by April 6, 2012. As of the date of this report, the Company has not made this investment. Skystar Jingzhou is currently in the process of getting the government's approval and will fulfill the requirement of remaining capital of $399,168 (RMB 2,520,000) thereafter. The company expects the process will be completed by the end of the 2nd quarter of 2012.

On March 15, 2011, Xi’an Tianxing formed Xi’an Sikaida Bio-products Co., Ltd. (“Xi’an Sikaida”) with registered capital of approximately $1,584,000 (RMB 10,000,000) paid by Xi’an Tianxing.

Hereinafter, Skystar, Skystar Cayman, Fortunate Time, Sida, Xi’an Tianxing, Skystar Kunshan, Kunshan Sikeda, Skystar Jingzhou, Shanghai Siqiang, and Xi’an Sikaida are sometimes collectively referred to as the “Company.”

Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented have been made. The accompanying results of operations are not necessarily indicative of the operating results that may be expected for the entire year ending December 31, 2012. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto of the Company, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (“SEC”).

Principles of consolidation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries, and its VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Actual results may differ from these estimates in amounts that may be material to the consolidated financial statements and accompanying notes. Significant estimates and assumptions made by the Company are used for, but not limited to the allowance for uncollectible receivables, obsolescence reserve against the inventory, tax provision and the fair value for derivatives instruments.

Foreign currency translation

The Company uses the United States dollar (“U.S. dollar”) for financial reporting purposes and the Chinese Renminbi (“RMB”) as its functional currency. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency, being the primary currency of the economic environment in which their operations are conducted.

The Company translates the subsidiaries’ and VIEs’ assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet dates, and the statements of income and comprehensive income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the subsidiaries’ and VIEs’ financial statements are recorded as accumulated other comprehensive income.

The quotation of the exchange rates does not imply free convertibility of RMB to other foreign currencies. All foreign exchange transactions continue to take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China.

Approval of foreign currency payments by the People’s Bank of China or other institutions requires submitting a payment application form together with invoices, shipping documents, and signed contracts. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.

Fair values of financial instruments

The accounting standards regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires fair value disclosures of those financial instruments. This accounting standard defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosures requirements for fair value measures. Certain current assets and current liabilities are financial instruments. Management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and, if applicable, their current interest rates are equivalent to interest rates currently available. The three levels of valuation hierarchy are defined as follows:

•	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

•	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

•	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Outstanding warrants and purchase options do not trade in an active securities market, and as such, the Company estimates the fair value of these warrants and purchase options using the Black-Scholes Option Pricing Model (“Black-Scholes Model”) using the following assumptions:

	Warrants – (1)					Purchase Options – (2)
	March 31, (2012		December 31, 2011			March 31, 2012			December 31, 2011
Stock price	$	-	$	2.74		$	2.69		$	2.74
Exercise price	$	-	$	5.00		$	8.11		$	8.11
Annual dividend yield		-		-			-			-
Expected term (years)		-		0.16			2.25			2.50
Risk-free interest rate		-		0.01	%		0.33	%		0.25	%
Expected volatility		-		68	%		65	%		64	%

(1)	As of December 31, 2011, 34,230 warrants with an exercise price of $5.00 were outstanding. All of these warrants expired on February 28, 2012. As of March 31, 2012, none of these warrants was outstanding.

(2)	As of December 31, 2011, 140,000 purchase options with an exercise price of $8.11 were outstanding. As of March 31, 2012, 140,000 of these options were outstanding.

Expected volatility is based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the term of the warrants. The Company believes this method produces an estimate that is representative of future volatility over the expected term of these warrants and purchase options. The Company has no reason to believe future volatility over the expected remaining life of these warrants and purchase options is likely to differ materially from historical volatility. The expected life is based on the remaining term of the warrants and purchase options. The risk-free interest rate is based on U.S. Treasury securities according to the remaining term of the warrants and purchase options.

As required by the FASB’s accounting standards, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Depending on the product and the terms of the transaction, the fair values warrant/purchase option liability were modeled using a series of techniques, including closed-form analytic formula, such as the Black-Scholes Model, which does not entail material subjectivity because the methodology employed does not necessitate significant judgment, and the pricing inputs are observed from actively quoted markets.

The fair value of the 140,000 purchase options outstanding as of March 31, 2012 was determined using the Black-Scholes Model, utilizing level 2 inputs, and recorded the change in earnings. As a result, the warrant/purchase option liability is carried on the consolidated balance sheets at fair value. The Company recognized gains of $5,600 and $735,494 for the three months ended March 31, 2012 and 2011, respectively.

The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2012:

	Carrying Value at March 31,		Fair Value Measurement at March 31, 2012
	2012		Level 1		Level 2		Level 3
Purchase option liability (unaudited)	$	37,800	$	—	$	37,800	$	—

Below is the reconciliation for the warrant/purchase option liability changes from December 31, 2011 to March 31, 2012.

Balance, December 31, 2011		43,400
Change in fair value		(5,600	)
Balance, March 31, 2012	$	37,800

The net carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term nature of these instruments as well as the variable interest rate for short-term debt.

In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company is required to record assets and liabilities at fair value on a non-recurring basis. Generally, assets are recorded at fair value on a non-recurring basis as a result of impairment charges. For the three months ended March 31, 2012, there were no impairment charges.

Revenue recognition

Revenue of the Company is primarily derived from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected on these consolidated financial statements as sales returns historically have been insignificant.

There are two types of sales upon which revenue is recognized:

a.	Credit sales: revenue is recognized when the products have been delivered to the customers.

b.	Full payment before delivering: Cash received is recorded as “deposits from customers” and revenue is recognized when the products have been delivered to the customers.

Shipping and handling costs related to costs of goods sold are included in selling expenses, which totaled $383,703 and $194,216 for the three months ended March 31, 2012 and 2011, respectively.

The Company’s revenues and cost of revenues by product line were as follows:

	Three Months Ended March 31,
	2012		2011
Revenues
Micro-organism	$	3,135,040	$	1,596,094
Veterinary Medications		3,008,587		4,865,047
Feed Additives		1,034,772		326,407
Vaccines		747,938		299,406
Total Revenues	$	7,926,337	$	7,086,954

Cost of Revenues
Micro-organism	$	906,841	$	494,182
Veterinary Medications		1,792,647		2,821,906
Feed Additives		849,884		140,866
Vaccines		94,286		34,392
Total Cost of Revenues		3,643,658		3,491,346
Gross Profit	$	4,282,679	$	3,595,608

Cash

Cash includes currency on hand, demand deposits with banks, and liquid investments with an original maturity of three months or less.

Accounts receivable and other receivables

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as needed. The Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, a bad debt percentage is estimated by management based on historical experience and current economic climate. The resulting percentage is applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. The ultimate collection of the Company’s accounts receivable may take one year. Delinquent account balances are reserved after management determines that the likelihood of collection is not probable, and known bad debts are written-off against allowance for doubtful accounts when identified.

Inventories

Inventories are stated at the lower of cost or market, as determined on a moving weighted-average basis using the first-in, first-out (FIFO) cost method. Inventories include purchases and related costs incurred in bringing the inventories to their present location and condition. Management reviews inventories for obsolescence and cost in excess of net realizable value at least annually and records a reserve against the inventory and additional cost of goods sold when the carrying value exceeds net realizable value.

Plant and equipment

Plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs that do not improve or extend the useful lives of the assets are charged to operations as incurred, while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:

	Estimated Useful Life
Buildings		10-40 years
Machinery and equipment		10 years
Computer, office equipment and furniture		5 years
Vehicles		5-10 years

Management assesses the carrying value of plant and equipment annually or more often when factors indicating impairment are present, and reduces the carrying value of such assets by the amount of the impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted) and comparing such amount to the net asset carrying value. An impairment loss, if it exists, is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Based on its review, management believes that, as of March 31, 2012 and December 31, 2011, there was no impairment for its plant and equipment.

Construction-in-progress

Construction-in-progress includes direct costs of construction of a factory building. Interest incurred during the period of construction, if significant, is capitalized. All other interest is expensed as incurred. Construction-in-progress is not depreciated until such time as the asset is completed and put into service.

Intangible assets

Land use rights — Land use rights represent the amounts paid to acquire a long-term interest to utilize the land underlying the Company’s facilities. This type of arrangement is common for the use of land in the PRC. Land use rights are amortized on the straight-line method over the contractual lease terms. The land use right granted to the Company’s Huxian facility was for 50 years. The land use right granted to the Company’s Jingzhou facility was 30 years. The land use right granted to the Company’s Kunshan facility was for 41 years.

Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over estimated useful life between five to ten years that reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties. Drug approval licenses are typically granted in five year terms by the Ministry of Agriculture.

Impairment of Intangible assets — the Company evaluates the carrying value of intangible assets annually or more often when factors indicating impairment are present. The Company determines the existence of such impairment by measuring the estimated future cash flows (undiscounted) and comparing such amount to the net asset carrying value. If the undiscounted cash flow estimated to be generated by any such intangible asset is less than its carrying amount, a loss is recognized based on the amount by which the carrying amount exceeds the intangible asset’s fair market value. Loss on intangible assets to be disposed of is determined in a similar manner, except that fair market values are reduced by the cost of disposal. Based on its review, the Company believes that, as of March 31, 2012 and December 31, 2011, there was no impairment of its intangible assets.

Comprehensive income

Comprehensive income and loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income is comprised of the changes in foreign currency exchange rates.

Research and development costs

Research and development costs are charged to operations as incurred and include salaries, professional fees, and technical support fees related to such efforts.

Income taxes

The Company accounts for income taxes using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized.

A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of March 31, 2012, there are no unrecognized tax benefits, and the Company does not expect a significant change in tax benefits in the next 12 months. Penalties and interest levied by taxing authorities, if any, are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the three months ended March 31, 2012 and 2011.

The Company’s operations are subject to income and transaction taxes in the United States and in the PRC jurisdictions. Significant estimates and judgments are required in determining the Company’s worldwide provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. The ultimate amount of tax liability may be uncertain as a result.

According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational or other errors made by the taxpayer or the withholding agent. The statute of limitations extends to five years under special circumstances. In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Accordingly, the income tax returns of the Company’s PRC operating subsidiaries for the years ended December 31, 2006 through 2011 are open to examination by the PRC state and local tax authorities.

The Company does not anticipate any events that could cause a change to these uncertainties.

Stock-based compensation

The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. Stock compensation for stock granted to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.

Earnings per share

Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period or after the end of the period but before the release of the financial statements, by considering it outstanding for the entirety of each period presented. Diluted earnings per share is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

Related parties

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of such principal owners and management, and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

Operating Segments

While the chief decision-makers monitor the revenue streams of the various products lines, operations are managed and financial performance is evaluated on a Company-wide basis. Product lines are aggregated into one as operating results for all product lines are similar. Accordingly, all of the major product lines (micro organism, veterinary medicine, feed additives and vaccines) are considered by management to be aggregated in one reportable operating segment.

Recently issued accounting pronouncements

In May 2011, the FASB issued ASU No. 2011-04 – Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.GAAP and IFRSs. The amendments in this update intend to converge requirements for how to measure fair value and for disclosing information about fair value measurements in US GAAP with International Financial Reporting Standards. For public entities, this ASU is effective for interim and annual periods beginning after December 15, 2011. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05 – Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The amendments in this update require (i) that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements (the current option to present components of other comprehensive income (“OCI”) as part of the statement of changes in stockholders’ equity is eliminated) and (ii) presentation of reclassification adjustments from OCI to net income on the face of the financial statements. For public entities, the amendments in this ASU are effective for years, and interim periods within those years, beginning after December 15, 2011. The amendments in this update should be applied retrospectively. Early adoption is permitted. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.

In December 2011, the FASB issued ASU No. 2011-11 —Balance Sheet (Topic 210). The objective of this update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. An entity is required to apply the amendments for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The Company does not expect the adoption of the provisions in this update will have a significant impact on its consolidated financial statements.

In December 2011, the FASB issued ASU No. 2011-12 —Comprehensive Income (Topic 220). The amendments in this update supersede certain pending paragraphs in ASU No. 2011-05, to effectively defer only those changes in ASU No. 2011-05 that relate to the presentation of reclassification adjustments out of accumulated other comprehensive income. The amendments will be temporary to allow the Board time to redeliberate the presentation requirements for reclassifications out of accumulated other comprehensive income for annual and interim financial statements for public, private, and non-profit entities. The amendments in this update are effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

Note 3 - CONCENTRATIONS AND CREDIT RISK

The Company’s operations are all carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic, and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Financial instruments which subject the Company to concentration of credit risk consist of cash and accounts receivable. Balances at financial institutions or state-owned banks within the PRC are not covered by insurance. The Company has not experienced any losses in such accounts. The Company provides unsecured credit terms for sales to certain customers. As a result, there are credit risks with the accounts receivable balances. The Company constantly re-evaluates the credit worthiness of customers buying on credit and maintains an allowance for doubtful accounts.

For the three months ended March 31, 2012 and 2011, all of the Company’s sales occurred in the PRC. No major customers accounted for more than 10% of the Company’s total revenues. All accounts receivable at March 31, 2012 and December 31, 2011 are from customers located in the PRC.

The Company’s six largest vendors accounted for approximately 85% and 73% of the Company’s total purchases, respectively, for the three months ended March 31, 2012 and 2011.

The Company had one product that accounted for 23% and 15% of the Company’s total revenues for the three months ended March 31, 2012 and 2011, respectively.

Note 4 - ACCOUNTS RECEIVABLE, NET

Accounts receivable consisted of the following:

	March 31, 2012			December 31, 2011
Account receivable	$	6,264,068		$	3,830,171
Allowance for doubtful accounts		(480,237	)		(438,678	)
Account receivable, net	$	5,783,831		$	3,391,493

The following table presents the movement of allowance for doubtful accounts:

Allowance for doubtful accounts, January 1, 2012		438,678
Addition		38,869
Recovery		—
Translation adjustment		2,690
Allowance for doubtful accounts, March 31, 2012	$	480,237

Note 5 – INVENTORIES

Inventories consist of the following:

	March 31, 2012			December 31, 2011
Raw materials	$	12,341,645			12,646,663
Packing materials		231,596			181,304
Work-in-process		5,218			22,559
Finished goods		1,554,507			2,171,238
Other		52,219			51,085
Total		14,185,185			15,072,849
Less: Allowance for obsolete inventories		(223,098	)		(221,690	)
Total	$	13,962,087			14,851,159

The Company periodically reviews its reserves for slow-moving and obsolete inventories.

Note 6 - DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES

Deposits and prepaid expenses are comprised of the following:

	March 31, 2012		December 31, 2011
Prepayment for raw materials purchasing	$	31,521,801	$	28,824,123
Prepayment for packaging materials purchasing		366,792		402,838
Prepayment for enterprise income taxes		1,708,019		2,162,070
Other receivables		655,918		508,392
Other		661,946		751,025
Total	$	34,914,476	$	32,648,448

As part of the Company’s strategy to reduce inventory costs, the Company maintains a balance for prepayment to suppliers in order to secure favorable pricing for raw materials. As inventory is received throughout the year, this balance will fluctuate with the business operations.

Note 7 - PLANT AND EQUIPMENT, NET

Plant and equipment consist of the following:

	March 31, 2012			December 31, 2011
Building and improvements	$	26,030,763		$	25,866,428
Machinery and equipment		5,764,470			5,675,995
Office equipment and furniture		328,571			320,498
Vehicles		592,175			588,436
Total		32,715,979			32,451,357
Less: accumulated depreciation		(4,442,951	)		(4,074,798	)
Plant and equipment, net	$	28,273,028		$	28,376,559

Depreciation expense was $343,129 and $332,428 for the three months ended March 31, 2012 and 2011, respectively.

Note 8 - CONSTRUCTION-IN-PROGRESS

Construction-in-progress (“CIP”) relates to a plant being built in accordance with the PRC’s Good Manufacturing Practices (“GMP”) Standard.

Xi’an facility

We started constructing our Huxian vaccine facility in 2005, and it was completed in 2010 and resulted in a transfer to plant and equipment of $9,448,505. In 2011, the Company started two projects at the vaccine facility to modify air filtration, water treatment, and other facility changes based on recommendations by outside experts hired by the Company to advise on the GMP qualification process for the vaccine facility. The Company has finished installing, tooling, and testing of equipment on this facility and resulted in a transfer to plant and equipment of approximately $589,270 (RMB 3,720,142) in 2011. As of March 31, 2012, the facility had a total in construction-in-progress of $2,360,086 (RMB 14,899,533). The facility is currently waiting for GMP certification from the Ministry of Agriculture. The Company expects the GMP certification process to be complete by the second half of 2012.

In 2011, the Company started a facility improvement project in the amount of approximately $316,800 (RMB 2,000,000) for the Huxian Animal Laboratory, and it was completed in 2011. The facility is a supporting project to the Huxian vaccine facility and is currently waiting for GMP certification from the Ministry of Agriculture. The Company expects the GMP certification process to be complete by the second half of 2012.

In 2011, the Company started a facility improvement project in the amount of $1,127,808 (RMB 7,120,000) at the Huxian veterinary medicine facility to prepare its GMP re-examination, which is expected to take place in the first half of 2012. The project includes a renovation project to clean 3,160 square feet in area and to replace or implement an exhaust ventilation system, color steel enclosure, process water piping, purification equipment, fire alarm, and combined air supply unit. This facility improvement was completed in 2011 and is awaiting the GMP re-examination from Ministry of Agriculture. The Company expects that the GMP re-examination will be completed during the 3^rd quarter of 2012.

Jingzhou facility

In 2011, the Company started a facility improvement project to expand production capacity at the Jingzhou facility. The project includes plant construction and water supply and drainage and has an estimated total cost of $2,005,819 (RMB 12,663,000). As of March 31, 2012, the project was still under construction. The Company expects the project will be completed by the second half of 2012.

Kunshan facility

In 2010, the Kunshan micro-organism facility and some general facility improvements were completed and placed in service, which resulted in a transfer from Construction-in-Progress to plant and equipment of $1,389,602. In 2011, the Company started a supporting project at the Kunshan facility that includes the construction and installation of plumbing, sewer, electrical, HVAC, fire protection and alarm system, drainage, office, lab, road construction, parking, and landscaping. As of March 31, 2012, the facility had a total in construction-in-progress of $4,954,274 (RMB 31,276,982). The construction and installation were completed and the project will be inspected and accepted shortly. The Company expects the project will be completed by June 2012. We anticipate that Kunshan plant will start small-scale production in the second half of 2012. However, we don’t expect that will bring significant impact to our revenue in 2012 as a whole.

No depreciation is provided for construction-in-progress until such time as the assets are completed and placed into service.

The construction projects the Company was in the progress of completing are as follows:

	Total in CIP as of		Estimate cost to		Estimated		Estimated
Project	3/31/2012		Complete		Total Cost		Completion Date
Xi'an vaccine facility	$	2,360,086	$	-	$	2,360,086	Second half of 2012
Xi'an animal laboratory		316,800		-		316,800	Second half of 2012
Xi'an veterinary medication facility		1,127,808		-		1,127,808	The 3^rd Quarter of 2012
Jingzhou facility		675,259		1,330,560		2,005,819	Second half of 2012
Kunshan facility		4,954,274		-		4,954,274	June 2012
TOTAL CIP Balance	$	9,434,227	$	1,330,560	$	10,764,787

As of March 31, 2012 and December 31, 2011, the Company had construction in progress amounting to $9,434,227 and $8,839,055, respectively. No interest expense had been capitalized for construction in progress for the three months ended March 31, 2012 and 2011 as management determined the amount of capitalized interest would be insignificant.

Note 9 - LONG-TERM PREPAYMENTS

Long-term prepayments consist of the following:

	March 31, 2012		December 31, 2011
R&D project	$	316,800	$	314,800
Construction deposit		594,000		960,140
Deposit for equipment purchase		278,988		237,877
Deposit for potential asset acquisitions		652,609		569,788
Total	$	1,842,397	$	2,082,605

As of March 31, 2012 and December 31, 2011, deposits for potential acquisitions totaled $652,609 and $569,788, respectively, all of which was held by an unrelated third party engaged to facilitate potential acquisition projects.

Note 10 – INTANGIBLE ASSETS

Intangible assets consist of the following:

	March 31, 2012			December 31, 2011
Land use rights	$	4,791,602		$	4,761,352
Technological know-how		2,217,600			2,203,600
Patents		316,800			314,800
Total		7,326,002			7,279,752
Less: accumulated amortization		(1,715,867	)		(1,605,546	)
Intangible assets, net	$	5,610,135		$	5,674,206

The Company’s one year loan with Industrial and Commercial Bank of China Songzi Branch (see Note 12) is secured by the Company’s land use rights in Jingzhou, Hubei Province.

For the three months ended March 31, 2012 and 2011, the amortization expense for intangibles amounted to $100,373 and $230,922, respectively.

Amortization expense expected for the next five years and thereafter is as follows:

Years ending December 31,	Amount
2012	$	300,362
2013		242,082
2014		242,082
2015		242,082
2016		242,082
Thereafter		4,341,445
Total	$	5,610,135

Note 11 – LOANS RECEIVABLE

In November 2010, the Company provided an unsecured non-interest bearing loan to Xi’an Tiantai Investment, Ltd., the Company’s acquisition advisor, in the amount of $190,080 (RMB 1,200,000) for two years from November 26, 2010 through November 25, 2012. As of March 31, 2012, this loan has not been repaid.

As of March 31, 2012, the Company had unsecured non-interest bearing short-term loans in the amount of $791,619 (RMB 4,997,592) due from unrelated third parties.

Note 12 – SHORT-TERM LOANS

On May 5, 2011, the Company obtained a one year loan with Industrial and Commercial Bank of China Songzi Branch for $475,200 (RMB 3,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 8.528% at March 31, 2012. In 2011, the Company repaid $158,400 (RMB 1,000,000) and subsequently borrowed back $158,400 (RMB 1,000,000). This loan is secured by the Company’s land use rights in Jingzhou, Hubei Province and guaranteed by the legal representative of Skystar Jingzhou. On May 2, 2012, the Company repaid this loan of $475,200 (RMB 3,000,000).

On July 8, 2011, the Company obtained a one year loan with Chang’an Bank for $792,000 (RMB 5,000,000) at an annual interest rate of 8.203%. This loan is secured by the Company’s office buildings and its Chairman and CEO’s personal property located in Xi’an City, which includes an office building contributed by a shareholder in 2005 as additional capital of Xi’an Tianxing. As of March 31, 2012, the title to this property has not been passed to the Company. This loan is also personally guaranteed by the Company’s Chairman and CEO and his wife.

On August 25, 2011, the Company obtained a one year loan with Shaanxi Agricultural Yanta Credit Union for $792,000 (RMB 5,000,000) at an annual interest rate of 9.411%. This loan is secured by the Company’s office buildings located in Xi’an City. This loan is also personally guaranteed by the Company’s Chairman and CEO.

On December 22, 2011, the Company obtained a one year loan with Shaanxi Agricultural Yanta Credit Union for $475,200 (RMB 3,000,000) at an annual interest rate of 9.411%. This loan is secured by the Company’s office buildings located in Xi’an City. This loan is also personally guaranteed by the Company’s Chairman and CEO and his wife.

On December 1, 2011, the Company obtained a one year loan with Bank of Chengdu for $4,752,000 (RMB 30,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 8.528% at March 31, 2012. This loan is secured by the Company’s land use right and manufacturing plant located in Huxian County.

In 2011, the Company obtained two three-month loans with a third-party individual for a total amount of $125,920 (RMB 800,000). For the three months ended March 31, 2012, the Company borrowed another two short-term loans for a total amount of $63,360 (RMB 400,000) with this third-party individual. These four loans are non-interest bearing and are unsecured. On April 6, 2012, the Company repaid one loan of $47,520 (RMB 300,000). On April 9, 2012, the Company repaid the other three remaining loans totaling $142,560 (RMB 900,000).

Interest expense incurred and associated with the short-term loans amounted to $152,583 and $54,409 for the three months ended March 31, 2012 and 2011, respectively, none of which has been capitalized as part of construction-in-progress for the three months ended 2012 and 2011, respectively.

Outstanding short-term loans consisted of the following:

	March 31, 2012				December 31, 2011						Interest
Bank	Amt RMB		Amt USD		Amt RMB		Amt USD		Due Date		Rate

Chang’an Bank		5,000,000		792,000		5,000,000		787,000		07/07/12		8.203	%
Shaanxi Agricultural Yanta Credit Union		5,000,000		792,000		5,000,000		787,000		08/24/12		9.411	%
Shaanxi Agricultural Yanta Credit Union		3,000,000		475,200		3,000,000		472,200		12/21/12		9.411	%
Commercial Bank of China Songzi Branch		3,000,000		475,200		3,000,000		472,200		05/04/12			(1)
Bank of Chengdu		30,000,000		4,752,000		30,000,000		4,722,000		11/30/12			(1)
Third-party Individual		1,200,000		190,080		800,000		125,920		Various		0	%
Total		47,200,000	$	7,476,480		46,800,000	$	7,366,320

(1)

People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 8.528% at March 31, 2012.

Note 13 - DEFERRED GOVERNMENT GRANT

Deferred government grant represents subsidies for Good Manufacturing Practice projects granted by various levels of the PRC government. To date, the Company received government subsidies totaling $1,188,000 (RMB 7,500,000), of which $792,000 (RMB 5,000,000) was granted by the PRC government, and $158,400 (RMB 1,000,000) was re-paid on December 7, 2010, with the remaining amount to be repaid in 2012. The current portion of deferred government grant of $633,600 (RMB 4,000,000) is included in other payable in the current liabilities. $316,800 (RMB 2,000,000) was granted by Shaanxi provincial government, and $79,200 (RMB 500,000) was granted by Xi’an municipal government. The Shaanxi provincial government grant and Xi’an municipal government grant are not required to be repaid.

Note 14 - CAPITAL TRANSACTIONS

Stock-based compensation

On March 30, 2010, the Company agreed to issue 2,500 shares of common stock to a non-executive director in exchange for services unrelated to his services as a director at the fair market value of $11.74 per share based on the closing price on March 30, 2010. On April 16, 2010, the Company entered into another agreement to grant 10,000 shares of common stock to that director for his one year service from April 1, 2010. The closing price per share on the grant date was $10.61. The common stock compensation vests in four equal quarterly installments of 2,500 shares. Shares owed were accrued at the end of each quarter at the fair market value on the grant date of $10.61 per share. On August 31, 2011, the Company entered into another agreement to grant 36,000 shares of common stock to that director for his one year service from April 1, 2011. The closing price per share on the grant date was $2.58. The common stock compensation vests in four equal quarterly installments of 9,000 shares. Shares owed were accrued at the end of each quarter at the fair market value of the grant date at $2.58 per share. A total of $23,220 and $26,525 was charged to general and administrative expense for the three months ended on March 31, 2012 and 2011, respectively. On October 25, 2010, 5,000 shares were issued to the director for the shares vested in the first two quarters of 2010. As of March 31, 2012, 43,500 shares were accrued for the shares vested and pending to be issued.

On May 26, 2009, the Company agreed to issue 5,556 shares of common stock to a director at the beginning of each term of his directorship. The trading value of the common stock on May 26, 2009 was $4.50 per share. The Company issued 5,556 shares on February 26, 2010. As of March 31, 2012, 11,112 shares were accrued for the shares vested and pending to be issued. In accordance with the agreement between the Company and this director, this director must continue to serve as a member of the Board until his successor is duly elected and qualified in order to receive the shares. This director has continued in his position, and the Company is in the process of finalizing its agreement with this director and expects to complete this process shortly.

On July 29, 2011, the Company entered into a one-year employment agreement with its CFO. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, 4,000 shares of which shall be issuable on the 6 month anniversary and the remainder 4,000 shares of which shall be issuable on the 12 month anniversary. The closing price per share on the grant date was $4.20. A total of $22,584 was charged to general and administrative expense for the three months ended on March 31, 2012. As of March 31, 2012, 4,000 shares were accrued for the shares vested and pending to be issued.

Warrants and Purchase Options

On February 28, 2007, in connection with a financing the Company issued 195,000 warrants to four investors with an exercise price of $6.00 per share for a term of three years (number of warrants and exercise price adjusted for 1-for-10 reverse stock split on May 12, 2009 and 2-for-1 forward stock split on November 16, 2009). On the same date, the Company also issued warrants to the placement agent, exercisable for 114,100 shares of the Company’s common stock at a price of $5.00 per share for a five-year term (number of warrants and exercise price adjusted for 1-for-10 reverse stock split on May 12, 2009 and 2-for-1 forward stock split on November 16, 2009). For the year ended December 31, 2009, 56,846 warrants were exercised. For the year ended December 31, 2010, there was a cashless exercise of 218,024 warrants. For the year ended December 31, 2011, no warrants were exercised. As of March 31, 2012, the remaining 34,230 warrants expired.

In connection with the 2009 equity offering discussed below, the Company granted 140,000 common stock purchase options to five designees of the Underwriters with a vesting date of June 30, 2010. The options are exercisable from June 30, 2010 to June 30, 2014, and each option is exercisable for one share of the Company’s common stock at an exercise price at $8.11 per share. All options were provided for services performed. On June 30, 2010, the purchase options were reclassified from equity to warrant/purchase option liabilities, and the Company reclassified $779,674 from additional paid in capital to warrant/purchase option liability. As of March 31, 2012, 140,000 common stock purchase options were outstanding.

The fair value of each warrant and purchase option is estimated on the date of grant using the Black-Scholes option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock, and reflect the assumption that the historical volatilities are indicative of future trends, which may not necessarily be the actual outcome. Expected term of each warrant and purchase option award represents the period of time that options granted are expected to be outstanding and is estimated based on the historical exercise behavior of separate groups of employees or officers. The risk-free rate reflects the interest rate for United States Treasury Notes with similar time-to-maturity to that of the options.

	March 31, 2012			March 31, 2011
Expected term (year)		2.25			0.92 – 3.25
Expected volatility		65	%		53% - 147	%
Expected dividend yield		0	%		0	%
Risk-free rate		0.33	%		0.3% - 1.30	%

Following is an activity summary of the Company’s outstanding warrants and purchase options:

	Number of warrants/purchase options			Weighted – average exercise price		Weighted- average remaining contractual term (Year)
Outstanding at January 1, 2011		174,230		$	7.50
Granted		-
Forfeited		-
Exercised		-
Outstanding at December 31, 2011		174,230		$	7.50
Granted		-			-
Forfeited		(34,230	)		-
Exercised		-
Outstanding at March 31, 2012		140,000		$	8.11		2.25
Vested and expected to vest at March 31, 2012		140,000		$	8.11		2.25
Exercisable at March 31, 2012		140,000		$	8.11		2.25

Equity Compensation Plan

On December 8, 2009, the Company’s board of directors approved a stock incentive plan for officers, directors, employees and consultants entitled the “Skystar Bio-Pharmaceutical Company 2010 Stock Incentive Plan” (the “2010 Plan”). The maximum number of shares that may be issued under the 2010 Plan is 700,000 shares of common stock. The 2010 Plan was approved by the Company’s stockholders on December 31, 2009, and awards may be granted thereunder until December 7, 2019. As of March 31, 2012, there are 690,000 shares of the Company’s common stock remaining available for future issuance under the Plan. On May 4, 2012, the Board approved common stock grants in the total amount of 442,881 shares to the Company’s employees and members of the Board of Directors, all of which grants were made pursuant to the terms and provisions of the Plan.

Note 15 - STATUTORY RESERVES

Statutory reserves represent restricted retained earnings. Based on the legal formation of the entities, all PRC entities are required to set aside 10% of net income as reported in their statutory accounts on an annual basis to the statutory surplus reserve fund. Once the total statutory surplus reserve reaches 50% of the entity’s registered capital, further appropriations are discretionary. The statutory surplus reserve can be used to increase the entity’s registered capital (upon approval by relevant government authorities) and eliminate its future losses under PRC regulatory requirements (upon a resolution by the board of directors). The statutory surplus reserve is not distributable to shareholders except in the event of liquidation. As of March 31, 2012, Xi’an Tianxing has met the statutory surplus reserve requirement, and $11,192,619 still needs to be transferred to the statutory surplus reserve from other Chinese subsidiaries.

Appropriations to the above statutory reserves are accounted for as a transfer from unrestricted earnings to statutory reserves. There are no legal requirements in the PRC to fund these statutory reserves by the transfer of cash to any restricted accounts, and as such, the Company has not transferred any cash to these accounts. These reserves are not distributable as cash dividends.

Note 16 – TAXES

Skystar is subject to United States federal income tax provisions. Skystar Cayman is a tax-exempt company incorporated in the Cayman Islands and conducts all of its business through its subsidiaries, Fortune Time, Sida, Fortune Time’s subsidiary Skystar Kunshan, Sida’s subsidiary Skystar Jingzhou, Sida’s PRC VIEs, Xi’an Tianxing, Xi’an Tianxing’s subsidiary Shanghai Siqiang, Sida and Xi’an Tianxing’s joint venture Kunshan Sikeda, and Xi’an Tianxing’s subsidiary Xi’an Sikaida.

Sida, Skystar Jingzhou, Skystar Kunshan, Xi’an Tianxing, Shanghai Siqiang, Kunshan Sikeda and Xi’an Sikaida are subject to the PRC’s Enterprise Income Tax. Pursuant to the PRC Income Tax Laws, Enterprise Income Tax is generally imposed at a statutory rate of 25%. Xi’an Tianxing has been approved as a new technology enterprise, and under PRC Income Tax Laws is entitled to a preferential tax rate of 15%.

The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the three months ended March 31, 2012 and 2011:

	For the three months ended
	March 31, 2012			March 31, 2011
U.S. Statutory rate		34.0	%		34.0	%
Foreign income not recognized in the U.S.		(34.0	)		(34.0	)
China income tax rate		25.0			25.0
China income tax exemption		(10.0	)		(10.0	)
Other item (1)		4.8			4.8
Total provision for income taxes		19.8	%		19.8	%

(1)

Other item is for operating expenses incurred by Skystar that are not deductible in the PRC and expenses incurred by other subsidiaries that are not deductible on the consolidated level, which resulted in an increase in effective tax rate 4.8% and 4.8% for the three months ended March 31, 2012 and 2011, respectively.

Taxes payable consisted of the following:

	March 31, 2012		December 31, 2011
Value added tax	$	1,402,428	$	110,880
Other taxes		182,728		49,201
Total	$	1,585,156	$	160,081

Skystar was incorporated in the United States. As of March 31, 2012, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $6,228,689, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, beginning in 2026 and through 2030. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at March 31, 2012 and December 31, 2011. The valuation allowance at March 31, 2012 and December 31, 2011 was $2,117,754 and $2,071,840, respectively. The Company’s management reviews this valuation allowance periodically and makes adjustments as necessary. As of March 31, 2012, the Company has no other deferred tax amounts.

The Company has cumulative undistributed earnings of foreign subsidiaries of approximately $57 million as of March 31, 2012, which were included in consolidated retained earnings and will continue to be indefinitely reinvested in international operations. Accordingly, no provision has been made for U.S. deferred taxes related to future repatriation of these earnings, nor is it practicable to estimate the amount of income taxes that would have to be provided if we concluded that such earnings will be remitted in the future.

Note 17 - EARNINGS PER SHARE

The following is the calculation of earnings per share:

	For the three months ended March 31,
	2012		2011
Net income	$	1,904,754	$	1,931,832

Weighted average shares used in basic computation		7,210,256		7,166,919
Diluted effect of stock warrants and purchase options		-		12,390
Weighted average shares used in diluted computation		7,210,256		7,179,309

Earnings per share:

Basic	$	0.26	$	0.27
Diluted	$	0.26	$	0.27

For the three months ended March 31, 2011, the average stock price was greater than the exercise prices of warrants which resulted in additional weighted-average common stock equivalents of 12,390.

For the three months ended March 31, 2012 and 2011, the outstanding 140,000 options were excluded from the diluted earnings per share calculation as they are anti-dilutive as the average stock price was less than the exercise prices of the options.

Note 17 - RELATED PARTY TRANSACTIONS AND ARRANGEMENTS

Amounts receivable from and payable to related parties are summarized as follows:

	March 31, 2012		December 31, 2011

Shares to be issued to related party (1)
Scott Cramer – non-executive director (2)	$	172,455	$	149,235
Mark D. Chen – non-executive director (3)		50,004		50,004
Bing Mei – CFO (4)		16,800		-
Total	$	239,259	$	199,239

Amounts due to (from) related parties

Scott Cramer – non-executive director and shareholder (5)	$	132,561	$	147,877
Officer, shareholder and other related party (6)		248,108		(91,604	)
Total	$	380,669	$	56,273

	(1)	The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. As of March 31, 2012 and December 31, 2011, the shares to be issued to related parties included in the accrued expenses were $239,259 and $199,239, respectively.
	(2)	As of March 31, 2012 and December 31, 2011, the Company had the obligation under an agreement to issue 43,500 and 34,500 shares of common stock, respectively, to Scott Cramer as compensation valued at $172,455 and $149,235 for being a representative of the Company in the United States for the period April 1, 2010 to March 31, 2012.
	(3)	As of March 31, 2012 and December 31, 2011, the Company had the obligation under an agreement to issue 11,112 shares of common stock to Mark D. Chen as compensation valued at $50,004 for being a director for his 2011 and 2010 terms of directorship.
	(4)	As of March 31, 2012, the Company had the obligation under an agreement to issue 4,000 shares of common stock to Bing Mei as compensation valued at $16,800 for being CFO for the period July 29, 2011 to July 28, 2012.
	(5)	As of March 31, 2012 and December 31, 2011, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $132,561 and $147,877, respectively.

(6)

The amount due to (from) officer, shareholders and other related party at March 31, 2012 and December 31, 2011 includes unpaid reimbursement and compensation and, advances to Mr. Weibing Lu and other related parties for business expenses.

Note 18 - COMMITMENTS AND CONTINGENCIES

(a) Lease commitments

The Company recognizes lease expense on the straight-line basis over the term of the lease.

The Company entered into a tenancy agreement for the lease of factory premises in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009. As of March 31, 2012, the annual rent for the factory premises was adjusted to approximately $20,212 (RMB 127,600).

The Company leases office space in Xi’an from Mr. Weibing Lu, the Company’s Chairman and CEO, for a period of five years from January 1, 2007 to December 31, 2011, with annual rent of approximately $26,231 (RMB 165,600). In January 2012, the Company renewed the lease with Mr. Lu for another 5 years from January 1, 2012 to December 31, 2016 at rent of approximately $28,512 (RMB 180,000) per year.

The Company also entered into a tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiang’s office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017 with annual rent of approximately $22,810 (RMB 144,000).

The Company entered into a one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from April 15, 2011 to April 14, 2012 with annual rent of approximately $3,041 (RMB 19,200). On April 15, 2012, the Company entered into a new one year tenancy agreement for this office from April 15, 2012 to April 14, 2013 with annual rent of approximately $3,199 (RMB 20,196).

The Company entered into a tenancy agreement for the lease of warehouse premises in Xi’an for a period of three years from July 20, 2011 to July 19, 2014 with annual rent of approximately $37,224 (RMB 235,000) subject to a 10% increase every two years starting July 20, 2013.

The minimum future lease payments for the next five years and thereafter are as follows:

Period	Amount
Nine months ending December 31, 2012	$	81,568
Year ending December 31, 2013		111,038
Year ending December 31, 2014		67,859
Year ending December 31, 2015		51,322
Year ending December 31, 2016 and thereafter		64,628
Total	$	376,415

Rental expense for the three months ended March 31, 2012 and 2011 amounted to $28,020 and $14,396, respectively.

(b) Legal proceedings

From time to time, the Company is involved in legal matters arising in the ordinary course of business. Management currently is not aware of any legal matters or pending litigation which would have a significant effect on the Company’s consolidated financial statements as of March 31, 2012.

In May 2007, Andrew Chien filed suit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in United States District Court for the District of Connecticut, alleging causes of action for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 17, 2008, in a decision that is now published, the court granted defendants’ motion to dismiss and subsequently dismissed the lawsuit, entering judgment on behalf of the defendants. Chien appealed the dismissal. Defendants filed a postjudgment motion for sanctions against Chien. On February 5, 2009, the court found the action filed by Chien to have been frivolous, and to have constituted a “substantial” violation of Rule 11, and imposed monetary sanctions on both Chien and his former attorney. Chien appealed the award of sanctions. All appeals, including the one referenced below concerning Chien’s second lawsuit, were subsequently consolidated. The Court of Appeals issued a Mandate upholding the decision granting defendant’s motion to dismiss and found that the District Court did not “abuse its discretion” in issuing sanctions against Chien in light of the circumstances and facts on record. This Mandate was entered on or about November 8, 2010.

Andrew Chien, proceeding pro se (i.e., he represented himself without an attorney), filed his second lawsuit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in Connecticut Superior Court (which was removed to U.S. District Court) alleging causes of action similar to those alleged in his federal complaint described above as well as state law causes of action. The court held that all claims asserted against the defendants were barred and failed to state a claim on a multiplicity of grounds, including on the basis of res judicata . Defendants filed a second Motion for Sanctions under Rule 11 and the PSLRA, which was granted. Chien appealed the dismissal. The Court of Appeals for the Second Circuit consolidated all of Chien’s appeals from both of his lawsuits. On November 8, 2010, the Court of Appeals affirmed the dismissals and the awards of sanctions. On January 22, 2011, Chien filed a petition with the Supreme Court of the United States, appealing the lower court’s ruling. The Supreme Court denied review of the petition.

Andrew Chien, again proceeding pro se, commenced his third lawsuit against the Company, Scott Cramer, Steve Lowe, David Wassung, Weibing Lu (and also Weinberg & Company, P.A., Moore Stephens Wirth Frazer & Torbet, LLP, Frazer Frost, LLP, Crowe Horwath LLP, Richardson & Patel LLP, Kevin K. Leung, Harvey Kesner, and Jody M. Borrelli) alleging the same facts and circumstances as set forth in the above two matters, although adding the aforementioned accountants and lawyers as defendants to the claims. The matter commenced on August 8, 2011, and shortly thereafter was removed to U.S. District Court. On October 5, 2011, the court dismissed the entire action as to all defendants. As in the two previous lawsuits, sanctions were issued against Chien. Moreover, the District Court issued an order prohibiting Chien from filing any more lawsuits against the defendants without prior approval from the court. Chien has appealed the court’s rulings to the United States Court of Appeals for the second circuit, where all defendants have filed motions to dismiss. The United States Court of Appeals for the Second Circuit recently affirmed the judgments and orders of the United States District Court and dismissed all of Mr. Chien’s pending appeals.

Other than the above described legal proceedings, the Company is not aware of any legal matters in which any director, officer, or any owner of record or beneficial owner of more than five percent of any class of voting securities of the Company, or any affiliate of purchaser, or of any such director, officer, affiliate of the Company, or security holder, is a party adverse to the Company or has a material adverse interest to the Company. No provision has been made in the consolidated financial statements for the aforementioned matter.

In 2005, a shareholder contributed a leasehold office building as additional capital of Xi’an Tianxing. However, as of March 31, 2012, title to this leasehold property has not passed to the Company. The Company does not believe there are any legal barriers for the shareholder to transfer the ownership to the Company. However, in the event that the Company fails to obtain the ownership certificate for the leasehold property, there is a risk that we may be required to vacate the building. Management believes that this possibility is remote, and, as such, no provision has been made in the consolidated financial statements for this potential occurrence.

(d) R&D project

In 2008, Xi’an Tianxing contracted with Northwestern Agricultural Technology University to work jointly on an R&D project concerning the application of nano-technology in the prevention of major milk cow disease. The total projected budget for this project is approximately $633,600 (RMB 4,000,000), which is to be paid according to completed stages of the project. The project reached trial stage in September 2009. As of March 31, 2012, the Company incurred approximately $476,400 (RMB 3,000,000) of cumulative expenses relating to this project.

In 2009, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project on fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents. The contracted amount for this project is approximated $950,400 (RMB 6,000,000). As of March 31, 2012, the Company has incurred approximately $539,920 (RMB 3,400,000) of cumulative expenses relating to this project.

During the first quarter of 2011, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project to develop new treatment and diagnosis method for Mycoplasmal pneumonia of swine. The project term is from January 2011 through September 2013. The cost to the Company for the initial phase is approximately $316,800 (RMB 2,000,000). As of March 31, 2012, the Company has incurred approximately $79,400 (RMB 500,000).

During the second quarter of 2011, Xi’an Tianxing launched four new R&D projects to develop ceftiofur sodium for injection (powder for injection), a sulfuric acid injection neostigmine, dexamethasone sodium phosphate injection, and houttuynia preparation of compound application in weaning piglets. The projected budget for the R&D project of ceftiofur sodium for injection (powder for injection) is approximately $554,400 (RMB 3,500,000). As of March 31, 2012, the Company has incurred approximately $438,288 (RMB 2,760,000). The projected budget for the R&D project of a sulfuric acid injection neostigmine is approximately $475,200 (RMB 3,000,000). As of March 31, 2012, the Company has incurred approximately $269,971 (RMB 1,700,071). The projected budget for the R&D project of dexamethasone sodium phosphate injection is approximately $554,400 (RMB 3,500,000). As of March 31, 2012, the Company has incurred approximately $464,683 (RMB 2,926,215). The projected budget for the R&D project of houttuynia preparation of compound application in weaning piglets is approximately $712,800 (RMB 4,500,000). As of March 31, 2012, the Company has incurred approximately $681,828 (RMB 4,293,630).

In addition, the Company also launched various R&D projects in 2011 on veterinary products formula adjustment, pet drug development and fermentation engineering design and development and lab tests. As of March 31, 2012, approximately $858,272 (RMB 5,404,737) has been incurred related to these projects and lab tests.

R&D projects are summarized as follows:

Project	Amount incurred as of 3/31/2012		Amount expected to be incurred		Total amount of project
Project with the Fourth Military Medical University (1)	$	539,920	$	411,840	$	950,400
Project with Northwestern Agricultural Technology University (2)		476,400		158,400		633,600
Project with the Fourth Military Medical University (3)		79,400		237,600		316,800
In-house R&D project (4)		438,288		117,216		554,400
In-house R&D project (5)		269,971		205,909		475,200
In-house R&D project (6)		464,683		90,888		554,400
In-house R&D project (7)		681,828		32,689		712,800
Other in-house R&D projects (8)		858,273		15,840		871,950
TOTAL	$	3,808,763	$	1,270,382	$	5,069,550

(1) Project for fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents

(2) Project for application of nano-technology in the prevention of major milk cow disease

(3) Project for new treatment and diagnosis method for Mycoplasmal pneumonia of swine

(4) Project for ceftiofur sodium for injection (powder for injection)

(5) Project for sulfuric acid injection neostigmine

(6) Project for dexamethasone sodium phosphate injection

(7) Project for houttuynia preparation of compound application in weaning piglets

(8) Other projects for veterinary products formula adjustment, pet drug development and fermentation engineering design and development and lab tests

(e) Registered capital commitment

Skystar Kunshan’s remaining registered capital of $12,750,000 is originally required to be invested by May 7, 2012. With the government’s approval, this deadline to invest was extended and we are not required to make the capital investment immediately. As of the date of this report, we have not received the notice from the Government for a new due date. In 2011, the asset acquisition of Kunshan facility was completed. We are in the process of getting the government’s approval to transfer the asset purchased to satisfy some of our registered capital commitment. As of the date of this report, we have not received the approval.

As of March 31, 2012, Skystar Jingzhou has remaining registered capital of $399,168 (RMB 2,520,000) required to be invested. As of the date of this report, the Company has not made this investment. Skystar Jingzhou is currently in the process of getting the government's approval and will fulfill the requirement of remaining capital of $399,168 (RMB 2,520,000) thereafter. The company expects the process will be completed by the end of the 2nd quarter of 2012.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Overview

We were incorporated in Nevada on September 24, 1998. We are a holding company that, through our wholly owned subsidiaries in China, including Skystar Bio Technology (Jingzhou) Co. (“Skystar Jingzhou”), and a variable interest entity (“VIE”), Xi’an Tianxing Bio-Pharmaceutical Co., Ltd. (“Xi’an Tianxing”), researches, develops, manufactures, and distributes veterinary health care and medical care products in the People’s Republic of China (“PRC”).

All of our operations are carried out by our subsidiaries in China and Xi’an Tianxing, which the Company controls through contractual arrangements between Xi’an Tianxing and Sida Biotechnology (Xi’an) Co., Ltd. (“Sida”), the wholly owned subsidiary of Fortunate Time International Limited, the wholly owned subsidiary of Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (“Skystar Cayman”), which became our wholly owned subsidiary in 2005. Such contractual arrangements are necessary to comply with PRC laws limiting foreign ownership of certain companies. Through these contractual arrangements, we have the ability to substantially influence Xi’an Tianxing’s daily operations and financial affairs, appoint its senior executives, and approve all matters requiring shareholder approval. As a result of these contractual arrangements, which enable us to control Xi’an Tianxing, we are considered the primary beneficiary of Xi’an Tianxing.

In addition to Xi’an Tianxing, Skystar Jingzhou also manufactures and distributes veterinary medicines, including aquaculture medicines in China. Skystar Jingzhou is a wholly owned subsidiary of the Company’s Sida entity. It was formed with the August 2010 acquisition of a veterinary medicine manufacturing facility in Hubei Province, China.

On August 21, 2007, Xi’an Tianxing invested $79,200 (RMB 500,000) to establish Shanghai Siqiang Biotechnological Company Limited (‘Shanghai Siqiang’). Xi’an Tianxing is the 100% shareholder. Shanghai Siqiang serves as a research and development center for Xi’an Tianxing to engage in research, development, production and sales of feed additives and veterinary disease diagnosis equipments.

Our financial statements are prepared in U.S. dollars and in accordance with accounting principles generally accepted in the United States of America. See “Exchange Rates” below for information concerning the exchanges rates at which Renminbi were translated into U.S. dollars at various pertinent dates and for pertinent periods.

Nasdaq Listing Compliance Matters

On January 12, 2012, the Company received staff determination from the Nasdaq Stock Market (“Exchange”) indicating that since the Company did not hold its 2010 annual shareholder meeting by December 31, 2011, the Company was not in compliance with Nasdaq Listing Rule 5620(a) and (b) relating to the time frame of and proxy solicitation in connection with annual shareholder meetings and, therefore, the Exchange staff determined to initiate proceedings to delist the Company’s securities from Nasdaq at the open of business on January 23, 2012. On March 26, 2012, following its presentation at an oral hearing before the Nasdaq Listing Qualifications Panel, the Company received a letter informing the Company that the Panel had granted the Company’s request to remain listed on the Exchange, subject to the condition that by April 28, 2012, Skystar provided evidence that it held its 2011Annual Meeting of Shareholders. On April 27, 2012, the Company held its 2011 Annual Meeting of Shareholders, at which the shareholders of the Company elected all members of the Company’s Board and ratified the engagement of Crowe Horwath LLP as the Company’s independent registered public accounting firm. The Company continues to be in compliance with all other continued listing requirements.

On May 1, 2012, the Exchange confirmed that the Company had met the requirements of the Panel’s decision dated March 26, 2012, and was in compliance with all other applicable requirements for continued listing on Nasdaq. The matter is now closed.

Critical Accounting Policies and Estimates

In preparing the consolidated financial statements in accordance with U.S. GAAP, we make estimates and assumptions about the effect of matters that are inherently uncertain and may change in subsequent periods. The resulting accounting estimates will, by definition, vary from the related actual results. We consider the following to be the most critical accounting policies:

Principles of consolidation

Revenue recognition

Revenue of the Company is primarily from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected on these consolidated financial statements as sales returns are de minimal based on historical experience.

There are two types of sales upon which revenue is recognized:

a.	Credit sales: revenue is recognized when the products have been delivered to the customers.

b.	Full payment before delivering: revenue is recognized when the products have been delivered to the customers.

Accounts receivable and other receivables

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as needed. The Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages determined by management, based on historical experience and current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. The ultimate collection of the Company’s accounts receivable may take one year. Delinquent account balances are reserved after management determines that the likelihood of collection is not probable, and known bad debts are written-off against allowance for doubtful accounts when identified.

Intangible assets

Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over the weighted average useful life of nine years, which reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties.

Impairment of Intangible assets — The Company evaluates the carrying value of intangible assets annually or more often when factors indicating impairment are present. The Company determines the existence of such impairment by measuring the estimated future cash flows (undiscounted) and comparing such amount to the net asset carrying value. If the undiscounted cash flow estimated to be generated by any such intangible asset is less than its carrying amount, a loss is recognized based on the amount by which the carrying amount exceeds the intangible asset’s fair market value. Loss on intangible assets to be disposed of is determined in a similar manner, except that fair market values are reduced by the cost of disposal. Based on its review, the Company believes that, as of March 31, 2012, there was no impairment of its intangible assets.

Earnings per share

The Company reports earnings per share and present both basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period, or retroactively if the stock dividends or stock splits occur after the end of the period but before the release of the financial statements, by considering it outstanding of the entirety of each period presented. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

Recently Issued Accounting Pronouncements

See Item 1 of Part I, “Notes to the Condensed Consolidated Financial Statements — Note 2 – Summary of Significant Accounting Policies — Recently Issued Accounting Pronouncements.”

Results of Operations – Three Months ended March 31, 2012 and 2011

The following table summarizes our results of operations for the three months ended March 31, 2012 and 2011.

	Three Months Ended March 31,
	2012						2011
	Amount			% of total revenue			Amount		% of total revenue
Revenue	$	7,926,337			100.0	%	$	7,086,954		100.0	%
Gross Profit	$	4,282,679			54.0	%	$	3,595,608		50.7	%
Operating Expenses	$	1,814,705			22.9	%	$	1,951,674		27.5	%
Income from Operations	$	2,467,974			31.1	%	$	1,643,934		23.2	%
Other Income (Expense)	$	(94,252	)		(1.2	)%	$	765,348		10.8	%
Income Tax Expenses	$	468,968			5.9	%	$	477,450		6.7	%
Net Income	$	1,904,754			24.0	%	$	1,931,832		27.3	%

Revenues. All of our revenues are derived from the sale of veterinary healthcare and medical care products in the PRC. For the three months ended March 31, 2012, we had revenues of $7,926,337 as compared to revenues of $7,086,954 for the three months ended March 31, 2011, an increase of 11.8%. We generate revenue from sales of four product lines: veterinary medications, micro-organism, feed additives, and vaccines. The selling prices of our products increased less than 0.5% on average in the three months ended March 31, 2012 compared to the same period of 2011. The increase in revenue was primarily due to the increase of sales volume.

Revenue — Veterinary Medications. Revenue from sales of our veterinary medications decreased by $1,856,460 or 38.2% from $4,865,047 for the three months ended March 31, 2011 to $ 3,008,587 for the three months ended March 31, 2012. The decrease of revenue was primarily due to there being no production at Huxian plant for the most of the first quarter of 2012. On January 7, 2012, the current GMP certification of Huxian facility expired after five years and we are currently waiting for the Ministry of Agriculture to set a date to conduct its GMP re-examination. The Company has submitted all application materials necessary for a successful GMP re-examination and expects the re-examination will be initiated during the 2^nd quarter of 2012 and completed during the 3^rd quarter of 2012 according to current MOA’s GMP re-examination rules and our communication with the government. We currently have two veterinary medications plants located in Huxian and Jingzhou with Huxian being our main facility. The Jingzhou plant completed its GMP re-examination in 2011 and resumed its partial production in the first quarter of 2012 and is now under way to resume its normal production. We plan to increase the production and sales of veterinary medications in the Jingzhou plant to offset the negative impact during the period the Huxian plant is closed and waiting for GMP re-examination. In the unlikely event we are unable to pass the GMP re-examination at Huxian plant or the GMP re-examination at Huxian plant is significantly delayed by the Government, we will have less revenue than expected. Of the total revenues from veterinary medications during three months ended March 31, 2012, approximately 60% of total revenue resulted from the sale of Praziquantel tablets, which treats schistosomiasis. The selling prices of our veterinary medication products for the three months ended March 31, 2012 increased approximately 1.1% on average from the same period of last year. The decrease in revenue was primarily due to the decrease of sales volume.

Revenue — Micro-Organism. Revenue from sales of our micro-organism products increased by $1,538,946 or 96.4% from $1,596,094 for the three months ended March 31, 2011 to $3,135,040 for the three months ended March 31, 2012. The increase was primarily due to growing market demand for organic and environmental-friendly food products in China resulting in increasing utilizing non-drug feed additives in animal husbandry industry and our increased sales efforts to respond to this market trend. Due to the temporary reduction of veterinary medication production, we were able to shift some of our veterinary medication sales forces to focus on the selling of micro-organism products and penetrate the market. The revenue from sales of our micro-organism products was the largest revenue contributor for the entire company and contributed 39.6% of total revenue during the three months ended March 31, 2012. The increase in micro-organism sales also contributed the majority of revenue growth for the entire company during the three months ended March 31, 2012. The selling prices of our micro-organism products for the three months ended March 31, 2012 have not changed meaningfully on average from last year. The increase in revenue was mainly due to the increase of sales volume.

Revenue — Feed Additives. Revenue from sales of our feed additives product line increased by $708,365 or 217.0% from $326,407 for the for the three months ended March 31, 2011 to $1,034,772 for the three months ended March 31, 2012. The increase was primarily the result of increased market demand of our feed additive products and strong sales of our multi-enzyme feed additive products. Plus, added sales forces temporarily shifted from veterinary medication product line helped to increase the sales. The selling prices of our feed additives products for the three months ended March 31, 2012 have not changed meaningfully on average from last year. The increase in revenue was primarily due to the increase of sales volume.

Revenue — Vaccines. Revenue from sales of our vaccines increased by $448,532 or 149.8% from $299,406 for the three months ended March 31, 2011 to $747,938 for the three months ended March 31, 2012. We completed the construction of a new vaccine facility at our Huxian plant in 2010. The facility is currently waiting for GMP certification from the Ministry of Agriculture. The Company expects the GMP certification will be completed by the second half of 2012, and we expect to commence production shortly thereafter for large-scale production. The selling prices of our vaccine products have not increased approximately 0.2% on average for the three months ended March 31, 2012 compared to those in the same period of 2011. The increase in revenue was primarily due to the increase of sales volume.

Cost of Sales. Cost of sales, which consists of raw materials, direct labor, and manufacturing overhead for our four product lines, was $3,643,658 for the three months ended March 31, 2012, as compared to $3,491,346 for the three months ended March 31, 2011, an increase of $152,312 or 4.4%, as a result of increased sales. For the three months ended March 31, 2012, raw material costs comprised the majority or approximately 72.9% of total cost of sales, packing material costs comprised approximately 17.2% of total cost of sales, and labor costs comprised approximately 9.9% of total cost of sales. The increased gross margins in the first quarter of 2012 was mainly because the majority of our revenue growth during the quarter came from highly profitable micro-organism and vaccine product lines, while relatively less profitable veterinary medications product line reduced its production, and therefore sales, during the quarter, as described above.

Cost of Sales — Veterinary Medications. Cost of sales of our veterinary medications product line decreased from $2,821,906 for the three months ended March 31, 2011 to $1,792,647 for the three months ended March 31, 2012, a decrease of $1,029,259 or 36.5%. This decrease was mainly due to the decrease in corresponding sales. Cost of sales of veterinary medications product line comprised 49.2% of total cost of sales for the three months ended March 31, 2012.

Cost of Sales — Micro-Organism. Cost of sales of our micro-organism product line increased from $494,182 for the three months ended March 31, 2011 to $906,841 for the three months ended March 31, 2012, an increase of $412,659 or 83.5%. This increase was mainly due to the corresponding increased sales.

Cost of Sales — Feed Additives. Cost of sales of our feed additives product line increased from $140,866 for the three months ended March 31, 2011 to $849,884 for the three months ended March 31, 2012, an increase of $709,018 or 503.3%. This increase in cost of sales was mainly due to the corresponding increase in feed additive sales and significantly increased raw material costs of yeast extract, the main raw material used in the manufacture of feed additives products.

Cost of Sales — Vaccines. Cost of sales of our vaccines product line increased from $34,392 for the three months ended March 31, 2011 to $94,286 for the three months ended March 31, 2012, an increase of $59,894 or 174.2%. This increase was the result of the corresponding increase of vaccine product sales.

Operating Expenses

	Three Months Ended March 31,
	2012					2011
	Amount		% of total revenue			Amount		% of total revenue
Operating Expenses
Research and Development Costs	$	3,654		0.1	%	$	287,472		4.1	%
Selling Expenses	$	705,616		8.9	%	$	369,404		5.2	%
General and Administrative Expenses	$	1,105,435		13.9	%	$	1,294,798		18.2	%
Total Operating Expenses	$	1,814,705		22.9	%	$	1,951,674		27.5	%

Research and Development Costs. Research and development costs totaled $3,654 for the three months ended March 31, 2012 as compared to $287,472 for the three months ended March 31, 2011, a decrease of $283,818 or 98.7%. The decrease was primarily due to no significant new R&D efforts undertaken during the first quarter of 2012.

Selling Expenses. Selling expenses totaled $705,616 for the three months ended March 31, 2012 as compared to $369,404 for the three months ended March 31, 2011, an increase of $336,212 or 91.0%. This increase is primarily a result of significantly increased shipping and handling costs related to delivering our products to customers as we continued to expand our market to remote areas, and to rising oil price and continuing inflation pressure in China, which resulted in higher unit costs for transportation and delivery services. Shipping and handling costs totaled $383,703 and $194,216 for the three months ended March 31, 2012 and 2011, respectively, an increase of $189,487 or 97.6%. In addition, the increases in the sales forces and selling commission due to new sales incentive programs initiated later last year also contributed to the increase in selling costs. Selling salaries totaled $105,810 and $34,811 for the three months ended March 31, 2012 and 2011, respectively, an increase of $70,999 or 204.0%. Selling commission totaled $135,617 and $79,818 for the three months ended March 31, 2012 and 2011, respectively, an increase of $55,799 or 69.9%.

General and Administrative Expenses. General and administrative expenses totaled $1,105,435 for the three months ended March 31, 2012 as compared to $1,294,798 for the three months ended March 31, 2011, a decrease of $189,363 or 14.6%. The decrease was mainly due to decreased amortization expenses, G&A travel and office expenses during the first quarter of 2012. The decrease in amortization expense was because patent acquired through the acquisition of Jingzhou plant was fully amortized in 2011. Amortization expenses totaled $100,373 and $230,922 for the three months ended March 31, 2012 and 2011, respectively, a decrease of $130,549 or 56.5%. In addition, the decreases in the G&A travel and office expenses due to the Company’s continued efforts to optimize cost control also contributed to the decrease in G&A costs in the first quarter. G&A travel costs totaled $16,215 and $120,372 for the three months ended March 31, 2012 and 2011, respectively, a decrease of $104,157 or 86.5%. G&A office expenses totaled $31,042 and $142,140 for the three months ended March 31, 2012 and 2011, respectively, a decrease of $111,098 or 78.2%. The increase in the audit costs of $99,480 in the first quarter of 2012 partially offset the impact of the cost reduction in other G&A items.

Liquidity

For the three months ended March 31, 2012, cash provided by operating activities was $2,021,671 compared to cash used in operating activities of $6,288,315 for the three months ended March 31, 2011. The major operating activities that provided cash for the three months ended March 31, 2012 were net income of $1,904,754 and an increase in tax payable of $1,427,655. The major operating activities that used cash for the three months ended March 31, 2012 were an increase in accounts receivable of $2,415,647 and an increase in deposits, prepaid expenses and other receivables of $2,144,356. Although the inflation rate in China eased to 3.6% in March 2012 from 2011 peak, according to our observation on raw material marketplace we believe the rising oil price and inflationary impact will still exist for the rest of 2012, and cost of raw materials will likely continue to rise. We will continue the strategy to prepay our suppliers to ensure the supply of raw materials at relatively lower cost levels and to protect our profit margins from being eroded by inflation and rising oil prices which caused an increase in our transportation costs. As of March 31, 2012, we had approximately 60 suppliers that we made advances to in order to secure our raw material needs and to obtain favorable pricing. We will continue to closely manage these advances to balance the need for lower materials cost and sufficient cash flow.

Cash used in investing activities for the three months ended March 31, 2012 was $111,420, as compared to cash provided by investing activities of $6,462,736 for the three months ended March 31, 2011. Cash used in investing activities for the three months ended March 31, 2012 was primarily the result of purchase of plant and equipment of $54,965 and payment on construction-in-process of $44,940.

Cash provided by financing activities for the three months ended March 31, 2012 was $389,581, as compared to $1,319,841 for the three months ended March 31, 2011. Cash provided by financing activities for the three months ended March 31, 2012 was primarily the result of increase in due to related parties of $326,061.

As of March 31, 2012, we had cash of $9,386,584. Our total current assets were $65,028,677, and our total current liabilities were $19,188,340, which resulted in a net working capital of $45,840,337.

Capital Resources

We finance our ongoing operating activities by using funds from our operations and external credit or financing arrangements. We routinely monitor current and expected operational requirements and financial market conditions to evaluate the use of available financing sources. We secured $63,520 in short-term loans from a third-party individual during the three months ended March 31, 2012. Considering our existing working capital position and our ability to access debt funding sources, we believe that our operations and borrowing resources are sufficient to provide for our current and foreseeable capital requirements to support our ongoing operations for at least next twelve months.

Contractual Obligations and Off-Balance Sheet Arrangements

Contractual Obligations

	Payments Due by Period
Contractual Obligations	Total		Less than 1 year		1 – 3 years		3 – 5 years		More than 5 years
R&D Project Obligation	$	1,270,382	$	1,270,382	$	-	$	-	$	-
Operating Lease Obligations		376,415		81,568		178,897		115,950		-
Government Grant Obligation		633,600		633,600		-		-		-
Total	$	2,280,397	$	1,985,550	$	178,897	$	115,950	$	-

In addition to the contractual obligations listed above, we have a future registered capital commitment related to our subsidiaries Skystar Kunshan and Skystar Jingzhou.

Skystar Kunshan is located in Kunshan, Jiangsu province, China. Skystar Kunshan has a registered capital of $15,000,000, of which we invested $2,250,000 in cash. The remaining $12,750,000 of capital was originally required to be invested prior to May 7, 2012. With the government’s approval, this deadline to invest was extended and we are not required to make this capital investment immediately. As of the date of this report, we have not received the notice from the government for a new due date. In 2011, the asset acquisition of Kunshan facility was completed. We are in the process of getting the government’s approval to transfer the assets purchased to satisfy some of our registered capital commitment. As of the date of this report, we have not received the approval.

Skystar Jingzhou is located in Jingzhou, Hubei Province, China. Skystar Jingzhou has a registered capital of approximately $4.1 million (RMB 26,000,000), of which approximately $3.7 million (RMB 23,480,000) has been paid. As of March 31, 2012, Skystar Jingzhou has remaining registered capital of $399,168 (RMB 2,520,000) required to be invested. As of the date of this report, the Company has not made this investment. Skystar Jingzhou is currently in the process of getting the government's approval and will fulfill the requirement of remaining capital of $399,168 (RMB 2,520,000) thereafter. The company expects the process will be completed by the end of the 2nd quarter of 2012.

Off-Balance Sheet Arrangements

We do not have any outstanding financial guarantees or commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders’ equity or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity, or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk, or credit support to us or engages in leasing, hedging, or research and development services with us.

Exchange Rate

The Company’s operating subsidiaries in China maintain their books and records in Renminbi (“RMB”), the currency of China. In general, for consolidation purposes, we translate the subsidiaries’ assets and liabilities into US Dollars using the applicable exchange rates prevailing at the balance sheet date, and the statement of income is translated at average exchange rates during the reporting period. Adjustments resulting from the translation of the financial statements of the Company’s Chinese subsidiaries are recorded as accumulated other comprehensive income.

The exchange rates used to translate amounts in RMB into US Dollar for the purposes of preparing the consolidated financial statements or otherwise stated in this MD&A were as follows:

	March 31, 2011	December 31, 2011	March 31, 2012
Assets and liabilities	1 RMB = 0.15270 USD	1 RMB = 0.15740 USD	1 RMB = 0.15840 USD
Statements of operations and cash flows for the period/year ended	1 RMB = 0.15218 USD	1 RMB = 0.15496 USD	1 RMB = 0.15880 USD

Inflation

China's inflation averaged 3.8 percent in the first quarter as food prices remained volatile, which suggested that inflation would not cool sharply in coming months. However, inflation now is well below the levels of last year and remains below the government’s official target of 4 percent. Growth, rather than inflation, is the main economic concern for Chinese government. Growth in China has softened markedly in the past few months as the tightening measures taken by the government last year have dampened domestic activity. For the three months ended March 31, 2012, we were able to secure favorable pricing by prepaying for major components to certain suppliers to lock in prices ahead of time. As a result, we did not experience as much cost pressure as evidenced in the spot market prices of raw materials. To take precautions to minimize the negative impact of cost increases that erode our profit margin, we will continue the practice of prepayments to suppliers through the rest of the year.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer (the “Certifying Officers”), performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), which are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to our management, to allow timely decisions regarding required disclosure.

Based on the evaluation, the Certifying Officers concluded that, as of March 31, 2012, our disclosure controls and procedures were ineffective due to an ongoing material weakness related to the lack of accounting personnel with an appropriate level of knowledge, experience, and training in the application of U.S. GAAP. We have initiated a plan and are taking steps to implement the following measures to remediate this material weakness:

1.	Continue to recruit qualified accounting and finance personnel who have adequate U.S. GAAP experience and knowledge and finish the reorganization of accounting and finance department and the realignment of responsibilities among accounting and finance staff.
2.	Continue to standardize accounting processes in each subsidiary, provide accounting and finance staff with adequate training on accounting principles and internal control procedures and increase supervision and review over daily accounting operation and period-end closing.

We intend to implement these steps during the first half of 2012 and will conduct quarterly measurements and assessments of the Company’s financial reporting systems, as a whole.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company is involved in legal matters arising in the ordinary course of business. Management currently is not aware of any legal matters or pending litigation that would have a significant effect on the Company’s consolidated financial statements as of March 31, 2012.

Other than the above described legal proceedings, the Company is not aware of any other legal matters in which any director, officer, or any owner of record or beneficial owner of more than five percent of any class of voting securities of the Company, or any affiliate of any such director, officer, affiliate of the Company, or security holder, is a party adverse to the Company or has a material adverse interest to the Company. No provision has been made in the consolidated financial statements for the above contingencies.

ITEM 6. EXHIBITS

Exh. No.	Description
3.1		Articles of Incorporation, as amended (2)

3.2		Bylaws, as amended (1)

31.1		Certifications of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

31.2		Certifications of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *

32.1		Certifications of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *

32.2		Certifications of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *

101.INS**		XBRL Instance Document

101.SCH**		XBRL Taxonomy Extension Schema

101.CAL**		XBRL Taxonomy Extension Calculation Linkbase

101.DEF**		XBRL Taxonomy Extension Definition Linkbase

101.LAB**		XBRL Taxonomy Extension Label Linkbase

101.PRE**		XBRL Taxonomy Extension Presentation Linkbase

*	Filed herewith.

**	In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed.”

(1)	Incorporated by reference from the Registrant’s Current Report on Form 8-K filed on July 15, 2008.

(2)	Incorporated by reference from Registrant’s Quarter Report on Form 10-Q filed on November 15, 2010.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SKYSTAR BIO-PHARMACEUTICAL COMPANY

May 15, 2012	By:	/s/ Weibing Lu
		Weibing Lu
		Chief Executive Officer
		(Principal Executive Officer)


	By:	/s/ Bing Mei
		Bing Mei
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EX-31.1 2 v312439_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Weibing Lu, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weakness in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2012	/s/ Weibing Lu
	Weibing Lu, Chief Executive Officer

EX-31.2 3 v312439_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bing Mei, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Skystar Bio-Pharmaceutical Company;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 15, 2012	/s/ Bing Mei
	Bing Mei, Chief Financial Officer

EX-32.1 4 v312439_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Skystar Bio-Pharmaceutical Company, (the “Company”) on Form 10-Q for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Weibing Lu, Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13 (a) or 15 (d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated.

/s/ Weibing Lu

Weibing Lu

Chief Executive Officer

May 15, 2012

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 v312439_ex32-2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Skystar Bio-Pharmaceutical Company, (the “Company”) on Form 10-Q for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bing Mei, Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13 (a) or 15 (d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated.

/s/ Bing Mei

Bing Mei

Chief Financial Officer

May 15, 2012

GRAPHIC 6 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`H`"+`P$1``(1`0,1`?_$`-T```$#!0$!`0`````` M``````D'"`H#!`4&"P(!``$``@(#`0$!````````````!@<%"`,$"0$"`!`` M`0,#`@4"`P0%!0H&$P```0(#!!$%!@`'(1(3"`DQ05$B%&&1,B-Q@5(5"J'! M0C,6L=&")#0UU1@X&N%BPK.%=O!RHM)COZN.M%@>&R$><].8.,#X[W?()M+V-6[%IVY#,Z4,MDR(\-FVM]20LM)J M0J@4$G]FO$G11;+4_=2%(^BJ`#6NLF=.4Y<4?BE`X&_XA3M<;45.XUF:NJA* MT%<1*J)*E``?*.'#1RQTXJ>`.)!'$(2">OM*PM1>7*>45C_$,]J]#3&,P)IP M!@IH3]VLQZ=U8QQP[(R?ZA;=]L12_P!X8[7?Z.)Y8KXU@)33^_KX_@&K^TJ/ M?]0M!]L1;+_B&.V`K53%LO3Q]/HDT'Z/E]-??\!5*0)SG*(.I_,93I?4$+^& M>$>/]X7[8?\`Z7R__P!23_WFO1H&I6>$3,8?]1K7VX\_[PMVP'F/]E M,$3V?\`E2VC[QI^4P<)LEU@R,3L\Z[RD2@& M^I'AM./$%LFJ>HEOU^.@VZ:2J::N2SO(]<-VT=3F+G;U5L\DS]$X;%EOGX[< ML1RJ^XM,QW*%RK'<9=M?<9A)Z:G8CRV7"B@55/,@\=%!Z?5"J(.XXP!7#KY1 M4M4IAQ0XD]L:TY_$*=LS8HYC67*-?1$))2/@>;E]=8J+I[4D2`B,J/S#T:$< M3:QQ3WQ0/\0OVQ$\,9S`?8(2?[PU(?Y>57V3&C_J,:/^\CW_`+PMVU<*XWEU M/4DPTFU4L\7LG$JG\PE$D26OXH]N?Q#/:L$\,9S#U'_`)FD?'X)U^'3:J1B!Z(^ M'?S"6\I^F#C%_8?X@7M5OM]M-F-IRB&NZ3H<%AR3%1R)D2GNFAOY4ESFYB". M'OK1KM&*H6RMR?$((M+]5*;5M8FE004@[X.QC]ZB97:+-DL):EV^[VR%/BH4 MVILI;F-(?:45D`%2FW!4?'02XCE*+>P&+)45-I9E7ZS,)$!F:KFC%Y7X" M4*J.7CQUFLMK7>*D!L3!.68@*UWJYJP4BECX%`;,(`AM]W.;6>7+;:Y;']PK M%GQC>N(W)F8'=DJCM!$L(4ML1%J/(CJFE!0J/\FG'0Z>>TXENH6G[LB2 M*JZBU94ZWX:1E15VDSGW[X`'W+=L^Y/;-N1/P#<.SR83,=1;LM\4A?T%V@-D MK;?CO\B6RHMJ'-0GCIS6BNHJ^D2$\/,3F.^*YZNL%WH:SEJ24MXREA/*$%;1 M$10J"5`D!#GRJ0HFG*4D5]=2JJ)M2"M,BD"<+NI-=3S*BO#M,723'!K^6$@? M-P^/IK1Y+7V4^81H?B%7O7YXQRRE2U%)!23P(X#[J:VD4=.M`4H)G+=$@R^H MM@NXK.^//_9ZUUD31TZ#Q`))[H^UNA0DG`QD+?&3)>4TI*:/U3`6-XH'2W@W5 M9E,]"3#S"^CHNHY'!_[P?('*H5I0Z;5E#;E(TE?QHY8SQ$XJAKFI?I[NM!F% MER1WRA&6U*7SJ*"VE2B$)`HD\OK3[174@MII#TD)2!+8(T34@MI!2,LXJTUZ M$HW",?/3N^7FCYRM_LI^[4G*F^PCS",0>?3BE:@>\QZ;CLD^B4CW`2*5K_/K MUQVF;9P2@*[A&"IKJD?"%+GOG%1WZ9O@&F'$(4%+)`YE"H3R-`)/4<4HT"?? M4`:UGF%*R.&1C=M-/<+@L(FM0.\F#=>/+L*Q<8\CN^[DU1\:VCQ^MZL%GO24 ML/7=R$5.,%AIX(*RXXR:`<3[:`-05;=P6:%@3=WC=O)]$66Z-BVR^)XG#9V3O%P:QC'YBF>G-::AE,1M1025!E' M3!!]2-*^[Z;724_/4)K43[YQ8S2?4Y%UJTTS;JA(B?Q''&4CCB(D_?5M5IU4 M?Y'U_P`/MR\W4_[6O#2\Y+D_Z=/S=-2D\0:ZLY_\ZTX[OEBEG5!Q+)K@8Z9-W?6Q M^5Q)0I[F=((IQII1_P!ZTW6K4VI3K3I`D?AE(YB1._&+`4EVM_4$)0XE+3K8 MGA\4^+#;+=`'>XWM:W%[8=RKSMWGMLFQHT68I=COJF5FU7>W%:U-O1YI`:4M M:`"`#Z'3-LEY:K*%:G%R<"#).<^R%5U)TVUIM*E(^]*DDB8`V=DX0.1`;92M MQB4PL(2%=%PK0ZYPXA/#E)KZ<=?EW!\?JVTJ\I]T*.A2Q4RYPX#Y_=&-:<6CL/S_8W>/(=VK'9I=WP'.[G/N+MS@0WUM6F1+5UBW*#:5A++843S4X:> M.BM34*Z!#2UCF(!S,4FZP=.*ZBO2WTI64D!7T<,28"PXTMI2(2GD.NH)=HTA M?($NTH%K(`"Q\-'S54S5H-0@XSE+VSA,5='6"5,EDA0&?=%-;=.8-)6ZIL#J M`Y19CMU2792PE"BU%;ZBT\_I5->97ZJZT;F?#T1J`J9QP[HV[;; M%7"J32I3/'.4&8\>OCZ@YM`E]RG<06\6V9Q-ENY1[;=F_IE9"W%Y72VT'B@? M/RBE`:UTHKC?'G3RF$_>%4LSE%BK%H)FST*;K4*)2`!(I`SQS\D)%Y"^^ZY= MP61IVMVJ;&+[`8(\W:,8L%K)88EIMR4L)?G)86AMT.N!2O0_W=$MDMG`TFH= M^)U>0>H&^(0OCQIZZ\U;;T-4`>XIDDB4NR/GI#4U#]\:2HD)*@9SS^*.C1T1Z M\Q_S)_-35;^/&4O^9]D=+9GAE_\`SN'_`&IS@5'F?'+V6[D$@`=!@`\/6I]/ MAHLT'+Q:.^*]?F`;7X!6'U8@312ZJWMMIHP^GEZ;ZB""T17U%2#Q]]6FH%)Y M`2X9"6$KWC.06W);#<7[5?;%(9FVZ[1'S'6W)8Y ME-(44?,XA9'+3@!J!NEB3<0I3:9E.(\L&]@U:;(^T6/A<49$=T24NW_=':CR MS[/,=O\`O>R+5O=B$%A%@R=NC4F:J(R&VG"^0%K*N7U]*<-*>M?>L+Y0LE!G M@/T3&,/IIIKJ-3@.24XD9;?3`M.YGQ@]T/;KD%SB2L0G9_A8=<19+S8HC\J2 MTRIPAE3ZF65J/320#\=%FG-2,/`*J7$@=L#UXZ355N'$&%`'++WPVS#.T/N+ MS^YMV*S[/YB9Z@A*%RH$]AI:N;D0MP+CH%%*('V:.*C6&GVV.`K;+B1+(X^8 M0(T_3*X.7";K*^`F8RP'G@D.UGA2S6W0?[9]T6[%CVFQ5AA-Q?M*)\8WU+#? MS.,*BOK#O4('MPT`7/47CP6;6#S29@I!R&>,.:S].+;;6TUE2VDJ2,09><]T M$'V3WZ\4/8FJ&YB[L3,\P=6VQ-R=41NX3B['('7"GB\EA:U)J0D#CH(N-'J* MX?"XIS@@JL^HM(V>Z!)Y0"<#A\T'=[?.ZS:#NBQ)66;292U+A6P%$V)\C4B/ MRIJ0XTOG<2A#=>(X#2@O%CK&K@`X%!7SQ:73FM+-5VXFD<;6T!LF)><"&5=S MODT[&L4OUVV:W.GP8OL@]2 MI7RY9@B1WX$B%3U`U/I6I045!:6[MGLGY(#]E7:!XZ.\2X7*_=O.\D';/*IO M5=@X^ZY&C05372`T.B^[0,@GB$^FCZ@N-UM;2J>I2I*YY$S]4X05PH-.W1?' M0ALJE*8^>![[U>*#NFVC^JN-ML$//#] M&IIK5SC>#BI'RP$W/IFY7DKIVB1+9+WPT2V=N/#?.`UKHI?W:Y(0VZ69YX>TP8[M(\/&38 M]T=^^[.0SB."8I'1=Y&).I2B5/:91]0EF25`$!0%""::';CJ]5>KP5.H*F,A MZ8>^G>EC.G*%-=7IX2DDS/RGA#4O(7Y`KKO3YK1551= M+A4OB)(QPG#KO'Z2>\C8^I)KEUM/K_X9/'].@K625IMPG]&9EYH?71O_`!BG M(RFGUQT>/?\`Z%_FU5WZW[U[(Z7;/W+VP*3S/_F=E6X]>'Y48\/M/_#HOT%^ MV([X0G7\SH5C<#$"AI(^E0D^G1`_D`U:&G_4I[HYHUW^)N_^X8^1BGJ.M/.$ M1PTLU-`$K0`6ZJ]:D^FMEMPH/#]J,AIG'AS&\V\9POO;+O!>]DM]MN\TLLA^ M$8MVA-W/Z8J0]/A2)++/1J".9'(34>FEWJO3Z*TJ>4))"22=TH=716^5/XP* M91/!S$CR1T<]O9MNW$V\Q7*)L9ER%?;!:Y[;$QIMZBY$5MU1*%\R31:M5PO- M2NVUBF*=R6)&&W='22FL%KN-H:J*H!7P[<89QY"=_(G:5VZY9N/CMGA-Y`Q# MZ3N`W[N5RR#E.&K.6W3U%:VTO%`)X92EO[(HMJ/JQ=J]YRA944-E68PRV0WA0MJD*=>"^H MV25=0J4M=*5JNH(K3X:EN"C_`."GS0OT+N]4]XCG*Q.\Q($\#UWR)G)]^H4> MZS&+:<'NERB6OJWV19CIX_>/P M58YZIRW]D!1WSES;WOMN;=KY)-R?8G3K M=4,99YQ=BB7INKI>&'"D)P`PB&`(:2E1<<6XZ M@)6X\KYNJMP$J7SFI54IU9BG9\.R&>R.;EWNUQJZE;JU'EE-%)(K0 M$5-:^A_OZ^5O<"BF,=-0DL*J%_2E.'<^/S_;(V/_`.MMM_YY.A'5[O,M@&Y1 M_JP]NC*C^+L)W*'KCH\>_P#T+_R=5?V_O7LCI?L_K$SE$"YC_)&S[]%/'_``=6JMZ4EA,P/HQS M9K/\1<_GF*;3")'U#:B:EAQ2>/`J2`145^8CVUI(44W!))^`'+9&TBJ52K"\ MT',;#W[X4S9O#+SN7N7@F%V-AH,>,&T))]M:.NW MDU%J=33R0>2KZ.&SLE#+Z466MN&H354W$BGY@)*9@#?E*)K>^'DEV3["]JMN MMK,VDOY'N7:,.L;,C'+64K=2XS%92\'E-FB5)Y^''VU5VW:.K+A4N5#H*Y93 MQ]<7PO752UV2STUI2I/B&P`K'.6^$'=[O^VWRP;,Y!LHU)7B^;7%F0]8[5=5 M!MX7%IE:XR4.!92HAQ-*#XZ)+'055FN*5D*#:9=FV!75.I+5U&L?@Z/@34%' M"92!F!CB.^(HWZB8UQB`_ENQW%("5H(^ M!U8BV7NF6PAU2PN8D)F>>W&*0:FTG5Z8K%I>07$E6!4)Y]\-_++3)Y'@'E+H MH*X*!!H0*UI0?=J1J*=YU/-02$G<90/)>!M(?SG?)YP!;AVS MOS95PY2$QW!RJ!]0D`4TBM:)2FL:4D`*X]G?%M>C;C3VFJA3@"E!!D2)D&1@ M)6]R4HWCW-+:0@#-[V3R)"*#]X/\_I3@?Y=-RTT;;UF:E(*E%7-7J=K+[5!2 ME*"5G`DF0&0$:))FL-MI3S".X/QOA((]".1((^=2R0!ZZDVWV*9KDK7(C'.! MVT:;K[BKF-A2J<*E+,3@U7BR[)6'9C7=?O\`@8UM1A;PO5E-T28Z;F_&(>8? M;#E!SA:?;UX4TK]7UXJ%%ND^EV?-%P.E-+3:>9"ZM"$F6T#=!>,I\\W;)B6X M<7"[59[O=<9B2&[;+RJ.$"'#+9Z(*FPHUZ:0#S<10Z5CVCZJH1SBFQD>&PI*9J\PF0CJK* MT-%02MNG&NI_1]*NAJ^2L$.!7EELQ@'ZPUC6HK:30G`M#+?(SRB*"F4\J,PA M3M"&T\Z4*((^4*0%VK#V]0`!+L@02/_FZUC@:<5/I` M'ZSH+UFE(M0D`#Q'U0\NC`'XRW_1_K1T>/F^)_S+3U]ZTU5[#B_>O[,=(.)7 M#F?V+VP*GS.-A79=N,@DT*8J*CUH5'C^G19H+]K1WPANO^%`KNB!6Q_DJ!\& MZ?=PU:6D=+;*9#ZL(N#&8&$]T5@UE?KB_JJID9TX498F$0PK,C.+:#CJ%\Q0MM!3SI<]#3XZQW^Q,(HSRA]Z!G(3C9T9KJX:>N2'%)2IE2YF M:E`">$2.MJ=W]E_*_LDK9O=Q=OQSN6QJP/-6&_O(CQG+S*:84RVTB0LI+A<= M1\PX\=*ZG\5;WP5E7("LMWD]@BT3M+9.H%K\0I0152"I)D=Q. MW+.)N$[DV6=9Y,*4XQ;Y+T9P1+A&;=Y&7V99'1<2XT>;@:\=.BCU/1?AZ&U< M$Y9SBK^L]/U]KK%-,M$M`YR]T&<\"S;CN9[^]!+BD1=NKT$NAI90]]1%<5TT MK2"GJ)X\/LTA=57%%5V9@EWCZ\?`W*;/[K5[:3%7>6[>@R"PW]2II2@Z!Z`> M^@R]76H>K2W2F9/;LAY=+]/T-NM#KEX)29F4P,_+&O\`D(\@2=XEM[+["\^* M=OV($6>V6^VMF!^]WH'*V5.I:4GKL%*2>:AKJ5L-BY_WU625D8X#T;8']=ZK MIZ%PLT!2$#MEZH%(Q&CH85SH!7S%8:*4%IU1/S==LI/6YONJ7@L\`5L)@_?B4S^V[Z;6;T=G6;/L7"!<\?F3L8@R5I7]),, M=7TZ8K+E`E"5\`$Z5]UMYL]=X]B:@93!P2`.[&+3Z(KOXCMHIG53,E"8Q/R$ M`ZWIVXNFTF[F;[>W6$[%FXY?KA#>:6VI'Y"93@86T#PY0R$_?H^H;F'&4$`` MF4\^'>>/Y(=[QMD`:BF8VOT_XCZ"/OT'ZS/_:P/Y1_JP^NC"?^Y,N[ M20/,8Z/'^A_Y]5=^M^\_V8Z-_5_/1LA7*CE)200%>]5#@..K M--J#;"2LR$HYQ5#+KEQ%#<1E MYY+!?HE+D@LMK"`D*K\Q`^.HZY76VLVY_G.`+X<,#[H;73?1EVNUZ033E5*" MDDS2,SN)G$G'NAV4O/87XN8NWEE:E#(LMDLR,ON::\S3D[D4N+(<12@;YS[T M^&DI8JARLNW-;(4RAT$X[)]I^>+#]4*&XZ5M*46ULI06SQ2PPR,166(4HB,\ MIMWII0[),@IYDJ>=/.DK)J2E05PKZ`:L"]4N^#:Y(PP[(J15I:JRJH)F_P#6 M_3%%*UM.-)<;"^ANA4%-DR^D!@93S(B5GVLKVB\Q7;S.Q[?*R(M^X^#=. MWQ<@@,-M7"C+2D)E_4)45N%PH'!6DCO=SR1IR+>;O<%`2'(KB"CIT/%2`DT M5H(JKD:AX.J49@PZ]#]/J#2]J>H'4!`6E0&1S[IPT3+O"MVTS][;EOWD$B\J M:9NLS)IV.J56V2GDJ5*,4H22A3?/7A3B#HIH-45/A4T;))^+UPK&^DM!:KY4 M7>O;2FC7,\7TO0)GT0`?R9=]]XW$R:_=N>V;/]DMH,&G/V%BS65"+:],,-`B MNJD):4GG:6I-37UTVM+V)RK(KJ@`S0=H.9PCU/OIGTE&U3IW16F[U55<'.* M:B"<8LS+!(*'0I5:@*6$CWXDJ-!KVLXUJXF,6=_S&-VBMU$*,NNF3TMQ]T/$ M[&\]RC:/NFVGR'&.NJ1>[Y`@SX;`YE/17G^G\R$'F4A9/&H(T)ZB-O-"OF*' M'PX8'/S0^?R^N%VXEAP'@YB@,#V09WS1=BF1S7K5W2;:X],=1<;1&DYQ"@Q5 M/J$B4PAY4EQ#7YB^4D@FAI[Z7-AO;2B:92_O4KE+L&$X-^MG3Z]+=5=*:E)I M)CXN).T'83/T1&N7$D*??6I"WF8[265+4`CZ5Y!/40Z%$=):55K736I*ZG+2 M6UJ^]`Q$CZ\HIU4)73H4PZ%)="I$2._?#M/'VDI[R=D4JHE7]K[;U'I7U_1JM4CQ3_`.H]D=(.!7#D?V&?DXOEVPS#OMV:P;>K8K)<`SW.QMOC M$P-JG9040W&X]#7TFN-(!/V$ZFM+5E52$*1,JEW0']4+%2U]&H5(GA$>.P^( M;L,E2XS#_>U)?;4IOFC1UV0)EK4L#E"H\ZJ"X33AZ:857JB^(9DT@E`&&.SO MA#Z>Z::1KW4AX)#H..&W]$'G[.NP+M4[;+7#NNT=MM&2W22B/*EY=+<8NL;\`$DF4_)EZ8=' MO=L[M_OSMQ>]O]T;7%GXQ/"S)#SC3'0:`)9=;=*5%AQOV-#30W8:^ZT%1Q)) M)*O/V05]1-(V:^6_P]0$AHH()W`C$Q&>W&\0_8;$SN[QHO>'+P%MR0OJXQ)N M5JDL0BDTZ/6DOH4$I!('RC3R&H]0*HFSRU2PW8^GUQ3_`/RRT:FN=I@Z)3(C M5#X?NPL_U??`RL#@O_';(1S_`-+E*))04^GIK;;U;J%+A0&5S`WI]\0=5TET M.A:BNJ3,'*?T>SR1\/AZ[&W51VVN]AA0+K:0MR?8^D:FO*I1E!()`I6HU#W/ M4]X?414!24>2\?'9?L;VE81,8V9RA.>1 MLD>2[=,D+YDJ<4: MU]TQTX_=%OU%2EJ:LR?1E#6'?#YV,%NO^N['1Q)HN595G[>/U/IH@_BS4&QI M7H]\`/\`E?I+_P#0;\X]T8]/B`[%>9)7WR0"`>;C(LY',FI22!)]C\136/\` MBR_BG(#:O1[XSTO3?1Q6*?\`$&I'M^:":=AWBW[-MKLK:W,QC<-K>[)+86C; MYLJ=#DL6QY))$AF(U(6T"#Q%!I?7[55R6TIM^85W[\HL+TIZ>Z7TZZERE>2\ MYQE4QVRPGV0;#(;+9LBL\W&KK:&+E9)3"X4B))::=BO,+;+92EMT%OE2CT^& M@FW7"K-274&2I3F.^'CJBVT=SI#2U3:33'+#;(RB/GW>^)'L2NV23LC?W=>V M-FWA_P"KN-JASX2[4Y(=<25KZ+CH2SZ5*2:<=-.S:HNW!P\'$D"4XJ_K#I#I M!%-XB0#Q))PVS]T(OV[^,SLUP#?/;W/<2[QDY/D5ANT5=@L#*K0K]X2$+3RM MJ2W+"U54FE..M*]7^L?24U(DD3EW_HC'TXT39:&\H6V`0F7DQB4G]"Y_Z952D]EFY M*4K6VKIL$+;4I"D@D`\JD$*'ZM'NAVF:JM`)24^?;%:>OUWJ*&@6:=2IRV$C M9V&(&EM4\WT9$&]W"'*8+?*693Z*J%%!2E2$,)!)-`::$K_`*19=H'"4IP$\A[(?'3KK-7VU]*;FI1) MX0"22<"9YF)&7D^[L;O(["6-UMB;NIN)FKD+ZV]VR04O18\M@?4,=>,7.DIM M;M"DT]-+K2MF;3'8<8A=7BX7 M;*4JNF19+<+KW#J"GIHAI;723$@GBEC,#/S1 MM?QH^M$GR[QJQ.*O?'H1[FL`O3)W2"DDPVYLA+SIYA1+9#O!P^VH*]VNDQ^% M'F$?5KN]-4W%OF..#&?TE;/+$N3P3O[EX!LYFV2;NWBXX]@,F:P<4&;7!V/% M992E1YV%3PT"CEI2A]M([4]`RF80`"3LD(Z`=++\RS;4("EK2$C,DQ(>Q;-+ M!F<(77&,BM.0VY*BA<^SSH\V*%^[1DJ:!50M M/"L3V$1H.3[IX2+C-Q:'F.-LY&ZQ)CLVE5Y@IN7U:FE)0@12^'DN=2E!2M=; MU'1ME22LCBG"MU1K.N"U,TJ5\@#/'.(!WD7L>^N.=TFX[VZSV3)CS;S)F+B+M;CZC'1#>*@%,(1Z'@!JP6E;93NTH2J4N'LBDO56]U#UTX:A3B6B9R M"B,9=\,C;C7GJ"DR>Z%`$'ZZ1R_-0\!UJ4(T7?@E&B$O475`R<=_\2O?% MVF)=$*25.S4IJ`29#H`]ZG\SB.&L/X'1^&.*?1`Y_$%>#Q!2^+O5#V.QSN`W M7VG[C-M+9M_D=YFF_7R%"NMA^NE*M4F&7PE31C\RD]15>)`TO[SIBG>0ZM'+ M*>':$SBP70O6=[:O*&EO*\,%SDHDYRWDQ*L\FODIA=IVTUDL%B<:5NYF]@;> M@VUEY*OWI74M MZ@T_QTBIU/$)R&0D<>4@CK(/H5E)K^C2HU/I]RF*E+&&,H:71G5%\>O MC8JN/@(3*95GQ=\=&[K'UY?_`(/S^GO^&GW:47AQ_P#;*.C?CWI3X?\`DN+R MSE`G_,X2SV6[DJ2>;\N/^+[%?9311T\I@S5HX5J..V7NA!]?5\%`LD`CMB!" MU_5I*!1:N5=0?Z5!3A\*ZM>P\LTR$;`D1SO=J!XM?PI`XCA%\AYI,&?&6V77 M7(RT`D`\O,"%DU^ST/Q&M2MIQ4TRV5$@*&8CQVH4W4L+3L69^B)#/B\R&V]R M/:CNWVC91,:NL^#:YE]Q2%<70XAAQEM13T&5565=0`"E!I0FV-6>XI<;6LIY M@)XI93[`(M/I^YHO5B%#4!'!P2PG/TDB`(Y=BDW"/?L`D[N/#?+?28<)V,Q)IF_KF7IY45-[$*K[D2,M_IJ672U3T]#7T MTI+S?GGEJHVYE15Y8LWISIUIRGMXN5R*4O)3.1`'LBY\A?D2?W:=5LIL#"4ED.NOLA94A7(3S#U&LUETD_7'GU$R,\F`';];$;B]N&X]VV]SFU3[6_:I3S<*2^RXEBX0V_F1)C+(( M<0I)J*5%-$5/=C>&@`2D]F$*O7^EG--)XFT`I[A"-/KD,IZB7U2&5CF6$I55 M)K053P52JM%?A6_#GXMF^%I9%T%56!M\2$]L%W\->QL3-=\[[NQE\1",2VGM MDB^JFOT$9J8ALOA0D5Y4%*!Z'WTM+ZX$*-"@F>!P.<_3*+/Z/I**DI0NE2GA MQQ``,^^4X:1W_;[W;N&[GMPLJ7/+MBM=UE6?'$(HMF+$MSOTR"E0'$J0D'AZ MUU/Z;HPVVD2'%@298PH>I5[?37\I+KA`<&'$J6W9.&3N?4+H6U46CF+ZD&G5 M!%#S`_`>GIIMHN?*IDH"$$!.V<_7`&\&WJ,5"L%#9LAX/C_^?O&V.!)^7+;< M>;A4_G(''2JUV4*MQJ0!Q@G#9B(??1BK"KI3_`@DJ`RW&.CQTQ6E3_F3E_[C MF_NZJQSE;A^NG'2'@;E]$?LD_3EW0*'S0_[%NXP^)B?K^X&;VU=Q&$YRRIQ-ND3 M8MAO\9!3TY%OD.M,?F))HI-'"3\=+'4+"EESE_2D8>?2BKW[HL0+W=,9MX9#D=4YAEQF2KXD/,MA17EB!"5=I'B3W$CSE;O]XD1&V^ MVF#!=TE8]WRVR%.JV8^^(W1^@*;1 M#WBM0-#D@DS,C+<`>R$J\@OD%A;FL)V`V#0G%-AL22;:W$M_Y$BZNLM)8+R5 MH""8Y0*$*!!U[:[`Z\ZFXO@E6X98]AQ@9ZDZJ\:I2+"4>"F!A/MW&`]+:D5KPJ-Z1L^(>L1;+HD$M:7J0$@S;5GY8" M;OG'D.[O[H1UNAH?VVO;P6KC7EN#_*@^W(:\=-'3;JD4:2G.66S],5ZK%MC4 MM8XZ!(J(],:]A66Y1MYD5MS?$IJ[7?;-)CS8,VWEQEX28E%,\Y0I/,VH(-1Z M$ZA[U;A7516X,);-_EB:TEKJGT[5*"2GEDRQGM[HD:;8Y?M#Y<=G86W>Y2X& M*]T>'V;H6C(7$L1GKTZVQ1H4"DNO]3E'-55:'0B7UV%Q2FN$HE]:?L(A[U#= M)U$H$!&*BGZLMO?.!E9EXD^^VQ9PYAJ-JKED,-=P#%DRVV=)JUB,%CIO2@'/ MP_M5]1Z:W6=;LN4Q"U(!EV^^`)/1.]T->D!A8:GB98^Z"F;Q[>SO&!X\'L.6 M\VC=C=]I,+)YL9/*['DR6BE^*%!?SI92LBH/KJ!HJD7F[EX&:,!AV0QJBSJT MA;.`SF$S/%V]THC&&0XZ7)CJBJ1++CKZEE14XZXLN*<5\U"HJ/KIP45'X8)6 MW,DB6.X]T5*U97JN-X4[(2XMF6<6QJ:CT*N;T^)X<=2;RBD%M)G(?/$:^]PT MP;.!,L(>%X_$D=XNQX^&76Y/J/7K(_FT":SYGX,LK^6$/?HH5(NS',R"@?3' M1XYA6M>'[G_Y'+_=U5V1R_\`5CI;XIF69_8MW;`G_-%_L6[CG]D15#](5[Z8 M&@/VY/D]<5SZ_P#^'J\OJB!2T*04?X)^](.K,-_0'='-RK_Q%S^>8^-_C`^T M?W=??U#&13+CHFC8(W#$\?N63YKB-@LS+K]QN>0V<1D,GE6HMRVEN(KZ\:`< M-+G494EE\C,(5+S0?])JE]J\AN9D5B<=+#86PN6/9;;:U7%L,W&#AUBCR&7/ MQ(=1`9*P3P4:U^.JZ7*IJ/%$@XSCJAHRQTU59&7ZA,YB!Z>8RQY_=NSC,U8$ MF8_<(92[VMQQNUI2I<@.(0H+*.0?;Z:(=)A*J])>5\,P?T0O^M^GEUEC M=10-GE(3*8[`8@:1(4BR$J!!*OIEK%$^I!3 M[^^DMKJ2KXA(SXAZQ%L^CBTLZ6?6X0`6U#UP&??-75W=W'D4/*O,;[S&O"HG MO#A['3.T\VXBG05C[LI[XKC=$.)U-5(.2C/SY0G"+HW&94V$`5'*F0NB4`JX M"@40"-%+M(PL%TD`2.T3G$,=*O5;#E0@$R5//=C#PO'[8=R;YW:[8_\`VN;N M?[ZB7JUO7.=`6ZN*FW"8RN2EWI@L`K;2>!-2-)?5R0AU7`1MBP/0>Y.TU=X1 M]+A2%`2*3O$=%R"5MQ+.F>I*7E089D!:>52I*6`B2KEIP"E^VJWUE8[3U/** MI3.S$9[XZ/L@.%/[7VU7ZR\@?=H-UM_@:O+ZH??1W_`!5G^CZXZ.?^ MA_Y]5;V__)[(Z+[/W+VP*;S/$'LLW(`_I-,T_72FC?0#R17),\,/7"3Z_`>` M6._U1`?BMK^E;/MR5/'5I0!4T+249A&R.;E2!XYV?_$,7*8_48=6I],='36. MJHU(6!4)``K55-81<6*%E;3Y`)&$^R-RG"%O-LJ!/&980<+Q&]F$C+LYC]R6 M[;#6.;58!'$Z%<+V@1(MTE1T"W'<:Y6>0JU+G]1$>T,& M,X6`>KR\I92$\.4G093Z,J;BKB3M^@S,8O#:8LQNWSV7VWXCH6AWKLR!1=6U_HX:FVNG-?32?84H<.1^6R`1W M\TM/U>6SNW7"_N)N6\F891M M9=,-%ENO"3&^L>6\EM82`$I2I7J*5TQ]-=0Z5EDP--PLO; M?ME<,ZS".T8\O)W@%JF/M)+:I,>2X"%-.%-?D((T.UEKN%T/QJ,C$M2ZPTAI M.2VFT!\=D?<:_B/,UD9&$Y!L'#3BP=<"9,&XK-Q2R3S$E#J4`'O73ZM M&H&7J-/%](RBE.L],U^D;H:)\29EAWP@Z%](2F'%E;U>8D`D45[U'H`3K;J* M3B4:A$^!6,!KAXVE*.^'D^/O_;$V-_ZW6W_GD:#-7J!MI1M$_5#ZZ._M=.?Y M0CHY?Z'_`)]5?^O^]?V(Z*_5_PULIO[:6A0("?A$CAM@?734](Z`V?A2!M]?;%> M.^Y!>BRH3\ZWOQG`Z5Q)LAL.+%>4CD4VI)%>''AJ,?TXS=CQ*EB9[()+?JVK MI%A%*2%`;"8)5VD^4WN([8;W:F)F7SLWPAB3'87CEY>6ZB#")Y'2PMQ3C@*6 MO3C0D:%K_P!,VWFN)&[9A#5Z>=7[_17X-59(8V3)EZXFP]M'X6YH72$T^EUR!./!UAU*>*"*^XU6;46FGJ2O2TH&4_;'173'4BBN5G M4ZDIP$Y^2!0^4'RTPNW!;FSNS:X=YW*D-NMRYJ'PJ/CZ$K#57E(JI,@+5Z'V MTR])Z%6\P'W`6 MXY!'K\--BP:;11M*4=\LAMBI&J.I%1L%:\OFI49@[#&Y81N%EVW>5P6CQ01QBI5I/)2N0,MF<+9X_@E?>3L9T4+#`RVW`N*-2I0=;)">``IH7U>A(MA<$^ M(E4_-#;Z-+"[NQ3I^@"D^F.CKRL_%5/W-S?X-:?#XZJUQ*X_WR7^S'2?PS,M MLO!>V!>>7W&[[D_9ON'#L-MD7.7],VX(T9"G'UI;!6OD;0E2E$)2=%>F*]BE M?#JR0G/*$YUGLM;<:5;;*"I1$1;/'OX^;GO/-;W4WT@'"]A\4?,NZW2^IZ?I@+;;ICA`:;HH-!#CG,5J< M52A)*OF43[DZ9C3M!2M!IKZ$LDAERKBRM+HXBJ M2!Q^!_5J!KG''7YTQ3R>TRB,8J'J40A(H#RDG[ZZVZ>T- M+0*B9XU"9EE.,KUM34*#X61Q@$B<6ZGDK24K5RCXTXU'IJ40ERC`6F9`]L?( MM_AR'$GB(.0(CP>0-*#+R%N+"D*;("B4J]S45X>WPUKU5[JBG@*1(=AC<\34 ML:5UVM;JY)XBH9##/=%T^E5-7+TRXIUP?0/J[X!%W*Y5<,E[B=V^$57-;>/.THM(52K`-"V>/!7VZE_!U+*RS_N29]LX6CEM+"$H64\,MN<40 MXAQRCBE&@'&H^W[#PU[X1P9$QHK+C?T"GY>6+E+(VVZ^ MX-M\M*5\/;&.,TPY-&25=9/34Z#0-I)J:C6Q1K(>+3\BF4?):%0WS'R4NSVY MPH&W^<7C;/+;/N#B%Q7;\@L4IF5;WHCKD52I"'@ML.K:%'$\QXA8*:>N@K4U M"PZXOPR03*"S2VK;G8J]#;*PID_"09G`D=O9$BNV6_9GRX=OMN8N3\&T=WF) MVA2)LUH,-/W]4+Y4)=/Y?74M#:14T]![:6=D\?9J];E<96^>&,S+;ALVQ8?4 MU%9M8V-DVWA5?%(FXC*1V2.W"1@:':+V[;R;==^NV>W618;>XMSP_.HBY<@P M'4PUV]F0.65]2$%CEZ::GCH@U3J"W.V[X5*^*8&'9MW1[TLT'?*&^ME3/`EL M@DJ,@1/898G?'0-^G>].;C^[/IOZ/]=3FK]W"OIJNO$GBG_U/'_1X9>>+_>& M'RSBSO=DM=_MZX-R@1[E!>:4AZ');0\TZ%)*5)4A:5)(H=9&WS3'.4 M?KM2KJD\+R`H0#'RZ]MW.AVJUUZW+6VI()/$ M<<=VSOCP?%/W[`\RMBIR0.)Y9LM!S<>&LXU?9C\/&)1&#H5U`6>#A5CV M'W1]'BQ[\DUY-C+MQ]:/QC^CU4=9/XIL>U2?1[XR_P"GO7Y^J?,8PT_QB=\L M24&).P&0.NJ:0[U(X;?;*%%0',M"N5*P4FH]M;C.LK6$<+3J0D&68C7=Z':[ MIU4GF';WDRA7T+-/U_*H'7VK6="!\#J2K=,1C' M177$_O6%H3O$S[(KL^,_O=25+7VZY,XE(J4I8`72GJ'%KK3[-0M5K>F&U/DQ MC,GHAK)6QSS&"Z^(+M0[B]A\BWGD;E;97;$X^08M.A6I^YQTJ$J0_%D(;;*T M*)*>90!&@BZ7RGJ6`DF;H5/]$6>T5TWUM:=..4K[0#I2925/,;Y0,?=3QM=Y MN1[DY]?;=L9D,JWW7)[O+@RFHR0S(C/2W5M/-`T*6UI4"-3-GUPFC<2@*/*` MW;=L5XU1T@Z@5%Y55/LS9F,E3P[I0FA\8O>Z/_P)D@^WD/W?.HC1K_'%(OXE MN8>GUQC5T0UK<5I73TYY03C-4C/S1]'C*[W@.&Q&2#_R*/UC\6O@ZVMGVSYO MGC3>_+]K_B^&GP_G?^6/*?&3WMDFFPN15`J.9GE!/L`4*K76JG65O49!P^;Y MX]'0#7I$^`D=_P`T5T>,[OAH"OM\R4JX^C(*>7VXK/-K9_BVTAN2G?O?EVQI M5/0W6]/-"F%JPS$_=%=?C5[Y5L]/_5VR%/%)-$UJE/J/F50:CWM16UX?"Z.. M>,\,(AF>B^L342#+J%;#CYLH778;QU^1S`]P\8R_!-M<@P52+O`=ER$7),$+ MMZ'Q]8F2E#HY@6VU'D(^8:!-4WFF#!%.H$[Q%D.D/3'4%GN"7[LA2LIDSV?- M*)MF#;<6]JU8MD>18Q87*,I]D_3! M3LR^K**O,E#@;]2I))]A0"OWZD/#DXS,H^VVREHO'9#6-_.ZS9;MU3%D[I9? M;[`Y/="(,5QZLJ36E`W&35QSC_Q2-2]LMZW"93QA=7[4E$BY)IR1Q)(&?=#; M1Y3^TQ3B6D9)?76W&B[U6\?GNMD5H:+2P`#7T]CK=>H7VUX8F,YU)04"N-4B M%C<,)0L![X=B6=HIN^#N0_1[<6V0J%(N5PB.PWVWP:44EX`H)/H"..L(I*A1 MD`9DQ^.N;VL?=6%E+)PB7:Q?F;XMQIJ*BVA(VO,,?R3)\>S9,_'L1=D-7N M[183LF+%$1?(\X7DH(Z(4*!7'WU@-MJ2HS44F<1B->6\S*`CAGM$X63:??C; M'>O&$YAMUE<#),9<"Q]7&+25L/-<5B1S!(;&ODVZK3BA1*^V,R-:VRHFA[EA M$IY;HT%/=]L9*SN[;;6W-+3,RFT1W7KHRP^T]%@)CUZHFOMDI8*?UD:W&K'= M'Q,$B(>MUS8Z2E*VS17S=/@/MUOJLUQY?,1EY8'_P#,*T6RJ+:EHRW" M,OC'D0[35MM6[Z:W/K:D.N?@0A?3`//['0;=/Q>E-./8(6_#\XQO/,9M698K>F+IC]]@M M7"U264)*'HCR>9"N8"AJ-:X;>22A]1#@)^:"9O5UMJ*(/-K=CHSLQ)=R=;;MZ[A#7"C2"XM*:I=?2E'*'%4 M/'6VW97JD%$RHC.-AW6=(ZH!"0F!]E5!_70:VF7EJ1(RE'Y2RIHL'Z!B/QY/.P_? M3>G?+;3?;:21:\P9PI:?KMO#-HD)C*!3SEPAMP+2#6H]]%MM=#:$D?2VQ M7C7>FQ37)VY,ES%4Q,S&0V2C7[AN?W.;98$]>LR[&=L%VK'(IE715I9M3KKD M2(.9]39#:E&J4E0T0T[:'R53QEY(77\5UM*KA>:YVP2&4O?#?NYKNXVS[M/& M]NG+VVP=C#8UAOK5MR#'H<=AAN%=&EJ2]R):0V@*ZA(!X>FMAFC#;G,<5Q)F M-V`$8ZC6;[C"F_"%)*2)R],-4SW=/>]WMR[0MFK^W<]N.V7)[9:+-E6:6QQX M/W"&ZZRV\U,=9Y4I8<3P/,J@KJ4=%`VT7T@Q,CYX MDS]NG;!VU8AL;$PS;"QV6;@6762/%N$B.EF*)#@FEM29XYP!CNCQS?3QC[U3,6[>KU!>VI[CW MW++9,7NBWU#&KK-=,9QZ$I1Y(RAUZ@(H#34ZQ'#<8(9L3XU&<&[7-P6%W5R9OWN[9)UPNF9RU+5(BSKE$6]]'%EK M`=:0E3I'R$<-8UZK6+HEC"0@TI+$N\Z8\75I()&[LA@W:OL/W1=I\#),(RSM M%Q+=QV7=Y=R>SJX+B29
MM'MWW!8UM'O=VFVS:W*\UD&UX_$^<0.:PL%O- MR35)8X'%$"??LA9>Q;;+9;'^R7:K0+NAW_ M(C;MNL-L5\Q7;A3GU#<%JZL(>88<0&PAM2D*0#0>^C6C4Q3T99$B3VRSS]$! MM324=S2*M*3SF\?-#Z/#KW=28$C->TO*[NB]R,%NLYC#KM-D*'U%@;=>$%EE M$@I5R]%20`*TT'7.SM.+\0@RQB;9<0MMEHT^%>(U*I9IV[:4I(!GN&$1#E?XJX< M[EJF8I^0G=.Q;N2MNMK;?VWW+M^8G9C"9M>>7RUFU..-&4A;S+;T="!53Q-! M6GQUDLS%&EM3BB2\9SW>:-^IJ2AQ"FPH+)&!RB5=VU8K_8K9/;7%%7TWU^UX MM:FDW4U6B2T8S2DJ2X35?+6FEGJ%]::QQ2``)GT18C2=$E5L2^X5<2@-L.&Y MT4KU.'2I6GMS\O/Z_'A^C0AXY_\`DY[OG@NY*-YREG%U\=;[0*$R,988_P!V M7;3N1OP_CCN![S9#M,;.ZX9BK*GJ)N"%`4*T$4J?0@ZF:6H"$@3@+U31NUK9 M;0F8,,NO/C*WYRFU3[1=^\K/KC`FQU178C\-MMDMN?*\D],CG2XW4<=27XJE MH?`2"8`;;H/F%:W9`F66/GC--^(G;&T=K67=MEBR*Z6Q6:S3>LCS",R$S9]Q M"RXH\H/RAY1))]M>*O2BD@DRB4_@*G';V$9PXNT=A&WL[M;QSMGSQE.36/&\ M>:M%MO3[85O/&WP(*I2V_IC9:T32-#B#* M./Y=D7_9OVD91VF8S<,`9W'NN<8.F8Y,Q^'>2MZX6IR25I++3CBR4166ZKV',=WE^VHN4[)7K"[MGD35_#S M;)<77K5PKN_,LOCN_R%]I@KY8IMR&VE)><4^UU%<3\B3Z MZ(J:]L).!5.%X_HZL?7Q.(43&"P+Q(WB=OQB.^&_.]-^W/NV&RDS[';9+03% MB2$JYTJ*BLY!J-?=SU!SZ;E(,T=N<2MHTJ[1U'.D4N]^R'T]Z':8SW:; M/3]I95__]C&0/]G5G[6;%N5.L"8%M;L;V2VYKE=7`">5ZH'%!>;5Q&MM- MU/B/$#]8!G\T>7O3JJFC#+B4\`W9Q=]L/C9V&V&VRMN!2\9MF9R8[KDJXWB] M06%/SICM>J^Z25.$N$U))]3K.[J&J^J1,]D0=CT93I0IPI^)6>Z$2SWQ0XX_ MW$8WW"[+Y2-K;Q:I4&[;=]D) M"D!Q1!/,![ZUG[\7&2T@X'LB3I]")9=#[J$$Y0H/?/V(XGWD8!8,3O%W>QR9 MCN0L7ZTWJVM)3+9=9=;<4@K0!ZJ14&GKK);+R*=2@X5<)&R/+WHNG64N-)`= M!$]@AU6S6W[NUVW6+;?N727>%8W:8=N1>)O&2^W%;#203[U2G4+=W?%.J<0< B%93@ZLE.IBW(8(D4CR>2%A_O5_X?OT.>$=_DY[_FB4C_V3\_ ` end EX-101.INS 7 skbi-20120331.xml XBRL INSTANCE DOCUMENT 0001076939 2011-01-01 2011-03-31 0001076939 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0001076939 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-03-31 0001076939 us-gaap:RetainedEarningsAppropriatedMember 2012-01-01 2012-03-31 0001076939 us-gaap:RetainedEarningsUnappropriatedMember 2012-01-01 2012-03-31 0001076939 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-01-01 2012-03-31 0001076939 2011-12-31 0001076939 us-gaap:SeriesBPreferredStockMember 2011-12-31 0001076939 2012-01-01 2012-03-31 0001076939 2012-03-31 0001076939 us-gaap:SeriesBPreferredStockMember 2012-03-31 0001076939 2012-05-10 0001076939 2010-12-31 0001076939 2011-03-31 0001076939 us-gaap:CommonStockMember 2011-12-31 0001076939 us-gaap:CommonStockMember 2012-03-31 0001076939 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0001076939 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0001076939 us-gaap:RetainedEarningsAppropriatedMember 2011-12-31 0001076939 us-gaap:RetainedEarningsAppropriatedMember 2012-03-31 0001076939 us-gaap:RetainedEarningsUnappropriatedMember 2011-12-31 0001076939 us-gaap:RetainedEarningsUnappropriatedMember 2012-03-31 0001076939 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-12-31 0001076939 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2012-03-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares SKYSTAR BIO-PHARMACEUTICAL CO 0001076939 --12-31 Smaller Reporting Company skbi 7604800 10-Q false 2012-03-31 Q1 2012 7048968 9386584 3391493 5783831 14851159 13962087 32648448 34914476 964088 981699 58904156 65028677 28376559 28273028 8839055 9434227 1512817 1189788 569788 652609 5674206 5610135 7756811 7452532 103876581 110188464 1047067 2046341 5274598 6059237 7366320 7476480 1432529 1640457 160081 1585156 56273 380669 15336868 19188340 393500 396000 43400 37800 436900 433800 15773768 19622140 7162 7162 35784378 35784378 5708135 5708135 38492031 40396785 8111107 8669864 88102813 90566324 88102813 90566324 7162 7162 35784378 35784378 5708135 5708135 38492031 40396785 8111107 8669864 103876581 110188464 438678 480237 0.001 0.001 0.001 0.001 50000000 48000000 50000000 48000000 0 0 0 0 0 0 0 0 0.001 0.001 40000000 40000000 7161919 7161919 7161919 7161919 7086954 7926337 3491346 3643658 3595608 4282679 287472 3654 369404 705616 1294798 1105435 1951674 1814705 1643934 2467974 182 53760 29672 -153612 735494 5600 765348 -94252 2409282 2373722 477450 468968 1931832 0 0 0 1904754 0 1904754 465593 558757 2397425 2463511 0.27 0.26 0.27 0.26 7166919 7210256 7179309 7210256 7161919 7161919 558757 0 0 0 0 558757 332428 343129 230922 100373 0 38869 757356 2415647 6826437 -985908 2603343 2144356 -360449 -606331 197277 980926 14989 199329 1566418 1427655 -6288315 2021671 451722 0 0 11515 7609000 0 22275 54965 634222 44940 6462736 -111420 1257007 63520 62834 326061 1319841 389581 21296 37784 1515558 2337616 7048968 9386584 5887831 7403389 54409 152583 421843 333480 0 3633 Note 1 - ORGANIZATION   Organization and description of business   Skystar Bio-Pharmaceutical Company (“Skystar” or the “Company”) was incorporated in Nevada on September 24, 1998. Since its acquisition on November 7, 2005 of Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (“Skystar Cayman”), a Cayman Islands company, the Company has been engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the Company are in the People’s Republic of China (“China” or the “PRC”).   All of the Company’s operations are carried out by Xi’an Tianxing Bio-Pharmaceutical Co., Limited (“Xi’an Tianxing”), a PRC joint stock company that the Company controls through contractual arrangements originally between Skystar Cayman and Xi’an Tianxing. On March 10, 2008, the Company entered into a series of agreements transferring all of the rights and obligations of Skystar Cayman under the contractual arrangements to Sida Biotechnology (Xi’an) Co., Ltd. (“Sida”), a PRC company. Sida is the wholly owned subsidiary of Fortunate Time International Limited (“Fortunate Time”), a Hong Kong company and wholly owned subsidiary of Skystar Cayman. Xi’an Tianxing also has a wholly owned subsidiary, Shanghai Siqiang Biotechnological Co., Ltd. (“Shanghai Siqiang”), a PRC company.   As a result of these contractual arrangements, which obligate Sida to absorb all of the risk of loss from Xi’an Tianxing’s activities and enable Sida to receive all of its expected residual returns, the Company accounts for Xi’an Tianxing as a variable interest entity (“VIE”) under the Financial Accounting Standards Board’s (“FASB”) interpretation on consolidation of variable interest entities. Accordingly, the Company consolidates Xi’an Tianxing’s results, assets, and liabilities.   On September 18, 2009, Skystar Bio-Pharmaceutical Inc. (“Skystar California”) was incorporated in California and became a wholly owned subsidiary of Skystar. On December 20, 2010, we dissolved Skystar California.   On April 21, 2010, Kunshan Sikeda Biotechnology Co., Ltd. (“Kunshan Sikeda”) was incorporated in Kunshan, Jiangsu province, China with registered capital of RMB 500,000, of which Xi’an Tianxing and Sida each contributed RMB 250,000. Kunshan Sikeda is jointly owned by Xi’an Tianxing and Sida.   On May 7, 2010, Fortunate Time formed Skystar Biotechnology (Kunshan) Co., Limited (“Skystar Kunshan”) in Kunshan, Jiangsu province, China with registered capital of $15,000,000, of which $2,250,000 was paid by Fortunate Time in cash, and of which the remaining $12,750,000 is required to be invested in the future. Kunshan was formed in connection with an acquisition of assets to meet part of the registered capital requirements, and was intended to be a micro-organism manufacturing facility for the Company once the acquisition was complete. The asset acquisition was completed in September 2011, and the Company is in the process of transferring the assets acquired to meet part of the registered capital requirements.   On August 11, 2010, Sida became the parent company of Skystar Biotechnology (Jingzhou) Co., Limited (“Skystar Jingzhou”), a company established in Jingzhou, Hubei Province, China on February 5, 2010, with registered capital of approximately $4.1 million (RMB 26,000,000), of which approximately $3.7 million (RMB 23,480,000) has been paid. The remaining approximately $399,168 (RMB 2,520,000) is required to be invested by April 6, 2012. As of the date of this report, the Company has not made this investment.  Skystar Jingzhou is currently in the process of getting the government's approval and will fulfill the requirement of remaining capital of $399,168 (RMB 2,520,000) thereafter. The company expects the process will be completed by the end of the 2nd quarter of 2012.   On March 15, 2011, Xi’an Tianxing formed Xi’an Sikaida Bio-products Co., Ltd. (“Xi’an Sikaida”) with registered capital of approximately $1,584,000 (RMB 10,000,000) paid by Xi’an Tianxing.   Hereinafter, Skystar, Skystar Cayman, Fortunate Time, Sida, Xi’an Tianxing, Skystar Kunshan, Kunshan Sikeda, Skystar Jingzhou, Shanghai Siqiang, and Xi’an Sikaida are sometimes collectively referred to as the “Company.” Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented have been made. The accompanying results of operations are not necessarily indicative of the operating results that may be expected for the entire year ending December 31, 2012. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto of the Company, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (“SEC”).   Principles of consolidation   The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries, and its VIEs.  All significant inter-company transactions and balances between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.   Use of estimates   The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Actual results may differ from these estimates in amounts that may be material to the consolidated financial statements and accompanying notes. Significant estimates and assumptions made by the Company are used for, but not limited to the allowance for uncollectible receivables, obsolescence reserve against the inventory, tax provision and the fair value for derivatives instruments.   Foreign currency translation   The Company uses the United States dollar (“U.S. dollar”) for financial reporting purposes and the Chinese Renminbi (“RMB”) as its functional currency. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency, being the primary currency of the economic environment in which their operations are conducted.   The Company translates the subsidiaries’ and VIEs’ assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet dates, and the statements of income and comprehensive income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the subsidiaries’ and VIEs’ financial statements are recorded as accumulated other comprehensive income.   The quotation of the exchange rates does not imply free convertibility of RMB to other foreign currencies. All foreign exchange transactions continue to take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China.   Approval of foreign currency payments by the People’s Bank of China or other institutions requires submitting a payment application form together with invoices, shipping documents, and signed contracts. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.   Fair values of financial instruments   The accounting standards regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires fair value disclosures of those financial instruments.  This accounting standard defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosures requirements for fair value measures.  Certain current assets and current liabilities are financial instruments.  Management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and, if applicable, their current interest rates are equivalent to interest rates currently available.  The three levels of valuation hierarchy are defined as follows:    <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 3%;">•</td> <td style="text-align: justify; width: 97%;">Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 3%;">•</td> <td style="text-align: justify; width: 97%;">Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.</td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 3%;">•</td> <td style="text-align: justify; width: 97%;">Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.</td> </tr> </table>    Outstanding warrants and purchase options do not trade in an active securities market, and as such, the Company estimates the fair value of these warrants and purchase options using the Black-Scholes Option Pricing Model (“Black-Scholes Model”) using the following assumptions:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap">Warrants – (1)</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6" nowrap="nowrap">Purchase Options – (2)</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">March 31, (2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">March 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 48%;">Stock price</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">2.74</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">2.69</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">2.74</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Exercise price</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">5.00</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">8.11</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">8.11</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Annual dividend yield</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Expected term (years)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.16</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.25</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2.50</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Risk-free interest rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.01</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.33</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.25</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Expected volatility</td> <td style="font-weight: bold;"> </td> <td style="text-align: left; font-weight: bold;"> </td> <td style="text-align: right; font-weight: bold;">-</td> <td style="text-align: left; font-weight: bold;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">68</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">65</td> <td style="text-align: left;">%</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">64</td> <td style="text-align: left;">%</td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 4%;">(1)</td> <td style="text-align: justify; width: 96%;"> As of December 31, 2011, 34,230 warrants with an exercise price of $5.00 were outstanding. All of these warrants expired on February 28, 2012. As of March 31, 2012, none of these warrants was outstanding.</td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 4%;">(2)</td> <td style="text-align: justify; width: 96%;">As of December 31, 2011, 140,000 purchase options with an exercise price of $8.11 were outstanding. As of March 31, 2012, 140,000 of these options were outstanding.</td> </tr> </table>   Expected volatility is based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the term of the warrants. The Company believes this method produces an estimate that is representative of future volatility over the expected term of these warrants and purchase options. The Company has no reason to believe future volatility over the expected remaining life of these warrants and purchase options is likely to differ materially from historical volatility. The expected life is based on the remaining term of the warrants and purchase options. The risk-free interest rate is based on U.S. Treasury securities according to the remaining term of the warrants and purchase options.   As required by the FASB’s accounting standards, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Depending on the product and the terms of the transaction, the fair values warrant/purchase option liability were modeled using a series of techniques, including closed-form analytic formula, such as the Black-Scholes Model, which does not entail material subjectivity because the methodology employed does not necessitate significant judgment, and the pricing inputs are observed from actively quoted markets.   The fair value of the 140,000 purchase options outstanding as of March 31, 2012 was determined using the Black-Scholes Model, utilizing level 2 inputs, and recorded the change in earnings. As a result, the warrant/purchase option liability is carried on the consolidated balance sheets at fair value. The Company recognized gains of $5,600 and $735,494 for the three months ended March 31, 2012 and 2011, respectively.   The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2012:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: center; padding-bottom: 1pt;" colspan="2">Carrying Value at March 31,</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="10">Fair Value Measurement at March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Level 1</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Level 2</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Level 3</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: center; width: 48%;">Purchase option liability (unaudited)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">37,800</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">—</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">37,800</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">—</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> </table>   Below is the reconciliation for the warrant/purchase option liability changes from December 31, 2011 to March 31, 2012.   <table style="width: 85%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 82%;">Balance, December 31, 2011</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 15%;">43,400</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Change in fair value</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(5,600</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Balance, March 31, 2012</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">37,800</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   The net carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term nature of these instruments as well as the variable interest rate for short-term debt.   In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company is required to record assets and liabilities at fair value on a non-recurring basis.  Generally, assets are recorded at fair value on a non-recurring basis as a result of impairment charges.  For the three months ended March 31, 2012, there were no impairment charges.        Revenue recognition   Revenue of the Company is primarily derived from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected on these consolidated financial statements as sales returns historically have been insignificant.   There are two types of sales upon which revenue is recognized:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 3%;">a.</td> <td style="text-align: justify; width: 97%;">Credit sales: revenue is recognized when the products have been delivered to the customers.</td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 3%;">b.</td> <td style="text-align: justify; width: 97%;">Full payment before delivering: Cash received is recorded as “deposits from customers” and revenue is recognized when the products have been delivered to the customers.</td> </tr> </table>    Shipping and handling costs related to costs of goods sold are included in selling expenses, which totaled $383,703 and $194,216 for the three months ended March 31, 2012 and 2011, respectively.   The Company’s revenues and cost of revenues by product line were as follows:    <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">Three Months Ended March 31,</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Revenues</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="width: 70%;">Micro-organism</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">3,135,040</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">1,596,094</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Veterinary Medications</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,008,587</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4,865,047</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Feed Additives</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,034,772</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">326,407</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Vaccines</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">747,938</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">299,406</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Total Revenues</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">7,926,337</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;">$</td> <td style="border-bottom: black 1pt solid; text-align: right;">7,086,954</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Cost of Revenues</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Micro-organism</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">906,841</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">494,182</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Veterinary Medications</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,792,647</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,821,906</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Feed Additives</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">849,884</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">140,866</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Vaccines</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">94,286</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">34,392</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Total Cost of Revenues</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">3,643,658</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">3,491,346</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Gross Profit</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">4,282,679</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">3,595,608</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Cash   Cash includes currency on hand, demand deposits with banks, and liquid investments with an original maturity of three months or less.   Accounts receivable and other receivables   Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as needed. The Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, a bad debt percentage is estimated by management based on historical experience and current economic climate.  The resulting percentage is applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. The ultimate collection of the Company’s accounts receivable may take one year. Delinquent account balances are reserved after management determines that the likelihood of collection is not probable, and known bad debts are written-off against allowance for doubtful accounts when identified.   Inventories   Inventories are stated at the lower of cost or market, as determined on a moving weighted-average basis using the first-in, first-out (FIFO) cost method. Inventories include purchases and related costs incurred in bringing the inventories to their present location and condition. Management reviews inventories for obsolescence and cost in excess of net realizable value at least annually and records a reserve against the inventory and additional cost of goods sold when the carrying value exceeds net realizable value.   Plant and equipment   Plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs that do not improve or extend the useful lives of the assets are charged to operations as incurred, while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Estimated Useful Life</td> </tr> <tr style="vertical-align: top;"> <td style="width: 80%;">Buildings</td> <td style="width: 5%;"> </td> <td style="text-align: right; width: 15%;">10-40 years</td> </tr> <tr style="vertical-align: top;"> <td>Machinery and equipment</td> <td> </td> <td style="text-align: right;">10 years</td> </tr> <tr style="vertical-align: top;"> <td>Computer, office equipment and furniture</td> <td> </td> <td style="text-align: right;">5 years</td> </tr> <tr style="vertical-align: top;"> <td>Vehicles</td> <td> </td> <td style="text-align: right;">5-10 years</td> </tr> </table>   Management assesses the carrying value of plant and equipment annually or more often when factors indicating impairment are present, and reduces the carrying value of such assets by the amount of the impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted) and comparing such amount to the net asset carrying value. An impairment loss, if it exists, is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Based on its review, management believes that, as of March 31, 2012 and December 31, 2011, there was no impairment for its plant and equipment.   Construction-in-progress   Construction-in-progress includes direct costs of construction of a factory building. Interest incurred during the period of construction, if significant, is capitalized. All other interest is expensed as incurred. Construction-in-progress is not depreciated until such time as the asset is completed and put into service.   Intangible assets   Land use rights — Land use rights represent the amounts paid to acquire a long-term interest to utilize the land underlying the Company’s facilities. This type of arrangement is common for the use of land in the PRC. Land use rights are amortized on the straight-line method over the contractual lease terms.  The land use right granted to the Company’s Huxian facility was for 50 years.  The land use right granted to the Company’s Jingzhou facility was 30 years. The land use right granted to the Company’s Kunshan facility was for 41 years.      Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over estimated useful life between five to ten years that reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties.  Drug approval licenses are typically granted in five year terms by the Ministry of Agriculture.   Impairment of Intangible assets — the Company evaluates the carrying value of intangible assets annually or more often when factors indicating impairment are present. The Company determines the existence of such impairment by measuring the estimated future cash flows (undiscounted) and comparing such amount to the net asset carrying value. If the undiscounted cash flow estimated to be generated by any such intangible asset is less than its carrying amount, a loss is recognized based on the amount by which the carrying amount exceeds the intangible asset’s fair market value. Loss on intangible assets to be disposed of is determined in a similar manner, except that fair market values are reduced by the cost of disposal. Based on its review, the Company believes that, as of March 31, 2012 and December 31, 2011, there was no impairment of its intangible assets.   Comprehensive income   Comprehensive income and loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income is comprised of the changes in foreign currency exchange rates.   Research and development costs   Research and development costs are charged to operations as incurred and include salaries, professional fees, and technical support fees related to such efforts.   Income taxes   The Company accounts for income taxes using an asset and liability method.  Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized.   A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of March 31, 2012, there are no unrecognized tax benefits, and the Company does not expect a significant change in tax benefits in the next 12 months.  Penalties and interest levied by taxing authorities, if any, are classified as income tax expense in the year incurred.  No significant penalties or interest relating to income taxes have been incurred during the three months ended March 31, 2012 and 2011.    The Company’s operations are subject to income and transaction taxes in the United States and in the PRC jurisdictions. Significant estimates and judgments are required in determining the Company’s worldwide provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. The ultimate amount of tax liability may be uncertain as a result.   According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational or other errors made by the taxpayer or the withholding agent.  The statute of limitations extends to five years under special circumstances. In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Accordingly, the income tax returns of the Company’s PRC operating subsidiaries for the years ended December 31, 2006 through 2011 are open to examination by the PRC state and local tax authorities. The Company does not anticipate any events that could cause a change to these uncertainties.   Stock-based compensation   The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. Stock compensation for stock granted to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.   Earnings per share   Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period or after the end of the period but before the release of the financial statements, by considering it outstanding for the entirety of each period presented. Diluted earnings per share is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.    Related parties   Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of such principal owners and management, and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.   Operating Segments   While the chief decision-makers monitor the revenue streams of the various products lines, operations are managed and financial performance is evaluated on a Company-wide basis.  Product lines are aggregated into one as operating results for all product lines are similar.  Accordingly, all of the major product lines (micro organism, veterinary medicine, feed additives and vaccines) are considered by management to be aggregated in one reportable operating segment.   Recently issued accounting pronouncements   In May 2011, the FASB issued ASU No. 2011-04 – Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.GAAP and IFRSs. The amendments in this update intend to converge requirements for how to measure fair value and for disclosing information about fair value measurements in US GAAP with International Financial Reporting Standards. For public entities, this ASU is effective for interim and annual periods beginning after December 15, 2011. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.   In June 2011, the FASB issued ASU No. 2011-05 – Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The amendments in this update require (i) that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements (the current option to present components of other comprehensive income (“OCI”) as part of the statement of changes in stockholders’ equity is eliminated) and (ii) presentation of reclassification adjustments from OCI to net income on the face of the financial statements. For public entities, the amendments in this ASU are effective for years, and interim periods within those years, beginning after December 15, 2011. The amendments in this update should be applied retrospectively. Early adoption is permitted. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.   In December 2011, the FASB issued ASU No. 2011-11 —Balance Sheet (Topic 210). The objective of this update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. An entity is required to apply the amendments for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The Company does not expect the adoption of the provisions in this update will have a significant impact on its consolidated financial statements.   In December 2011, the FASB issued ASU No. 2011-12 —Comprehensive Income (Topic 220). The amendments in this update supersede certain pending paragraphs in ASU No. 2011-05, to effectively defer only those changes in ASU No. 2011-05 that relate to the presentation of reclassification adjustments out of accumulated other comprehensive income. The amendments will be temporary to allow the Board time to redeliberate the presentation requirements for reclassifications out of accumulated other comprehensive income for annual and interim financial statements for public, private, and non-profit entities. The amendments in this update are effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.   Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption. Note 3 - CONCENTRATIONS AND CREDIT RISK   The Company’s operations are all carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic, and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.   Financial instruments which subject the Company to concentration of credit risk consist of cash and accounts receivable. Balances at financial institutions or state-owned banks within the PRC are not covered by insurance. The Company has not experienced any losses in such accounts. The Company provides unsecured credit terms for sales to certain customers.  As a result, there are credit risks with the accounts receivable balances.  The Company constantly re-evaluates the credit worthiness of customers buying on credit and maintains an allowance for doubtful accounts.   For the three months ended March 31, 2012 and 2011, all of the Company’s sales occurred in the PRC. No major customers accounted for more than 10% of the Company’s total revenues. All accounts receivable at March 31, 2012 and December 31, 2011 are from customers located in the PRC.   The Company’s six largest vendors accounted for approximately 85% and 73% of the Company’s total purchases, respectively, for the three months ended March 31, 2012 and 2011.   The Company had one product that accounted for 23% and 15% of the Company’s total revenues for the three months ended March 31, 2012 and 2011, respectively Note 4 - ACCOUNTS RECEIVABLE, NET   Accounts receivable consisted of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Account receivable</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">6,264,068</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">3,830,171</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Allowance for doubtful accounts</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(480,237</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(438,678</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Account receivable, net</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">5,783,831</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">3,391,493</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   The following table presents the movement of allowance for doubtful accounts:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 85%;">Allowance for doubtful accounts, January 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 12%;">438,678</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Addition</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">38,869</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Recovery</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Translation adjustment</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">2,690</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Allowance for doubtful accounts, March 31, 2012</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">480,237</td> </tr> </table> Note 5 – INVENTORIES   Inventories consist of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Raw materials</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">12,341,645</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 12%;">12,646,663</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Packing materials</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">231,596</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">181,304</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Work-in-process</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,218</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">22,559</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Finished goods</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,554,507</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,171,238</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Other</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">52,219</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">51,085</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Total</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">14,185,185</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">15,072,849</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Less: Allowance for obsolete inventories</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(223,098</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(221,690</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">13,962,087</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">14,851,159</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   The Company periodically reviews its reserves for slow-moving and obsolete inventories. Note 6 - DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES   Deposits and prepaid expenses are comprised of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">December 31,  2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Prepayment for raw materials purchasing</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">31,521,801</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">28,824,123</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Prepayment for packaging materials purchasing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">366,792</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">402,838</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Prepayment for enterprise income taxes</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,708,019</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,162,070</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Other receivables</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">655,918</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">508,392</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Other</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">661,946</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">751,025</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">34,914,476</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">32,648,448</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   As part of the Company’s strategy to reduce inventory costs, the Company maintains a balance for prepayment to suppliers in order to secure favorable pricing for raw materials.  As inventory is received throughout the year, this balance will fluctuate with the business operations. Note 7 - PLANT AND EQUIPMENT, NET   Plant and equipment consist of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Building and improvements</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">26,030,763</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">25,866,428</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Machinery and equipment</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,764,470</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,675,995</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Office equipment and furniture</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">328,571</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">320,498</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Vehicles</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">592,175</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">588,436</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Total</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">32,715,979</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">32,451,357</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Less: accumulated depreciation</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(4,442,951</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(4,074,798</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Plant and equipment, net</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">28,273,028</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">28,376,559</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Depreciation expense was $343,129 and $332,428 for the three months ended March 31, 2012 and 2011, respectively. Note 8 - CONSTRUCTION-IN-PROGRESS   Construction-in-progress (“CIP”) relates to a plant being built in accordance with the PRC’s Good Manufacturing Practices (“GMP”) Standard.   Xi’an facility   We started constructing our Huxian vaccine facility in 2005, and it was completed in 2010 and resulted in a transfer to plant and equipment of $9,448,505. In 2011, the Company started two projects at the vaccine facility to modify air filtration, water treatment, and other facility changes based on recommendations by outside experts hired by the Company to advise on the GMP qualification process for the vaccine facility. The Company has finished installing, tooling, and testing of equipment on this facility and resulted in a transfer to plant and equipment of approximately $589,270 (RMB 3,720,142) in 2011. As of March 31, 2012, the facility had a total in construction-in-progress of $2,360,086 (RMB 14,899,533). The facility is currently waiting for GMP certification from the Ministry of Agriculture. The Company expects the GMP certification process to be complete by the second half of 2012.   In 2011, the Company started a facility improvement project in the amount of approximately $316,800 (RMB 2,000,000) for the Huxian Animal Laboratory, and it was completed in 2011. The facility is a supporting project to the Huxian vaccine facility and is currently waiting for GMP certification from the Ministry of Agriculture. The Company expects the GMP certification process to be complete by the second half of 2012.   In 2011, the Company started a facility improvement project in the amount of $1,127,808 (RMB 7,120,000) at the Huxian veterinary medicine facility to prepare its GMP re-examination, which is expected to take place in the first half of 2012. The project includes a renovation project to clean 3,160 square feet in area and to replace or implement an exhaust ventilation system, color steel enclosure, process water piping, purification equipment, fire alarm, and combined air supply unit. This facility improvement was completed in 2011 and is awaiting the GMP re-examination from Ministry of Agriculture. The Company expects that the GMP re-examination will be completed during the 3rd quarter of 2012.   Jingzhou facility   In 2011, the Company started a facility improvement project to expand production capacity at the Jingzhou facility. The project includes plant construction and water supply and drainage and has an estimated total cost of $2,005,819 (RMB 12,663,000). As of March 31, 2012, the project was still under construction. The Company expects the project will be completed by the second half of 2012.   Kunshan facility   In 2010, the Kunshan micro-organism facility and some general facility improvements were completed and placed in service, which resulted in a transfer from Construction-in-Progress to plant and equipment of $1,389,602. In 2011, the Company started a supporting project at the Kunshan facility that includes the construction and installation of plumbing, sewer, electrical, HVAC, fire protection and alarm system, drainage, office, lab, road construction, parking, and landscaping. As of March 31, 2012, the facility had a total in construction-in-progress of $4,954,274 (RMB 31,276,982). The construction and installation were completed and the project will be inspected and accepted shortly. The Company expects the project will be completed by June 2012. We anticipate that Kunshan plant will start small-scale production in the second half of 2012. However, we don’t expect that will bring significant impact to our revenue in 2012 as a whole.   No depreciation is provided for construction-in-progress until such time as the assets are completed and placed into service.   The construction projects the Company was in the progress of completing are as follows:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="2">Total in CIP as of</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2">Estimate cost to</td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2">Estimated</td> <td> </td> <td> </td> <td style="text-align: center;">Estimated</td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid;">Project</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">3/31/2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Complete</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Total Cost</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;">Completion Date</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 35%;">Xi'an vaccine facility</td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="text-align: right; width: 12%;">2,360,086</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="text-align: right; width: 12%;">-</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;">$</td> <td style="text-align: right; width: 12%;">2,360,086</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: right; width: 18%;">Second half of 2012</td> <td style="width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Xi'an animal laboratory</td> <td> </td> <td> </td> <td style="text-align: right;">316,800</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">316,800</td> <td> </td> <td> </td> <td style="text-align: right;">Second half of 2012</td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Xi'an veterinary medication facility</td> <td> </td> <td> </td> <td style="text-align: right;">1,127,808</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">1,127,808</td> <td> </td> <td> </td> <td style="text-align: right;" nowrap="nowrap">The 3rd Quarter of 2012</td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Jingzhou facility</td> <td> </td> <td> </td> <td style="text-align: right;">675,259</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">1,330,560</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">2,005,819</td> <td> </td> <td> </td> <td style="text-align: right;">Second half of 2012</td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Kunshan facility</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">4,954,274</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">4,954,274</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;">June 2012</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">TOTAL CIP Balance</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">9,434,227</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,330,560</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">10,764,787</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: center; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> </tr> </table>   As of March 31, 2012 and December 31, 2011, the Company had construction in progress amounting to $9,434,227 and $8,839,055, respectively. No interest expense had been capitalized for construction in progress for the three months ended March 31, 2012 and 2011 as management determined the amount of capitalized interest would be insignificant. Note 9 - LONG-TERM PREPAYMENTS   Long-term prepayments consist of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 70%;">R&D project</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">316,800</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">314,800</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Construction deposit</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">594,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">960,140</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Deposit for equipment purchase</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">278,988</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">237,877</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Deposit for potential asset acquisitions</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">652,609</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">569,788</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,842,397</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">2,082,605</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   As of March 31, 2012 and December 31, 2011, deposits for potential acquisitions totaled $652,609 and $569,788, respectively, all of which was held by an unrelated third party engaged to facilitate potential acquisition projects. Note 10 – INTANGIBLE ASSETS   Intangible assets consist of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Land use rights</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">4,791,602</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">4,761,352</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Technological know-how</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,217,600</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,203,600</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Patents</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">316,800</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">314,800</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Total</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">7,326,002</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">7,279,752</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Less: accumulated amortization</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(1,715,867</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(1,605,546</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Intangible assets, net</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">5,610,135</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">5,674,206</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   The Company’s one year loan with Industrial and Commercial Bank of China Songzi Branch (see Note 12) is secured by the Company’s land use rights in Jingzhou, Hubei Province.   For the three months ended March 31, 2012 and 2011, the amortization expense for intangibles amounted to $100,373 and $230,922, respectively.   Amortization expense expected for the next five years and thereafter is as follows:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-weight: bold;">Years ending December 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Amount</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 85%;">2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">300,362</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">2013</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">242,082</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">2014</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">242,082</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">2015</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">242,082</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">2016</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">242,082</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Thereafter</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">4,341,445</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">5,610,135</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table> Note 11 – LOANS RECEIVABLE   In November 2010, the Company provided an unsecured non-interest bearing loan to Xi’an Tiantai Investment, Ltd., the Company’s acquisition advisor, in the amount of $190,080 (RMB 1,200,000) for two years from November 26, 2010 through November 25, 2012. As of March 31, 2012, this loan has not been repaid.   As of March 31, 2012, the Company had unsecured non-interest bearing short-term loans in the amount of $791,619 (RMB 4,997,592) due from unrelated third parties. Note 12 – SHORT-TERM LOANS   On May 5, 2011, the Company obtained a one year loan with Industrial and Commercial Bank of China Songzi Branch for $475,200 (RMB 3,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 8.528% at March 31, 2012. In 2011, the Company repaid $158,400 (RMB 1,000,000) and subsequently borrowed back $158,400 (RMB 1,000,000). This loan is secured by the Company’s land use rights in Jingzhou, Hubei Province and guaranteed by the legal representative of Skystar Jingzhou. On May 2, 2012, the Company repaid this loan of $475,200 (RMB 3,000,000).   On July 8, 2011, the Company obtained a one year loan with Chang’an Bank for $792,000 (RMB 5,000,000) at an annual interest rate of 8.203%. This loan is secured by the Company’s office buildings and its Chairman and CEO’s personal property located in Xi’an City, which includes an office building contributed by a shareholder in 2005 as additional capital of Xi’an Tianxing. As of March 31, 2012, the title to this property has not been passed to the Company. This loan is also personally guaranteed by the Company’s Chairman and CEO and his wife.   On August 25, 2011, the Company obtained a one year loan with Shaanxi Agricultural Yanta Credit Union for $792,000 (RMB 5,000,000) at an annual interest rate of 9.411%. This loan is secured by the Company’s office buildings located in Xi’an City. This loan is also personally guaranteed by the Company’s Chairman and CEO.   On December 22, 2011, the Company obtained a one year loan with Shaanxi Agricultural Yanta Credit Union for $475,200 (RMB 3,000,000) at an annual interest rate of 9.411%. This loan is secured by the Company’s office buildings located in Xi’an City. This loan is also personally guaranteed by the Company’s Chairman and CEO and his wife.   On December 1, 2011, the Company obtained a one year loan with Bank of Chengdu for $4,752,000 (RMB 30,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 8.528% at March 31, 2012. This loan is secured by the Company’s land use right and manufacturing plant located in Huxian County.   In 2011, the Company obtained two three-month loans with a third-party individual for a total amount of $125,920 (RMB 800,000). For the three months ended March 31, 2012, the Company borrowed another two short-term loans for a total amount of $63,360 (RMB 400,000) with this third-party individual. These four loans are non-interest bearing and are unsecured. On April 6, 2012, the Company repaid one loan of $47,520 (RMB 300,000). On April 9, 2012, the Company repaid the other three remaining loans totaling $142,560 (RMB 900,000).   Interest expense incurred and associated with the short-term loans amounted to $152,583 and $54,409 for the three months ended March 31, 2012 and 2011, respectively, none of which has been capitalized as part of construction-in-progress for the three months ended 2012 and 2011, respectively.   Outstanding short-term loans consisted of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">March 31, 2012</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6">December 31, 2011</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" colspan="2"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold;" colspan="2">Interest</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1pt; font-weight: bold;">Bank</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Amt RMB</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Amt USD</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Amt RMB</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Amt USD</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Due Date</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Rate</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold;" colspan="2"> </td> <td style="font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold;" colspan="2"> </td> <td style="font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold;" colspan="2"> </td> <td style="font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold;" colspan="2"> </td> <td style="font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold;" colspan="2"> </td> <td style="font-weight: bold;"> </td> <td style="font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold;" colspan="2"> </td> <td style="font-weight: bold;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 28%;">Chang’an Bank</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">5,000,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">792,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">5,000,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">787,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: center; width: 9%;">07/07/12</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">8.203</td> <td style="text-align: left; width: 1%;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Shaanxi Agricultural Yanta Credit Union</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">792,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">5,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">787,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">08/24/12</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9.411</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Shaanxi Agricultural Yanta Credit Union</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">475,200</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">472,200</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">12/21/12</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">9.411</td> <td style="text-align: left;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Commercial Bank of China Songzi Branch</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">475,200</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">472,200</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">05/04/12</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;">(1)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Bank of Chengdu</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">30,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4,752,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">30,000,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4,722,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: center;">11/30/12</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;">(1)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Third-party Individual</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">1,200,000</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">190,080</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">800,000</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">125,920</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: center; padding-bottom: 1pt;">Various</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;">0</td> <td style="text-align: left; padding-bottom: 1pt;">%</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: right; padding-bottom: 2.5pt; font-weight: bold;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">47,200,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,476,480</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">46,800,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,366,320</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 3%;"> </td> <td style="width: 3%;">(1)</td> <td style="width: 94%;">People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 8.528% at March 31, 2012</td> </tr> </table> Note 13 - DEFERRED GOVERNMENT GRANT   Deferred government grant represents subsidies for Good Manufacturing Practice projects granted by various levels of the PRC government. To date, the Company received government subsidies totaling $1,188,000 (RMB 7,500,000), of which $792,000 (RMB 5,000,000) was granted by the PRC government, and $158,400 (RMB 1,000,000) was re-paid on December 7, 2010, with the remaining amount to be repaid in 2012. The current portion of deferred government grant of $633,600 (RMB 4,000,000) is included in other payable in the current liabilities. $316,800 (RMB 2,000,000) was granted by Shaanxi provincial government, and $79,200 (RMB 500,000) was granted by Xi’an municipal government. The Shaanxi provincial government grant and Xi’an municipal government grant are not required to be repaid Note 14 - CAPITAL TRANSACTIONS   Stock-based compensation   On March 30, 2010, the Company agreed to issue 2,500 shares of common stock to a non-executive director in exchange for services unrelated to his services as a director at the fair market value of $11.74 per share based on the closing price on March 30, 2010. On April 16, 2010, the Company entered into another agreement to grant 10,000 shares of common stock to that director for his one year service from April 1, 2010. The closing price per share on the grant date was $10.61. The common stock compensation vests in four equal quarterly installments of 2,500 shares. Shares owed were accrued at the end of each quarter at the fair market value on the grant date of $10.61 per share. On August 31, 2011, the Company entered into another agreement to grant 36,000 shares of common stock to that director for his one year service from April 1, 2011. The closing price per share on the grant date was $2.58. The common stock compensation vests in four equal quarterly installments of 9,000 shares. Shares owed were accrued at the end of each quarter at the fair market value of the grant date at $2.58 per share. A total of $23,220 and $26,525 was charged to general and administrative expense for the three months ended on March 31, 2012 and 2011, respectively. On October 25, 2010, 5,000 shares were issued to the director for the shares vested in the first two quarters of 2010. As of March 31, 2012, 43,500 shares were accrued for the shares vested and pending to be issued.   On May 26, 2009, the Company agreed to issue 5,556 shares of common stock to a director at the beginning of each term of his directorship. The trading value of the common stock on May 26, 2009 was $4.50 per share. The Company issued 5,556 shares on February 26, 2010. As of March 31, 2012, 11,112 shares were accrued for the shares vested and pending to be issued. In accordance with the agreement between the Company and this director, this director must continue to serve as a member of the Board until his successor is duly elected and qualified in order to receive the shares. This director has continued in his position, and the Company is in the process of finalizing its agreement with this director and expects to complete this process shortly.   On July 29, 2011, the Company entered into a one-year employment agreement with its CFO. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, 4,000 shares of which shall be issuable on the 6 month anniversary and the remainder 4,000 shares of which shall be issuable on the 12 month anniversary. The closing price per share on the grant date was $4.20. A total of $22,584 was charged to general and administrative expense for the three months ended on March 31, 2012. As of March 31, 2012, 4,000 shares were accrued for the shares vested and pending to be issued.   Warrants and Purchase Options   On February 28, 2007, in connection with a financing the Company issued 195,000 warrants to four investors with an exercise price of $6.00 per share for a term of three years (number of warrants and exercise price adjusted for 1-for-10 reverse stock split on May 12, 2009 and 2-for-1 forward stock split on November 16, 2009).  On the same date, the Company also issued warrants to the placement agent, exercisable for 114,100 shares of the Company’s common stock at a price of $5.00 per share for a five-year term (number of warrants and exercise price adjusted for 1-for-10 reverse stock split on May 12, 2009 and 2-for-1 forward stock split on November 16, 2009).  For the year ended December 31, 2009, 56,846 warrants were exercised.  For the year ended December 31, 2010, there was a cashless exercise of 218,024 warrants. For the year ended December 31, 2011, no warrants were exercised. As of March 31, 2012, the remaining 34,230 warrants expired.   In connection with the 2009 equity offering discussed below, the Company granted 140,000 common stock purchase options to five designees of the Underwriters with a vesting date of June 30, 2010. The options are exercisable from June 30, 2010 to June 30, 2014, and each option is exercisable for one share of the Company’s common stock at an exercise price at $8.11 per share. All options were provided for services performed. On June 30, 2010, the purchase options were reclassified from equity to warrant/purchase option liabilities, and the Company reclassified $779,674 from additional paid in capital to warrant/purchase option liability. As of March 31, 2012, 140,000 common stock purchase options were outstanding.   The fair value of each warrant and purchase option is estimated on the date of grant using the Black-Scholes option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock, and reflect the assumption that the historical volatilities are indicative of future trends, which may not necessarily be the actual outcome. Expected term of each warrant and purchase option award represents the period of time that options granted are expected to be outstanding and is estimated based on the historical exercise behavior of separate groups of employees or officers. The risk-free rate reflects the interest rate for United States Treasury Notes with similar time-to-maturity to that of the options.   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 70%;">Expected term (year)</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: right; width: 12%;">2.25</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: right; width: 12%;">0.92 – 3.25</td> <td style="width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Expected volatility</td> <td> </td> <td> </td> <td style="text-align: right;">65</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right;">53% - 147</td> <td>%</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Expected dividend yield</td> <td> </td> <td> </td> <td style="text-align: right;">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right;">0</td> <td>%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Risk-free rate</td> <td> </td> <td> </td> <td style="text-align: right;">0.33</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right;">0.3% - 1.30</td> <td>%</td> </tr> </table>   Following is an activity summary of the Company’s outstanding warrants and purchase options:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Number of warrants/purchase options</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;" colspan="2"> Weighted – average exercise price </td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;" colspan="2"> Weighted- average remaining contractual term (Year) </td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Outstanding at January 1, 2011</td> <td> </td> <td> </td> <td style="text-align: right;">174,230</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right;">7.50</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right;">-</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right;">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Exercised</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;" colspan="2"> </td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Outstanding at December 31, 2011</td> <td> </td> <td> </td> <td style="text-align: right;">174,230</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right;">7.50</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right;">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">-</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right;">(34,230</td> <td>) </td> <td> </td> <td> </td> <td style="text-align: right;">-</td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Exercised</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="border-bottom: black 1pt solid;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;" colspan="2"> </td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 49%;">Outstanding at March 31, 2012</td> <td style="width: 1%;"> </td> <td style="width: 5%;"> </td> <td style="text-align: right; width: 11%;">140,000</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 5%;">$</td> <td style="text-align: right; width: 10%;">8.11</td> <td style="width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="width: 4%;"> </td> <td style="text-align: right; width: 10%;">2.25</td> <td style="width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Vested and expected to vest at March 31, 2012</td> <td> </td> <td> </td> <td style="text-align: right;">140,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right;">8.11</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">2.25</td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Exercisable at March 31, 2012</td> <td> </td> <td> </td> <td style="text-align: right;">140,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right;">8.11</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right;">2.25</td> <td> </td> </tr> </table>   Equity Compensation Plan   On December 8, 2009, the Company’s board of directors approved a stock incentive plan for officers, directors, employees and consultants entitled the “Skystar Bio-Pharmaceutical Company 2010 Stock Incentive Plan” (the “2010 Plan”). The maximum number of shares that may be issued under the 2010 Plan is 700,000 shares of common stock. The 2010 Plan was approved by the Company’s stockholders on December 31, 2009, and awards may be granted thereunder until December 7, 2019. As of March 31, 2012, there are 690,000 shares of the Company’s common stock remaining available for future issuance under the Plan. On May 4, 2012, the Board approved common stock grants in the total amount of 442,881 shares to the Company’s employees and members of the Board of Directors, all of which grants were made pursuant to the terms and provisions of the Plan. <div> </div> Note 15 - STATUTORY RESERVES   Statutory reserves represent restricted retained earnings. Based on the legal formation of the entities, all PRC entities are required to set aside 10% of net income as reported in their statutory accounts on an annual basis to the statutory surplus reserve fund. Once the total statutory surplus reserve reaches 50% of the entity’s registered capital, further appropriations are discretionary. The statutory surplus reserve can be used to increase the entity’s registered capital (upon approval by relevant government authorities) and eliminate its future losses under PRC regulatory requirements (upon a resolution by the board of directors). The statutory surplus reserve is not distributable to shareholders except in the event of liquidation. As of March 31, 2012, Xi’an Tianxing has met the statutory surplus reserve requirement, and $11,192,619 still needs to be transferred to the statutory surplus reserve from other Chinese subsidiaries.   Appropriations to the above statutory reserves are accounted for as a transfer from unrestricted earnings to statutory reserves. There are no legal requirements in the PRC to fund these statutory reserves by the transfer of cash to any restricted accounts, and as such, the Company has not transferred any cash to these accounts. These reserves are not distributable as cash dividends. Note 16 – TAXES   Skystar is subject to United States federal income tax provisions. Skystar Cayman is a tax-exempt company incorporated in the Cayman Islands and conducts all of its business through its subsidiaries, Fortune Time, Sida, Fortune Time’s subsidiary Skystar Kunshan, Sida’s subsidiary Skystar Jingzhou, Sida’s PRC VIEs, Xi’an Tianxing, Xi’an Tianxing’s subsidiary Shanghai Siqiang, Sida and Xi’an Tianxing’s joint venture Kunshan Sikeda, and Xi’an Tianxing’s subsidiary Xi’an Sikaida.   Sida, Skystar Jingzhou, Skystar Kunshan, Xi’an Tianxing, Shanghai Siqiang, Kunshan Sikeda and Xi’an Sikaida are subject to the PRC’s Enterprise Income Tax. Pursuant to the PRC Income Tax Laws, Enterprise Income Tax is generally imposed at a statutory rate of 25%. Xi’an Tianxing has been approved as a new technology enterprise, and under PRC Income Tax Laws is entitled to a preferential tax rate of 15%.   The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the three months ended March 31, 2012 and 2011:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">For the three months ended</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">U.S. Statutory rate</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 12%;">34.0</td> <td style="text-align: left; width: 1%;">%</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 12%;">34.0</td> <td style="text-align: left; width: 1%;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Foreign income not recognized in the U.S.</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(34.0</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(34.0</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">China income tax rate</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">25.0</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">25.0</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">China income tax exemption</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(10.0</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(10.0</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Other item (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">4.8</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">4.8</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total provision for income taxes</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">19.8</td> <td style="text-align: left; padding-bottom: 2.5pt;">%</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">19.8</td> <td style="text-align: left; padding-bottom: 2.5pt;">%</td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 5%;">(1)</td> <td style="width: 95%;">Other item is for operating expenses incurred by Skystar that are not deductible in the PRC and expenses incurred by other subsidiaries that are not deductible on the consolidated level, which resulted in an increase in effective tax rate 4.8% and 4.8% for the three months ended March 31, 2012 and 2011, respectively.</td> </tr> </table>   Taxes payable consisted of the following:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">March 31, 2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 70%;">Value added tax</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">1,402,428</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">110,880</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Other taxes</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">182,728</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">49,201</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,585,156</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">160,081</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Skystar was incorporated in the United States. As of March 31, 2012, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $6,228,689, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, beginning in 2026 and through 2030. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at March 31, 2012 and December 31, 2011. The valuation allowance at March 31, 2012 and December 31, 2011 was $2,117,754 and $2,071,840, respectively. The Company’s management reviews this valuation allowance periodically and makes adjustments as necessary. As of March 31, 2012, the Company has no other deferred tax amounts.   The Company has cumulative undistributed earnings of foreign subsidiaries of approximately $57 million as of March 31, 2012, which were included in consolidated retained earnings and will continue to be indefinitely reinvested in international operations.  Accordingly, no provision has been made for U.S. deferred taxes related to future repatriation of these earnings, nor is it practicable to estimate the amount of income taxes that would have to be provided if we concluded that such earnings will be remitted in the future.Note 17 - EARNINGS PER SHARE   The following is the calculation of earnings per share:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="6">For the three months ended March 31,</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt; width: 70%;">Net income</td> <td style="padding-bottom: 2.5pt; width: 1%;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 12%;">1,904,754</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"> </td> <td style="padding-bottom: 2.5pt; width: 1%;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left; width: 1%;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right; width: 12%;">1,931,832</td> <td style="text-align: left; padding-bottom: 2.5pt; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Weighted average shares used in basic computation</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">7,210,256</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">7,166,919</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Diluted effect of stock warrants and purchase options</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">12,390</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Weighted average shares used in diluted computation</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,210,256</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">7,179,309</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Earnings per share:</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Basic</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.26</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.27</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Diluted</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.26</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">0.27</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   For the three months ended March 31, 2011, the average stock price was greater than the exercise prices of warrants which resulted in additional weighted-average common stock equivalents of 12,390.   For the three months ended March 31, 2012 and 2011, the outstanding 140,000 options were excluded from the diluted earnings per share calculation as they are anti-dilutive as the average stock price was less than the exercise prices of the options. Note 17 - RELATED PARTY TRANSACTIONS AND ARRANGEMENTS   Amounts receivable from and payable to related parties are summarized as follows:   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">March 31, 2012</td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2" nowrap="nowrap">December 31, 2011</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-decoration: underline;">Shares to be issued to related party (1)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 70%;">Scott Cramer – non-executive director (2)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">172,455</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">149,235</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Mark D. Chen – non-executive director (3)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">50,004</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">50,004</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Bing Mei – CFO (4)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">16,800</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">239,259</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">199,239</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; text-decoration: underline;">Amounts due to (from) related parties</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Scott Cramer – non-executive director and shareholder (5)</td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">132,561</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">147,877</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Officer, shareholder and other related party (6)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">248,108</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(91,604</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">380,669</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">56,273</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 1%;"> </td> <td style="width: 2%;">(1)</td> <td style="text-align: justify; width: 97%;">The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. As of March 31, 2012 and December 31, 2011, the shares to be issued to related parties included in the accrued expenses were $239,259 and $199,239, respectively.</td> </tr> <tr style="vertical-align: top;"> <td> </td> <td>(2)</td> <td style="text-align: justify;">As of March 31, 2012 and December 31, 2011, the Company had the obligation under an agreement to issue 43,500 and 34,500 shares of common stock, respectively, to Scott Cramer as compensation valued at $172,455 and $149,235 for being a representative of the Company in the United States for the period April 1, 2010 to March 31, 2012.</td> </tr> <tr style="vertical-align: top;"> <td> </td> <td>(3)</td> <td style="text-align: justify;">As of March 31, 2012 and December 31, 2011, the Company had the obligation under an agreement to issue 11,112 shares of common stock to Mark D. Chen as compensation valued at $50,004 for being a director for his 2011 and 2010 terms of directorship.</td> </tr> <tr style="vertical-align: top;"> <td> </td> <td>(4)</td> <td style="text-align: justify;">As of March 31, 2012, the Company had the obligation under an agreement to issue 4,000 shares of common stock to Bing Mei as compensation valued at $16,800 for being CFO for the period July 29, 2011 to July 28, 2012.</td> </tr> <tr style="vertical-align: top;"> <td> </td> <td>(5)</td> <td style="text-align: justify;">As of March 31, 2012 and December 31, 2011, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $132,561 and $147,877, respectively. </td> </tr> </table> <table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 1%;"> </td> <td style="width: 2%;">(6)</td> <td style="text-align: justify; width: 97%;">The amount due to (from) officer, shareholders and other related party at March 31, 2012 and December 31, 2011 includes unpaid reimbursement and compensation and, advances to Mr. Weibing Lu and other related parties for business expenses</td> </tr> </table> Note 18 - COMMITMENTS AND CONTINGENCIES   (a)  Lease commitments   The Company recognizes lease expense on the straight-line basis over the term of the lease.   The Company entered into a tenancy agreement for the lease of factory premises in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009. As of March 31, 2012, the annual rent for the factory premises was adjusted to approximately $20,212 (RMB 127,600).   The Company leases office space in Xi’an from Mr. Weibing Lu, the Company’s Chairman and CEO, for a period of five years from January 1, 2007 to December 31, 2011, with annual rent of approximately $26,231 (RMB 165,600). In January 2012, the Company renewed the lease with Mr. Lu for another 5 years from January 1, 2012 to December 31, 2016 at rent of approximately $28,512 (RMB 180,000) per year.   The Company also entered into a tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiang’s office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017 with annual rent of approximately $22,810 (RMB 144,000).   The Company entered into a one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from April 15, 2011 to April 14, 2012 with annual rent of approximately $3,041 (RMB 19,200). On April 15, 2012, the Company entered into a new one year tenancy agreement for this office from April 15, 2012 to April 14, 2013 with annual rent of approximately $3,199 (RMB 20,196).   The Company entered into a tenancy agreement for the lease of warehouse premises in Xi’an for a period of three years from July 20, 2011 to July 19, 2014 with annual rent of approximately $37,224 (RMB 235,000) subject to a 10% increase every two years starting July 20, 2013.   The minimum future lease payments for the next five years and thereafter are as follows:   <table style="font: 10pt times new roman, times, serif; width: 100%; border-collapse: collapse;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-weight: bold;">Period</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2">Amount</td> <td style="padding-bottom: 1pt; font-weight: bold;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 85%;">Nine months ending December 31, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">81,568</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Year ending December 31, 2013</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">111,038</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Year ending December 31, 2014</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">67,859</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Year ending December 31, 2015</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">51,322</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Year ending December 31, 2016 and thereafter</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">64,628</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;"> Total</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">376,415</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Rental expense for the three months ended March 31, 2012 and 2011 amounted to $28,020 and $14,396, respectively.    (b)  Legal proceedings   From time to time, the Company is involved in legal matters arising in the ordinary course of business. Management currently is not aware of any legal matters or pending litigation which would have a significant effect on the Company’s consolidated financial statements as of March 31, 2012.   In May 2007, Andrew Chien filed suit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in United States District Court for the District of Connecticut, alleging causes of action for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 17, 2008, in a decision that is now published, the court granted defendants’ motion to dismiss and subsequently dismissed the lawsuit, entering judgment on behalf of the defendants. Chien appealed the dismissal. Defendants filed a postjudgment motion for sanctions against Chien. On February 5, 2009, the court found the action filed by Chien to have been frivolous, and to have constituted a “substantial” violation of Rule 11, and imposed monetary sanctions on both Chien and his former attorney. Chien appealed the award of sanctions. All appeals, including the one referenced below concerning Chien’s second lawsuit, were subsequently consolidated. The Court of Appeals issued a Mandate upholding the decision granting defendant’s motion to dismiss and found that the District Court did not “abuse its discretion” in issuing sanctions against Chien in light of the circumstances and facts on record. This Mandate was entered on or about November 8, 2010.   Andrew Chien, proceeding pro se (i.e., he represented himself without an attorney), filed his second lawsuit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in Connecticut Superior Court (which was removed to U.S. District Court) alleging causes of action similar to those alleged in his federal complaint described above as well as state law causes of action. The court held that all claims asserted against the defendants were barred and failed to state a claim on a multiplicity of grounds, including on the basis of res judicata . Defendants filed a second Motion for Sanctions under Rule 11 and the PSLRA, which was granted. Chien appealed the dismissal. The Court of Appeals for the Second Circuit consolidated all of Chien’s appeals from both of his lawsuits. On November 8, 2010, the Court of Appeals affirmed the dismissals and the awards of sanctions. On January 22, 2011, Chien filed a petition with the Supreme Court of the United States, appealing the lower court’s ruling. The Supreme Court denied review of the petition.   Andrew Chien, again proceeding pro se, commenced his third lawsuit against the Company, Scott Cramer, Steve Lowe, David Wassung, Weibing Lu (and also Weinberg & Company, P.A., Moore Stephens Wirth Frazer & Torbet, LLP, Frazer Frost, LLP, Crowe Horwath LLP, Richardson & Patel LLP, Kevin K. Leung, Harvey Kesner, and Jody M. Borrelli) alleging the same facts and circumstances as set forth in the above two matters, although adding the aforementioned accountants and lawyers as defendants to the claims. The matter commenced on August 8, 2011, and shortly thereafter was removed to U.S. District Court. On October 5, 2011, the court dismissed the entire action as to all defendants.  As in the two previous lawsuits, sanctions were issued against Chien.  Moreover, the District Court issued an order prohibiting Chien from filing any more lawsuits against the defendants without prior approval from the court.  Chien has appealed the court’s rulings to the United States Court of Appeals for the second circuit, where all defendants have filed motions to dismiss. The United States Court of Appeals for the Second Circuit recently affirmed the judgments and orders of the United States District Court and dismissed all of Mr. Chien’s pending appeals.   Other than the above described legal proceedings, the Company is not aware of any legal matters in which any director, officer, or any owner of record or beneficial owner of more than five percent of any class of voting securities of the Company, or any affiliate of purchaser, or of any such director, officer, affiliate of the Company, or security holder, is a party adverse to the Company or has a material adverse interest to the Company. No provision has been made in the consolidated financial statements for the aforementioned matter.   (c)  Ownership of leasehold property   In 2005, a shareholder contributed a leasehold office building as additional capital of Xi’an Tianxing. However, as of March 31, 2012, title to this leasehold property has not passed to the Company. The Company does not believe there are any legal barriers for the shareholder to transfer the ownership to the Company. However, in the event that the Company fails to obtain the ownership certificate for the leasehold property, there is a risk that we may be required to vacate the building. Management believes that this possibility is remote, and, as such, no provision has been made in the consolidated financial statements for this potential occurrence.   (d) R&D project   In 2008, Xi’an Tianxing contracted with Northwestern Agricultural Technology University to work jointly on an R&D project concerning the application of nano-technology in the prevention of major milk cow disease. The total projected budget for this project is approximately $633,600 (RMB 4,000,000), which is to be paid according to completed stages of the project. The project reached trial stage in September 2009. As of March 31, 2012, the Company incurred approximately $476,400 (RMB 3,000,000) of cumulative expenses relating to this project.   In 2009, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project on fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents. The contracted amount for this project is approximated $950,400 (RMB 6,000,000). As of March 31, 2012, the Company has incurred approximately $539,920 (RMB 3,400,000) of cumulative expenses relating to this project.   During the first quarter of 2011, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project to develop new treatment and diagnosis method for Mycoplasmal pneumonia of swine. The project term is from January 2011 through September 2013. The cost to the Company for the initial phase is approximately $316,800 (RMB 2,000,000). As of March 31, 2012, the Company has incurred approximately $79,400 (RMB 500,000).   During the second quarter of 2011, Xi’an Tianxing launched four new R&D projects to develop ceftiofur sodium for injection (powder for injection), a sulfuric acid injection neostigmine, dexamethasone sodium phosphate injection, and houttuynia preparation of compound application in weaning piglets. The projected budget for the R&D project of ceftiofur sodium for injection (powder for injection) is approximately $554,400 (RMB 3,500,000). As of March 31, 2012, the Company has incurred approximately $438,288 (RMB 2,760,000). The projected budget for the R&D project of a sulfuric acid injection neostigmine is approximately $475,200 (RMB 3,000,000). As of March 31, 2012, the Company has incurred approximately $269,971 (RMB 1,700,071). The projected budget for the R&D project of dexamethasone sodium phosphate injection is approximately $554,400 (RMB 3,500,000). As of March 31, 2012, the Company has incurred approximately $464,683 (RMB 2,926,215). The projected budget for the R&D project of houttuynia preparation of compound application in weaning piglets is approximately $712,800 (RMB 4,500,000). As of March 31, 2012, the Company has incurred approximately $681,828 (RMB 4,293,630).   In addition, the Company also launched various R&D projects in 2011 on veterinary products formula adjustment, pet drug development and fermentation engineering design and development and lab tests. As of March 31, 2012, approximately $858,272 (RMB 5,404,737) has been incurred related to these projects and lab tests.   R&D projects are summarized as follows:   <table style="font: 10pt times new roman, times, serif; width: 88%; border-collapse: collapse;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify;">Project</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Amount incurred as of 3/31/2012</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Amount expected to be incurred</td> <td style="padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: center;" colspan="2">Total amount of project</td> <td style="padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 55%;">Project with the Fourth Military Medical University (1)</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">539,920</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">411,840</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 12%;">950,400</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Project with Northwestern Agricultural Technology University  (2)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">476,400</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">158,400</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">633,600</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Project with the Fourth Military Medical University (3)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">79,400</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">237,600</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">316,800</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>In-house R&D project (4)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">438,288</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">117,216</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">554,400</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>In-house R&D project (5)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">269,971</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">205,909</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">475,200</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>In-house R&D project (6)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">464,683</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">90,888</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">554,400</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>In-house R&D project (7)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">681,828</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">32,689</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">712,800</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Other in-house R&D projects (8)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">858,273</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">15,840</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">871,950</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">TOTAL</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">3,808,763</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,270,382</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">5,069,550</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   (1) Project for fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents (2) Project for application of nano-technology in the prevention of major milk cow disease (3) Project for new treatment and diagnosis method for Mycoplasmal pneumonia of swine (4) Project for ceftiofur sodium for injection (powder for injection) (5) Project for sulfuric acid injection neostigmine (6) Project for dexamethasone sodium phosphate injection (7) Project for houttuynia preparation of compound application in weaning piglets (8) Other projects for veterinary products formula adjustment, pet drug development and fermentation engineering design and development and lab tests   (e) Registered capital commitment   Skystar Kunshan’s remaining registered capital of $12,750,000 is originally required to be invested by May 7, 2012. With the government’s approval, this deadline to invest was extended and we are not required to make the capital investment immediately. As of the date of this report, we have not received the notice from the Government for a new due date. In 2011, the asset acquisition of Kunshan facility was completed. We are in the process of getting the government’s approval to transfer the asset purchased to satisfy some of our registered capital commitment. As of the date of this report, we have not received the approval.   As of March 31, 2012, Skystar Jingzhou has remaining registered capital of $399,168 (RMB 2,520,000) required to be invested. As of the date of this report, the Company has not made this investment.  Skystar Jingzhou is currently in the process of getting the government's approval and will fulfill the requirement of remaining capital of $399,168 (RMB 2,520,000) thereafter. The company expects the process will be completed by the end of the 2nd quarter of 2012 38045 0 558757 EX-101.SCH 8 skbi-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - ORGANIZATION link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - CONCENTRATIONS AND CREDIT RISK link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - ACCOUNTS RECEIVABLE, NET link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - INVENTORIES link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - PLANT AND EQUIPMENT, NET link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - CONSTRUCTION-IN-PROGRESS link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - LONG-TERM PREPAYMENTS link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - LOANS RECEIVABLE link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - SHORT-TERM LOANS link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - DEFERRED GOVERNMENT GRANT link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - CAPITAL TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - STATUTORY RESERVES link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - TAXES link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - EARNINGS PER SHARE link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - RELATED PARTY TRANSACTIONS AND ARRANGEMENTS link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 9 skbi-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 skbi-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 skbi-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] DOCUMENT AND ENTITY INFORMATION Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Cash, Cash Equivalents, and Short-Term Investments Cash Cash Accounts Receivable, Net, Current Accounts receivable, net of allowance for doubtful accounts of $480,237 (Unaudited) and $438,678 as of March 31, 2012 and December 31, 2011, respectively Accounts Receivable, Net, Current, Total Inventory, Net Inventories Inventories Prepaid Expense, Current Deposits, prepaid expenses and other receivables Deposits and prepaid expenses Notes, Loans and Financing Receivable, Net, Current Loans receivable Loans receivable Assets, Current Total current assets Total current assets Property and Equipment, Net Other PLANT AND EQUIPMENT, NET This element represents capitalized assets classified as property, plant and equipment excluding construction in progress gross. Construction In Progress, Gross CONSTRUCTION-IN-PROGRESS Assets, Noncurrent [Abstract] OTHER ASSETS: Prepaid Expense, Noncurrent Long-term prepayments Long-term prepayments Long Term Prepayments For Acquisitions Long-term prepayments for acquisitions The total of the carrying amounts as of the balance sheet date of amounts paid in advance for acquisitions. Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Intangible assets, net Assets, Noncurrent Total other assets Total other assets Assets Total assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Other Payable and Accrued Expenses Other payable and accrued expenses The carrying amount as of the balance sheet date of other payable and accrued expenses. Short-Term Debt Short-term loans Short-term loans Customer Advances, Current Deposits from customers Taxes Payable, Current Taxes payable Taxes payable Due To Related Parties, Current Due to related parties Due to related parties Liabilities, Current Total current liabilities Total current liabilities Liabilities, Noncurrent [Abstract] OTHER LIABILITIES: Deferred Revenue and Credits, Noncurrent Deferred government grant Deferred government grant Derivative Liabilities, Noncurrent Warrant/purchase option liability Warrant/purchase option liability Liabilities, Noncurrent Total other liabilities Total other liabilities Liabilities Total liabilities Total liabilities Stockholders Equity Attributable To Parent [Abstract] SHAREHOLDERS' EQUITY Common Stock, Value, Issued Common stock, $0.001 par value, 40,000,000 shares authorized, 7,161,919 shares issued and outstanding as of March 31, 2012 (Unaudited) and December 31, 2011 Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Additional Paid In Capital, Common Stock Paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Statutory Reserves Statutory reserves The entire disclosure for statutory reserve. Retained Earnings (Accumulated Deficit) Retained earnings Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Accumulated Other Comprehensive Income (Loss), Net Of Tax Accumulated other comprehensive income Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Stockholders Equity Attributable To Parent Total shareholders' equity Total shareholders' equity BALANCE BALANCE Liabilities and Equity Total liabilities and shareholders' equity Total liabilities and shareholders' equity Condensed Balance Sheets [Parentheticals] [Abstract] Condensed Balance Sheets [Parentheticals] [Abstract] Class Of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series B Preferred Stock [Member] Series B Preferred Stock Allowance For Doubtful Accounts Receivable, Current Allowance for doubtful accounts (in dollars) Allowance for Doubtful Accounts Receivable, Current, Beginning Balance Allowance for Doubtful Accounts Receivable, Current, Ending Balance Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Income Statement [Abstract] Income Statement [Abstract] Sales Revenue, Goods, Net REVENUE, net REVENUE, NET Cost Of Goods Sold COST OF REVENUE COST OF REVENUE Gross Profit GROSS PROFIT GROSS PROFIT Operating Expenses [Abstract] OPERATING EXPENSES: Research and Development Expense Research and development costs Research and development Selling Expense Selling expenses General and Administrative Expense General and administrative expenses General and administrative Operating Expenses Total operating expenses Total operating expenses Operating Income (Loss) INCOME FROM OPERATIONS INCOME FROM OPERATIONS Nonoperating Income (Expense) [Abstract] OTHER INCOME (EXPENSE): Other Nonoperating Income (Expense) Other income, net Other income (expense), net Interest Income (Expense), Net Interest income (expense), net Gain (Loss) On Derivative Instruments, Net, Pretax Change in fair value of warrant/purchase option liability Change in fair value of warrant/purchase option liability Nonoperating Income (Expense) Total other income (expense), net Total other income (expense), net Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest INCOME BEFORE PROVISION FOR INCOME TAXES Income Tax Expense (Benefit) PROVISION FOR INCOME TAXES PROVISION FOR INCOME TAXES Net Income (Loss) Attributable To Parent Net income NET INCOME NET INCOME Other Comprehensive Income (Loss), Net Of Tax, Portion Attributable To Parent [Abstract] OTHER COMPREHENSIVE INCOME: Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net Of Tax, Portion Attributable To Parent Foreign currency translation adjustment Foreign currency translation adjustment Comprehensive Income (Loss), Net Of Tax, Attributable To Parent COMPREHENSIVE INCOME COMPREHENSIVE INCOME Earnings Per Share, Basic and Diluted [Abstract] EARNINGS PER SHARE: Earnings Per Share, Basic Basic (in dollars per share) Basic Earnings Per Share, Diluted Diluted (in dollars per share) Diluted Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] WEIGHTED AVERAGE NUMBER OF COMMON SHARES: Weighted Average Number Of Shares Outstanding, Basic Basic (in shares) Basic Weighted Average Number Of Shares Outstanding, Diluted Diluted (in shares) Diluted Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation Depreciation Depreciation Amortization Amortization Amortization Provision For Doubtful Accounts Provision for doubtful accounts Increase (Decrease) In Operating Capital [Abstract] Change in operating assets and liabilities Increase (Decrease) In Accounts Receivable Accounts receivable Accounts receivable Increase (Decrease) In Inventories Inventories Inventories Inventories Increase (Decrease) In Prepaid Expense Deposits, prepaid expenses and other receivables Deposits, prepaid expenses and other receivables Increase (Decrease) In Other Receivables Other payable and accrued expenses Other payable and accrued expenses Increase (Decrease) In Accounts Payable Accounts payable Accounts payable Increase (Decrease) In Customer Advances Deposits from customers Increase (Decrease) In Accrued Taxes Payable Taxes payable Taxes payable Net Cash Provided By (Used In) Operating Activities Net cash provided by (used in) operating activities Net cash provided by (used in) operating activities Net Cash Provided By (Used In) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments To Acquire Intangible Assets Purchases of intangible assets Purchases of intangible assets Payments Of Long Term Prepayments Payments of long-term prepayments The cashflow for long-term prepayments during the period. Payments of long-term prepayments Payments To Acquire Loans Receivable Loans to third parties Loans receivables Proceeds From Collection Of Loans Receivable Collection of loans receivables Payments To Acquire Other Property, Plant, and Equipment Purchases of plant and equipment Purchases of plant and equipment Payments For Construction In Process Payments on construction-in-progress Payments on construction-in-progress Payments on construction-in-progress Payments on construction-in-progress Net Cash Provided By (Used In) Investing Activities Net cash (used in) provided by investing activities Net cash (used in) provided by investing activities Net Cash Provided By (Used In) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds From Short-Term Debt Proceeds from short-term loans Proceeds from short-term loans Proceeds From (Repayments Of) Accounts Payable (Receivable) To Related Party Due to related parties Due (from) to related parties The net cash inflow or outflow from the proceeds and repayments made on the accounts payable (receivable) to related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and such forth. Net Cash Provided By (Used In) Financing Activities Net cash provided by financing activities Net cash provided by financing activities Effect Of Exchange Rate On Cash and Cash Equivalents EFFECT OF EXCHANGE RATE CHANGES ON CASH EFFECT OF EXCHANGE RATE CHANGES ON CASH Cash, Period Increase (Decrease) INCREASE IN CASH INCREASE IN CASH Cash and Cash Equivalents, At Carrying Value CASH, beginning of period Cash and Cash Equivalents, at Carrying Value, Total CASH, beginning of period CASH, end of period Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest Paid Cash paid for interest Cash paid for interest Noncash Investing and Financing Items [Abstract] Non-cash investing and financing activities Long Term Prepayment Transferred To Construction In Progress Long-term prepayment transferred to construction-in-progress Long-term prepayment transferred to construction-in-progress The long-term prepayment transferred to construction-in-progress in non cash investing and financing activities. Construction In Progress Transferred To Property Plant and Equipment Construction-in-progress transferred to property, plant and equipment Construction-in-progress transferred to property, plant and equipment The construction-in-progress transferred to property, plant and equipment in non cash investing and financing activities. Statement Of Stockholders Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement, Equity Components [Axis] Statement, Equity Components [Axis] Common Stock [Member] Common Stock Paid-In Capital [Member] Paid-in Capital Retained Earnings, Appropriated [Member] Retained Earnings Statutory Reserves Retained Earnings, Unappropriated [Member] Retained Earnings Unrestricted Accumulated Other Comprehensive Income [Member] Accumulated Other Comprehensive Income Shares, Outstanding BALANCE (in shares) BALANCE (in shares) BALANCE (in shares) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net Of Tax Foreign currency translation Foreign currency translation Foreign currency translation Organization, Consolidation and Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Significant Accounting Policies [Text Block] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Concentration Risk Disclosure [Text Block] Concentration Risk Disclosure [Text Block] Accounts Receivable Disclosure [Abstract] Accounts Receivable Disclosure [Abstract] Accounts Receivable Disclosure [Text Block] Accounts Receivable Disclosure [Text Block] The entire disclosure for accounts receivable disclosure during the reporting period. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Inventory Disclosure [Text Block] Deposits and Prepaid Expenses Disclosure [Abstract] Deposits and Prepaid Expenses Disclosure [Abstract] Deposits and Prepaid Expenses Disclosure [Text Block] Deposits and Prepaid Expenses Disclosure [Text Block] The entire disclosure for deposits and prepaid expenses and any other receivables during the reporting period. Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Property and Equipment Net Excluding Constion Work In Progress [Text Block] Property and Equipment, Net [Text Block] The entire disclosure for long-lived, physical assets excluding construction work in progress that are used in the normal conduct of business to produce goods and services and not intended for resale. Construction In Progress Disclosure [Abstract] Construction In Progress Disclosure [Abstract] Construction In Progress Disclosure [Text Block] Construction In Progress Disclosure [Text Block] The entire disclosure for long-lived, physical assets that are used in the construction-in-progress during the reporting period. Long Term Prepayments Disclosure [Abstract] Long Term Prepayments Disclosure [Abstract] Long Term Prepayments Disclosure [Text Block] Long Term Prepayments Disclosure [Text Block] The entire disclosure for long term prepayments during the reporting period. Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Intangible Assets Disclosure [Text Block] Receivables [Abstract] Receivables [Abstract] Loans Receivable Disclosure [Text Block] Loans Receivable Disclosure [Text Block] The entire disclosure for loans receivable during the reporting period. Debt Disclosure [Abstract] Debt Disclosure [Abstract] Short-Term Debt [Text Block] Short-term Debt [Text Block] Deferred Government Grant Disclosure [Abstract] Deferred Government Grant Disclosure [Abstract] Deferred Government Grant Disclosure [Text Block] Deferred Government Grant Disclosure [Text Block] The entire disclosure for deferred government grant during the reporting period. Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Note [Abstract] Stockholders Equity Note Disclosure [Text Block] Stockholders' Equity Note Disclosure [Text Block] Taxes Disclosure [Abstract] Taxes Disclosure Abstract Taxes Disclosure [Text Block] Taxes Disclosure Text Block The entire disclosure for income taxes and other taxes which are payable during the reporting period. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share [Text Block] Earnings Per Share [Text Block] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Statement, Scenario [Axis] Scenario, Unspecified [Domain] Other Receivables, Net, Current Other receivables Other receivables Commitments and Contingencies COMMITMENTS AND CONTINGENCIES Preferred Stock, Value, Issued Preferred stock, $0.001 par value, 50,000,000 shares authorized, No Series "A" shares authorized. 48,000,000 Series "B" shares authorized. No Series "B" shares issued and outstanding Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Series A Preferred Stock [Member] Increase (Decrease) In Other Payable and Accrued Expenses Other payables and accrued expenses The increase (decrease) during the reporting period in other obligations and expenses incurred but not yet paid. Equity Component [Domain] Equity Component [Domain] EX-101.PRE 12 skbi-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6

COMMITMENTS AND CONTINGENCIES
3 Months Ended

Mar. 31, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]
Note 18 - COMMITMENTS AND CONTINGENCIES

(a) Lease commitments

The Company recognizes lease expense on the straight-line basis over the term of the lease.

The Company entered into a tenancy agreement for the lease of factory premises in Sanqiao for a period of ten years from October 1, 2004 to December 31, 2014. The annual rent for the factory premises is subject to a 10% increase every two years starting October 1, 2009. As of March 31, 2012, the annual rent for the factory premises was adjusted to approximately $20,212 (RMB 127,600).

The Company leases office space in Xi’an from Mr. Weibing Lu, the Company’s Chairman and CEO, for a period of five years from January 1, 2007 to December 31, 2011, with annual rent of approximately $26,231 (RMB 165,600). In January 2012, the Company renewed the lease with Mr. Lu for another 5 years from January 1, 2012 to December 31, 2016 at rent of approximately $28,512 (RMB 180,000) per year.

The Company also entered into a tenancy agreement with Mr. Weibing Lu for the lease of Shanghai Siqiang’s office in Shanghai for a period of ten years from August 1, 2007 to August 1, 2017 with annual rent of approximately $22,810 (RMB 144,000).

The Company entered into a one year tenancy agreement for an office lease in Kunshan, Jiangsu Province from April 15, 2011 to April 14, 2012 with annual rent of approximately $3,041 (RMB 19,200). On April 15, 2012, the Company entered into a new one year tenancy agreement for this office from April 15, 2012 to April 14, 2013 with annual rent of approximately $3,199 (RMB 20,196).

The Company entered into a tenancy agreement for the lease of warehouse premises in Xi’an for a period of three years from July 20, 2011 to July 19, 2014 with annual rent of approximately $37,224 (RMB 235,000) subject to a 10% increase every two years starting July 20, 2013.

The minimum future lease payments for the next five years and thereafter are as follows:

Period Amount

Nine months ending December 31, 2012 $ 81,568

Year ending December 31, 2013 111,038

Year ending December 31, 2014 67,859

Year ending December 31, 2015 51,322

Year ending December 31, 2016 and thereafter 64,628

Total $ 376,415

Rental expense for the three months ended March 31, 2012 and 2011 amounted to $28,020 and $14,396, respectively.

(b) Legal proceedings

From time to time, the Company is involved in legal matters arising in the ordinary course of business. Management currently is not aware of any legal matters or pending litigation which would have a significant effect on the Company’s consolidated financial statements as of March 31, 2012.

In May 2007, Andrew Chien filed suit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in United States District Court for the District of Connecticut, alleging causes of action for violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 17, 2008, in a decision that is now published, the court granted defendants’ motion to dismiss and subsequently dismissed the lawsuit, entering judgment on behalf of the defendants. Chien appealed the dismissal. Defendants filed a postjudgment motion for sanctions against Chien. On February 5, 2009, the court found the action filed by Chien to have been frivolous, and to have constituted a “substantial” violation of Rule 11, and imposed monetary sanctions on both Chien and his former attorney. Chien appealed the award of sanctions. All appeals, including the one referenced below concerning Chien’s second lawsuit, were subsequently consolidated. The Court of Appeals issued a Mandate upholding the decision granting defendant’s motion to dismiss and found that the District Court did not “abuse its discretion” in issuing sanctions against Chien in light of the circumstances and facts on record. This Mandate was entered on or about November 8, 2010.

Andrew Chien, proceeding pro se (i.e., he represented himself without an attorney), filed his second lawsuit against the Company, R. Scott Cramer, Steve Lowe, David Wassung and Weibing Lu in Connecticut Superior Court (which was removed to U.S. District Court) alleging causes of action similar to those alleged in his federal complaint described above as well as state law causes of action. The court held that all claims asserted against the defendants were barred and failed to state a claim on a multiplicity of grounds, including on the basis of res judicata . Defendants filed a second Motion for Sanctions under Rule 11 and the PSLRA, which was granted. Chien appealed the dismissal. The Court of Appeals for the Second Circuit consolidated all of Chien’s appeals from both of his lawsuits. On November 8, 2010, the Court of Appeals affirmed the dismissals and the awards of sanctions. On January 22, 2011, Chien filed a petition with the Supreme Court of the United States, appealing the lower court’s ruling. The Supreme Court denied review of the petition.

Andrew Chien, again proceeding pro se, commenced his third lawsuit against the Company, Scott Cramer, Steve Lowe, David Wassung, Weibing Lu (and also Weinberg & Company, P.A., Moore Stephens Wirth Frazer & Torbet, LLP, Frazer Frost, LLP, Crowe Horwath LLP, Richardson & Patel LLP, Kevin K. Leung, Harvey Kesner, and Jody M. Borrelli) alleging the same facts and circumstances as set forth in the above two matters, although adding the aforementioned accountants and lawyers as defendants to the claims. The matter commenced on August 8, 2011, and shortly thereafter was removed to U.S. District Court. On October 5, 2011, the court dismissed the entire action as to all defendants. As in the two previous lawsuits, sanctions were issued against Chien. Moreover, the District Court issued an order prohibiting Chien from filing any more lawsuits against the defendants without prior approval from the court. Chien has appealed the court’s rulings to the United States Court of Appeals for the second circuit, where all defendants have filed motions to dismiss. The United States Court of Appeals for the Second Circuit recently affirmed the judgments and orders of the United States District Court and dismissed all of Mr. Chien’s pending appeals.

Other than the above described legal proceedings, the Company is not aware of any legal matters in which any director, officer, or any owner of record or beneficial owner of more than five percent of any class of voting securities of the Company, or any affiliate of purchaser, or of any such director, officer, affiliate of the Company, or security holder, is a party adverse to the Company or has a material adverse interest to the Company. No provision has been made in the consolidated financial statements for the aforementioned matter.

(c) Ownership of leasehold property

In 2005, a shareholder contributed a leasehold office building as additional capital of Xi’an Tianxing. However, as of March 31, 2012, title to this leasehold property has not passed to the Company. The Company does not believe there are any legal barriers for the shareholder to transfer the ownership to the Company. However, in the event that the Company fails to obtain the ownership certificate for the leasehold property, there is a risk that we may be required to vacate the building. Management believes that this possibility is remote, and, as such, no provision has been made in the consolidated financial statements for this potential occurrence.

(d) R&D project

In 2008, Xi’an Tianxing contracted with Northwestern Agricultural Technology University to work jointly on an R&D project concerning the application of nano-technology in the prevention of major milk cow disease. The total projected budget for this project is approximately $633,600 (RMB 4,000,000), which is to be paid according to completed stages of the project. The project reached trial stage in September 2009. As of March 31, 2012, the Company incurred approximately $476,400 (RMB 3,000,000) of cumulative expenses relating to this project.

In 2009, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project on fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents. The contracted amount for this project is approximated $950,400 (RMB 6,000,000). As of March 31, 2012, the Company has incurred approximately $539,920 (RMB 3,400,000) of cumulative expenses relating to this project.

During the first quarter of 2011, Xi’an Tianxing contracted with the Fourth Military Medical University to jointly work on an R&D project to develop new treatment and diagnosis method for Mycoplasmal pneumonia of swine. The project term is from January 2011 through September 2013. The cost to the Company for the initial phase is approximately $316,800 (RMB 2,000,000). As of March 31, 2012, the Company has incurred approximately $79,400 (RMB 500,000).

During the second quarter of 2011, Xi’an Tianxing launched four new R&D projects to develop ceftiofur sodium for injection (powder for injection), a sulfuric acid injection neostigmine, dexamethasone sodium phosphate injection, and houttuynia preparation of compound application in weaning piglets. The projected budget for the R&D project of ceftiofur sodium for injection (powder for injection) is approximately $554,400 (RMB 3,500,000). As of March 31, 2012, the Company has incurred approximately $438,288 (RMB 2,760,000). The projected budget for the R&D project of a sulfuric acid injection neostigmine is approximately $475,200 (RMB 3,000,000). As of March 31, 2012, the Company has incurred approximately $269,971 (RMB 1,700,071). The projected budget for the R&D project of dexamethasone sodium phosphate injection is approximately $554,400 (RMB 3,500,000). As of March 31, 2012, the Company has incurred approximately $464,683 (RMB 2,926,215). The projected budget for the R&D project of houttuynia preparation of compound application in weaning piglets is approximately $712,800 (RMB 4,500,000). As of March 31, 2012, the Company has incurred approximately $681,828 (RMB 4,293,630).

In addition, the Company also launched various R&D projects in 2011 on veterinary products formula adjustment, pet drug development and fermentation engineering design and development and lab tests. As of March 31, 2012, approximately $858,272 (RMB 5,404,737) has been incurred related to these projects and lab tests.

R&D projects are summarized as follows:

Project Amount
incurred as
of 3/31/2012 Amount
expected to
be
incurred Total amount
of
project

Project with the Fourth Military Medical University (1) $ 539,920 $ 411,840 $ 950,400

Project with Northwestern Agricultural Technology University (2) 476,400 158,400 633,600

Project with the Fourth Military Medical University (3) 79,400 237,600 316,800

In-house R&D project (4) 438,288 117,216 554,400

In-house R&D project (5) 269,971 205,909 475,200

In-house R&D project (6) 464,683 90,888 554,400

In-house R&D project (7) 681,828 32,689 712,800

Other in-house R&D projects (8) 858,273 15,840 871,950

TOTAL $ 3,808,763 $ 1,270,382 $ 5,069,550

(1) Project for fish diseases linked immunosorbent detection kit and fish diseases multi-linked monoclonal antibody therapeutic agents

(2) Project for application of nano-technology in the prevention of major milk cow disease

(3) Project for new treatment and diagnosis method for Mycoplasmal pneumonia of swine

(4) Project for ceftiofur sodium for injection (powder for injection)

(5) Project for sulfuric acid injection neostigmine

(6) Project for dexamethasone sodium phosphate injection

(7) Project for houttuynia preparation of compound application in weaning piglets

(8) Other projects for veterinary products formula adjustment, pet drug development and fermentation engineering design and development and lab tests

(e) Registered capital commitment

Skystar Kunshan’s remaining registered capital of $12,750,000 is originally required to be invested by May 7, 2012. With the government’s approval, this deadline to invest was extended and we are not required to make the capital investment immediately. As of the date of this report, we have not received the notice from the Government for a new due date. In 2011, the asset acquisition of Kunshan facility was completed. We are in the process of getting the government’s approval to transfer the asset purchased to satisfy some of our registered capital commitment. As of the date of this report, we have not received the approval.

As of March 31, 2012, Skystar Jingzhou has remaining registered capital of $399,168 (RMB 2,520,000) required to be invested. As of the date of this report, the Company has not made this investment. Skystar Jingzhou is currently in the process of getting the government's approval and will fulfill the requirement of remaining capital of $399,168 (RMB 2,520,000) thereafter. The company expects the process will be completed by the end of the 2nd quarter of 2012

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONCENTRATIONS AND CREDIT RISK
3 Months Ended

Mar. 31, 2012

Risks and Uncertainties [Abstract]

Concentration Risk Disclosure [Text Block]
Note 3 - CONCENTRATIONS AND CREDIT RISK

The Company’s operations are all carried out in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC’s economy. The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic, and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

Financial instruments which subject the Company to concentration of credit risk consist of cash and accounts receivable. Balances at financial institutions or state-owned banks within the PRC are not covered by insurance. The Company has not experienced any losses in such accounts. The Company provides unsecured credit terms for sales to certain customers. As a result, there are credit risks with the accounts receivable balances. The Company constantly re-evaluates the credit worthiness of customers buying on credit and maintains an allowance for doubtful accounts.

For the three months ended March 31, 2012 and 2011, all of the Company’s sales occurred in the PRC. No major customers accounted for more than 10% of the Company’s total revenues. All accounts receivable at March 31, 2012 and December 31, 2011 are from customers located in the PRC.

The Company’s six largest vendors accounted for approximately 85% and 73% of the Company’s total purchases, respectively, for the three months ended March 31, 2012 and 2011.

The Company had one product that accounted for 23% and 15% of the Company’s total revenues for the three months ended March 31, 2012 and 2011, respectively

X

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 21, 22, 24

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13531-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R9C-B-#5A9%]A8C!B7S0R-#E?.#(Q-%]E,S,Y M-38W,C!C9#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5- M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1%4$]325137U!215!!241?15A014Y315-?04Y$7SPO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!,04Y47T%.1%]%455) M4$U%3E1?3D54/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DQ/3D=415)-7U!215!!64U%3E13/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I% M>&-E;%=O#I%>&-E;%=O#I7;W)K M#I7;W)K#I7;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H M:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S)F,V(T-6%D7V%B,&)?-#(T.5\X,C$T7V4S,SDU-C'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^43$\'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C-B-#5A M9%]A8C!B7S0R-#E?.#(Q-%]E,S,Y-38W,C!C9#D-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,F8S8C0U861?86(P8E\T,C0Y7S@R,31?93,S.34V M-S(P8V0Y+U=O'0O:'1M;#L@8VAA6UE;G1S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$X.2PW.#@\6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@ M8VQA3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^)FYBF5D+B!.;R!397)I97,@(D(B M('-H87)E3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'!E;G-E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2`H=7-E9"!I;BD@;W!E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'!E;G-E'!E;G-E M2`H=7-E9"!I;BD@;W!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(&]N(&-O;G-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE7-T87(@0FEO+5!H87)M86-E=71I M8V%L($-O;7!A;GD@*"8C.#(R,#M3:WES=&%R)B,X,C(Q.R!O7-T87(@0FEO+5!H87)M86-E M=71I8V%L("A#87EM86XI($AO;&1I;F=S($-O+BP@3'1D+B`H)B,X,C(P.U-K M>7-T87(@0V%Y;6%N)B,X,C(Q.RDL(&$@0V%Y;6%N($ES;&%N9',@8V]M<&%N M>2P@=&AE($-O;7!A;GD@:&%S(&)E96X@96YG86=E9"!I;B!T:&4@2!A3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!C;VYT M6UA;B!U;F1E2`H6&DF(S@R,3<[86XI($-O+BP@3'1D+B`H)B,X M,C(P.U-I9&$F(S@R,C$[*2P@82!04D,@8V]M<&%N>2X@4VED82!I2!A;F0@=VAO;&QY(&]W;F5D('-U M8G-I9&EA3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E&EN9R!A2`H)B,X,C(P M.U9)128C.#(R,3LI('5N9&5R('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3 M=&%N9&%R9',@0F]A2P@=&AE($-O;7!A;GD@8V]N M3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M2!O9B!3:WES=&%R+B!/;B!$ M96-E;6)E7-T87(@0V%L:69O M2!#;RXL($QT9"X@*"8C M.#(R,#M+=6YS:&%N(%-I:V5D828C.#(R,3LI('=A3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E7-T87(@2W5N2!I3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-EFAO=2D@ M0V\N+"!,:6UI=&5D("@F(S@R,C`[4VMYFAO=28C.#(R,3LI M+"!A(&-O;7!A;GD@97-T86)L:7-H960@:6X@2FEN9WIH;W4L($AU8F5I(%!R M;W9I;F-E+"!#:&EN82!O;B!&96)R=6%R>2`U+"`R,#$P+"!W:71H(')E9VES M=&5R960@8V%P:71A;"!O9B!A<'!R;WAI;6%T96QY("0T+C$@;6EL;&EO;B`H M4DU"(#(V+#`P,"PP,#`I+"!O9B!W:&EC:"!A<'!R;WAI;6%T96QY("0S+C<@ M;6EL;&EO;B`H4DU"(#(S+#0X,"PP,#`I(&AA2`D,SDY+#$V."`H4DU"(#(L-3(P+#`P M,"D@:7,@2!I;B!T:&4@<')O8V5S M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6UA;BP@1F]R='5N871E(%1I;64L(%-I9&$L(%AI)B,X,C$W.V%N(%1I86YX M:6YG+"!3:WES=&%R($MU;G-H86XL($MU;G-H86X@4VEK961A+"!3:WES=&%R M($II;F=Z:&]U+"!3:&%N9VAA:2!3:7%I86YG+"!A;F0@6&DF(S@R,3<[86X@ M4VEK86ED82!A2!R969E'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE65A2P@=VAI8V@@87)E(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)B,X,C$W M.W,@06YN=6%L(%)E<&]R="!O;B!&;W)M(#$P+4L@9F]R('1H92!F:7-C86P@ M>65A&-H86YG92!#;VUM:7-S:6]N("@F(S@R,C`[4T5# M)B,X,C(Q.RDN/"]P/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E2P@:71S M('-U8G-I9&EA6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE2P@ M8F5I;F<@=&AE('!R:6UA2!T&-H86YG92!R871E2!F3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!P87EM96YT2!T:&4@4&5O<&QE)B,X M,C$W.W,@0F%N:R!O9B!#:&EN82!O6UE;G0@87!P;&EC871I;VX@9F]R;2!T M;V=E=&AE&-H86YG92!R871E(&9L=6-T=6%T:6]N M2!O M=&AE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE'!E8W1E9"!R96%L:7IA=&EO;B!A;F0L(&EF(&%P<&QI8V%B M;&4L('1H96ER(&-U3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`S)3LG/B8C.#(R-CL\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2P@9F]R('-U M8G-T86YT:6%L;'D@=&AE(&9U;&P@=&5R;2!O9B!T:&4@9FEN86YC:6%L(&EN M6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W=I9'1H.B`S)3LG/B8C.#(R-CL\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE28C,38P.V5S=&EM M871E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W=I9'1H.B`T."4[)SY3=&]C:R!P6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`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`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`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE2!L979E;"!W:71H:6X@=&AE(&9A M:7(@=F%L=64@:&EE6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A M8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M,3`E.R<^,S6QE/3-$)W=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\ M+W1A8FQE/@T*/'`@3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E M.R<^-#,L-#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M86QI M9VXZ(')I9VAT.R<^*#4L-C`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^*3PO=&0^#0H\+W1R M/@T*/'1R('-T>6QE/3-$)V)A8VMG'0M86QI9VXZ(&QE M9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,S&EM871E('1H96ER(&9A:7(@=F%L M=64@9'5E('1O('1H92!S:&]R="UT97)M(&YA='5R92!O9B!T:&5S92!I;G-T M3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E2!I6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M2!H96%L=&AC87)E(&%N9"!M961I8V%L(&-A&ES=',L(&1E;&EV M97)Y(&AA2!A3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE/3-$)W9E6QE/3-$)W9E3L@=VED=&@Z M(#DW)3LG/D9U;&P@<&%Y;65N="!B969O6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE2X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE28C.#(Q-SMS(')E=F5N=65S(&%N9"!C M;W-T(&]F(')E=F5N=65S(&)Y('!R;V1U8W0@;&EN92!W97)E(&%S(&9O;&QO M=W,Z)B,Q-C`[/"]P/@T*/'`@6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M M8V]L;&%P'0M86QI9VXZ(&-E;G1E'0M86QI M9VXZ(&-E;G1E6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W=I9'1H.B`W,"4[)SY-:6-R M;RUO6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^,2PU M.38L,#DT/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY&965D($%D9&ET M:79E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/"]T'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\ M='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`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`[/"]T9#X-"CQT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^,RPT.3$L,S0V/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@ M,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W!A M9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E2!O;B!H86YD+"!D96UA;F0@9&5P;W-I=',@=VET:"!B86YK6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE2!UF5D(&)Y('1H92!N=6UB97(@;V8@;6]N M=&AS('1H92!U;F1E28C.#(Q-SMS(&%C8V]U;G1S(')E8V5I=F%B;&4@;6%Y('1A:V4@ M;VYE('EE87(N($1E;&EN<75E;G0@86-C;W5N="!B86QA;F-E3L@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E'1E;F0@=&AE('5S969U;"!L M:79E6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L M;&%P6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@,34E.R<^,3`M-#`@>65A6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M-2!Y96%R6QE/3-$)W9E6EN9R!V86QU92!O9B!P;&%N="!A;F0@97%U:7!M96YT(&%N;G5A M;&QY(&]R(&UO'!E8W1E M9"!F=71U6EN9R!A;6]U M;G0@;V8@=&AE(&%S3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE2!B=6EL9&EN9RX@26YT97)E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E65AFAO=2!F86-I;&ET>2!W87,@,S`@>65A6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!G65A2!T:&4@36EN:7-T3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E6EN M9R!V86QU92!O9B!I;G1A;F=I8FQE(&%S2!O2!S=6-H(&EN=&%N9VEB;&4@87-S970@ M:7,@;&5S6EN9R!A;6]U;G0L(&$@;&]SF5D(&)A&-E<'0@=&AA="!F86ER(&UA6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&5S(&%R92!R96-O9VYI>F5D(&9O"!B87-E&ES=&EN9R!AF5D M+CPO<#X-"CQP('-T>6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!I9B!I="!I"!P;W-I=&EO;B!W;W5L9"!B92!S=7-T M86EN960@:6X@82!T87@@97AA;6EN871I;VXL('=I=&@@82!T87@@97AA;6EN M871I;VX@8F5I;F<@<')E2!O9B!B96EN9R!R96%L M:7IE9"!O;B!E>&%M:6YA=&EO;BX@1F]R('1A>"!P;W-I=&EO;G,@;F]T(&UE M971I;F<@=&AE("8C.#(R,#MM;W)E(&QI:V5L>2!T:&%N(&YO="8C.#(R,3L@ M=&5S="P@;F\@=&%X(&)E;F5F:70@:7,@F5D('1A>"!B96YE M9FET&EN9R!A=71H;W)I=&EE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE28C.#(Q M-SMS('=O&ES=&EN9R!T87@@;&%W2!B92!U;F-E M3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E65A2!T:&4@=&%X<&%Y97(@;W(@=&AE('=I=&AH M;VQD:6YG(&%G96YT+B8C,38P.R8C,38P.U1H92!S=&%T=71E(&]F(&QI;6ET M871I;VYS(&5X=&5N9',@=&\@9FEV92!Y96%R65A M"!R971U6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E&5R8VES960N($9U2!I M9B!T:&4@2!S=&]C:R!M971H;V0N(%5N9&5R('1H:7,@;65T M:&]D+"!O<'1I;VYS(&%N9"!W87)R86YT&5R8VES960@870@=&AE(&)E9VEN;FEN9R!O9B!T:&4@<&5R:6]D("AO2!W97)E('5S960@=&\@<'5R8VAA3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!O2P@:71S M(&UA;F%G96UE;G0L(&UE;6)E3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!M M961I8VEN92P@9F5E9"!A9&1I=&EV97,@86YD('9A8V-I;F5S*2!A2!M86YA9V5M96YT('1O(&)E(&%G9W)E9V%T960@:6X@;VYE M(')E<&]R=&%B;&4@;W!E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2`Q+"`R,#$S M+"!A;F0@:6YT97)I;2!P97)I;V1S('=I=&AI;B!T:&]S92!A;FYU86P@<&5R M:6]D2!T:&]S92!A;65N9&UE;G1S(')E=')O2!F;W(@86QL(&-O;7!A2!D;V5S(&YO="!E>'!E8W0@=&AE(&%D;W!T:6]N(&]F('1H92!P M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE2!D M969E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!T:&4@1D%30B!O28C.#(Q-SMS(&-O;G-O;&ED871E9"!F:6YA;F-I86P@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`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`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!I;G-U M'!E2!R M92UE=F%L=6%T97,@=&AE(&-R961I="!W;W)T:&EN97-S(&]F(&-U28C.#(Q-SMS('-I>"!L M87)G97-T('9E;F1O6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`W,"4[)SY!8V-O=6YT(')E8V5I=F%B M;&4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@'0M86QI9VXZ M(')I9VAT.R<^*#0X,"PR,S<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M'0M86QI9VXZ(&QE9G0[ M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-2PW.#,L.#,Q/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I M;F6QE/3-$)V)A8VMG2`Q+"`R,#$R/"]T9#X-"CQT M9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,S@L.#8Y/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^)B,X,C$R.SPO=&0^#0H\=&0@6QE/3-$)V)A M8VMG6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)O6QE/3-$ M)V)O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA2!$ M:7-C;&]S=7)E(%M!8G-T'0@ M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL M93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^,3(L-C0V+#8V M,SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,3@Q+#,P-#PO M=&0^#0H\=&0@6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M,2PU-30L-3`W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^,BPQ-S$L,C,X/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\ M='(@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^-3(L,C$Y/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,30L,3@U+#$X-3PO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(')I9VAT.R<^*#(R,2PV.3`\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R<^,3,L.38R+#`X-SPO=&0^#0H\=&0@6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2!R979I97=S(&ET'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS M1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)W!A M9&1I;F6QE/3-$ M)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R<^,S0L.3$T+#0W-CPO=&0^#0H\=&0@6QE/3-$)V)O6QE M/3-$)V)O2!C;W-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\R9C-B-#5A9%]A8C!B7S0R-#E?.#(Q-%]E,S,Y-38W,C!C9#D-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F8S8C0U861?86(P8E\T,C0Y M7S@R,31?93,S.34V-S(P8V0Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'`@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE M/3-$)V)A8VMG2!A;F0@97%U:7!M96YT/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-2PW-C0L-#
6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^-2PV-S4L.3DU/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,C@L,S3L@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE2!I;B`R,#`U M+"!A;F0@:70@=V%S(&-O;7!L971E9"!I;B`R,#$P(&%N9"!R97-U;'1E9"!I M;B!A('1R86YS9F5R('1O)B,Q-C`[<&QA;G0@86YD(&5Q=6EP;65N="!O9B`D M.2PT-#@L-3`U+B8C,38P.TEN(#(P,3$L('1H92!#;VUP86YY('-T87)T960@ M='=O('!R;VIE8W1S(&%T('1H92!V86-C:6YE(&9A8VEL:71Y('1O(&UO9&EF M>2!A:7(@9FEL=')A=&EO;BP@=V%T97(@=')E871M96YT+"!A;F0@;W1H97(@ M9F%C:6QI='D@8VAA;F=E'!E2!H860@82!T;W1A;"!I;B!C;VYS=')U8W1I M;VXM:6XM<')O9W)E2!E>'!E8W1S('1H92!'35`@8V5R=&EF:6-A=&EO;B!P M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M2!I;7!R;W9E;65N="!P2`D,S$V+#@P,"`H4DU"(#(L M,#`P+#`P,"D@9F]R('1H92!(=7AI86X@06YI;6%L($QA8F]R871O2!O9B!!9W)I8W5L='5R92X@5&AE M($-O;7!A;GD@97AP96-T2!T:&4@2!S M=&%R=&5D(&$@9F%C:6QI='D@:6UP2!M961I8VEN92!F86-I;&ET>2!T;R!P6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE2!I;7!R;W9E M;65N="!PFAO=2!F86-I;&ET>2X@5&AE('!R;VIE8W0@:6YC;'5D97,@ M<&QA;G0@8V]N2!T:&4@3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3PO8CX\+W`^#0H\ M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!A;F0@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@,3@E.R<^4V5C;VYD(&AA;&8@;V8@,C`Q,CPO=&0^#0H\ M=&0@3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,S$V+#@P,#PO=&0^#0H\ M=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO M=&0^#0H\=&0@6QE M/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@;F]W M6QE/3-$ M)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PS,S`L-38P/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(L,#`U+#@Q.3PO=&0^ M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^4V5C;VYD(&AA;&8@;V8@,C`Q,CPO M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE M/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)W!A M9&1I;F6QE/3-$ M)V)O6QE/3-$)W!A M9&1I;F6QE/3-$ M)W!A9&1I;F6QE M/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E2!H860@8V]N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6UE;G1S($1I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L M;&%P'0M86QI9VXZ(&-E;G1E'0M M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`W,"4[)SY2)F%M<#M$('!R;VIE8W0\+W1D M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SY#;VYS=')U8W1I;VX@9&5P;W-I=#PO=&0^ M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R M:6=H=#LG/C4Y-"PP,#`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`[=V%S(&AE;&0@8GD@86X@=6YR96QA=&5D('1H:7)D('!A M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W9E6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`R M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[ M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^-RPR-SDL-S4R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)V)O6QE/3-$)V)A8VMG'0M86QI M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^-2PV M,3`L,3,U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P M861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W!A9&1I;F3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E65A'!E;G-E(&9O2X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE M'!E8W1E9"!F;W(@=&AE(&YE M>'0@9FEV92!Y96%R6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE M/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXR,#$T/"]T9#X-"CQT9#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,C0R+#`X,CPO M=&0^#0H\=&0@6QE/3-$)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ#0H@;&5F=#LG/C(P,38\+W1D/@T*/'1D/B8C,38P.SPO M=&0^#0H\=&0@'0M86QI9VXZ(')I M9VAT.R<^-"PS-#$L-#0U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO M='(^#0H\='(@6QE/3-$)W!A9&1I M;F6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'`@3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E2!P M28C.#(Q-SMS(&%C<75I65A3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C-B-#5A9%]A8C!B M7S0R-#E?.#(Q-%]E,S,Y-38W,C!C9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,F8S8C0U861?86(P8E\T,C0Y7S@R,31?93,S.34V-S(P8V0Y M+U=O'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-EFD@0G)A;F-H(&9O2!U2!T:&4@0V]M<&%N>28C.#(Q M-SMS(&QA;F0@=7-E(')I9VATFAO=2P@2'5B96D@4')O=FEN M8V4@86YD(&=U87)A;G1E960@8GD@=&AE(&QE9V%L(')E<')E7-T87(@2FEN9WIH;W4N($]N($UA>2`R+"`R,#$R+"!T:&4@0V]M M<&%N>2!R97!A:60@=&AI2!L;V-A M=&5D(&EN(%AI)B,X,C$W.V%N($-I='DL('=H:6-H(&EN8VQU9&5S(&%N(&]F M9FEC92!B=6EL9&EN9R!C;VYT2!A('-H87)E:&]L9&5R(&EN M(#(P,#4@87,@861D:71I;VYA;"!C87!I=&%L(&]F(%AI)B,X,C$W.V%N(%1I M86YX:6YG+B!!2X@5&AI2!G=6%R86YT965D(&)Y M('1H92!#;VUP86YY)B,X,C$W.W,@0VAA:7)M86X@86YD($-%3R!A;F0@:&ES M('=I9F4N/"]P/@T*/'`@3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!O8G1A:6YE9"!A(&]N92!Y96%R(&QO86X@=VET M:"!3:&%A;GAI($%G2!T:&4@0V]M<&%N>28C.#(Q-SMS($-H86ER;6%N M(&%N9"!#14\N/"]P/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M65A2!U&EA;B!# M;W5N='DN/"]P/@T*/'`@3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!I;F1I=FED=6%L(&9O2!I;F1I=FED=6%L+B!4:&5S92!F;W5R(&QO86YS(&%R92!N;VXM:6YT97)E M2P@;F]N92!O9B!W:&EC M:"!H87,@8F5E;B!C87!I=&%L:7IE9"!A3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W!A9&1I M;F6QE/3-$)W9E6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H M=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([ M(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!C96YT97([(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[ M/"]T9#X-"CPO='(^#0H\='(@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`R."4[)SY#:&%N9R8C.#(Q M-SMA;B!"86YK/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[)SXU+#`P,"PP,#`\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[)SXW.#6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B4\+W1D M/@T*/"]T6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SY3:&%A;GAI($%G6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^-2PP,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-S@W+#`P M,#PO=&0^#0H\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^,RPP,#`L,#`P/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-#6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SY#;VUM97)C:6%L($)A;FL@;V8@0VAI;F$@4V]N9WII($)R86YC:#PO M=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#LG/C,L,#`P+#`P,#PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^*#$I/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^-"PW,C(L,#`P/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^*#$I/"]T9#X-"CPO='(^#0H\='(@'0M86QI9VXZ(')I9VAT.R<^,2PR,#`L M,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D M:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P M861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`Q,#`E.R!B;W)D97(M8V]L;&%P6QE/3-$)W=I9'1H.B`Y-"4[)SY0 M96]P;&4G3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\R9C-B-#5A9%]A8C!B7S0R-#E?.#(Q-%]E,S,Y-38W,C!C9#D-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F8S8C0U861?86(P8E\T,C0Y7S@R M,31?93,S.34V-S(P8V0Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE2!T:&4@ M4%)#(&=O=F5R;FUE;G0L(&%N9"`D,34X+#0P,"`H4DU"(#$L,#`P+#`P,"D@ M=V%S(')E+7!A:60@;VX@1&5C96UB97(@-RP@,C`Q,"P@=VET:"!T:&4@3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C-B-#5A9%]A8C!B7S0R-#E?.#(Q M-%]E,S,Y-38W,C!C9#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,F8S8C0U861?86(P8E\T,C0Y7S@R,31?93,S.34V-S(P8V0Y+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M&-H86YG92!F;W(@65A2!E;G1E2!I;G-T86QL;65N=',@;V8@ M.2PP,#`@2X@3VX@3V-T;V)E2`R-BP@,C`Q,"X@07,@;V8@36%R8V@@,S$L(#(P,3(L(#$Q M+#$Q,B!S:&%R97,@=V5R92!A8V-R=65D(&9O2!I'!E8W1S('1O(&-O;7!L971E('1H:7,@<')O8V5S M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6UE;G0@86=R965M96YT('=I M=&@@:71S($-&3RX@56YD97(@=&AE(&%G6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE2`R."P@,C`P-RP@:6X@8V]N;F5C=&EO M;B!W:71H(&$@9FEN86YC:6YG('1H92!#;VUP86YY(&ES65A28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A M('!R:6-E(&]F("0U+C`P('!E&5R8VES92!P&5R8VES960N)B,Q-C`[($9O65A3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!O9F9E28C.#(Q-SMS(&-O;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P2!R96-L87-S:69I960@)#3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E65E6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`W M,"4[)SY%>'!E8W1E9"!T97)M("AY96%R*3PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@,3(E.R<^,BXR-3PO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\=&0@'!E8W1E9"!V;VQA=&EL:71Y/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^-3,E("T@,30W/"]T9#X-"CQT9#XE/"]T9#X-"CPO='(^ M#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XS,SPO=&0^ M#0H\=&0^)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XS)2`M(#$N M,S`\+W1D/@T*/'1D/B4\+W1D/@T*/"]T2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&]U='-T86YD:6YG('=A6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O#L@9F]N=#H@,3!P="!T:6UE#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W!A9&1I M;F6QE/3-$)W!A M9&1I;F6QE/3-$ M)V)O#L@9F]N=#H@,3!P="!T:6UE#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^,36QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^-RXU,#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT M9#XF(S$V,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\ M=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\ M=&0@8V]L6QE/3-$)W!A9&1I M;F&5R8VES960\+W1D/@T*/'1D('-T>6QE/3-$ M)W!A9&1I;F6QE M/3-$)V)O6QE/3-$ M)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG M6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,36QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-RXU,#PO=&0^#0H\=&0^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D(&-O;'-P86X],T0R/B8C M,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)V)A8VMG6QE/3-$)V)A8VMG'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$ M)W=I9'1H.B`U)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG'!E8W1E9"!T;R!V97-T(&%T($UA6QE/3-$)V)A8VMG&5R8VES86)L92!A="!-87)C:"`S,2P@,C`Q,CPO=&0^#0H\=&0^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^,30P+#`P,#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^."XQ,3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE65E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\R9C-B-#5A9%]A8C!B7S0R-#E?.#(Q-%]E,S,Y-38W,C!C9#D- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,F8S8C0U861?86(P8E\T M,C0Y7S@R,31?93,S.34V-S(P8V0Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE M/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E2!R97-E2!R97-E2!C87-H('1O('1H97-E(&%C8V]U;G1S+B!4:&5S M92!R97-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&5S($1I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`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`Q,#`E.R!B;W)D97(M M8V]L;&%P'0M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^ M,S0N,#PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@,3(E.R<^,S0N,#PO=&0^#0H\=&0@6QE/3-$)V)A8VMGF5D(&EN('1H92!5 M+E,N/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^*#,T+C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#,T+C`\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CPO='(^#0H\='(@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SY#:&EN82!I;F-O;64@=&%X(')A=&4\+W1D/@T*/'1D/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^,C4N,#PO=&0^#0H\=&0@6QE/3-$)V)A8VMG M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$P+C`\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$P+C`\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X- M"CPO='(^#0H\='(@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^-"XX/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C M:R`Q<'0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F&5S/"]T9#X-"CQT9"!S='EL M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI M9VXZ(')I9VAT.R<^,3DN.#PO=&0^#0H\=&0@6QE/3-$)VUA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`U)3LG/B@Q*3PO=&0^#0H\=&0@'!E M;G-E2!3:WES=&%R('1H870@87)E(&YO="!D961U8W1I M8FQE(&EN('1H92!04D,@86YD(&5X<&5N6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE&5S('!A>6%B;&4@8V]N6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D M97(M8V]L;&%P6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W!A9&1I;F#PO=&0^#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^,3$P+#@X,#PO M=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A M8VMG'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X- M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2PU.#4L,34V/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE7-T87(@ M=V%S(&EN8V]R<&]R871E9"!I;B!T:&4@56YI=&5D(%-T871E'!I2P@ M=&AE($-O;7!A;GD@:&%S('!R;W9I9&5D(&$@,3`P)2!V86QU871I;VX@86QL M;W=A;F-E(&%T($UA2!A;F0@;6%K97,@861J=7-T;65N=',@87,@;F5C97-S M87)Y+B!!"!A;6]U;G1S+CPO<#X-"CQP('-T>6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE2`D-3<@;6EL;&EO;B!A M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R9C-B-#5A9%]A M8C!B7S0R-#E?.#(Q-%]E,S,Y-38W,C!C9#D-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,F8S8C0U861?86(P8E\T,C0Y7S@R,31?93,S.34V-S(P M8V0Y+U=O'0O:'1M;#L@8VAA6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W=I9'1H.B`Q,#`E.R!B;W)D97(M M8V]L;&%P'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$ M)V)A8VMG'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M,3(E.R<^,2PY,#0L-S4T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^-RPR,3`L,C4V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-RPQ-C8L.3$Y/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X-"CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG6QE M/3-$)W!A9&1I;F'0M86QI9VXZ M(')I9VAT.R<^-RPR,3`L,C4V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^-RPQ-SDL,S`Y/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[ M)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)V)A8VMG6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/"]T6QE/3-$ M)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A M9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R<^,"XR-SPO=&0^#0H\=&0@6QE/3-$)V)O M6QE/3-$)V)O6QE/3-$)W!A9&1I M;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE&5R M8VES92!P'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M2!46QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V)O6QE/3-$)W9E6QE/3-$)V)A8VMG&5C=71I=F4@9&ER96-T;W(@*#(I/"]T9#X-"CQT9"!S='EL93TS1"=W:61T M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@,3(E.R<^,36QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M,3(E.R<^,30Y+#(S-3PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SY-87)K($0N($-H96X@)B,X,C$Q.R!N;VXM97AE8W5T:79E(&1I6QE/3-$)V)A8VMG'0M86QI9VXZ(')I9VAT.R<^,38L.#`P/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X-"CPO='(^#0H\='(@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M9&5C;W)A=&EO;CH@=6YD97)L:6YE M.R<^06UO=6YT6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO M='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$T M-RPX-S<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F2`H-BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)W=I9'1H.B`R)3LG/B@Q*3PO=&0^#0H\=&0@3L@=VED=&@Z(#DW)3LG/E1H92!#;VUP M86YY(')E8V]R9',@86YD(')E<&]R=',@&-H86YG92!F;W(@86X@87=A2X\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&IU2!I;B!T:&4@56YI=&5D(%-T871E6QE/3-$)W9E3LG/D%S(&]F($UA6QE/3-$)VUA#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)W=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@2!A="!-87)C M:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$@:6YC;'5D97,@=6YP M86ED(')E:6UB=7)S96UE;G0@86YD(&-O;7!E;G-A=&EO;B!A;F0L(&%D=F%N M8V5S('1O($UR+B!796EB:6YG($QU(&%N9"!O=&AE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE2!E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE2`R M,#$R+"!T:&4@0V]M<&%N>2!R96YE=V5D('1H92!L96%S92!W:71H($UR+B!, M=2!F;W(@86YO=&AE2`Q+"`R,#$R('1O M($1E8V5M8F5R(#,Q+"`R,#$V(&%T(')E;G0@;V8@87!P2`D M,C@L-3$R("A234(@,3@P+#`P,"D@<&5R('EE87(N/"]P/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E2!E;G1E65A&EM871E;'D@)#,L,#0Q("A234(@,3DL,C`P*2X@3VX@07!R:6P@,34L(#(P M,3(L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&YE=R!O;F4@>65A&EM871E;'D@)#,L,3DY("A234(@,C`L,3DV*2X\+W`^#0H\<"!S M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE2!E;G1E6QE/3-$)VUA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W9E6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@,3(E.R<^.#$L-38X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^,3$Q+#`S.#PO=&0^#0H\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A M9&1I;F6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)VUA#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE2!I2!I3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M86QI9VXZ M(&IU#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE2DL(&9I;&5D(&AI6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UEF5R($9R;W-T M+"!,3%`L($-R;W=E($AO2!+97-N97(L(&%N9"!* M;V1Y($TN($)O2!O=VYE2!C;&%S M2P@;W(@86YY M(&%F9FEL:6%T92!O9B!P=7)C:&%S97(L(&]R(&]F(&%N>2!S=6-H(&1I2!A9'9E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&EN9R!C;VYT&EM871E;'D@)#0W-BPT,#`@*%)-0B`S+#`P,"PP,#`I(&]F(&-U;75L M871I=F4@97AP96YS97,@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE2!T;R!J;VEN=&QY('=O2!T:&5R87!E=71I8R!A9V5N=',N(%1H92!C M;VYT&EM M871E9"`D.34P+#0P,"`H4DU"(#8L,#`P+#`P,"DN($%S(&]F($UA2!H87,@:6YC=7)R960@87!P2`D-3,Y+#DR,"`H4DU"(#,L-#`P+#`P,"D@;V8@8W5M=6QA=&EV92!E>'!E M;G-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E2!T;R!J;VEN=&QY('=O6YI M82!P3L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!P2`D M.#4X+#(W,B`H4DU"(#4L-#`T+#6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V)O3LG/E!R;VIE8W0\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O'0M86QI9VXZ(&-E M;G1E6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG28C,38P.R`H,BD\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,34X M+#0P,#PO=&0^#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T2`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,RPX,#@L-S8S M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)VUA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@,"XQ:6X[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU"`P<'0@,"XQ:6X[(&9O M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)VUA"`P M<'0@,"XQ:6X[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE3L@;6%R9VEN M.B`P<'0@,'!X(#!P="`P+C%I;CL@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@,"XQ:6X[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE'1087)T7S)F F,V(T-6%D7V%B,&)?-#(T.5\X,C$T7V4S,SDU-C XML 17 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended

Mar. 31, 2012

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]
Note 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles (“U.S. GAAP”) applicable to interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (which include all significant normal and recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented have been made. The accompanying results of operations are not necessarily indicative of the operating results that may be expected for the entire year ending December 31, 2012. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes thereto of the Company, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission (“SEC”).

Principles of consolidation

The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the financial statements of the Company, its wholly-owned subsidiaries, and its VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.

Use of estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The level of uncertainty in estimates and assumptions increases with the length of time until the underlying transactions are completed. Actual results may differ from these estimates in amounts that may be material to the consolidated financial statements and accompanying notes. Significant estimates and assumptions made by the Company are used for, but not limited to the allowance for uncollectible receivables, obsolescence reserve against the inventory, tax provision and the fair value for derivatives instruments.

Foreign currency translation

The Company uses the United States dollar (“U.S. dollar”) for financial reporting purposes and the Chinese Renminbi (“RMB”) as its functional currency. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency, being the primary currency of the economic environment in which their operations are conducted.

The Company translates the subsidiaries’ and VIEs’ assets and liabilities into U.S. dollars using the applicable exchange rates prevailing at the balance sheet dates, and the statements of income and comprehensive income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the subsidiaries’ and VIEs’ financial statements are recorded as accumulated other comprehensive income.

The quotation of the exchange rates does not imply free convertibility of RMB to other foreign currencies. All foreign exchange transactions continue to take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rate quoted by the People’s Bank of China.

Approval of foreign currency payments by the People’s Bank of China or other institutions requires submitting a payment application form together with invoices, shipping documents, and signed contracts. Transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency are included in the results of operations as incurred.

Fair values of financial instruments

The accounting standards regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires fair value disclosures of those financial instruments. This accounting standard defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosures requirements for fair value measures. Certain current assets and current liabilities are financial instruments. Management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and, if applicable, their current interest rates are equivalent to interest rates currently available. The three levels of valuation hierarchy are defined as follows:



• Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

• Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.



Outstanding warrants and purchase options do not trade in an active securities market, and as such, the Company estimates the fair value of these warrants and purchase options using the Black-Scholes Option Pricing Model (“Black-Scholes Model”) using the following assumptions:

Warrants – (1) Purchase Options – (2)

March 31,
(2012 December 31,
2011 March 31,
2012 December 31,
2011

Stock price $ - $ 2.74 $ 2.69 $ 2.74

Exercise price $ - $ 5.00 $ 8.11 $ 8.11

Annual dividend yield - - - -

Expected term (years) - 0.16 2.25 2.50

Risk-free interest rate - 0.01 % 0.33 % 0.25 %

Expected volatility - 68 % 65 % 64 %

(1) As of December 31, 2011, 34,230 warrants with an exercise price of $5.00 were outstanding. All of these warrants expired on February 28, 2012. As of March 31, 2012, none of these warrants was outstanding.

(2) As of December 31, 2011, 140,000 purchase options with an exercise price of $8.11 were outstanding. As of March 31, 2012, 140,000 of these options were outstanding.

Expected volatility is based on historical volatility. Historical volatility was computed using daily pricing observations for recent periods that correspond to the term of the warrants. The Company believes this method produces an estimate that is representative of future volatility over the expected term of these warrants and purchase options. The Company has no reason to believe future volatility over the expected remaining life of these warrants and purchase options is likely to differ materially from historical volatility. The expected life is based on the remaining term of the warrants and purchase options. The risk-free interest rate is based on U.S. Treasury securities according to the remaining term of the warrants and purchase options.

As required by the FASB’s accounting standards, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Depending on the product and the terms of the transaction, the fair values warrant/purchase option liability were modeled using a series of techniques, including closed-form analytic formula, such as the Black-Scholes Model, which does not entail material subjectivity because the methodology employed does not necessitate significant judgment, and the pricing inputs are observed from actively quoted markets.

The fair value of the 140,000 purchase options outstanding as of March 31, 2012 was determined using the Black-Scholes Model, utilizing level 2 inputs, and recorded the change in earnings. As a result, the warrant/purchase option liability is carried on the consolidated balance sheets at fair value. The Company recognized gains of $5,600 and $735,494 for the three months ended March 31, 2012 and 2011, respectively.

The following table sets forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2012:

Carrying
Value at
March 31, Fair Value Measurement at
March 31, 2012

2012 Level 1 Level 2 Level 3

Purchase option liability (unaudited) $ 37,800 $ — $ 37,800 $ —

Below is the reconciliation for the warrant/purchase option liability changes from December 31, 2011 to March 31, 2012.

Balance, December 31, 2011 43,400

Change in fair value (5,600 )

Balance, March 31, 2012 $ 37,800

The net carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term nature of these instruments as well as the variable interest rate for short-term debt.

In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company is required to record assets and liabilities at fair value on a non-recurring basis. Generally, assets are recorded at fair value on a non-recurring basis as a result of impairment charges. For the three months ended March 31, 2012, there were no impairment charges.

Revenue recognition

Revenue of the Company is primarily derived from the sales of veterinary healthcare and medical care products in China. Sales are recognized when the following four revenue criteria are met: persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable, and collectability is reasonably assured. Sales are presented net of value added tax (“VAT”). No estimated allowance for sales returns is reflected on these consolidated financial statements as sales returns historically have been insignificant.

There are two types of sales upon which revenue is recognized:

a. Credit sales: revenue is recognized when the products have been delivered to the customers.

b. Full payment before delivering: Cash received is recorded as “deposits from customers” and revenue is recognized when the products have been delivered to the customers.



Shipping and handling costs related to costs of goods sold are included in selling expenses, which totaled $383,703 and $194,216 for the three months ended March 31, 2012 and 2011, respectively.

The Company’s revenues and cost of revenues by product line were as follows:

Three Months Ended
March 31,

2012 2011

Revenues

Micro-organism $ 3,135,040 $ 1,596,094

Veterinary Medications 3,008,587 4,865,047

Feed Additives 1,034,772 326,407

Vaccines 747,938 299,406

Total Revenues $ 7,926,337 $ 7,086,954

Cost of Revenues

Micro-organism $ 906,841 $ 494,182

Veterinary Medications 1,792,647 2,821,906

Feed Additives 849,884 140,866

Vaccines 94,286 34,392

Total Cost of Revenues 3,643,658 3,491,346

Gross Profit $ 4,282,679 $ 3,595,608

Cash

Cash includes currency on hand, demand deposits with banks, and liquid investments with an original maturity of three months or less.

Accounts receivable and other receivables

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as needed. The Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, a bad debt percentage is estimated by management based on historical experience and current economic climate. The resulting percentage is applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. The ultimate collection of the Company’s accounts receivable may take one year. Delinquent account balances are reserved after management determines that the likelihood of collection is not probable, and known bad debts are written-off against allowance for doubtful accounts when identified.

Inventories

Inventories are stated at the lower of cost or market, as determined on a moving weighted-average basis using the first-in, first-out (FIFO) cost method. Inventories include purchases and related costs incurred in bringing the inventories to their present location and condition. Management reviews inventories for obsolescence and cost in excess of net realizable value at least annually and records a reserve against the inventory and additional cost of goods sold when the carrying value exceeds net realizable value.

Plant and equipment

Plant and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures for maintenance and repairs that do not improve or extend the useful lives of the assets are charged to operations as incurred, while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. Estimated useful lives of the assets are as follows:

Estimated Useful Life

Buildings 10-40 years

Machinery and equipment 10 years

Computer, office equipment and furniture 5 years

Vehicles 5-10 years

Management assesses the carrying value of plant and equipment annually or more often when factors indicating impairment are present, and reduces the carrying value of such assets by the amount of the impairment. The Company determines the existence of such impairment by measuring the expected future cash flows (undiscounted) and comparing such amount to the net asset carrying value. An impairment loss, if it exists, is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Based on its review, management believes that, as of March 31, 2012 and December 31, 2011, there was no impairment for its plant and equipment.

Construction-in-progress

Construction-in-progress includes direct costs of construction of a factory building. Interest incurred during the period of construction, if significant, is capitalized. All other interest is expensed as incurred. Construction-in-progress is not depreciated until such time as the asset is completed and put into service.

Intangible assets

Land use rights — Land use rights represent the amounts paid to acquire a long-term interest to utilize the land underlying the Company’s facilities. This type of arrangement is common for the use of land in the PRC. Land use rights are amortized on the straight-line method over the contractual lease terms. The land use right granted to the Company’s Huxian facility was for 50 years. The land use right granted to the Company’s Jingzhou facility was 30 years. The land use right granted to the Company’s Kunshan facility was for 41 years.



Technological know-how — Purchased technological know-how includes confidential formulas, manufacturing processes, and technical and procedural manuals, and is amortized using the straight-line method over estimated useful life between five to ten years that reflects the period over which such confidential formulas, manufacturing processes, and technical and procedural manuals are kept confidential by the Company as agreed between the Company and the selling parties. Drug approval licenses are typically granted in five year terms by the Ministry of Agriculture.

Impairment of Intangible assets — the Company evaluates the carrying value of intangible assets annually or more often when factors indicating impairment are present. The Company determines the existence of such impairment by measuring the estimated future cash flows (undiscounted) and comparing such amount to the net asset carrying value. If the undiscounted cash flow estimated to be generated by any such intangible asset is less than its carrying amount, a loss is recognized based on the amount by which the carrying amount exceeds the intangible asset’s fair market value. Loss on intangible assets to be disposed of is determined in a similar manner, except that fair market values are reduced by the cost of disposal. Based on its review, the Company believes that, as of March 31, 2012 and December 31, 2011, there was no impairment of its intangible assets.

Comprehensive income

Comprehensive income and loss is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income is comprised of the changes in foreign currency exchange rates.

Research and development costs

Research and development costs are charged to operations as incurred and include salaries, professional fees, and technical support fees related to such efforts.

Income taxes

The Company accounts for income taxes using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred income taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred tax asset will not be realized.

A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. As of March 31, 2012, there are no unrecognized tax benefits, and the Company does not expect a significant change in tax benefits in the next 12 months. Penalties and interest levied by taxing authorities, if any, are classified as income tax expense in the year incurred. No significant penalties or interest relating to income taxes have been incurred during the three months ended March 31, 2012 and 2011.

The Company’s operations are subject to income and transaction taxes in the United States and in the PRC jurisdictions. Significant estimates and judgments are required in determining the Company’s worldwide provision for income taxes. Some of these estimates are based on interpretations of existing tax laws or regulations. The ultimate amount of tax liability may be uncertain as a result.

According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational or other errors made by the taxpayer or the withholding agent. The statute of limitations extends to five years under special circumstances. In the case of transfer pricing issues, the statute of limitations is ten years. There is no statute of limitations in the case of tax evasion. Accordingly, the income tax returns of the Company’s PRC operating subsidiaries for the years ended December 31, 2006 through 2011 are open to examination by the PRC state and local tax authorities.

The Company does not anticipate any events that could cause a change to these uncertainties.

Stock-based compensation

The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. Stock compensation for stock granted to non-employees is determined as the fair value of the consideration received or the fair value of equity instruments issued, whichever is more reliably measured.

Earnings per share

Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares, including convertible preferred shares, warrants and stock options were converted or exercised. Further, the method requires that stock dividends or stock splits be accounted for retroactively if the stock dividends or stock splits occur during the period or after the end of the period but before the release of the financial statements, by considering it outstanding for the entirety of each period presented. Diluted earnings per share is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

Related parties

Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of such principal owners and management, and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.

Operating Segments

While the chief decision-makers monitor the revenue streams of the various products lines, operations are managed and financial performance is evaluated on a Company-wide basis. Product lines are aggregated into one as operating results for all product lines are similar. Accordingly, all of the major product lines (micro organism, veterinary medicine, feed additives and vaccines) are considered by management to be aggregated in one reportable operating segment.

Recently issued accounting pronouncements

In May 2011, the FASB issued ASU No. 2011-04 – Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.GAAP and IFRSs. The amendments in this update intend to converge requirements for how to measure fair value and for disclosing information about fair value measurements in US GAAP with International Financial Reporting Standards. For public entities, this ASU is effective for interim and annual periods beginning after December 15, 2011. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05 – Comprehensive Income (Topic 220): Presentation of Comprehensive Income. The amendments in this update require (i) that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements (the current option to present components of other comprehensive income (“OCI”) as part of the statement of changes in stockholders’ equity is eliminated) and (ii) presentation of reclassification adjustments from OCI to net income on the face of the financial statements. For public entities, the amendments in this ASU are effective for years, and interim periods within those years, beginning after December 15, 2011. The amendments in this update should be applied retrospectively. Early adoption is permitted. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.

In December 2011, the FASB issued ASU No. 2011-11 —Balance Sheet (Topic 210). The objective of this update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. An entity is required to apply the amendments for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. An entity should provide the disclosures required by those amendments retrospectively for all comparative periods presented. The Company does not expect the adoption of the provisions in this update will have a significant impact on its consolidated financial statements.

In December 2011, the FASB issued ASU No. 2011-12 —Comprehensive Income (Topic 220). The amendments in this update supersede certain pending paragraphs in ASU No. 2011-05, to effectively defer only those changes in ASU No. 2011-05 that relate to the presentation of reclassification adjustments out of accumulated other comprehensive income. The amendments will be temporary to allow the Board time to redeliberate the presentation requirements for reclassifications out of accumulated other comprehensive income for annual and interim financial statements for public, private, and non-profit entities. The amendments in this update are effective for public entities for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of the provisions in this update did not have a significant impact on the Company’s consolidated financial statements.

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)

Mar. 31, 2012

Dec. 31, 2011

ASSETS

Cash $ 9,386,584 $ 7,048,968

Accounts receivable, net of allowance for doubtful accounts of $480,237 (Unaudited) and $438,678 as of March 31, 2012 and December 31, 2011, respectively 5,783,831 3,391,493

Inventories 13,962,087 14,851,159

Deposits, prepaid expenses and other receivables 34,914,476 32,648,448

Loans receivable 981,699 964,088

Total current assets 65,028,677 58,904,156

PLANT AND EQUIPMENT, NET 28,273,028 28,376,559

CONSTRUCTION-IN-PROGRESS 9,434,227 8,839,055

OTHER ASSETS:

Long-term prepayments 1,189,788 1,512,817

Long-term prepayments for acquisitions 652,609 569,788

Intangible assets, net 5,610,135 5,674,206

Total other assets 7,452,532 7,756,811

Total assets 110,188,464 103,876,581

LIABILITIES AND SHAREHOLDERS' EQUITY

Accounts payable 2,046,341 1,047,067

Other payable and accrued expenses 6,059,237 5,274,598

Short-term loans 7,476,480 7,366,320

Deposits from customers 1,640,457 1,432,529

Taxes payable 1,585,156 160,081

Due to related parties 380,669 56,273

Total current liabilities 19,188,340 15,336,868

OTHER LIABILITIES:

Deferred government grant 396,000 393,500

Warrant/purchase option liability 37,800 43,400

Total other liabilities 433,800 436,900

Total liabilities 19,622,140 15,773,768

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY

Preferred stock, $0.001 par value, 50,000,000 shares authorized, No Series "A" shares authorized. 48,000,000 Series "B" shares authorized. No Series "B" shares issued and outstanding

Common stock, $0.001 par value, 40,000,000 shares authorized, 7,161,919 shares issued and outstanding as of March 31, 2012 (Unaudited) and December 31, 2011 7,162 7,162

Paid-in capital 35,784,378 35,784,378

Statutory reserves 5,708,135 5,708,135

Retained earnings 40,396,785 38,492,031

Accumulated other comprehensive income 8,669,864 8,111,107

Total shareholders' equity 90,566,324 88,102,813

Total liabilities and shareholders' equity $ 110,188,464 $ 103,876,581

X

- Definition

The total of the carrying amounts as of the balance sheet date of amounts paid in advance for acquisitions.

+ References

No definition available.

+ Details

Name: skbi_LongTermPrepaymentsForAcquisitions

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amount as of the balance sheet date of other payable and accrued expenses.

+ References

No definition available.

+ Details

Name: skbi_OtherPayableAndAccruedExpenses

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

This element represents capitalized assets classified as property, plant and equipment excluding construction in progress gross.

+ References

No definition available.

+ Details

Name: skbi_PropertyAndEquipmentNetOther

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The entire disclosure for statutory reserve.

+ References

No definition available.

+ Details

Name: skbi_StatutoryReserves

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Topic 210

-SubTopic 10

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

-Section S99

-Name Accounting Standards Codification

-Publisher FASB

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Section 45

-SubTopic 10

-Topic 210

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

-Publisher FASB

-Name Accounting Standards Codification

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.10-17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 8, 9, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

+ Details

Name: us-gaap_CashCashEquivalentsAndShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 19

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_ConstructionInProgressGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The current portion of prepayments received from customers for goods or services to be provided in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CustomerAdvancesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP, and which are expected to be recognized as such after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.Q4)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenueAndCreditsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FIN39-1

-Paragraph 10A, 10B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 4, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

-Subparagraph 1

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 42, 45

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 25

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

An amount representing an agreement for an unconditional promise by the maker to pay the Company (holder) a definite sum of money within one year from the balance sheet date (or the normal operating cycle, whichever is longer), net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6375948&loc=d3e4531-111522

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesAndLoansReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6787-107765

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PrepaidExpenseNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Article 9

-Subparagraph 2, 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 16

-Subparagraph a(1)

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_TaxesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)

Common Stock [Member]

Paid-In Capital [Member]

Retained Earnings, Appropriated [Member]

Retained Earnings, Unappropriated [Member]

Accumulated Other Comprehensive Income [Member]

Total

BALANCE at Dec. 31, 2011 $ 7,162 $ 35,784,378 $ 5,708,135 $ 38,492,031 $ 8,111,107 $ 88,102,813

BALANCE (in shares) at Dec. 31, 2011 7,161,919

Foreign currency translation 0 0 0 0 558,757 558,757

Net income 0 0 0 1,904,754 0 1,904,754

BALANCE at Mar. 31, 2012 $ 7,162 $ 35,784,378 $ 5,708,135 $ 40,396,785 $ 8,669,864 $ 90,566,324

BALANCE (in shares) at Mar. 31, 2012 7,161,919

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 55

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 24

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 19, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 52

-Paragraph 13, 20, 31

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of shares issued and outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 20 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

TAXES
3 Months Ended

Mar. 31, 2012

Taxes Disclosure [Abstract]

Taxes Disclosure [Text Block]
Note 16 – TAXES

Skystar is subject to United States federal income tax provisions. Skystar Cayman is a tax-exempt company incorporated in the Cayman Islands and conducts all of its business through its subsidiaries, Fortune Time, Sida, Fortune Time’s subsidiary Skystar Kunshan, Sida’s subsidiary Skystar Jingzhou, Sida’s PRC VIEs, Xi’an Tianxing, Xi’an Tianxing’s subsidiary Shanghai Siqiang, Sida and Xi’an Tianxing’s joint venture Kunshan Sikeda, and Xi’an Tianxing’s subsidiary Xi’an Sikaida.

Sida, Skystar Jingzhou, Skystar Kunshan, Xi’an Tianxing, Shanghai Siqiang, Kunshan Sikeda and Xi’an Sikaida are subject to the PRC’s Enterprise Income Tax. Pursuant to the PRC Income Tax Laws, Enterprise Income Tax is generally imposed at a statutory rate of 25%. Xi’an Tianxing has been approved as a new technology enterprise, and under PRC Income Tax Laws is entitled to a preferential tax rate of 15%.

The following table reconciles the U.S. statutory rates to the Company’s effective tax rate for the three months ended March 31, 2012 and 2011:

For the three months ended

March 31,
2012 March 31,
2011

U.S. Statutory rate 34.0 % 34.0 %

Foreign income not recognized in the U.S. (34.0 ) (34.0 )

China income tax rate 25.0 25.0

China income tax exemption (10.0 ) (10.0 )

Other item (1) 4.8 4.8

Total provision for income taxes 19.8 % 19.8 %

(1) Other item is for operating expenses incurred by Skystar that are not deductible in the PRC and expenses incurred by other subsidiaries that are not deductible on the consolidated level, which resulted in an increase in effective tax rate 4.8% and 4.8% for the three months ended March 31, 2012 and 2011, respectively.

Taxes payable consisted of the following:

March 31,
2012 December 31,
2011

Value added tax $ 1,402,428 $ 110,880

Other taxes 182,728 49,201

Total $ 1,585,156 $ 160,081

Skystar was incorporated in the United States. As of March 31, 2012, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $6,228,689, which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized, beginning in 2026 and through 2030. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at March 31, 2012 and December 31, 2011. The valuation allowance at March 31, 2012 and December 31, 2011 was $2,117,754 and $2,071,840, respectively. The Company’s management reviews this valuation allowance periodically and makes adjustments as necessary. As of March 31, 2012, the Company has no other deferred tax amounts.

The Company has cumulative undistributed earnings of foreign subsidiaries of approximately $57 million as of March 31, 2012, which were included in consolidated retained earnings and will continue to be indefinitely reinvested in international operations. Accordingly, no provision has been made for U.S. deferred taxes related to future repatriation of these earnings, nor is it practicable to estimate the amount of income taxes that would have to be provided if we concluded that such earnings will be remitted in the future.

X

- Details

Name: skbi_TaxesDisclosureAbstract

Namespace Prefix: skbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes and other taxes which are payable during the reporting period. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

No definition available.

+ Details

Name: skbi_TaxesDisclosureTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

RELATED PARTY TRANSACTIONS AND ARRANGEMENTS
3 Months Ended

Mar. 31, 2012

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]
Note 17 - RELATED PARTY TRANSACTIONS AND ARRANGEMENTS

Amounts receivable from and payable to related parties are summarized as follows:

March 31, 2012 December 31, 2011

Shares to be issued to related party (1)

Scott Cramer – non-executive director (2) $ 172,455 $ 149,235

Mark D. Chen – non-executive director (3) 50,004 50,004

Bing Mei – CFO (4) 16,800 -

Total $ 239,259 $ 199,239

Amounts due to (from) related parties

Scott Cramer – non-executive director and shareholder (5) $ 132,561 $ 147,877

Officer, shareholder and other related party (6) 248,108 (91,604 )

Total $ 380,669 $ 56,273

(1) The Company records and reports stock-based compensation by measuring the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which services are received. As of March 31, 2012 and December 31, 2011, the shares to be issued to related parties included in the accrued expenses were $239,259 and $199,239, respectively.

(2) As of March 31, 2012 and December 31, 2011, the Company had the obligation under an agreement to issue 43,500 and 34,500 shares of common stock, respectively, to Scott Cramer as compensation valued at $172,455 and $149,235 for being a representative of the Company in the United States for the period April 1, 2010 to March 31, 2012.

(3) As of March 31, 2012 and December 31, 2011, the Company had the obligation under an agreement to issue 11,112 shares of common stock to Mark D. Chen as compensation valued at $50,004 for being a director for his 2011 and 2010 terms of directorship.

(4) As of March 31, 2012, the Company had the obligation under an agreement to issue 4,000 shares of common stock to Bing Mei as compensation valued at $16,800 for being CFO for the period July 29, 2011 to July 28, 2012.

(5) As of March 31, 2012 and December 31, 2011, the Company had unpaid reimbursement and compensation due to Scott Cramer valued at $132,561 and $147,877, respectively.

(6) The amount due to (from) officer, shareholders and other related party at March 31, 2012 and December 31, 2011 includes unpaid reimbursement and compensation and, advances to Mr. Weibing Lu and other related parties for business expenses

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 23 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

ORGANIZATION
3 Months Ended

Mar. 31, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Note 1 - ORGANIZATION

Organization and description of business

Skystar Bio-Pharmaceutical Company (“Skystar” or the “Company”) was incorporated in Nevada on September 24, 1998. Since its acquisition on November 7, 2005 of Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (“Skystar Cayman”), a Cayman Islands company, the Company has been engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the Company are in the People’s Republic of China (“China” or the “PRC”).

All of the Company’s operations are carried out by Xi’an Tianxing Bio-Pharmaceutical Co., Limited (“Xi’an Tianxing”), a PRC joint stock company that the Company controls through contractual arrangements originally between Skystar Cayman and Xi’an Tianxing. On March 10, 2008, the Company entered into a series of agreements transferring all of the rights and obligations of Skystar Cayman under the contractual arrangements to Sida Biotechnology (Xi’an) Co., Ltd. (“Sida”), a PRC company. Sida is the wholly owned subsidiary of Fortunate Time International Limited (“Fortunate Time”), a Hong Kong company and wholly owned subsidiary of Skystar Cayman. Xi’an Tianxing also has a wholly owned subsidiary, Shanghai Siqiang Biotechnological Co., Ltd. (“Shanghai Siqiang”), a PRC company.

As a result of these contractual arrangements, which obligate Sida to absorb all of the risk of loss from Xi’an Tianxing’s activities and enable Sida to receive all of its expected residual returns, the Company accounts for Xi’an Tianxing as a variable interest entity (“VIE”) under the Financial Accounting Standards Board’s (“FASB”) interpretation on consolidation of variable interest entities. Accordingly, the Company consolidates Xi’an Tianxing’s results, assets, and liabilities.

On September 18, 2009, Skystar Bio-Pharmaceutical Inc. (“Skystar California”) was incorporated in California and became a wholly owned subsidiary of Skystar. On December 20, 2010, we dissolved Skystar California.

On April 21, 2010, Kunshan Sikeda Biotechnology Co., Ltd. (“Kunshan Sikeda”) was incorporated in Kunshan, Jiangsu province, China with registered capital of RMB 500,000, of which Xi’an Tianxing and Sida each contributed RMB 250,000. Kunshan Sikeda is jointly owned by Xi’an Tianxing and Sida.

On May 7, 2010, Fortunate Time formed Skystar Biotechnology (Kunshan) Co., Limited (“Skystar Kunshan”) in Kunshan, Jiangsu province, China with registered capital of $15,000,000, of which $2,250,000 was paid by Fortunate Time in cash, and of which the remaining $12,750,000 is required to be invested in the future. Kunshan was formed in connection with an acquisition of assets to meet part of the registered capital requirements, and was intended to be a micro-organism manufacturing facility for the Company once the acquisition was complete. The asset acquisition was completed in September 2011, and the Company is in the process of transferring the assets acquired to meet part of the registered capital requirements.

On August 11, 2010, Sida became the parent company of Skystar Biotechnology (Jingzhou) Co., Limited (“Skystar Jingzhou”), a company established in Jingzhou, Hubei Province, China on February 5, 2010, with registered capital of approximately $4.1 million (RMB 26,000,000), of which approximately $3.7 million (RMB 23,480,000) has been paid. The remaining approximately $399,168 (RMB 2,520,000) is required to be invested by April 6, 2012. As of the date of this report, the Company has not made this investment. Skystar Jingzhou is currently in the process of getting the government's approval and will fulfill the requirement of remaining capital of $399,168 (RMB 2,520,000) thereafter. The company expects the process will be completed by the end of the 2nd quarter of 2012.

On March 15, 2011, Xi’an Tianxing formed Xi’an Sikaida Bio-products Co., Ltd. (“Xi’an Sikaida”) with registered capital of approximately $1,584,000 (RMB 10,000,000) paid by Xi’an Tianxing.

Hereinafter, Skystar, Skystar Cayman, Fortunate Time, Sida, Xi’an Tianxing, Skystar Kunshan, Kunshan Sikeda, Skystar Jingzhou, Shanghai Siqiang, and Xi’an Sikaida are sometimes collectively referred to as the “Company.”

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Name FASB Interpretation (FIN)

-Publisher FASB

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)

Mar. 31, 2012

Dec. 31, 2011

Allowance for doubtful accounts (in dollars) $ 480,237 $ 438,678

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 50,000,000 50,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 40,000,000 40,000,000

Common stock, shares issued 7,161,919 7,161,919

Common stock, shares outstanding 7,161,919 7,161,919

Series B Preferred Stock [Member]

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized 48,000,000 48,000,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6965416&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 25 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

LOANS RECEIVABLE
3 Months Ended

Mar. 31, 2012

Receivables [Abstract]

Loans Receivable Disclosure [Text Block]
Note 11 – LOANS RECEIVABLE

In November 2010, the Company provided an unsecured non-interest bearing loan to Xi’an Tiantai Investment, Ltd., the Company’s acquisition advisor, in the amount of $190,080 (RMB 1,200,000) for two years from November 26, 2010 through November 25, 2012. As of March 31, 2012, this loan has not been repaid.

As of March 31, 2012, the Company had unsecured non-interest bearing short-term loans in the amount of $791,619 (RMB 4,997,592) due from unrelated third parties.

X

- Definition

The entire disclosure for loans receivable during the reporting period.

+ References

No definition available.

+ Details

Name: skbi_LoansReceivableDisclosureTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

DOCUMENT AND ENTITY INFORMATION
3 Months Ended

Mar. 31, 2012

May 10, 2012

Entity Registrant Name SKYSTAR BIO-PHARMACEUTICAL CO

Entity Central Index Key 0001076939

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Trading Symbol skbi

Entity Common Stock, Shares Outstanding 7,604,800

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2012

Document Fiscal Period Focus Q1

Document Fiscal Year Focus 2012

X

- Definition

If the value is true, then the document as an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 27 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

SHORT-TERM LOANS
3 Months Ended

Mar. 31, 2012

Debt Disclosure [Abstract]

Short-term Debt [Text Block]
Note 12 – SHORT-TERM LOANS

On May 5, 2011, the Company obtained a one year loan with Industrial and Commercial Bank of China Songzi Branch for $475,200 (RMB 3,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 8.528% at March 31, 2012. In 2011, the Company repaid $158,400 (RMB 1,000,000) and subsequently borrowed back $158,400 (RMB 1,000,000). This loan is secured by the Company’s land use rights in Jingzhou, Hubei Province and guaranteed by the legal representative of Skystar Jingzhou. On May 2, 2012, the Company repaid this loan of $475,200 (RMB 3,000,000).

On July 8, 2011, the Company obtained a one year loan with Chang’an Bank for $792,000 (RMB 5,000,000) at an annual interest rate of 8.203%. This loan is secured by the Company’s office buildings and its Chairman and CEO’s personal property located in Xi’an City, which includes an office building contributed by a shareholder in 2005 as additional capital of Xi’an Tianxing. As of March 31, 2012, the title to this property has not been passed to the Company. This loan is also personally guaranteed by the Company’s Chairman and CEO and his wife.

On August 25, 2011, the Company obtained a one year loan with Shaanxi Agricultural Yanta Credit Union for $792,000 (RMB 5,000,000) at an annual interest rate of 9.411%. This loan is secured by the Company’s office buildings located in Xi’an City. This loan is also personally guaranteed by the Company’s Chairman and CEO.

On December 22, 2011, the Company obtained a one year loan with Shaanxi Agricultural Yanta Credit Union for $475,200 (RMB 3,000,000) at an annual interest rate of 9.411%. This loan is secured by the Company’s office buildings located in Xi’an City. This loan is also personally guaranteed by the Company’s Chairman and CEO and his wife.

On December 1, 2011, the Company obtained a one year loan with Bank of Chengdu for $4,752,000 (RMB 30,000,000) at an annual interest rate determined by using the People's Bank of China floating benchmark lending rate over the same period plus 30% of that rate, which was 8.528% at March 31, 2012. This loan is secured by the Company’s land use right and manufacturing plant located in Huxian County.

In 2011, the Company obtained two three-month loans with a third-party individual for a total amount of $125,920 (RMB 800,000). For the three months ended March 31, 2012, the Company borrowed another two short-term loans for a total amount of $63,360 (RMB 400,000) with this third-party individual. These four loans are non-interest bearing and are unsecured. On April 6, 2012, the Company repaid one loan of $47,520 (RMB 300,000). On April 9, 2012, the Company repaid the other three remaining loans totaling $142,560 (RMB 900,000).

Interest expense incurred and associated with the short-term loans amounted to $152,583 and $54,409 for the three months ended March 31, 2012 and 2011, respectively, none of which has been capitalized as part of construction-in-progress for the three months ended 2012 and 2011, respectively.

Outstanding short-term loans consisted of the following:

March 31, 2012 December 31, 2011 Interest

Bank Amt RMB Amt USD Amt RMB Amt USD Due Date Rate

Chang’an Bank 5,000,000 792,000 5,000,000 787,000 07/07/12 8.203 %

Shaanxi Agricultural Yanta Credit Union 5,000,000 792,000 5,000,000 787,000 08/24/12 9.411 %

Shaanxi Agricultural Yanta Credit Union 3,000,000 475,200 3,000,000 472,200 12/21/12 9.411 %

Commercial Bank of China Songzi Branch 3,000,000 475,200 3,000,000 472,200 05/04/12 (1)

Bank of Chengdu 30,000,000 4,752,000 30,000,000 4,722,000 11/30/12 (1)

Third-party Individual 1,200,000 190,080 800,000 125,920 Various 0 %

Total 47,200,000 $ 7,476,480 46,800,000 $ 7,366,320

(1) People's Bank of China floating benchmark lending rate over the same period plus 30%, which was 8.528% at March 31, 2012

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for short-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 16

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Article 9

+ Details

Name: us-gaap_ShortTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

REVENUE, net $ 7,926,337 $ 7,086,954

COST OF REVENUE 3,643,658 3,491,346

GROSS PROFIT 4,282,679 3,595,608

OPERATING EXPENSES:

Research and development costs 3,654 287,472

Selling expenses 705,616 369,404

General and administrative expenses 1,105,435 1,294,798

Total operating expenses 1,814,705 1,951,674

INCOME FROM OPERATIONS 2,467,974 1,643,934

OTHER INCOME (EXPENSE):

Other income, net 53,760 182

Interest income (expense), net (153,612) 29,672

Change in fair value of warrant/purchase option liability 5,600 735,494

Total other income (expense), net (94,252) 765,348

INCOME BEFORE PROVISION FOR INCOME TAXES 2,373,722 2,409,282

PROVISION FOR INCOME TAXES 468,968 477,450

NET INCOME 1,904,754 1,931,832

OTHER COMPREHENSIVE INCOME:

Foreign currency translation adjustment 558,757 465,593

COMPREHENSIVE INCOME $ 2,463,511 $ 2,397,425

EARNINGS PER SHARE:

Basic (in dollars per share) $ 0.26 $ 0.27

Diluted (in dollars per share) $ 0.26 $ 0.27

WEIGHTED AVERAGE NUMBER OF COMMON SHARES:

Basic (in shares) 7,210,256 7,166,919

Diluted (in shares) 7,210,256 7,179,309

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 8, 9, 10, 11, 12, 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6508144

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 2

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 36, 37, 38

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 11, 12, 36

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 20

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 7

-Paragraph 18

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 10

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net amount of operating interest income (expense).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 10

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.10)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax, attributable to the parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569643-111683

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Expenses recognized in the period that are directly related to the selling and distribution of products or services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_SellingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 29 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES
3 Months Ended

Mar. 31, 2012

Deposits and Prepaid Expenses Disclosure [Abstract]

Deposits and Prepaid Expenses Disclosure [Text Block]
Note 6 - DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES

Deposits and prepaid expenses are comprised of the following:

March 31,
2012 December 31,
2011

Prepayment for raw materials purchasing $ 31,521,801 $ 28,824,123

Prepayment for packaging materials purchasing 366,792 402,838

Prepayment for enterprise income taxes 1,708,019 2,162,070

Other receivables 655,918 508,392

Other 661,946 751,025

Total $ 34,914,476 $ 32,648,448

As part of the Company’s strategy to reduce inventory costs, the Company maintains a balance for prepayment to suppliers in order to secure favorable pricing for raw materials. As inventory is received throughout the year, this balance will fluctuate with the business operations.

X

- Details

Name: skbi_DepositsAndPrepaidExpensesDisclosureAbstract

Namespace Prefix: skbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for deposits and prepaid expenses and any other receivables during the reporting period.

+ References

No definition available.

+ Details

Name: skbi_DepositsAndPrepaidExpensesDisclosureTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

INVENTORIES
3 Months Ended

Mar. 31, 2012

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]
Note 5 – INVENTORIES

Inventories consist of the following:

March 31,
2012 December 31,
2011

Raw materials $ 12,341,645 12,646,663

Packing materials 231,596 181,304

Work-in-process 5,218 22,559

Finished goods 1,554,507 2,171,238

Other 52,219 51,085

Total 14,185,185 15,072,849

Less: Allowance for obsolete inventories (223,098 ) (221,690 )

Total $ 13,962,087 14,851,159

The Company periodically reviews its reserves for slow-moving and obsolete inventories.

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

EARNINGS PER SHARE
3 Months Ended

Mar. 31, 2012

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]
Note 17 - EARNINGS PER SHARE

The following is the calculation of earnings per share:

For the three months ended
March 31,

2012 2011

Net income $ 1,904,754 $ 1,931,832

Weighted average shares used in basic computation 7,210,256 7,166,919

Diluted effect of stock warrants and purchase options - 12,390

Weighted average shares used in diluted computation 7,210,256 7,179,309

Earnings per share:

Basic $ 0.26 $ 0.27

Diluted $ 0.26 $ 0.27

For the three months ended March 31, 2011, the average stock price was greater than the exercise prices of warrants which resulted in additional weighted-average common stock equivalents of 12,390.

For the three months ended March 31, 2012 and 2011, the outstanding 140,000 options were excluded from the diluted earnings per share calculation as they are anti-dilutive as the average stock price was less than the exercise prices of the options.

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

DEFERRED GOVERNMENT GRANT
3 Months Ended

Mar. 31, 2012

Deferred Government Grant Disclosure [Abstract]

Deferred Government Grant Disclosure [Text Block]
Note 13 - DEFERRED GOVERNMENT GRANT

Deferred government grant represents subsidies for Good Manufacturing Practice projects granted by various levels of the PRC government. To date, the Company received government subsidies totaling $1,188,000 (RMB 7,500,000), of which $792,000 (RMB 5,000,000) was granted by the PRC government, and $158,400 (RMB 1,000,000) was re-paid on December 7, 2010, with the remaining amount to be repaid in 2012. The current portion of deferred government grant of $633,600 (RMB 4,000,000) is included in other payable in the current liabilities. $316,800 (RMB 2,000,000) was granted by Shaanxi provincial government, and $79,200 (RMB 500,000) was granted by Xi’an municipal government. The Shaanxi provincial government grant and Xi’an municipal government grant are not required to be repaid

X

- Details

Name: skbi_DeferredGovernmentGrantDisclosureAbstract

Namespace Prefix: skbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for deferred government grant during the reporting period.

+ References

No definition available.

+ Details

Name: skbi_DeferredGovernmentGrantDisclosureTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

LONG-TERM PREPAYMENTS
3 Months Ended

Mar. 31, 2012

Long Term Prepayments Disclosure [Abstract]

Long Term Prepayments Disclosure [Text Block]
Note 9 - LONG-TERM PREPAYMENTS

Long-term prepayments consist of the following:

March 31,
2012 December 31,
2011

R&D project $ 316,800 $ 314,800

Construction deposit 594,000 960,140

Deposit for equipment purchase 278,988 237,877

Deposit for potential asset acquisitions 652,609 569,788

Total $ 1,842,397 $ 2,082,605

As of March 31, 2012 and December 31, 2011, deposits for potential acquisitions totaled $652,609 and $569,788, respectively, all of which was held by an unrelated third party engaged to facilitate potential acquisition projects.

X

- Details

Name: skbi_LongTermPrepaymentsDisclosureAbstract

Namespace Prefix: skbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long term prepayments during the reporting period.

+ References

No definition available.

+ Details

Name: skbi_LongTermPrepaymentsDisclosureTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

PLANT AND EQUIPMENT, NET
3 Months Ended

Mar. 31, 2012

Property, Plant and Equipment [Abstract]

Property and Equipment, Net [Text Block]
Note 7 - PLANT AND EQUIPMENT, NET

Plant and equipment consist of the following:

March 31,
2012 December 31,
2011

Building and improvements $ 26,030,763 $ 25,866,428

Machinery and equipment 5,764,470 5,675,995

Office equipment and furniture 328,571 320,498

Vehicles 592,175 588,436

Total 32,715,979 32,451,357

Less: accumulated depreciation (4,442,951 ) (4,074,798 )

Plant and equipment, net $ 28,273,028 $ 28,376,559

Depreciation expense was $343,129 and $332,428 for the three months ended March 31, 2012 and 2011, respectively.

X

- Definition

The entire disclosure for long-lived, physical assets excluding construction work in progress that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

No definition available.

+ Details

Name: skbi_PropertyAndEquipmentNetExcludingConstionWorkInProgressTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSTRUCTION-IN-PROGRESS
3 Months Ended

Mar. 31, 2012

Construction In Progress Disclosure [Abstract]

Construction In Progress Disclosure [Text Block]
Note 8 - CONSTRUCTION-IN-PROGRESS

Construction-in-progress (“CIP”) relates to a plant being built in accordance with the PRC’s Good Manufacturing Practices (“GMP”) Standard.

Xi’an facility

We started constructing our Huxian vaccine facility in 2005, and it was completed in 2010 and resulted in a transfer to plant and equipment of $9,448,505. In 2011, the Company started two projects at the vaccine facility to modify air filtration, water treatment, and other facility changes based on recommendations by outside experts hired by the Company to advise on the GMP qualification process for the vaccine facility. The Company has finished installing, tooling, and testing of equipment on this facility and resulted in a transfer to plant and equipment of approximately $589,270 (RMB 3,720,142) in 2011. As of March 31, 2012, the facility had a total in construction-in-progress of $2,360,086 (RMB 14,899,533). The facility is currently waiting for GMP certification from the Ministry of Agriculture. The Company expects the GMP certification process to be complete by the second half of 2012.

In 2011, the Company started a facility improvement project in the amount of approximately $316,800 (RMB 2,000,000) for the Huxian Animal Laboratory, and it was completed in 2011. The facility is a supporting project to the Huxian vaccine facility and is currently waiting for GMP certification from the Ministry of Agriculture. The Company expects the GMP certification process to be complete by the second half of 2012.

In 2011, the Company started a facility improvement project in the amount of $1,127,808 (RMB 7,120,000) at the Huxian veterinary medicine facility to prepare its GMP re-examination, which is expected to take place in the first half of 2012. The project includes a renovation project to clean 3,160 square feet in area and to replace or implement an exhaust ventilation system, color steel enclosure, process water piping, purification equipment, fire alarm, and combined air supply unit. This facility improvement was completed in 2011 and is awaiting the GMP re-examination from Ministry of Agriculture. The Company expects that the GMP re-examination will be completed during the 3^rd quarter of 2012.

Jingzhou facility

In 2011, the Company started a facility improvement project to expand production capacity at the Jingzhou facility. The project includes plant construction and water supply and drainage and has an estimated total cost of $2,005,819 (RMB 12,663,000). As of March 31, 2012, the project was still under construction. The Company expects the project will be completed by the second half of 2012.

Kunshan facility

In 2010, the Kunshan micro-organism facility and some general facility improvements were completed and placed in service, which resulted in a transfer from Construction-in-Progress to plant and equipment of $1,389,602. In 2011, the Company started a supporting project at the Kunshan facility that includes the construction and installation of plumbing, sewer, electrical, HVAC, fire protection and alarm system, drainage, office, lab, road construction, parking, and landscaping. As of March 31, 2012, the facility had a total in construction-in-progress of $4,954,274 (RMB 31,276,982). The construction and installation were completed and the project will be inspected and accepted shortly. The Company expects the project will be completed by June 2012. We anticipate that Kunshan plant will start small-scale production in the second half of 2012. However, we don’t expect that will bring significant impact to our revenue in 2012 as a whole.

No depreciation is provided for construction-in-progress until such time as the assets are completed and placed into service.

The construction projects the Company was in the progress of completing are as follows:

Total in CIP
as of Estimate cost to Estimated Estimated

Project 3/31/2012 Complete Total Cost Completion Date

Xi'an vaccine facility $ 2,360,086 $ - $ 2,360,086 Second half of 2012

Xi'an animal laboratory 316,800 - 316,800 Second half of 2012

Xi'an veterinary medication facility 1,127,808 - 1,127,808 The 3^rd Quarter of 2012

Jingzhou facility 675,259 1,330,560 2,005,819 Second half of 2012

Kunshan facility 4,954,274 - 4,954,274 June 2012

TOTAL CIP Balance $ 9,434,227 $ 1,330,560 $ 10,764,787

As of March 31, 2012 and December 31, 2011, the Company had construction in progress amounting to $9,434,227 and $8,839,055, respectively. No interest expense had been capitalized for construction in progress for the three months ended March 31, 2012 and 2011 as management determined the amount of capitalized interest would be insignificant.

X

- Details

Name: skbi_ConstructionInProgressDisclosureAbstract

Namespace Prefix: skbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets that are used in the construction-in-progress during the reporting period.

+ References

No definition available.

+ Details

Name: skbi_ConstructionInProgressDisclosureTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

INTANGIBLE ASSETS
3 Months Ended

Mar. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]
Note 10 – INTANGIBLE ASSETS

Intangible assets consist of the following:

March 31,
2012 December 31,
2011

Land use rights $ 4,791,602 $ 4,761,352

Technological know-how 2,217,600 2,203,600

Patents 316,800 314,800

Total 7,326,002 7,279,752

Less: accumulated amortization (1,715,867 ) (1,605,546 )

Intangible assets, net $ 5,610,135 $ 5,674,206

The Company’s one year loan with Industrial and Commercial Bank of China Songzi Branch (see Note 12) is secured by the Company’s land use rights in Jingzhou, Hubei Province.

For the three months ended March 31, 2012 and 2011, the amortization expense for intangibles amounted to $100,373 and $230,922, respectively.

Amortization expense expected for the next five years and thereafter is as follows:

Years ending December 31, Amount

2012 $ 300,362

2013 242,082

2014 242,082

2015 242,082

2016 242,082

Thereafter 4,341,445

Total $ 5,610,135

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16373-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 44, 45, 46

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16265-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

STATUTORY RESERVES
3 Months Ended

Mar. 31, 2012

Stockholders Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]
Note 15 - STATUTORY RESERVES

Statutory reserves represent restricted retained earnings. Based on the legal formation of the entities, all PRC entities are required to set aside 10% of net income as reported in their statutory accounts on an annual basis to the statutory surplus reserve fund. Once the total statutory surplus reserve reaches 50% of the entity’s registered capital, further appropriations are discretionary. The statutory surplus reserve can be used to increase the entity’s registered capital (upon approval by relevant government authorities) and eliminate its future losses under PRC regulatory requirements (upon a resolution by the board of directors). The statutory surplus reserve is not distributable to shareholders except in the event of liquidation. As of March 31, 2012, Xi’an Tianxing has met the statutory surplus reserve requirement, and $11,192,619 still needs to be transferred to the statutory surplus reserve from other Chinese subsidiaries.

Appropriations to the above statutory reserves are accounted for as a transfer from unrestricted earnings to statutory reserves. There are no legal requirements in the PRC to fund these statutory reserves by the transfer of cash to any restricted accounts, and as such, the Company has not transferred any cash to these accounts. These reserves are not distributable as cash dividends.

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 38 0001144204-12-029585-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-029585-xbrl.zip M4$L#!!0````(`.R"KT#ZN*JYI(H``/N`4@")$``Q%"B MUTHJL8EY]*][NGMZWN__]CSQI4=,(Q(&/QXH1_*!A`,W]$@P^O'@\_U%SS[X MVX<__^G]?_1ZTF\GMQ\E+W23"0YBR:48Q=B3GD@\EL[_Z/'4K"9)/Y+A7TOZ M7]GH*TI?E155DO5C73U6%&EP]7]2KS>O]01%4`N4X16H1XJT3.2?SN84KP#6 MD.1(_DKP$Z;2KQE10'^D'VFLKCL4)]1#LT/I"LTD13V44@C.L6X=:[9T7Z@/CEF_Y=`$D%T''UY(#\>C.-X>MSO/ST]'45?9E&,Z`,)>],QHA/DXB0F M+O*/W'#".9,U33G(BOLD^%(HSJH^"ND((B MZUK53QK/JSB.T^>IBZP1*/ MJ$M#'_>'R(U[^'GJHP#%(9U=P.]Y110/*VLP^Y"Z@(CC#:0X'6RU)*"'B;E92"A M)#M^=L?E^5E*20$2/.(H+B^2II44"A!QH_(R/*FD2$3<\@*04)8]GM**_)!2 M4B")>B.$IHLR0Q0]\#;,$JJ+]%`<5Q>#1$H>DAA'N6),QZ/2,CREA-:SO\$L M?_O(?`5XO^_>,Z]Q''%_<(N'$O(^^@SW&PCN`T#&+\'$MWV(V9.T\]]'>9BW:S5`(V MG>7\7;LZ_UU3>E>(LCH5SM(\/W08))[Q+_-/Q&,?H0>A$F>YR.&\P4\O?SGX M((.KE"W3T9SW_=7"*97^&IF,"@B%A%Z!,.L_XC/P1_!UWE:R`KU/?SW]NQP' M7J&,!NV[++-,78)9DIY_R:363HZ_W\50,^MRS_^5`'>GX60:!O`S&CR3Z'?X M.0F#NSATOUSAR0.F+RGWA4CQB`%,OZ4?/2`.;IRX)$YQ21Z!/&EDD]G7\4;6 M#C[,LZWQ^+Y?2B+#U%\'M:6",-M(U:.997"* MIB1&_K^MDFSD]TUAZA7F%L>(!-@[1S2``4,K;?U*=!5^6ZR23QF="NXS&F+)GB,6N51WP9P,@>_]OJ4&/>OTU% M&D2_7P^9*IUA=[^'%>F$3#P?((!0\@.$9>H.9+(TKU,?1='UD(?*W+3N@`:. M3FY@O(FL#+"5K<88:N['&$O#&CO M)5G0K369[,2IS&7RYE3VQJF\0,,K,C3\[.LR!J.GR"_3P\I?ATSD%XDZ]GZ" M=Z5#?@FG.=>3M\G:EYZLG3?G,O9Z$>5_:^A7;.B5\>9K6O3;+/N+S;+OIZ6_ M*>8"W99-76#;93U_PI@JOJPI[[!7>5L3>/,.;.KRJ.NR1=WA;\'SU M!<_]]!-OBK%/BM'98["-M)\#4K6+-F%)3%WNQHAB$$7V?8)1E%#$>.$)\ZK MGZ?-?[,ZRJK\?'>V5E]V`N`8TK:H[@93CG-1K4<>05,^Y+)^8CO_V;[]+2FO ME6#6^GD\KIW\_/@]FIP>O[Y_O)T\%$ZO7[?KZJ< M0UHFG@(JBOS+P,//O^!9,])Y`Z^L:D'HE!]'B"](Y"+_'QC1\W3EM1FMWMR7 M;JIJA:D+XH.UP_=12!NR=#=!/A22;O$TI#&$%A+S%BB8Y3DLU+N@>4\1.T]U M-YL\A'XS:FR??%IQH?!JVRSG0U-[ODYBYC!8@5(ZZRMO$M-"GB?S")*'70*\ M1C\>R`3++BH/?;WP43EO M:S4.@0F<5EDHO0;RAGO45DJ7=]655:T12M4RS7,!WZ)FQ/Z^0F2MF@I"3/]; MD&'_+R.TJ(:36><:>'=C,(Y[3">7_"P/JZ2<^OHNJZ4F MLHYD10U!"QW3?M]O3WTGH!="VP3:T6S3L/7.H"%*8>>\HEOL8BCWX.-/.,X< MG0#9:IJCZ(ZVA+F)GB!@C>1G6+9F,P-K#8Q),F!G^2!=@(04W384Q7"62/($ MMJ3<2`2*YIBJ;%L-*-]0/$7$.W^>0OB*!:J':NJVKN=LKY125RR-Q*'IH*JZ M9;;!\BF,,3.SCR$*=F5"CJG+=DY"M31%(FSFBVS%=)QM$0ZB",>1.'D9MB/K MBI%KQP*%;6DWDH1IR*IM6M8FVBSZ`M7BYQMG("7FL*?,,8-\^$!1@`Q46[-, M@SF56FHB,#62C6JKE@;B:8IIN2X/XU2:$'+90#%1A`61C_1,!+1^=NVYLB& MD>M'J\F)@=7,I'1-5U6K/:RBS_H4!JXPPU(,1;45J\H_+FD)`-2L`U-LQ[(K M.X\50%SK/H;!B(5#/.>,AT,7(1VXH($17P<6H5.&F<)J2%$>^C4PV/-GUT_8\.RG,/2>B%\^!FTK0$M793,?F-33%0RT611I M*K*B&1V`9ME$VJEE&::M**M]4(5]M@/02"J6;JB&IK8"(,(_R9H-O9Z]QGEK M<@V]CZS8MF[JF\EEPXH;-&,QD+@P1Y%U2S:M]0%,D5)G,,WZ=EDW-;UD-%4" MAOL=WLUGB1`!0'::X+GC%N*#5=!"9^Z$-Y,3`ZN9\Y4-1]6LYK`6BP[S@?Q) M2&GXQ%8?1;@*S30U55ZV6PF9;C`:.@P+QH$M8)PF41Q.,!UXC^S2((&C!T77 M5$/-#68J2'6'T\S)P.!/-ZQV<.[1,]Z!PS%E.>];2ZAT0]%,((9M%`9W=3#. M$GP?WF*^#G>#^)4R`L>:)HQIEEBJ:0F!U&P:PY9-TVF-Z2-!#\0G8L6C&)IF MVOFIU74RG5`T4QD'^FE-EQNC.,M.1]WB1QPDS#.?PB\B.$S3',V0&>MJ/;T"&9JJI4.*252:;%:G ME8H$.E!O%NDUIUZQ,S]71H03-BQ;!R/-C5QJR0I%VK< MX@C31S'#*PMB03;Q44YA:^(-U^[JB5=NYU[NRH*NC.VV$J%%MNZHQ$).V[:+"%Y'YGO,@;CSCHUBD==MASWG0N0I MLW:!V'XT1VM&UF.U5_)0C0]PM`KC7LE9B6%F-:BK828WMF<;,G<1Q96L?-91 M%0AQV]725A`'OA\^L16/BY">A\L:X MKX?1 MZ%78*K&%_9*[,,U_&;E?1E$B2M=K4*6DA"+:C9!?CH^FVOSRB/99LLT..(I3 MW-6SC4*QO8J@=\*1(&7>*;:]DG9N(O3E@_8&Q,6"[1+%=@"[F[!.7PLO-I`4 M`ZVI>0F$)C(XL!13<11G`ZH2[[\5HJ:"$H-(>&=4#ZN!/]F1Z]X>VQWR<91M M1F,'+**JL[&KS_EM/A%NFXZ1G^(KH2("1LUF&4&P8JM$*ZX-QS#E'.%< MY1V(UDS;J;9J6DX]4;;-!5%W/`B\,U`%/^1')[-#`YUY5VU+MW(+HQNI"<55 MIPQY>VR.Z@[[/O@,4>+13$>7\XZA4'TWRC7.0#9,Q6Q$^2<<8(I\=J+$FY"` M7[_#]IR*$H*B.KKEY.UC,T'!X&H7&@P]OY39!MSUE-W7M!1KD\M-:F3E&(II MY31FC41G`#7RL!4==*(:$QUS'R/5$5'%)C- M\NDIAF8J;>'\A$C`%.PZ6)X`N.0'^OF1:\@.X_NX8L]AJ\A5,W0GI^1-">\* M;=WQZ?QP);.[8*&$T:7!`F4R+Q? M&$0G>!C2;/L#/TQW_@P]9$AAJ(7H[#+&$WX:`TK2D(<<86V]-5!Q9M_*#\1=4 M#R$;^'8B]KH3?XUE5L78!;AX,@K2?5KN[)ZB($+\.B@8V?)?/N\-!MX_D_2B MQ_DIDAMVI2PDQ#$E#TG,=GO=AS>H\SYRN`)BHC;7D9E M*Y/L5NNC_'5OI;2$H&FP3IJB,;N@.2-^$EKJUO;:-75:MJ9F%5K16"G6*O7Q%4%5G-W_,B''O61,U6 M-%M+WG(TN5[R51AVC%^8]!OAWVX]N\OYQ&9KS$)1"QB#B4"]@SB"WP0/M5", M(@R-P__L'!J\0`!4"GQOI;6KP?N;8%]@RN%-R"\U4?(FZ1U/[[S)^H6GH_:B M)SS#0,XEO(+NFV0T55=SL^SYRKM0K7N_05/R%W=64ET*B%UU/6'S)'^(85R% MF#^_=%-)21B>FFE'6=;R]U,VPW-#PT?"GKPK.3#:642%+>W5=$0"JKLOT\Y? ME]D8U*HY70;KAVJ[KT$;EF84[D&O)[H+E'4S:HIAZI90F/.G:*INW&LC1=-6 M35W;B"]'3BBPNB5]VW!D6PRPXN,'W7V9*6O@4C=A*U(4#:]&YQ1=KS&-5O!X MK[O4SNY*U]-,6=>=30!7:8J'6*-^IFQJ^/H,-OY)^;X5N]W;N[`'7'WJB#JQ3%`ZQ;&74T523"[!+]_+7@W:5HF*:N M;/33)61W`K1&FKK*WGWJ`I2]TH6B,8^#/.R=S#Y'&,8.B]VR`QAR/%;?A-O* M19JJ;6M*#FYSXKO#7/?2A:J8EK(UY/3MJ^RIG>MAR?L[W=?D#85O(*LG)0[1 M9J')C<$LPO#LXWW(WR*B>.4MN6Y"ZFG%@4@-,='(Z@XP&'F3:`>.AB[&7K93 MT/?3]YZ9N`5*C^^-E9V5VR(:$=X1V%KMZP1SM0'25UNRY^MN?!3$^3?LN@?> MJFIM:O_-Y'<,O697B^Z8@J'#,/QT]>D["`($#`K9`WOJ.M@J@J+1U6Q4U1V] MQ$,U`E?1(Z4O`(OMP4V=/8!BUO:&);1W![GN`(<"49+<&7+>E2R>*SK##]T= M@*(:EBQ;Y5ZK0$H8H)I'JS1#K7"BZW#FCWLNLMPN>OCKXP4;M;<$O'Y<`C1QO7P_-D=HV"$;Z$MK@-6$WM#I_AP>_<80E&=_.ZT%K1W M";KNK1PK_Z#]UJ!YZ^QFUPH+S8W"E025M,1!JCLOI%F%@^$M(*T+<@"Z3>D, MU%C8>S.R7CQSTXBP:*C-9O,TVS3R*O@J4,^:O%5@V+9EYZ=N7U.J-0J@RYJ6 MGX1L#W5^7HWMT.F^\TS7Y<*$X[+N+D3KGBU4#5O;0+7B-6:^KI]>_'4?KH7^ M_`WP[O-%JF*SA9[M(>R>@YJ>0]/X\Z$B."A/+U2QN['_G(+K3%TA()LRP*K-/2)A[(=,-#<$>1'Z81.%HTA?[&#)SHCD>N'44+Q/?!R MXE<]S;7*Y(?O_?C=5(KBF8]_/)@@.B+!L21/8_CO^9TTA&+'DL)^QV0"\6:` MGR0(RE%PF'XXE"+HC8?O#KX?Q>]870_L+Y_"&$O*]V@R??>?BBF_ZTG7MS\- M/EW^S^#^\OH3R]9_F!?H3]G?_OPGH4`6E'=&`>I*V%_RK2:AP`,]B5Q*IOQW M.)0>DH@$H!`<2/+*3#,5Z"&?C(`*VRQ#AK-W4D>R=U]F48RH=$+"WLT8T0ER M<1(3%_D2V^>%@IGTUQ2:K:KR//OBB_)."JD4C[&4RY05S&7Z07I"D40"-Z33 MD+*1'OR0/N%'Y"$))'V'IS'?C2:I^J&D.(Y])-U!=BP1"-X1FZ&+2-HF4"Q\ M3/-:AY(JRP9KIPUL_/44/"T*?I!^#GV//PI]&AX=2A]C[ZB,-2G-G@=_**'L MJW09@1/P6*_`63SDK,\%-08>'S`.)!R,T"CED:73[$:H0]"NQ850A]*4AE[J M>`Y9*W[!;$;GD&MAQ"Y38WP]8NB+^5%Y:8R1'X]==N/?\BJBHZD M@0^?LOOZP\4I?%95'BDKDX&[P>'4QW-V%>M=),&8/7GPBD%._,MF M!;BY/0>0U0;Z1;D=52LOA%LA=XJHJKI#Z8[-GXP1`>;_!>5&!=GF]'U- MF"OE-@GVFW`_3,K0T21^G&E^5*W(A]`>!*PM,PB<:AZSK8):Y$?9@4%Z-?KT\+X0I2R>PB-*E;-J: M57S'SK4A"@'`20A_%%@N6-S@[J10+\R%I!THY9)=03$BJ((\S^A??SE9]CG.X*8J\#-RJ M<-$GH(P!*?CVTGAWF94+_0&["/QWI7/,^5K>0YZ!U:0Q,N\D65?YA"6/1*`! MCU!R'=&WTI:#*26^I"ISL?R2!!'T#^!OON"U[KJ\/RD6J6W*+/NA]%^L\XD2 M%H$_L@'+818Q/Y%X#+8V(E$:NKCIT3W6IK=7)Y(ARX(8S@,=Y"KS9%F7,2WXJ^7*%9.GADRK(23H'E M3'+&M!+J95+^H3H*GQ?,":RK:5L\9>80M( MNR@:I^Y^438=G4[^O[TW[6W3BZ!YQ%["SB"B7>$*H"IQ@\E M_\'!QT(DL.XHT4+']/;E8J3X0A(J7(PDI(5IUX#*@2I$,4 M@$@K@$_(Y!Y)>#"Y:(B6!OS"7"*.CQ*D#RKXL76+O^**9SY#VS8,&=5:C1=J MSN3%"GP3&8V#6S95ET1-).T>\@"6A=&^7.63=`2#635-^XE42M9*<%9%D>11 M#V==[5\!^G_?A>D"=UL]6E0ZU"1P3T"2\^([1@KUN&W]DO:%9UT5KCP@TB?1 MCU+D^2W-VF?3`:-X7(#>?^^>5P#O/=]1,@CX@EM12;>&72B\%;CN%-X MJV$WN_Q69LE":L+(GY&)XD"]GEUK=^4@=JLNQYA#08`\,F]@9>DV95_!+7&T0)H!-KN#W>":\",=6]ESQ^'")TE8&&YF^ER.1 M).I*CL)[T+)QQ/^,&0+WJ%0A'0(@9G,,4W\(7\@KJN\C#I=!T*3IL\"'X8C" M&<+A,_PU;I&B%.=!(A>=?8F+0I!GQ*G_2&L23/[Q8QT^_@5(!U/@5W00>T(U MI+&)+QN0CIF2D61HQ=]!R'*D(:BB;*\S!,L9K^8ES(7O>LUN=9O$H`E?:E5] MTS7CGVEEVX>S_07@!R05KXU6Y^R"Q:HH\C'/F(T$V?M:>,L+V]D#&:4OVJ?L M4@NHPB,T"0*IAAX(MX:?V;=JE@WOWWYGYV:$+J>K(2GXN9N:YI87.MH38*QOIZ@+!T+Z2TA&$=D5:`D'F@ND'D_;>` M!J9K%8-H08T_?+)HHL[@*M,FK@-D(YAE@CY`DY7\=GQS;/U\"J MD>402`09#[VQL5*/UI%YN)&">%G0`VE@0!#'`+;*_](3)U'B#6"X6I7,%6*4 MS6 MT`\?>*NXG`G%3\9J;(!%AH`H`4M=U<3K&>,#T\%S4ROV2`A&KS*R'B4EZCK^ M>A3R$XX==/5E9GNE4J/-&L9]%,`-!=>FTW;+1DV)^[?*/;'P)8N!J_IH,X5E M..J"_9D&AHE!NNZ>&`BAF@,.HR2)VW!B>1>NYBFD\4#Q7J+/D/TFE8+?Q!/20(B/_'Y^%A\;QZ(_G10(._'- MB@Z%R`I8\9WK.S[7%%#A#5.+F3V_09^%[XV]0#D1YQ%SAM^0N6C"W*S'OE%STSF9>7")XD)C']\3'L#M\'>4%$6(0P(7O?;,AX,CTESKBP M+X(1?,2UHT,%CXWE7(H9\(GPYNE&9-C?4&Y..*R!I2@4H%P/8!]Q6`5';&0K M0J(L-VX*7/ACA""#TWV)P(/11AGUFPT(LJE*VZ$9/9C&+/395C]-2(STI<%< M+@SP-WP@AH*2#P!>&C503XFRHCVV%?9A`R(>"'P69=H((T-&#NHH4H_@,E.H M;CC?V&$62Z4B;P9%,=NZI]P0G-35K;IBJ?$\X1IYF\1(DU]9A5':M`>2C?F[ M+_PHQ$QCEN0+=-(%U`-I>TJ5YN]SRC2B37:+#&J21J"NR?M!=^$.X\(%B/H! M`'23>R\*R>.!@VI_,0Q= MC&4%-2Y%)7`O-`T3W]3]DEAG'IEQEOKT%C&6?-BM4<57-G:8%9VS?V0F2'PQ/6^ M79S/X;K[Q47-Y!LZ2X%CY8)PF":^^6W92R9G&%%2P>%#C-W MYV5KSSQ<)%C9)&3KA9;\RZ;,@1EX*I?BS:(4IX%UY\58,1%-``0F`(5A?6*( MD.-)R@0F#5=W=!D\FZG],<'`16&@@2X6;(5H"2G%A+VYWG^E89(#>!&S0\$. M9P^$NTH:B=.@-:-5WWF2"[[KA(#4T+[2)R$Y$&#D. M:&H4\[9(*F>J',8L;"$#B#R0A(ABY5%DZ*>H],B,BR"/W*Y`04,;0QQ#%)'H M[:A`LRE)IM0@.\/*3RT`F#846(=HA^) MD4..*E,OG`4>*40S#S2>'PL';1S\C"N&*/7/'4'>3F.(S%(BS9AA+,J'*+54 MWF)`4\D&L]7HJ6PC\@P%+.`00E38^H$/,%VX\^!R1(,[CH,LK*Y\ZS*)XXXE M(?,5,^:0M:>I`N&<)'58VD(4< MM-!)^93H5(I#3E)1MI`"-#"D,(VU[2K&XE)2G-4V(=,X+%/BE!@1I^15S&,+ M+\E(?8&KD>4BVY8W-(1^6^U`0D>GB;!0@OL0NF2%=@5G#V21;@XJ"SBD`3O2 M0PE?V%K&V:4V?C"WVZW7V[S+Q"U[J1301P[UF6A!#7!CDG+P->)J=LYC M$!9"ER-B\:2ED#>)4&JPCM*`?=W"95.)YZ*_%Y49>7WAN[PZRYE@0B8X2]N; MN8'W263^@:>V<2'Q@#NS<:>^$.XH?UX>?Q!E8F_LH35NI@&D@#'2ER;G9'%3 MH-%81%R"53G6IS'PT5:JD@LL:D"Y,!&%./!?-B\(M&E@J8E''A<6.#&"18#T M/.6HF#(C'U#Y[:)R8V$RF`8&PBDU23E/Y-OEDM-SL>05..2JYC+[4#Y0FK&\ MUY,4)`:L(Q=*9Y(,%`,UT*6,)$=?]C@+<>%[;TM/%`E.N9S7;$.9UZH`?YT` M/7\YF6GU@^\,OE9N!G?HB;(NN?S+%1`M?.!+Z`*RF/;]_./T>SZ+6`_,XA'G M)&NG&@E+_U&I6)\\X;L_6N^OT'Q:J:Q5.7O3T05OC*+UPR0)Q^5$S:1/`RIL M40K(2&=J:`Q2&N1[@ M]`0V'9!I?`G:QE:*:669E>J(]0Z MFY7D.?M0LLX/2[!\$\Z^&"9:%5*C?+_@RU1&*WN[*E^OO&3NA7:PC;NN'W>: M>[KQ=F]/-[ZV$U^8U#S<>8E8C-#@Y[-O(AJ@8W8677D^<)\!T>6IQ=.'__H; M:!U7JV]]#]WCN=QR+_>P7G9?OAR9*^9ZV*HC<*U'-`:M'KI+O[JU]_6PD\-. M7I6+SE_,F7+;DZ?H"!,ZXS([S:Y`>*,[J1[7VCNSF?IQO;5#FVFM5"3:!"N^ M]N*O%0KCS<7,;!>@=^DR5Y>7WG[8MCTT&F]_#\^@0]-[V"#KO0\Q,P)#/>;L M`WU_E0>!^\;)?/=%=H55C28-#3.&6\ZN]IPU;1#OVMVW?G/:J[@WF]W!4N:L M16[^VD)9<.Q7C5QX`Q$&3\5,-:7=<;[??6ZL5'O*=,E%.J?*U=A6HVG7&]4L MVD95_!4Y$R25NT0+FO4@,(0O"QOB7*CIJ!WQ;4)EHLP"J?5NOF:H=IW1M[85 MA$%9`!!6ZC5GW!`N[P7.S0U76`CG9F):K:@'!H+RU"N%'W4!!J# M]`3%`;8-@]8:8%HB<6'UW+X3\_4TTEJS)XST@E_*?M?ELZF:/0?-N0XFYTYD MZ)V,NN03P&!=K!P1)+H&&L4#9_FZ*A33C-U5%""7:6]FA<`V.-Q3=M&B=/LL M"X2FX%+$NE`B5T?C`NCF?K!&L,R4-&U#BX4CYA?(-8UE7@K73Z85+S1K5FG8 M]X8+AT/")GWO*]8ED:1)5;H327,/QC'.FE>O9:4X3.9)<^>BRPYD#D*A< M-\]-0`GSMQ%%W3Z:L:2.JE6H,.,YRWC5B[:IS-5\448$BMG#1O;TF4ZRLXW8 M^%F%?[!$A`\_>D-/)VMBVA-5"@3\S>&)'S[@$>N*/12AK2_AXF'7P#PFLOY@ MJ`M[8YD*704!$4#7%3,R4^W"L+%"C_<%S,CR#)@YC#$.6!,RLTT9E9GW_DH1 MZ)P9057:_!`V7J$T72=P_$?@MI2TF_J.S0ECLN!O2;RQJDRH<]&1,GE^5A\H M3OM_"N["]*B3UW`P,[9=C"=^^`AKUL-PB00/:P7DH/UGZHYDQ4P)/T6C90Q] MEI6!"91(*QQ5PE@F@>12@';\/MV6!:3/EEX,N0+/?$HN(4[I8B_(,27>S8I< MEZB1(EW^F^A_+F?'-DK%"#Y%F:Z-Q;"<"`EC7"C.8=#'.1<`*^FKEH9/ULG` M>@(9%"3C9G)0&NPU0P[5_WVFT[&:OJ;-^.&5Q#(=S%\MZF@70 MX6LL/**4H.IJ[P\6Z@P$J6((3M0%<1D(/>,'"L^JJTN&M%G.9YA&3]-YHM%$ M""6CD%5A-V.$8I7/[5(6Z#.5G9Y3NLPXV*]CG%;('2D(VK?*@42..$PY&-&=B9'6QH+ZBU;Q9O=_./HU'OVZHN2WU4>^KFD/6SIL M:0-;VF7?V`?AAP]H`6,'PR`,L,VLKL&XH`5-%:$ET^ET2Y@D+-A'-E#,L,P^ MTFUMTCRR!F&UZ)/NUB5S^L`V3'OZ<%Z;63\WUDP-TY+C-!MVKS MFJD#G6H3=V:'W`I];TF"O7W M`B>1K739T/H*#:=_F%[%J!Y//`0N0F26MV4P%= M5#`KB?^DRRI7D:S8ZIS'F=,(J3AX$`:5P@2E96U_5HVA;#WX$\LN&9D*_DOW M+D58P!Z\B&KE@@P:C6;4Z_VTJ,/5YEZ*[`H,PD7'?^+3;B$F3D"UN*^YH95R M>^]TIQZUUWPK/[P\W(P&`_^H99,*("&2Y\A6CO<8_>`%&`)\)QP_N1M0Y6:X M7&/A4D#:@)L:RF[L(.YQXP'KAH90-T4&%SS!=+0 M>V,!VYR(*$X=ZH71I"I#=TDULBYZ M`Y@I'`/E.50;?F5DZ+\8&3YA&6G5F*4OL"&,.F!8[X_6*6H0K"M@7&R<:\ED MD&E74*=P:1K4&&&0;AG6MWEL>\VJQ>O`[!O5%0@?_\;F= MA9B%`$S/G>I(H[B\ZE(J`W:SC25AXF"X\/>-;L/N5!LUZK;W&^,8W MRQ9+VR3F.L+BN>3:Q/8?==@W'(;42S,V2L:7?;>(]6NJ/7KP/T28!(=T(>GOMM8WXU MN]IHVIW./!GI;2%-H]ZVF]7-H,RS*,Y,&>UW9S#`UIE;(8"^3A1(I]FQ>XVE M"B_-#@/9,A'^=2!8[_4`_9>J0ODL"+XJ&9V]PELT3UES%(M-GO/2P3,+7!"[ M!_2MT5B*OKW!*[(6T%6[;;O76DXNW2X->EN9[D&'WJ#TB9]/I4WY8&)YTUM: M'^5XTJ#RPDT]HSU"K]JVN\TWW^6AV6O:M>Y*%:C7UU'?@H&C9G=Z=;N]6G/` M1G=4M[OUFMU;3ES?1OO8-ILXNLV>W>TN7TAV6Y$&RS-UVYM!F6?0FX-YP^!X M3;O>7;]NOKL`;#3M1F\I5KM%"MRSS1L+"/<[>^#`[^'?UL$D^!(8-GLUN]'< M=:.@D1+V*DWWA:'7(7$)`[RS6_?"D0=@R(#;O5PUS4EU&< M0WHB3D#Y01A`3#/O8K8014?+@-K8HOR98/!(M<:=P,4$FS&&?.K@:"H`WW>" MK[+*J>_]E7H8B0MJ4\+9)ZI&?`A("1HY%DQD1/F$2ZF<9EU<--8L")YQ.3%Y(B*,CW1&E%:0Y8;U M'P'^@3,JE*`\>^11]ER%*)-%SFQL$Q*./8&UL"G,4MS0JG^.R6J4KY< M;C'.9.)[,AR_F!)1Z_RD]PG'DX@1+.;OK+1YD%+]#C@_>=_QRQ3!X3]R2>O[ MT,-W*5>":\;CQG+M(V`/#N5A3<)(K<\+98Y?=C"J]#$NV47L53G"E#['#S/> MZ$X(A03=X@D=6W]@4L?0P6R...W'XJ\4X.)3F6^`@^7<.YY/APT3>0$9'64C M@_S:)E&(F8RNREYFM*55REK?1G,%PG#]&^YG[+@Z-3T;5*(V[\(H+RV1YSA_ MO'BVA,X*70%[\@FBN7#_DAQ[6`:84)<#ATX`QAU1?#N0KB`6`$@6ZC'-=,!C/TL9?-K$#X$^@KQ?`_` M91(15,+A$(X2ZUHGA;N+LE,R3/ULAY2Y@WFF"17.WUE>=`X<.D!JLZ MCWEL:D+/&(AI@A>I=&38(?L]9)9.P#49#%+P);N!D;CWQ$.<&Q!O2-B/L<;] M(&,EN`^D+-^P90'"KY1A.\B1';QPU'`;\Z9U$7Q):)$6Z'MI;H:?534D,,=< M&HR,Q"^=8:?E`)X7ER7Y')K&_XE8\=)!"2R&8F)#/LZDTOV6OAQA,* ML8PX&*38[`-_<+&]T("KQE'S$OT7]5;(-TFB*@))Y"`-J%!BFY0/LU9`6E0# M01+9"F9ZZFXG7#SDV,*N3G@7TTC>,11T@$\YZHJ!<.,`^6!6Z(;$[;PQB@T" MZ13`3\AN(+.GX08P5/F#))\0Y"39T/2`3B* M,_$2O$DH+?],[2%(U0MC)%8`*M<#426FUPOIF(D6)6EYV2(`"@O`BL8S$P=? M'6O?0+K@S-3JS6=SZ3/.9OR-#_NS-YRN!K=@!M]3N>1=E73S(?5\A,`\!X-\ MI[7B(G^U:J59);%X>O+G;A,_?P'E!RB/9)%YPKX"CZ[IEEW'\D^9HD8VW/,A MUF$QR#7L9YA&`='%->RGM8;M_"[NO(&_N@`!<[F5Q0Y@QZRLAD2*+"!6]IB" ME`=<8E+&\I6LB4PUI$)MP"I95D3%/8QBI9F3P2&KD654\5'MFK@I8?GDLDT8 M\2AIW9#F!,F_LJ'S!J:4/+RXHL4>M& M:I/BJF)W\D%9N#RR0:"F8IOF`Z.OI,,* MW'0O+P1)26M3636-^SX:&T>Y#&<)W?[3>7Z$J6*G,E:O7 M)>KOC3IS&E*M13(!@89=`7%X!!=V$>O%#H%C%A0RGXWK16CAU,52!L8;5#E- M4L)'JR_%(S1'R!*5VL[@9E2'#:S%H8@H&%7";&Y&EVD*&8"HRS2Y.'0I3"]6 M%5I<4QTQ7IJ]4;;^:4?$AW838X'586M8CS=H9 MD!4?+I8?@K9%95TUHL/OW!:2/4<^C9RY/&89W.&*RL*E*#Y@D?O'"=<]-(H> M,F:/C7KWN&9XB&:1VO?5]>FQ5=P0J=5C=*#\37PUV_J4C2/[J6#LR'X`L@!O M#!(0O@I(A5\)B1A M@Z#T8<8YYHRCL>A-;'`=>R2J\55,DOSH4OU1"@[Z'X%1"U=O(_>KM%OJ8JQ. M1$2N#/D^1NF(:W3?(V$!3AW$TI$#U%#6+%5WSY/@0CC)'M-R85^\`-26B*)- M3D:1-TA]5)[V@NN?9_H,['Z*]9=S/_.\!*IE@*"S]&!O:LB5J."KU)GU%5NG MTGP^5,$,>KQL(F,-,%!?6",J*"XC.G"'O(L"+)&#F_JH=^U=@; M>[Y#H0`!6@5Q*1/9>'YJ-A5$@(89'52B7(/*!W%LE1H+3*1>@[4`=T=NV@(4 M]H+*&"KZ&"XPW'0JUPT,-QR+_5(ORB"@G65\`8:$_5)%-0)U0(G@D$@'%/,8 MJ1U6'H7K,HF\6"B%W%$+G8%TZ^E(0DRKD"T0!EXT2,<8/S507:ZP M.4'X`-?-BD,0FE#%.#%"%SK,,U4G+(W5$`%BS\%&XUKQ1 MI'I[=BFN@:,1;>&XV7OAAVRL)@O-?EV/^;`P7=8&;LWR7;/(+8-G@/([&+-B MH^`ZA+O#@2-#,2W=QND$8P?I-[.\,#%A,03DW3>Z?<[7.W&^[7`PF"E1ZF@_ MLO(;NY=:&\9CD@AF=I%YU-%;AC=;!O.22X3B>+/?@-0+&;-E3%!HB*$+3CO? MR+Q*0:4#&0D,8BW]`D7$R8?.1"!SR!V&82THV71R'B"Q'Z@Y4 M/*H4?J4:&>9'-!2UDOX1TPV9E!:'D_4I8@U62V(Y/57:@(=%>KA>:)S&F)%2 MZ!#[RYABMIN\B.L%FB4%IAI,NMX5+9QQZ\.!'?+,O9$3:[H65 MGACT&C9.R2$RB,H`+,4F]T'Y&7J(`P!5#6JE9]2K/Y5!7?]<^RD+$,[-]!"F M/MH<@(P#YF8:!CXDOCG8WH7=%IR.4OP>WF23B(C3L8R8PO8QC+9243)Q));V M7.RLE)@N3KP35J$%7@QC4<<6M7\RMLF^ MC[$0B=)OEP$WN1("`M[CYJ?*P>.M^('J5` MF",B0N2T@J79+&KX<$$IREN*%9(.*=>46@O9E$I<5-BXQ]S11"\H-%Q=)&'0 M:85Y6F>VVYGVNBW>@>!X@3O_-JG*K.X#ICR(09YI_T]*Z@A-C1]*=9 M*LIG1]J66`)C[YLW]M1A$)O`B\R"EZ?-A'!DLD4-@YU%'-ETDN..'1G\CD'X MK-9'$5I/*?]'6K_@31@'TQADPVM@;G>ASUE#(XI5F>$9F[%@CBTF$5';TV-> ML(5M3E`RS-D4,'A`6A79^4CW#H0@:K1&)MXX3D7\))B4DX.0,Q+LYY_Y0F%. M)-KW3DP\4Q\E-FQDFZ:F[*KOV9Q<)SQX26#("MR//==S=#Z$8@B**!>,A-4V M'GB8CNZ(-M-5A=&H$69.W'C46$:"MC02H7Y*DF/&LUY7%;TMX]]9AJ/%3@&B M>R3=#$CL&CCH#=62.U^AV"`=\S?R-DF&5I]ODG#PM<($&:\NR`[.3K>4-)%$ M9_1PW@(:3V#JV>4]5Z&XJ@$0V:DVFK(6;:6\^!$Y$B0ME*S^6[.Z4%. MP8I+[7:G8PMQ%"0R*BDDKZ/H7`ZI4DJ13/I6U3*E%D]+!3Z-^\WOE)HWTM=& M=`!:7D&G]\-'(>E]Y@YQ9L5"4N:S*P6>##Z2%.6?+P$,45]7ML$2N#FEV()@ MZE%#2Q7,N;,7],R)4!J+\4RM^,Z)%O%*O,T]?P`F.+#$U(;AU(L)X]35DH2& M8E9CEJ@MXXMHB#B?B?W1\RDW:J&YE#<2D'$\89&X[%>0=J6513WW0'%1TNK$]RZ=\TIAI>)]-@)HF%!(TM0[DYE@9C9O@O6VL86'E!A=F0&0![ M-:&F8\I!P!T.?7#',&K)<$U3'M7HX M"7W0C+*T55X.!@4'K$I+(S"=U%"2/6F7RL+?K#'%D?:)L]US(W%RU0]3C*0" MPA*G3*MCA`6@&;R(,%-&QMW5K2XUJ&\$V]OVRV/^!Z5G\$W!UO43R;-6*.$;..M8X>0\4(4SCK!4QAJ'&=M&*RBC.7O5,6*#Z5/ M;3(UA(P8,^?)&7RD)XXO[9]A5!CB:(QUXRU5-]ZV[K-"X4B)L(*OC:$!JO[$ MO;3WWLOJON^*%#U7E$G2]]P^:9>L&I,WUC`N,4IO\O*NCJT/N!@2ZYM*)I9A MQD&(EJ!%K^_;O*GG@?4%^(R.$[0^G=Q\4.`XN?G-N@B/Z==*M9D%WM9^LCZA M"O\[J?!?6!,G3#JZ#2>@RG7KU7<_6B?PE^)OR+IG#$`AC%X\ M\$/\"M@XJ372*A!8OQW?'/]\&XN6 M2SR>$M8"92'_I,G5M2X+=H,:C1.Y,3M1)VG?1\484))E*]H8'@M2-8I*0!UT MJ#QWWIBE?XIFEM)Y;"@4K)5IXV^MQ1&B$H0N:RQ:[5`^GBF0NIY+%E;R!>;] MHQA=RJ$2LRS52(2P%@-'-YWL1Q03W[M<4*.PB%Z^5NWCY8$T9!"6O79VN MW15KNXXZS+(WGKHU\HI81]Z[S.B1Q6`:89.D,*+WIE!33UKU^B+3OBWAR81* MPAI@?2SD>T&*K#Z+W6$;SG0H)^&YE3R$F3")Q@0*01JP/2;#(^N(!!!90U#B M-FJ\,BL.9P`F%\@B+[,#2(^,:(7+TW,C..$=R@$H#JL[D]_"PD#"VXR.HL#1 M(?U''D!^4CA)4*6D]U^5R-(U]F28+*R/;+8BT3"3(5+.8*Z)92;!*<421%"4 M*/(TB#Q,=A;8`.1(T2"D?_1R&`OUW*)T:2:2QG"0S%GK\V)!U;)TY M$1;Q4J3-(S//&`OLN0>JMPFJIP]Y`CN(JCI]IF2A%O(B!I-XVEMH_*:]EQD6=4JA5L M>I0Q@G"'PD0FF:GOJ-@<1QEFB;"4@((*-]ZU0AYMILC(""J93YL/$IP[H\R9 M)2]50J4DXSB4F>>JMG')U+FX-QT1:7QK!$=FEQJNXB"<%"$_=7T54RD]@_ZC M_%TF6&'=,+=,V-+`,1U&')H=>?=.PI0[^XG9%T[+W.>H]@[K^%"N4D`B?^02 M8A%8Y$,W,E0"\*M2KU::+82S^K);PSHW\LNC^CLSEH?`"FL>"%EO-$;25G+^ M9$V7B424>\CF(8]*J&:8_'`GV#IS)Q[9+[^:I5/)%$8`]B7*4"#<`MJ[BY2? MO9DD5Q:KV)H2I@PL)7K^*V9@@H;*H5^-!1A#7G`UERA)O;K%N#@3>?3R*4*! MAC+1+L<4M)K.67.,,&HYF:<@G\Q7"`I,EN(<1%GFL@W*DSNPB&>PB+K)(IZ2 MC9\4*%+`@U@`@JG@,:IYR#9/N*3.Y([>*QXJ(57S*5!-B`K+*/.,J$.)%JJ?0H+ MI@7;@EA,WPV!_,`:UB3S'J32UYOVDE#0L/W%R@K#E],(>68*Q/99SA"6(7%$ MH'3,HQZ@$DO&WP]=3PF:LC:JDH;T67-!($=EO6A> M3"IX:>LF$;*CBQBA.A3<>U$8&%2>ELN/R"&XK(&\#(K>PD.YE?/@CX5^!$_` MS`C0+P3\4TSR$!M:F&%R,@[(H.`1W!F6.[/:(44]CJ38@$NR@V`1P5,H/+ M@"DR\&"T<^[O3Z6:N:KO(Y'?4*K8)9-Q"+*9@HSI,>+G2G5A&YWL"WP0ZY20 MLV.ZRP=6TU`-/(H&`R])I2P:\94GB[;+W:!,BX:ZMGC[!HAJC(`P1AKAV.6T M`)ASIBAR*QN7PL]EW7&T!5.)%KGJO)HIU5M,74"#-DXI`<+%@2@^U_$%F9^4 MBJ([VI1F39QDV2]F3IP!YSB+GBGKF*)[`,W*R5"+ISJ+'(82B4JA!@]/]X#D MB8M$X!&JA0-C>)3&`_D@!\U@81*NV_Y4`Y2]D%,_J:QK(\DN6\K<;+M-O6\Z_Q?`[X93ITC%R[Y1DAUIF,+:563%1(AR6H.Y3^:'[=4C`.%P.\Y.1/VRVSIU,O<%G46LM M<;N>`?O\Z94I@XMH=J0*QE_[WH^J?]ZUOM#;IPAF&-`T-<*3T]/+WRYN;ZSK ML].S\]]//GP^LZV+L]NMT`77T-90BEI"Q^QS$Q/@SHU.LD(`%V&R'J/W^)56]NR-[_IG-A0V'=MQ2M_[1[V\I9T5#,9><>-*SYG M@^J*/;>K3&X):I1Y_:'GM*2IR]?;=KW=M*OMY1I!/V+=7D&MT[7;G M90WCYT#NM2GYG%[VDJB;9DY%W6T,-5GBU(U1GW\X-`A=6U_,.OIYA'#)0:D<5ZB@R&8(/G.+S7 M</P"5G#+H2MS5.$UB(Q+CW*#-'Q.>QPLX(CG8YLGURR M[.>#^"5P90K9M;OMWBJG7(\T@9^O!7FK'K<+@D:0WD;`N%[]Y1:SH_UB;-X> M"=]UN]VKKD;RWB)CRCP1_"DNDC>M[X\P.4M_G2'X_=?[Q3T$N=BR\P!+#H31 MXS:[$EI%GSFG\)U?_'YV<7MY?7YV0]!XXWX$=108?B/]!P?OP<%[O'CE MF_8>7#L/.LQX@7;T6V4ZK]7M1K-FMYNMM6MC6ZT'`AS:S;;=;B]GWME2'X*L M4C7XBG:7>:BY05VG#I2AU6NO=LX-[J?6K=F-:O-MJ+]_A-%7V7EYH/IL;PTD M6W:]MI1%9JOQHEZW6ZW-6$561DH^89GT.^%:HS!TMPQ;@(JTFG:KNI0S<+LQ M!EW9H!ZN]`ZL5TB:*;91UMA62*JO8^)IU8%X+77;GV7CV6$`UNQJ=SEA=*TZ MPY*6^5N,*MTN/L91+(?K;SQ-.S# MO1%4J4W;D?:(+!S5ZPV[VEM;W,I.0ZZV.K_#"R)^GB&-SK'ZSR*T.^HPJ#7L M7KL.K/%E,6]O)H9G':/G>6(7)(W:4AY5649CGMLH29CX**OP5GP3N520FCN>><7._>/N\758[ M.R`C<>;CV=7ES?GMC6U=79]=G9Q_M,[^>75V<7/&914N;W\YNS:2:G;"$::. MC5!BP@>GVC*JFOI9(_*#@^S@(%O]LC>_Z9D.LFP%.^@J(SK-O1&I]I7I.5-Y ML;"G.;O>1B<:>C)`R.Y6UY6`LMW;KW?M;KUIU^H[Y#O+XRF0YZ_.*.=,FX^M M&[2---IMN].;1SK?EJVG6:W;W;=D"U$HP1W]O5BLX5IJ45GDV8VNU/MVM7E M[-E;C4QUNX9:=&NQ9?E,VT9WK1;+;NW0R[<%MR"QFI)ZL$=]RK& MSW:[9O>:2P69'/QQ.0AVT"%7?YL.N8,9>4HX;`)A;MK-SLNNQ)LQ(Z$BA@L MV+6;S9>YH]Z6]=C#S'K\2#V^XUPE5;,> MGBK*QRI<)G]C:=&46J%$5&J0$"^I6J"UM"Y#R.9K(I-XT;3MHI9102SI7E& MOW/9TQ.KP>)2LA.$S85(SK[)MLRG6*D09L18P?,`GAY%L)*M,:AWK(IU]?GD MXI8LY6?_^]OYU9>SB]N=J3MUY3NRT9M0IW/(&SF8Q??5++Z#QO`/J>>[RC_ED?33?D/VW;5<;5;NSMMR)+=]^R^ZVVW:S_I:J",PW7'QQ!EB`&,28'/_9 M,JL,8!RJ,BNUY6UX1^U.R^[U5AJHN0EC]^5PZ(%4FPDN5.P^C0(/>W9L%]`; M]:[=6JYTW%8C4:->M9O+!4INDVU&,^[?Q9TW*#=M[ZJMK=7#U(_UV]IV&(+= MKMULK-_>N[[,O"U,(&C4[4X-^%)G=_R`L*5FJV8W6BO-&MN2.CNEGAP_U,&VC:U4[3[JPOY6+3Z3:&^;W$UK9G M)4)!"*YW&G9U227VX!@J0K'1:2^;[WUP#)7%B&N&I6+#K00I-3V_2J"CQ[V;3.G M__E+?OH;V5UUZUH$K0I!_^D9@'(""P#D^5[RN``6;FCGZYCV#W3".1%*^0.- MI=@E+HVL7])O'@#F'O#,"X0&$*)>O8H-NQD?8K6K+$6?!T:WP[E%R$ MW;AAW]CB6K86[3]BSU9L-LJM"6$E=UZ4=5(UFC(Z[CU&[\I^PG#[K+]2.%O= M?5R6UM&\J;B5?$]#;(@X5%56L`.CX_MPC-@S/>0/N!T@)WRX0Q/8LM6UWN7+ M#B[?V.S[5K<'DF'5.KK^\L%JV)UZU:XUZ^\DEM2.K1/J4IAGLWS`>D'8M,N1 M#;>P%>,L:HIH4[<;[:I=[;9Y1DS4[/7L5J,AV])G2!S+UJ/82O'!\1(5J(%' M@5T?LZ.@7G>XHB\(X21ZQ)E.1I$W`!@!#\X?!3>1CO6QYL=2QPH8T!?ZUBC\ MB+'MJPL;]H[$=X]`R+Z>ZZZKEH#.F%CS3&-BHM>UN56)@ MW:Y6J_CO.WVQ))4[">`-W_KL@/CN8`C.7/)6F\8FAZ*"PH@022T.CMF88XH< MT0P'1-Q11/R^!JI&!Y"OR\C7@3\E\DG^I/!"8%R8;(SL>E,LBX+/(D$9TGB2 MV/GUFS.&-R3OHNZ_@$AF`_O$^2I0;J2(-R:H7A0G^3,EA,DV0/VJN9=M$-YK M1%&H//`%K!84J';5BH%=8;";$"R+`N-D'H-Q=CPMX+"':"5=>+"Z.R?ECIB) M)PMYQX]Q(L:V1;8:@+00V.=:*C>VQE+FSA-O0KQL`H*L1F3#Y`(;Q`;J3C3F MRPM8W?>P[S`R>XK9>[32P$MPVR;',T^S]+:KB^JH^ZGN5/XD^((N>3DE*I2, M1E%]QN5T+9'R>@B5@3XBUD4N71/Z%@D2$X-JGBZO%^E\!0'_?A>F>RO,O M(6!P=0$M.:V>VJ,B$@X1 MH#]0C$5"`;`8.TS'4.C#.%TIW:'>T:WUI'17QXJK1%'G"9)J;7BU862X5&F` M(;OFXF:S3OWVU&W<&EZI<+^`K62?Z1!?+>W2C5?PBICGP+%V!M$826, M1@ZPAW%>!HPQ@W,D`A$!MI?=4>"`(C)QCVXIFW6LU05]N2GVY!I_;=J];E]KK?,"4H$@9 M`8-WI)1(,!D,Q`3_B._@O/S'9Q+"7U.065FD_`-I>0)2[`1S$>ATU9DS7M$` MA"I6##J77P%P^L)D.E)@+:.LUB_A@[C',W\0EAL&AA$ODZ#.1-44) M'BXYH#V.BG`CW2>.19(5X2DA590F0\1J+P`\=6FUA=(DFRB82)0WR8$$(85X M1P1CSM@X-+-;7;[&LR*!9F4?W"HBC[X-VOL=SRHZE;QLA[?( MI.L4",,.;=(X.^2]'YV5'^%Z@]`DGVVHKJK_]/ZSQ(LP9TLKR)%Z:7:3\L>M M=Y4;V%EEYW:T36R%<^2W)Y_1;&]]X))J2VQK]4EG:TPQZ]G-!N!@?5[B\O9GY:T1 M0/.$DP.`$$!5*IS3F=M*:M,0*K$&;RC9]'72+''LW65,L*?!9+>E[32O#?CRI2;,Y^MK&: MY6P_R<(K>!6?XGKVWESCWE^_C*Z=J][NXT&ZHW.G:WLXMU MZ4RLFH"4#\J4,`,W@1ZS"L!6RRROU)VK5[7;U9=6BME7Z>Z6*G^V> MW5GN^F]1Q<]%+-O[U:&H9G>;=;O1VY,^]VNJ0V=7NTA87E9*>)OLH]MOQW15 M6_,">S,8&R<1"M?Z7M)]MEU*$I:W7-J6X_LX.V6$9OO'5*,[X5/.GA-8:^`+KT< M2]TV&6^)OB[.&$LT_;UW?5UJU)"HVWZ9D7`_^[J@P-VR6\T5-G=U[@6#=A,/K;LSY$3C"X MLXYB(2RV\&)Y^AB+SZ73I?MSD_MY\PF&_*KD3]OZ)>T+S[K"[0#X2WU) M93#2];Y5@'D`>[.&``"Z%+&J`1D)9XBYTEC"^E!%+B=7K+!F%ZVT\B"0&.!` MOLPI_!<>1084N!"PGNQO97#.OH%KLJ1(.6OJ=5G-R^8K&M)/Z,*N?R,;,J)W M556FE16>><5(522?[;=D.9ZO?L,1-+;+E%!O4A#%&S8D*,"692OO*6!7B:]E M6M6>@O6E^/KO_Y8';9FNM:>@74&6O#;5W&HY;+C"";CP4X M1(ANPJPUPR+S7^^7"'@S2A/86JT\8N[SY26@5FYG>>@Y@EF>=!_?P.'?'^IRXQ_9,6Y89TTF]*WK3/M:(<3310\TNEBE6$*M/3A3'($9EYPK15*IODI-N]?K MV*U>_9WEIH)/LRQ2V!.E8;]/4:E[1:9?4VPC[0&.JOMSH[/!*2[YM8O;"JN\;JGIT.]1%T M@B"E/@L2S2.,3CC+, M\7!`H=BB&CMC84T`'B%V,4ECJU']@:.?'9Y9-5W"R/KN<:O>_0&7F;^Q,]HE M,1T#HMKJVLVJ)JK9=K$U5-J/Q5\IMP<%J2<*'W"+*.[,>D^V-Z236+DC@Q8U M2ATXK41DH_IB!$<283.9&-;JH!$>P73S]1$[_>CACBV)4/4R6B8!DI%]:HI4 MC@RSR?^;O6B_IG#&W>5OVBGVIZ96E0G)I82.3U4]FAR@$VZ$3B+O2Q]Y_L84X-GT"R1[$'&PUR M-1T$0)E$]>V)GE^)E_B">_YR)R7>2TYVF6`L@:L:`TL0%N#L^'&H80(H,7W= MRD!?A#!W5(3A'KSA?O@?X0J=I"-L,5M_!K^ZN7/PB(V>K8`)_T(YVCH%K/<2 MZ[>`BEH__U;UCINUVBINU1/78RWXM"\HI!-`ZO4U(]$SQ)RWCD1[290T1I56 MK9N/4)G8*H*1FTK$P2#5C/XTJKL@(K],:"7$@B-(A\X@X3;9W&W2P'+9;OT4 MM=[M"Q!9D^EI#L*AP89B=2H4JR.-`X1V#JOY%4X(]N#8[ST740KQ3[4S->U" MP'%[=8F/7:V(+!P1E%^AUG,"-D5B6?F^ MJ.TI11VED1P>>RZ6FE.H;2K\J*TNI-2<3"+/M]ISU!J\W8968[?J^OXJ>.EQ M>G/5([A\#!8":R3&<)[*'"C3Q/'/[VO-.I:RY5EZ3RI..X7XA:*=H"FD4:2: MWL9QB#U/X4^)&&(:O?(!9T!O6UT9<-9J@MK=>T95SV*.?H`HH9+T24^8JBL* MWR&N7:1(G#G.MJ1.6R>P`ID,Z>YGO\:5NXQ=%I6U_ MF%N;YLY?]=?\R*T'E MZDU?9A75FU@@3;YI?%TC:'Z[^7@`S0%K#EBS"M!\3,5SFC;O!6RN7P4N*^"1 M+X'=JH6258EDAST=]G38TV%/JUW7AA+9ZJJA^HPPDCE[7$MNVS-S+=0P/3F, M=LJO?2W;#`49I[#7,#A@`F%"M[-',%#4O`"$:N<]_#/73+M+4"C'!(KM>\DZ M?G@^ZUI9"N6"@38EVWS^>;PX%?!9E.CI63>XHV?PEZW>SPZ>T/)T?_OVHXHU M$PWOOJ\WEZ3AV[,+B/`*"P2\23+U=O.$'&KS=.]HY&EQMO:_NE"C\@FF/:B^H M);R41(R?"VD9VP7%+!]D9Q!#9[SLS(YV\Y#J.W!(.2FW]KY1/5#8EU/8U58B MRU)XSG4*SYS][%I5,EUX9YDS/'2$R<.0*QD=(/AL"'8/./A2'.2LR3<#P56O M9M'$`1KQ=R?RPG1>VZ_]`99T[,X<<$4HM4D?PXPM]GUQ=?SBYNK9^O3RYN"1!]]?H.%;Y4)V6-]%%9(SRKK)QH3&50 M/=<37.SDYQ#PZTNNV--5!!^QOMDD"O\4`WB%QN`24O>L.@+2W@L_5M4^KJY/ MC3F/K=O0N=;M92:Z.W9+E=NRLP,O,JH%X-8SE M3B_.YL(SLPK%XON1J,@J0UF]L8XM"X[K*C=9K2!9,2D)X5*KRD)4%9-K<0F+ MZN7`$Q-L/!92U2)WYE%QX27J,*YJ2.O5>;&JTTDS<.FBB?-(A%F6HE:3^9[3 M]WR/2DM;W\N^USQB?2:\5!#:A&O48AS$%.@ZO:S47FO&.,4J>.,T\`;>)#<< MPV;NC!(D..TB(ZK'J=P4(OU?J1=QV2%],MF%E%6V%R=ON6K;V>^70\1P$<34 M4>Z::WN?AG$2WV"9U`].+-PKYQ%'CK>'5#9-4GEZ_+9N@7R>'-R>GM^ MN<-UN#4@\$.*'VX2.)%*'P\*SB4[2UI6JD&PB\"@&M(D/U05A3-IMC.*!%\@ M+XY3`90#;CR7_XVYD-9X#`0M1@#B4P[5>1/?Q""ENM4NW+]!0OTG+?%M@&EQ MW(\2EG`//"8VJ^&'5,Y2_X(%A;,!0-"ANE*.%^&>OXH$>)&?"JZ95SON-%%: MXJ59?)2A)(AP3:F(881,+2QNV"@55VN7P8"LJ41P<8.RC!X!AF@.?,EDIT:D M<`YPJ(JCWA!"`?>K*U7*C7.3`+D@M<3;J7UDFY7;Y$4@VR5B_#V\UJ[)-\V% MF`AN84\+*E).U?J`7@(]A?]$L&,?B_K%P)1]HERX(?/TCZT;N5&L+O@`$,*& MZ%&*A=;XJ$"LQ9>$`\"68\XYQ:E-T+GB'K*M\E%Q7>)&:0701<^JT5[36=6> M=5:@_G57>U0]8W^K/JIA<0_P*&W!/*D364X2C['>L.OUJFPQV[9;]19M&\A! M-.*+/Q*!B&1[`\<=@UP5)Q&7OC>[V,XHS9?=Z?EE`@E_+N%$C8XI<-E;)BX0 M>(C8Z=+B.33@`H?T*)X("V($*"\"M,3RFA*"?&7H^I87.F\V3&J:.Y?RF7!7 M$ZDMLDS#"]V/^H.RVP'1Z&IO/I]JV:U6>RZ?*C*6OH#%D3BO+@*5-X0_\.*K MI^,[;\(7%="3SB%W)W+3A/D%\TUO'K>JYC4QNG$KK,NO/;`^B7X$&/6HN__, MPB=`]QK@_@KP"9MLP*MAY#K8J$+K/!DE[8OD`0MLY@XAD`TG%+3L_)\@L\,- M0<'7"U*J[H]D5#"C'[.>)0'Y(70B;,:3`&$EH2`=@$@0A]1XV<7F#L+G?LTX M*=)";^A)I0A-43BXU#>-?I68#(?=NLE7+9^-\U%T'9067 M@ZL=>@%,_C>"$)LS9!#*ZN1FJ`8#)O/LB$;K)`8U)M36WL*;HBIIR MU'M/\VWDLQ7BLP(@%)+J5(0L=<+X='EL_1:XTF2FG["M.T1E'!7[2+@F-F!) M[Q$\.$+&U9TC!=BL>!N_LND!_O9]=5=(\99,O)&,WC>K7`E;$.;W/-G'@F[YOBN:MF?5M_(Z;UT#^<"$^-6[U< MI0`QT&.LRPF2HW@_E-&,V5'WGFJ'6N_P$%K/1;I M'A0\`6-(:O:HB1^P<3D,*J68[A,+I1VB\>VX:K!H51M="@.,\]R;[RA(%<]Z M,$^N,*;C(GPD9M^\U&>T-!!;:0&'*_>U#,>+S)P#:NKSUSD MG"9.F86\T;3K#>,^`B=!P^S6R3CKF/9\FGPA<`CAT$"=/&(_&4&N%]>+!REU MM>H+/WRPLR5/W2G\4AG<:TTV/>4NV$3QCY#Y!Q%!LLF)H]%W-QB-1ZB'R M2'F5A!8))BU-VF1^30-AV,Y0$E$3.!EB,'5`XTCN>5R#^463A6Q2MW@4$ML* M%`:M+E*V68*X3-%VM%)TCVLY>]()2%UJ^838JH=LWD@);\#?8]F?(K>Z/OTOO"FZ;:9UD!R`W[?Z?3L=J?)(QN]UY0#2O5@ M6V"VQYDZY4*H1;L-LP8!>W&Q;Y5U3)L`"(\EJ%EB+8`;D1LF'Y.]6PKJZF*Q MP)[U$OJ`$4^5F\%=Z.-5I0$JB,GXP#ATA<]&RC1&[RFJ/\#`Q_)`@M"T3*E> M#!9Y_X^M,])!X8'[T`?1GK'-RAG.02,%.0E#*[*''N?=/ZDSX:XC,43EO+`H M7BU^5S:V6@#VD1GHGI?#-$DCM+4`9XI5],,86#:Z]X"D`G]S(@_;>;*:CSYL MU&[2!/#5W*@2WYX\(8>8ON$NI]O-81BX>\`"WHA"?46#F?BIZ4A#,2X$-V\T M3S_GHC`@HHE67]PY]UY(XDXL)@Z%AV!D\(0N*FO&1,4CV9`LBID>1U[\M3*D M?C;XCCP.WDJ^CQ42N=\"#]=SD\`7L74;"2=.0?Y&+Z%D`K$W]GP4PF#SE22L MP`;22)(QA@6CA03)2E6RMQ^2]*R\K"W+X5!Y?,7RG9I;D"X;6=9[_/89W3MV M8M/+=N-8*MQOY1D"\K9TJC)@+4\KCU`A6"#>[55+^>6+\-7JKL:KMKB/C-(=)F>10LMXG8?0"(-*2VF50PL_3N3BOL)I6 MXP>K`N)T9^%%K:_D@CX@2OA%Y^^C)WQW$V`I"]+?V!DMOIAU79WKG.BV$1@< M-\HJFF[N3([YXAPWGGDZKQ\GOZH9/FF]S:.V[!B6>X]R-ZA48[21SU''3-TC M9RPMZNZ'_GS[)K1?*"MZ3GY52*)-1+E?0\,']>:D^BD(S#$.J=SI%R+_'Y1/ M*]RB;X`DN(6L5"M:B`.8[8S$:TZI+!C9WLG^6ES"`8^6P*/*CN.,=A6]YJ08 M^A-)DR$JO:\Y]]&_M'Z]GCNQ/NW!;`3L)-:O3D`.^]D=2=5Z>\JPDY./6>M:S5`>=5>'(DEK,SVP3WP0J5-:&!)M^8",'OS1Q^!1&0^'M MU^$_L:I=Q(M5UJ`[4[$D&Y/KUJ)^/8&7;T'>73=<7F&+:WA[9:W'MT:$6Z2M M_$&(VR.:O9]"W$96=1#KG@3\46,>97AWP(J#4'<0ZEX=+@<);DLB>)JJ&V5! MJGNB+M1*@EU:*PIV47/+<./U+/8E&UQ.>M3[JNI&H7.CPUYY4\T5G5IUU0%8 MZY)E?\^2",T87.@=YY2,G6_>.!U;60JNS/>E!!!,R=$I^5:J*S+H`3&"K5.=5R"+I\E> MH"Q6!5)9R7%FWM%=Z+M4<"5RK9%"OG/16 M+%D`_[9[Q5TME*%H5(^\=SQ?YSK*C"7U_^RKL]NSJY_/]O=RHZ8PY8" M^F&B+)46BK-,/OPJB3P2_2.1P.43F'@+T9P33#CUU'U6KE* M6J+R<@&YL:RL^H8H@5EN-!:@6,0>8#HH2?A^`%\`0PC'5.X(5A5&68:FA^*H M6CK674JIBEM`0;]!@/%)?1A-7]#L8<`[*@XM]POD(Z`I/YNQ^)D1=S?1Z94FS#1!'7UD.J,XD\)TL!QR1V@##F(JM:-;-7,(`M M`D%.8UF]*QA@`J)8?"G643I!2!'U0T#AX?OB'HF+41G629.[,*+#>L=ZH.^- MO0"3(+&2D"2[<)%CJDF)1!1=8$-;!&HOD"=PR`*"**-?L6J]NMVL]>,V#.Q$(X<8R^S4!FA_+(L=/ MXRVFL'.U1JR3+K!0!Y>&=B(L8/RJ9&1#U.LD?Y4DS)P^(+$!.4W9'*Z9A+1" MEBN@NA\*[`Q2K*ZJR9ZB=H1;4P,:Z'.KI9L@E,0PA_T2"?&"8%&)E*L4Q*7+ ME-="+PO%/B>^HR)\5-%`+T\1/BFP4=&WNWRA&D14O"HF;N'W:D1>A1J([ETL M\B";OFE8_PK?5\E0)K895?(7Y?Y9X?Q;YYN(5R,?K+4.,@L-[5R2X>W)/Q<2 M%';H_BFMBLH-]O^D"@9A(3U^*%RJCB99>>)\,P368TL-<0J")"L]#CZ#!9'' MDX0*_E&9*G@[`@G`,8HTR%?.8Y!V7:T*NBDF[DM9&AE5'PM$8%F?Y"X*TQ'7 MP3-)I8TE?1*L4'(+.[2M&^`.^>_RZI-Z]5$O_A]I`)PGX%>?>OA7("A_WX5I MR=-('GX_/XMG,Y[9O\R<%BM(WSD>S/87/#KB:4L+Q)<.]6?H`=]$YHGL7NX4 MQO@J$$H+#V.LJ/@\C.7`DO:"8S%NE:!"$9-F(\#T@>8/I?1,)(R)GAM75?*D MW$F=8;0^,%5@`^=\9X$J'V-QO9S^B;B:_6Y]=AY@IZ7OXJ66-1*Q[/)X$L9< M1]DQN9^LZ5)O_7`\7^SJ8Q'5S'2$!`-!GHC!71#ZX4B6QJ15,()FPFEAP<6* MEUA>#7L;X'>8X0"/J7758%T;U/U647@G7],&*R.%P<#S92V@,3'.J7,XH-GU(I5PTE7)AJ_TFLR7;,@DWRN;*54LS$2/[EC!DQ3N: MX;O:&4@7ZJI8))E&^U5,IKCIMU5,9KK#7;&\#%'DFQQ%GK/#E]92R:UAU159 M&LWCY7I+%M915D=A3S>^SMC$\IZC0,\%?*4T..X3-0A'@?=WIHPALJ[*V;QD M__/9,;#+P9[>*BO@M`.;>&5:1D]Q^T9#[W]N@9;U@;?>>@9T5Q]=L9V;>7U* M,X4Q;`52?<6V!M)'M>H.D)85;>*UQ:29HMPE.4,`%U52.J]5]BVYM[4!GDPV&;T5RY0K>K6>]^L8W8S][+T0 M`0Q`S--3#O![#OP.#=R?LF$]UXXS^BUC%9XE50P-0:',YB^N9G#J4ZE84#4G?R"U&%; MU3R/!`:%LH+J!%F8#+95G39=`Q/X@=9%'Y8W9!>Z)FX;&J_,CX`\0K?/1N![ ME"8B(Z&TB^%@UW\CUN9__[>#O?F)3>?"HPO[?ELFYZ*!^7?JP@'+1.^G\^UI M[K!:&^LS$P25:;5F-ZMUNUE?3OC81)GRM>R^5K6[W1?9EK=67REH],LJ)F]= M(:UUZW9G2;1^*T3VE53ZG@W$>7NT^F=1ZZ>T^&U4-><1M1=HF':KV[)KK?:J MU,QG78JW#L1VU:YV7W8I%@/!MN@ZZXQXQ5R[LIC47.SKO$Z/65LKS'/)=&O, MI[`&3A0]JGZ:K'U3,(`90YM&&$<7R]0TCE_[OFW7ZUV[W>V9G;_ZPLB8H[[. MH$4+E$! M+/5JO2W;\G'\;;W:J!X#4`)GI#JC^YZX5\H^]\&$<_L[ETK4%X$84K_PR*.. M;Q2M3WW`"6;.9$(M9CF5(@T&0&H=F-[EONFSPM@PIX4T6'T"W%GL4<438ZMS M=3!B_EG`>5,'>'C-$AU23*D)'F_10;69DA>GLN%I&5/5YC@_Y@4# M<(?KNEVK=>Q.J\G)*76[VJG9W6:U:,TPTQQ*H3C.#C,2]YYXB/EDRE;(K>&0 M"_H,Y+'S%?&8>M!RM@3F+,A6=3/;+$XG.4CSD2M4"@T<#=^.U398VP(R=%O8 M_"`=8](5FK1`[%"Y&F8""[8&E'$<.?L:?$^QM-^(&L&)?-_J6&.XW71H99#/ MMLPDAE)4X3;XJ3FTHD%GR! M(YMURJM*Z0-&`I=Y]0`9,A^'#AJF/%I]@4T\H;1'RF_E]!RBC)&8.(E,+I)4 M"`BAV@=.0ID/7@)S8:.1@2*PBK9S-I)*'AS3?#*`$C#[U#S82\PFEK2-7&K.W"2;_]%YNV=RZ"L14:KO]N3I M=JR*=79R?7%^\?.-=75V;=W\+Z1BRN*XRDSOXL#:G.&2N)B&JS91(5B!F>!98-I'B`,M[C;F M494U0'Q=90.W-39V7=/NW);65_1/->:R9+,L54*)"IF`RH+U6@:4\)TFSO;% M_';L>JUJUY#/>CV''SV?[1\4ZD/%UZBXU]S&GELA MFKV.AVQ>*>Z#=_$)_VS=;O26\[QOG^`\Q[7S%*%VY=V:3ZHW[D9;<]CKL_C! MVW5*KAV:M4[/;E27XD6K\$\>9-^W*+J\-=GW;(:]=L)O(&@:+11))R$*O<[LF*S;(C'SU`HDC;?E>3XP;'(`*$':<"H MJ*ER]?VQ+.^]XU.@&1;V(VO.0L4G__W?WGKYR46/RDQLQ.=#HT^:[)6CC*8< M_R6^R?@D&94IM)5H.E0E%]7B4*#+(]=F#A*O0N]A(!O_,A-=?"[I.AM7:-V\ MQM+RQ#.#G'(M#&3;@RLG2AYOL88R1GK!D-O8Q`"#HZ[//I_7U[<6"<7'ZV3:_CFY[,O9Q>WN]O4X(2#/K%*E8"K3HU"$"W) MYB]S5RD.FB/^)G"VJB-!G(YA;1V@4M'DLZ'U2D%$FS.NS`J@>ME,6[.4UP[:HF]< M,0@YL/M'+MGL>X'(&!WU4KO1;9>RYED%4OY(&Z"G9]2!VCG;TPYNZ77C"(K1 M@3<#>-TZC9PQ"*TZTZ7V$U##`%L3#%A$50UKK*/Z`K55MBM_O%.WFZUY/6AW M.'<>\X,;Z]K[)DIM@O#RU?IX;)W>B6`A?&UL&5ULH4ZY5-3I5M/$U6]G2^*J M/J`%X(OPY_4ZGJS:]>JA\J'SX?@4:]FMY>S/,V& MX&OW^C@HU>H8&]VJW6X?E.HE!_WW?\L98=MVO=-X;:WZT*.@Q#'_5(^"Y[B4 MZ@OU-2B-+U+-#CIR"+.<&K:VBV0[\4A,P@B[A6/L6:7OQ#+K400Q1Z_U'ZVQ M<.(THK:ZU(\@YFQC$=U3(!K'('&(HO@VP-[-7(/,"2P':RGBTQB2F&"3\SB) M4BZ!QY/)+@"\XYH_K[H%& M38OE`$J]3(?JG?%2RRONE=<1Y/#`^&FOO,>M'G21.%KY8!#AH[H7!(42?B\M MBER34-K&ENJOL`0>+B3YSO?NEF$8VS"6A&)6T,_EX,4^#,IXQAVL$65&D>`Z MBP!?@K35;-BM:I4&;C3IHSP.F-P,?,V#$*8,LXWGE!^L)V@B.6$;->S^7GJ- MY=&P&Y6PN2\0J1R\,3`+K(^+$4H453LK*Y*JFVU(_#R91)YO,6"JN,L\`%_[ MZ$L=I=MR]/!Z#08N/V\)N\PO/.=8YUD$J>^1,?6'\+K(T'XG,Y8CB>9:#^-O0"S(I0\M2C29CD12V0[ MY+(DX):./2[>?!*XIU38=R2"@5=::';CB1+=#/LJUNGEER_GMY0102D2IY<7 MM^<7/Y]=G)Z?[6Z.Q)'S+IN9*H5Z^/5GZI$VR(Z3%N7M(`"*.A^I2YA6A`"0 M-TCI7Z"6.6A7J*"#D@J5Q9E>A9*0$G3I[85RR=YZ)ID)/@I`)[4.2)8#``F` M@#T:DI*28QBX6(K<&5"-_0G6K.8N@-:-$_SE.2$KQTKD0;B"Z$I-"CB)YQ+> M1!I+)!9D5IBR2'>;7![?"8+4\>%PC15,3QQC/?0_L4@8+;Y6_2'K%2C@C!^M MY"&4"\#6#]0C(+^(WKP:]0NM`A/:N``^:\Z%DNSUJET''G-T_>6#5:MW[':U M^F[OL(R0)Y:,VD(QA9HY_M/3SKK.3R"?$Y+D^69.DC2>CD$O MZ!FFU1(823P(U[A*-`]N%H0#-BJQ>-":N61`HY(EMU&BF;70KMW2R->EW,]W ME,R)4^P=%CI^'#Y-\/2Y&,+;%!&\06,@(*!UXP'A"T8YS)1HCG11/?8$83Q) M1[!?$S'-;VJ=A9"R;G=!N>>S;I)>NW^$IG"Z8<`$8`9?/E-4U[0!0ZJ85>;BGA@LS.D'9=!?N@" M]2AL"\'QQ-:HA8OP1:0EQY()TTIOSV3 MF*987Y%`4):_R0G(7E0M&)!J;%%J+G1Z';M>;\KC:[28&3Q#@#)7TMAD=YX5 M'.O8"[QQ.E9M8_C0)LXC.W+460:`5*8TP1VQ``^<(5:]H/H'6Y-QOO"@UH)6 MJ+5EG"\:+X$[JG!A$!S(=WF8*[HL2WC%,3ABUF#K2L@NFZ^8[72_/91F0M2_K=(%!;-;M17ZKU MQW:EO>E0P7DP;Q=DG269U%L.QVPW[?8K=/+>4+'%;$7[%I[9:=O-4EJR8Z&% MJYKA&B."?.U6&2Y=AB[?YKC>M:OUJO+>[[C_DVJED?]&1ZZ$4`2E/*! M$(A0N^NA^T2E!+TQ]V^&_^?M6=AZ-;@/?1E-HF6$6?4&19M MX(,0O>]HV%#><@-7C);4@S1""XA/TV!S:XRRI/?8%6'.!<@\D:S/]Q(5,"2; MXV:-71TK!O!X0R"\,(%J3!/,]$WDVN@./;01>3!KC%%SNDWRE--II;:4C1[_ M>0!;>R1CMFV=!&X$#Y_>>2(`8/@`DCCUX%A&#D;-FD"TK>MCRPQHM*V;1,`! M?`X?`(4^.O>>:_WAQ'&*<6Y`0@P;/:!+/CCQ(_52AH,Z!<3)#'/Z:X#_:1@$ M2'@&:6)CFVOL?3ZR!DX:R_;*%$)!K]Y[H6[F:MT(CJT`@,!5EY3NR'FG?,GP M>QIY%-UQI@*'3WC*6J_1)'LOV^\Z9/+OVE0&U7+%@/L>4ZM@0M\':P+\S(OO ML#D[ARGC;BBL&/:*G9`#%^NJ&@@(9)E6"G?/]>*Q%[/)"IM'B[]2OAOR!^62 M_0D!EF!E4Q"0U+>UG_*H M<)WZ%,Q)(WIC;";O(EL4":XXVQ:",4SN%,3@8;30P]8I;!?DBB@0CZ4`U:'F M>K!CZ\3WY4.Q+2.55!@[.@8B[(\M@@%"0OB`0]B$6E#-5)XA1ZUB`3^[&0Y0 M*'<.64QZQ@YZOE.PJ!->A0H==^#B!Q3MGDXP$DNM2F,V(2Y^J]$HMY9RS%6G M["3Y*\RK<($H()TW3L[IH\'=PRQT+QY$@AH=&4>(CLXK%L9^+ ME2]^ZRX4DP?8A@2$'^$YZ\@[%L>V=2>R*'2!-V0<"R`\Z-Q`T*&S7]Z4=[:\ MZ0CR/`*O@;$8?,*Z2F6`+P)5@_86,.`%&*CS!H M\Z.Z(O`$1N+>>^@!'\H`>U[*'M)1NJ73U-2F(%!F_X@XR9T7/4$=%R2-MDD7 MCQ")**8&O@P`%T?,@?'?;.2KXQ,@[%_"$"@'C#NY$W`'__`B0)M/D?.W*MA` M+]V&45^``/+Y\Y6M?@5-,E9?G4:P).N7,'IPX'7ZZAKN*Z)P&!CC7*''FW__ M!^!*8/WCV/HL:/V_.-&]>(2OXP!WBEOX-70?K2_'UH<0Z)KO>P:AI@!2@(ED M]13TG1<#D/F0;@$+4JEQ1)#1<2ZU3%0MD(&-[BPV)/%C\!(I@X"[>*<&`[22 MZ`:G<%R/I`W')@$F!B$DN>8KPI,81PZ@D-%#775YN>`%+!)D.<-Q_333(F*@ M(B9;9G+'0(I>IA:!FXFT).[0W8D+<9J1:$,YBF;%_ZD ML@+M++&&8N5`B'L`HHDCL,)C4<);(.`AM&[I7^GFT&(I9@;$Y8&*2()!@';% M=/[W(=V^.+.5Y%-.];2(3;Z'\B4\H!H_\ZKDF'$*:R]9=^[-XM!RXD>+,X9L MA).CDH1<("2Q4+=/01+3*?'J(N#@=ZD&/-+TX*;QQ#((:'LP]*[_X,EDB MQHXK%/5[VEBHKEN!9?#I[87<4P>Q7/EX*W\"P1X(!TLIK\ M+IK7SP,TA`$_=G*5B#`W"RB"-&1E$!QH/W48X,,92SHEDL#9^*AAP=`6(Q* MO/68>FP:!+?=!5";RXJ\\S0-*<(]8?"'"4A(1 M`^?>H=%(.9:G=FP9/@X)FE@M%0:=A'$,$HU/U2A8KDN$+?,28R*1-H!U5=2( M9DP$&4>M<,!.E\&=..7(/P7&L5XR."$0-G=YS$@`8QBR8PM0%9'_"$ MK``7J`0]``\4$6@@(Q#D4C])T6QU*P9W0>B'HT<4^)!A(I("FC^$T5?KS]`C MH9&2:*T2&)O6:V*#$[0J:0L\H&A82;(I)"*C0L&LDF02YT]`V['G8P;K`XJ5 ME.Y'A"?!"`@U&9K,06`51AB]6H87%T.JVXT&)O]P3#6E7%!4M;(C>:JN"B40 MHX87L?H7LB5/X&QPLT:9["/GXH6IB4%?&]PA88CD51QQ=HF8)&P$>BJ1+2OB M0??4+>ZCB4$1:A\-O0\JB)".J=_;O#Q.@S!&*PJ9 MB!-V4UI?/5:F\B^1?;8B7QV'03CP21Y`_TP?;2+(KYR)2!-O`/JO(("S^2.\L:F&$-#UH3A9)N5H7NGEUVBEAISSW!7FK@61U[?20-BGT/`6)JF M!`-C$P4'8@AT0G(Y\%SC MC4``+GFC,6"F#;-\%Z9M%J>FE>ZNW@:=U5(:HW<%A.[5G[FU1 M9'O%H\/`ZFY#'5T/D^EKK6=N[\6WHV3?'=A--Q/J5[7O=K=F=^M=-6R]!ZI# M8T_(]WG6XSL/,'(?:@)][T3D`BJESU[`+!MKKPD*4G.H#$?HI@.V2J"\)TMQ MH.Q@HVO89=9732BJ()0+&O$(MMS?MY]P)32HW]&=^?7 M!W.OYU9$/#*L(%M.BEH5BM=3JXE&UX_LJSW^)VZ>=DBG#CW0#C, M?FJ\;]3>/Z>+],+;W$X@H=*,G#A;1!+F'NB+:8?T[6 MN^.3I%,ME=HM[_U2MH#YI;ZW,=M;VI9>LH)E*F5NU=Z;H%%WF_NY=VFJ M7-/>7[63S?1M7=))8T0NE5=2?_ZIO3@!6SHM5COG!O=3`X5AE_8CG6.KG',3 MS<6>Q>RVK4?1SR-^NOH(?DB&LENA)U!E7JU9?>J*ZUBM&'Q ME;Q';Y_FEW9VV"1@V<&T,XC2J]K='6)A.T3R.UN&^=+%N#.HTJC#1=X=BB\= MR]M.\6=;N6;W1:;\)&_.98FMH^X^M4-F[^_+.IANJWOD=2!8:RUM@3X`,(>" MG9K=:ZT?@J]GE-.._'G=IB]O3SXO<@!B0:ZWJ^V>W7HAP7E;I347B3+B_Q_7O !1S5WEG*^X!QD)O)^=C4 MYNOYS:\NZ6M3&VKD-[22/(>9>UG=LIOY93\K,/P5EMG*+W.!B.Y76%0[OZA% M@[$WA:&=_')?'%R]J7UTWUFLD6KEDRIX;C1J^$6PV!#K6AKPPDR6%B,OYO*' MJL)`UIN4EK6+:=,W7Q^Q49+J(Y8OZ2/&CD?W(YJ&#=RJ[VMUNT/MW*N8EA"" M<`7HZON/N=(`?204]X+:3?8?J?R"\>UDU"+[0OF]@)/&L7.%T3<_S30E2ZXYQLQS4.0F^`+>D?N=BR+-V506P1469DY ME4TK&^A16'EL1)5GB\Z^Q$4AA+,R"?U'66+.50"N3V6!UC.$R_JB+]??/-<: M_4HV@KL-3P8$BG,LT#?R0-T\P8L=+]`-O?:=E08>/_';SE^O5AOO\>?W M^.!W-/;[J<$7[7%?"J.3^/\NA_.@]"WV?@P\'RA9E(KOWJ]FLH]B4(HQ\R:[ MHE+?0))N$L#>WQT_%:O?T=*3/&P/47G\)(`*,XY0)# MC[?(7KG")$"7_N)B["=:A+\0R>7PUOG�+/94-+6!,WMGSII6BUNIU6)[L9 MK[5P@-9_O<=;X/V(_X4__Q]02P,$%`````@`[(*O0*?9+_B]"```I&T``!4` M'`!S:V)I+3(P,3(P,S,Q7V-A;"YX;6Q55`D``SR[LD\\N[)/=7@+``$$)0X` M``0Y`0``Y5U?<^(X$G_>K;KOX&5?EQ"2N=V95');!,@,5210P,S.VY2P!>C& M2*QD\V<__;6,'6)LR_(,@^7<2PB.6NKN7ZN[U9*5VS^W2]=:8RX(HW>UYL5E MS<+49@ZA\[O:Q\E#_6WMS__\Z^?;7^KUS_>COM5AMK_$U+,>H;]8AV5K/YFW5UV;RR+O]]T[R^ M>=.T6H]6O?[-0[RYN)9#C)'G\\,@5]$@[V[>_'%S_=8:1H.XA'Z=(H$MD)N* MN]K"\U8WC<9FL[G83KE[P?B\<75Y>=V(&M;V+6^V@L1:;ZZCMLW&Y\?^V%[@ M):H3*CQ$[0.5[":-KOGNW;M&\%=H*LB-".C[S$9>@$0N7U9F"_FM'C6KRT?U MYE7]NGFQ%4X-=/#3+6L9%[8;-E0U(TLGML!+Q"8]MW`ZWT@;,8SWCK8>I@)^):=GBZ\>7P M/]VZS(Z-Z4J(&(\K*APRP&&&Q#0`PQ?U.4(K`*79;$]$3J=)F_;(98O)K M^/A+2PCLB2=&;9]SF`#1&"Z:8C<8^4MFT\;9N1URO$+$Z6Y7F`JLQ74F2$OET%O=>+A940_XVR9H\UH:*;)O\6X@_E= M[0K-\M0CD0ZDY,=-J5Q">'`MID/Z=$0[1!$ M6HVXD$Y0LOED*SYA2AD"GREJ!#XS'!O<*7##?1PM%3+3\APJXY6O);J9<62\ M8-R3:XE[QCG;0.ZIBA]IK8U'1RFJF?EUVQ<>6V+>NK`QW#4_=!]&O<^=?=/3W)F0GNP\Q^GT&;M[#,F*)\/ M.9L15:[SLE4)LQJY6(2YI=P5E=NDJGF=UKSDF9VBYL0D3I723#_;9L(;S`(N MQ^!VE+M-\9;FXY"0+=^3ULO`8+#"'$2FS&D^QJY[D$WE8PKRN'(_ MR5D22H3'@Z5Z/BQYE%7!*5<#9N[@/,O7HY`5XK[Z7$9::U,`2@J0@.AE8*U` MO:*`:"EF:FA*\,0HB\N5[R.R:4J8,'+[_%N$R"$LV=9R)4I87(X>S,P6>M3# M'`LOQJQZJ99)4C7$LF4W-*=`A$J?-Z"'TG\O.%X7G"0'SH<<>VBK2BYTNZ@: MEOJZ,3/M``:U$HYXNS+\133X`X#69A00\@&D,-XR*N[QC'&\;Q><0.AN(?,# MK1.*^*X'L`<["4`)%N$&^.ZGH=+E_+A1R[;T-."3GNH':MW4P!2*$D[\>UA. MJ.N=6135`3A%6D.3UC9;KCA>`*N!GY7,RX/WLXDR^JBH2D9)0Z!CS(Z`-7,: M!5EIBG`/X"W(G.YWJ^W=A",J4'!*'Q;LP;<0!.>_OO"B%RND.H:,!W_P/$ZF MOBQTWLN=POQP$<9R64; MB<60LS4!Z>YW'P5V>O2Y1M("@UKGG<@IT$G%TN<2,X."L%0R!'4P.#6;!!I1 M'LU[T:SRR,2%-K.><(@9\B7TI8P7_^2AE$U3><@4ZC"S9A#(*J^2`7X[S)]Z M,]^-7B-30*@DJSR*:J68^4[*_U-A[[L!+ESI4[WJ4LKB&4(VQTC@#MY_]FAD MH"-L8Q!IZJKV3;3(*P^SGI(TWI`Q!.(>78-Y,JY.LM5TKQ#4F%HB-$VK=B79 MCE^E5`C0(])7B.FQF3(;`&59B#?RDV4Q/$KQ#:I((BB%D$\2O$-JD@B)L#2L5I5JEO(WCY:OL M12=N@OX5(IRJI@ADP\I.&?++3%!\;S4ZK9,2"C/AW8X3%ESM*/?EXU<&JJHS MN;1FFJ\"OD2))E\]^97L@DE%UF5Y(2N#6TLGCJ*R>_O%T.JIS9&#OAF2?7Q<&^M[1,;7`U>Z@^QKJJ,K,`GC#1 M_9ULX?6>0Q=1[^4=GT6F^J.I,K8H/#Q=B)RX-A36+3LZ42?IJ4,Y6 MCJF5\`S9'PB%I>AW9OMIG90;IIZO*NS@J?I?"631F&FJ"KA4H>A('>>[`?N9 M@]%S\CJ8'56X#F$Q=@%;VNTC)^FVLLB>1JEFGH$)5((Y8`5T9,I(#4X%[#ARBL@U3&8>1"J.YO!@F-W(RBSC=U4SF8BRE)>YV8=D#\]OG??,&7_P%02P,$%``` M``@`[(*O0&%Y*8CE$@``?!8!`!4`'`!S:V)I+3(P,3(P,S,Q7V1E9BYX;6Q5 M5`D``SR[LD\\N[)/=7@+``$$)0X```0Y`0``[5UM<]LV$OY\-W/_0>=^/=F6 ME+2-)[D;1B^-YAQ+9RGM]1,'(B&+%PI00=*V^NL/($6]$0!!BC0@CS^T<1PL MN,\^(+C8!18?__6\]!N/D`0>1I\N6I?7%PV('.QZZ.'3Q;?IH/GSQ;_^^;>_ M?OQ[L_G?S_>WC1YVHB5$8>,K;3/WH-MX\L)%H_]G\U\0$ MA!'9/:2=/N3#S;N?;CH?&N/T(;Z'OL]``!L4-PH^72S"<'5S=?7T]'3Y/"/^ M)28/5^WKZ\Y5VO`B:7GS''@'K9\Z:=O6U7^_WDZ"$"!G)\6ZX#=!+'^+'1#&3.3JU1"V8']KILV:[%?-5KO9:5T^!^Y6+]K& M#;>/V>_@_57RCQ?47'_Y"(A#L`_OX;RQ^?';_3`KYZ'PRO665YLV5\#WZ:.8 M$C?A>@4_703>`D\5(^F2=>G*1KWT5S"Y0R2*K4\Z/;JP6@31T8A9X#_$L'+Z]BL-).3]6X.[J;C&Z'/6O: M[WVV;JV[;G_RI=^?3DJK*^ZQ-EW'@%#[+&"L2?6*'W9?)8K)E/[_:_]N.AD- MAG?=T=>^==>C?XSO^U_Z=Y/AK_WDMY5@4GY870B[UN3+X';T6S5CB]]S7;I/ MOEC43*/;7O]^TO_/M^'T]\I!5^8<"?;>**=@V`6S[91T'P`8$5GW5;K"OIAD/Z&F;W5 MO&YMW*T?-K^V)R$((5.'8H5#^F.0/L4',^C'S[;%C>WKQ&AZ=)Z"V6Z(R?2- M&]JM5-<=PQ8YU)I^\=+^-A^_0B[EG."E@LG21^(<=1N8N)!\NJ`244`UP2NF M,YMSDP_JC8-12,=DWX_%Z`L&']@/NW_W<0#=3QQ_8.''H>,2(9NU,/.:+% MAH298XL+")(@>;TDV;W]%6"-9!TN8NMD:PNIW^90`EG68K)Q63=&,BDV<43JU\<_:!O$8TA6%*_==N&WM5DVAB)J&=4;YU/8?M-D^\:82 MQ0;T=[QHD+2]W:HKXE`/!UP`N\639B*86ZM.P[:UW3J/M:M$_2T%@@7LQZO# M-,!+9`;$J;RWM,!;6N#UI`6L((!A8,U80,D))40=-JPK$5#AI"-4O/IP67GS M=T&P8/_U_XB\1^!31(&%W,D"DW`*R7*('F$0,J"R=UZ]D]I2!&JT9:G@4U8( MD$&9`LMQ<$2UNH<.I(K3&>(.AIO8E>S5DHAICDRK,I8#P:17CHT>1/M>4PTE MI.PWTQRE5B7A2.7J@]/EC3XF<`4\M_^\@BB`^:\$M[WF8+4J#2+=JX]4E^?C M#H>0S:FW&*"BTU6NK.;8MBI/*CBJCW27YVP4+B#9Z1DHD246TAP95V5)"J#Z M,/FIGK3"UWZ_G>:0N/+G_4CG:J+?V2V([#=T_L0K2,(UVY1''<`5<_0HZ_%` MX-@U5T9W!#S/R$H`J@^'G[!HP8ABB1RFP!!1S1\(#()?"`ZDJQ2QE.X`NO*Z M1`ZA^G#ZJ;/1'49.\M(JK_"S(KI#[<4F*;[^U4?;J_*%=_HJN\,[$=T1>*G) M5;SC0RB5+.4%7Y5;C!Y8\"!^_CH.'@PPL1PZV0:QV7ASEZ*D[AA\`1H*(#)K MT1X"].!1!W"#%8;]9\>/6#;^%XS=)\_G;0VJ;S/F!#\1-T5 MZ9Z&;&N[K3=B4,&[(T!ETD37C8(0+R&QW$=6KT0AN"F0L-MZ0P@5T"5!9I)# M-P7/4/W#Q&EMM_6&%"J@2H#*I%Q.+X)3?`]]ZBRY8T`8VGRVQ$)V6V\`H@+2 MY.!,2O3L@W]<8?JF6.C\^D/%,/ MSB%5T+V'CQ!%S*WMTK]YBM$C!6F[K3>LD<^&8*Y4@V;0SK@>)-XC"+U'R,4L MI5$J:;?UQCO*4Y@+RZ0%6U'6!*","7@4XDH(QJ2UVIZ2:KS8G;.->`C0F)1_ M9\='O62/,IN>,0KI`A\B1TZ/1,KNG'W$(P>=23GZ4C%ZB5$Z9Q__D(,S*MTR M)AO_*-;Y5^!'LA-(G-9V1_?!1JFM^00)RB_2D]W1O1VCS!Q8'*-)\?DLYD(^N]W17::H!&5\&(9&Y+E+D!/V/MGO M7E,D0PCQK,ID'!:.?ZN9\58SX_74S-@"ZOH@"$;S^'55+:=]+'.>);4Y*$P* M-.QIEUNJ.=O8H$+:/#L+@@T\&*^)$_/J9I]&3GU%LT^8V2!A'LAA*/'K@?O# MF]O$4IK+E_!?"L'<)D5A'$F?2Y'$E=)M_&C M6:Q4>I=#7;&[$R_<$&YDD"$Q:8*KEB3S'(>3V3+1=[!\'S^QK?$#3'HXFH7S MR,^6!5,X+%6DGS,H[UX6ETG3YN'W=@S(B,30W3BO.88D+I&NG&07=7`&!>(+ M`S)IC]BATDE9>RL*%YAX?^[B@+GT'0OJ+K!3GC<>$I.RCSQMAT$0%28K$=)= M9^=4HG8H3$HN\C257Y>A**F[\,ZI=!U!,2E'N+>?H\373$%:=V6>(MPIPC$I MFYBYG47I,R:1TEW"IR1?/!@F'>')J)K[]1)(Z*[.3BICN M"CTGL72$(V<[NNYLN_*5YF^Y][?<^RO*O0,?!IMSCZS$62"OXLYK?D9W5PC4 M-RDTU,5!.)K'RDVP+_^R'[34?!=%L4_%L>8F177B^K-C@N?2OZ.T MA".IG.8;**2VY].5!\>@!-($^OX.FW0KPWY#S;=-E.`DH[])W_-?(**`?%9# MSEU2WV"E8H,:1JT4/W]2E5 M#J9BP[4VE*BT(E>Z;?1:G3?9U+$>,7H&__/A<#J=J@*T#6 M1D+W12[5T[4'S*0H9P[0^&O?\P*VVS$B2IM[2O:H^SJ8"F=2&<0M]R9$U'ZC M'MN"#>='2,`#O(N8B4;SS#;PO!FW4#^Z;X\YA3S^<"@,WZ`96Z#[QAA%SD,4 M[$GWG3,O-@QD!LCY$IATMJ)K3;X,;D>_3=X.4KP=I'A%!RGH&K8+@L68X$>/ MOCJ?U]^H-D.TW2!YIT6I8RNDELP M:N&XBPH&[/9+.FI M$"8A62:F^7#,R_*<8PB3=N&]Y"9+O9M`7G8(%#"*85O\"`0![,'DSSWTFPNH M%)P[]4XTG_9YV2%1R"PFG6#-*IXM%UEH.&3%=9\Q*L:-*K]\G`:YJ.YS.O6^<1RP1LVE!#L0NIO*`;X/XV.! M;$@JTZO6@^Y#/M6RK([9I$A39G`FBW'":HR$Z[$/4$B7Y.PV]]52?G"W8$^Z MCPS5^XKG8SJ/\"DB^.TB;#FKIYLL\4=WGA&JA60;6I%"5.OA* MECZZCPI5RG4QV";%L@2:#SP$D%/1PE?2F>Z30B\Q"G+@FQ3[VO=+)@M,0K:J MZ,&9]%,NDK';1D:V\NC(]]@R*&M=`>\]^'Z[O!O-CU)8.Z>1;3?RV>5F8T#= M">$:^;1N[;;>@%4EW%9E")/6V>J&J60>MSM&1KO*O>/%8)NT"N_/YW0).9KW MGYT%0`_PGH[/$6)@Z$J"_<%6$X_`%T3-RG1C=XR,HY5COBAPDQ;EL14@\;![ MG&Z3,"T6LCOG[,[Y7%]5`)))X8ZT0NT8>+(:1OO- M[([F,C8%+"W:D'&(QJ#]XJQ^,,6T6WDC=_LMCT>@VAT6:GW8G?.ISEP(5#6A M)<%2-)MFC&L_)G>B3W$FROE`^.'@\IW9'GLGPJ^#,J'33Y8MWWOXQN>_W[2?\_WX;3W]]J"+W5$'I%-82V M@-@;&JY9I5R,XK7*LZ/-_+`EZ\]K4=)D\I:;H'>DF8$5E<$,42H'E]!-D].`>1']9.U.8Q M+\34%I9!C%F.$RVC..$A*@__]<"?XI5H4>U#6Z7O)P%H@;HLV!JOQY5":GN49=T;DS!XI1R1N\7&(T";'S/9>B3%O--28+ MTL)3WZ@,#--L@7VJ4)!`DR[!CAMK+@I4;"'-4=ZD3U"1^N'9`MEG=/$W5WF3 M/B_U6$3DSZ7)>]Q/)]M)QG%<[Z0G'C]QRO6\XRR M1__R?U!+`P04````"`#L@J]`G#._[`LP``#XJP(`%0`<`'-K8FDM,C`Q,C`S M,S%?;&%B+GAM;%54"0`#/+NR3SR[LD]U>`L``00E#@``!#D!``#E?6USVSB6 M[N>]5?L?<'.GJI,J.;$[O3.=OC.S)=MR6K6VY)64=$]U;4W1)&1S0Y$:D/)+ M__H%0%*B"!($^'(`SW[H3F+C@.>0SW.``QP<_/G?GSL0D]J/P+V_.WI^^ M03AT(\\/[__RYLOJZN3'-__^UW_]/W_^ORT+T2[>O_Q_1\1_>L5\3WG981NG!=T=C9"WY^>?8]. M_^VGLX\__7"&QC?HY*3U(WYX_Y$]8NDD.W)XR/?Y0S[]],.??OKX"=WF#PG\ M\-N=$V-$[0[CO[QY2)+M3Q\^/#T]O7^^(\'[B-Q_^/[T]..'O.&;M.5/S[%_ MU/KI8][V[,.O-]=+]P%OG!,_C!,G=`]2K)LJN;-/GSY]X+^E36/_IYC+7T>N MD_`OT:@7JFW!_G62-SMA/SHY^_[DX]G[Y]A[0]_!O_R91`%>X#7BS_\I>=GB MO[R)_>\"/)_09Z0/^7_;C-X@U^K*8 M[GOA/>SB#[OXY-YQMFDG@7.'@[RK-Q\&T>X3,__LCT7MKMEC117+[_+345^I M$)B.MYCXD3<)VRE;D@;6>IDX).F@=T$>3/-5E#A!*YT+DF#:SG"[][N7@WNO MU%OC=N_U(-FKMHFHJ?;+/'J+W(M=T^>^D,V(+`^ M::>1>]1=P,:&B!Q;&G^[\T_84'?Z,?._["=_SX?0<4A=0.(G+]-P'9$-'UO& M=W%"'#?).^+*\^[_KB[[(=.1R1YI27`<[8B+M8Q.W_VQ.LZ=ACILM*62;,Z" MPY,ORS=_W4\BG-!#J2`J2*+?N[SLX?Q1?1LV MO_AR,YFMT'AVB>B?T]7?T'1V-5_$0-U>)_K7!G*S%!S>B MD[5M^X_;D\RGJ!&IO!:U%9"0Y8,\3;V0#M;0J"6XFB90!D MLXQ#.\0:PJ-V`)4A,-L$B1RQC7@8%J\7E"/$":8T8GG^#_PB!6RY+3!B155K MOG_6$/&6B#8U"=H^M8;%;0TT1.#6X6(HY%[L"*&/O/)CUPG^AATR";U+ZN]K MP%O;'`R_$H7+8,B:HK0M8HUIO.N.D(AL/(S%[%7_8T'GJM&FTT4+I/( M_;9\<.@7FN\2MN_*%)%/7&6"T+-8N1%UDT,NA;C8"*6"J"!I=(8+9!'P[%#Y&X:0B&SZ@,7,5CY=8=" MVY@^R6-/NPJ<.O=[W`8,;V75RI]S_WO$&IA!7%<=H3!7^9F+H*O^QD/[N'VB MBR3PKVX+[O7*JM8ZE[2AX7"_?ZVAO6,E-*K<9#4NAD9NNK:0/ON*_JQJ>TO> M'AS!52K7XB%;_,E@P9N;17+_VD,CNA8R5:BNQPL,LMFJF3JN#ZT-H;JH;A,J M^(*F-8CN2W,S:!9@4H]E$2,&LA'FZRL_=$+7I]R*8K\AI4Y+W$S&@MR@^G2` M^1KM!5$N:32QKC?3(FW3C&0_*$"Q-A]"!8=P[!K',4YB!1Z5&H(R1E!2"-5X M`RLHT*SKX23+'I"-8S(QV%%- M;H`P;F3-T:']"%$)Z@92&8-C7DM+2,&2$//9GQ,$T1,[R(G6$4%>M+M+UKL` M.;D(;?*''WX\'7W_\4_H[9?0V7E^@KUWW/']X8>//X[^^*W!Z51G8C+&*K6H6O&]3BO9/&?7Z:WK*X%M6&R,E630U/]U8,?(QRD>Z%T:DCU M8JNKR'6V/F6D_SOV,C8B-Z!_2:NT.3&=`J?/H?/[P,F*E.#\@71B[`8[?JJ! MLBU.R,[EVZI^R.3NZ4-B=$^B.'YOL-B'"M6.BGPH\0QPKZKP9J?A;?9>/[/7 M*MN&?/9WB_GG MQ61I>'-6`4G"1HT"C*!GE3-J;3H2*V<75(@8F&M6*EXW[3PTMBC[0,F"^>KG MR0*EV0@_V3"YJP=,]3Q/@A93JYT'E907/`LB!M<\CQ1O7/8\M+9EY5.J_W44 MWI\D+!^"KQ2^#)4/T6*%LP^]S2UNBG"7KV]68+U#<,9>#TM#N#V\G*N(C%TZ M&4S3ZJHF7JJ2<(&:DAE5T$`\Q:<@AJ@<*@H:BME:6R2`G2/N MEX9KCO>XSXTHOA:3@9LZ#8_"-PT.0F[X)_0#^G_*"J MY(*6.'""@))!XGYW+H;V$UT*R[=[690+OS.95=#5-B>S+1PD.4(Q\6!0(V!S M$]3)(^8L:##'7"2K$<&:C5R5(E9[PM3:+8@T,<&&S9+.RIH,J%4#:6,4:R26 M"3K5DL@T<6H1:`-1M)6#)X:<#@9(<.T[=WY`I[T\0X`7KWF(`@^3F&UM)"\* M*ZC*78`22<,P(2`\B.XW)9,7*U99NU@U'9]/KZ>KZ63)MRF7/X\7DY_GUY>3 MQ?([OFFY^IM9BNABL4PB;2#"'QFY=5Y8ZHWZ89&2@)%C(H+2M<<"LI8VY,1H MZ[Y-6YH^B='^95MU]J(:Z'6G+FI0WF&)EF_&9]U29T`?1'8X7PVN79YMD(); MFFU47]A3XQ%`)L%'K4PFWSLQM23;TI)MP1(GLZ0^RQIF*5;;E)6X\MJX\!HU MFF]RR56-5D?+K8J<`BSKD9\B/8\(B9[HMY'>,E+1&K9H1Z6Z0B&+P]'K2WQG M<.#549=ON@0L*]G4J-N7MJ"U0.KQ*Y3^D(`7,$%M%R?1!I-QNH>DD/5=)P&; MF%:KMEC[/FV)\J863(#5M=^?:&)00VXF9QCD#9@1TM`:``,']I7SC-7#O*K6 MH""O5E>8R+!6%D5W.EH;CNMZ4162>1(`EUDG0R\!4M<,#O$G8(6_YI M)IY$")1_4N4%3[W#-,9'67.4M;>`C]I6)!$BF17;M+TI?@ZB.B1?F^%?IJT" M]HUL0#2SMJ*QJ4T%R:G10R,+J*FD\O&IN^`@8HJ5?6MM:!NC@8@2.!LAH-;! M";F<*5HJ'4`X8JAEYRAT;4D/4Q0V]PR?J%""DX0(5IRMN,1K3'7P%O@1ASNV M;'E!_^4K)F2I2,-.,I7,$=<%4BF4B?'%Z$S0CF2NCG;=1_0Y(3^G>L^N7C4V M!1W:#-#IJ#IUA'FI!F\@?0'Q'QU6IJ_22TG]@%P2V`;K M6O.+0Q@Y/FRI1@].C%&TY6>(\VFCL1*,(*;`>@`EPHCL5V.+X9FQ[HS8@IFP M^@S8LFEO;G_#\4IU=%.[OD(2*L)MD(_6ET]L>ST:>S3_DO?6YQ M6ESX<`%S=67^D,;,TE!6&L);)6O:I\GEO:J<7B`QV8\CU=D<();Q_>FX45:C;"@ MF<1A*PC#'J=1,48X[;$70DR*E;S+Y$:HB#B#)VW:F,6:GOAA7E[2K*?JY-$*MJR$T2T'Y]@Y/FQ&T3QCJ1%F.*R'2:/!=5" M^>@D4#V.X684"YPX?HB]B4.82X['+OU2.YX*=XG7ONO+UD,4A$%G%$K&E"&5 M"Z%<"KTMR*%,T&!UI6Y6X4S*5.0VY#>Q(JX;UD"K)DO#FFK37$G=+9;G2AH^ M$;3<0JX$/WY*9VY;@A]P&/N/>!JZT09?1S&K]35?KYQG61"IV1-T@09-,RN* M">R1F1Z\/NH#I9V@MZR;=]F=#&M$^S):V:%'H],M6??(:)]W8K`0Q&NU3R?F M-@'=B$/7LD'&Z)NP:0QJZ;0K:HJT\M@F]V*U]F!-[[UVVG.U::.U-JV`[R1E M3;_CM]F82P^T3VT-+Z^D_/GX>CR[F)CTP=WT-+O?KK[/;F%Y08GC:Q2UJIQ@ M!5ZJRPA:D?>E:H*09<4-L()0EF^GW`[7AHFE9Q05DJGD^J4=H!^NVXB_\RFGUFCZ5@>Q1M M('NT?=$*KY!1!0UYV*;3!;N?<;[FQ!\_^]+B9K4RP#%&O>H"ZE@3M@C%&U%H MT69&TS=U58^:5(>=3C:`1IQ5-B$&,'FSH,)EM'%\8:NUF/4D-H9-X*Q2M@G< M:4.#\-;0.FK6&C3+K18<0IY;/3(`O3<-57%\?DNR,[!C"KSWQ(I6`\N M55]8+N*MT3G:M\^ADXJ8].>]&&+8J3=C27#K"D`"W+X+@NB)3;&N(G(9[>Z2 M]2[(2T4OL(O]1\4BZEK]P&[=:9HHK/GG\OSJO;P'M"\.?NC#@AI$_1G+,I^\ MW%@G-_:M']*?!H%#XB'R5G2VM7JU5.FSVK:=9>(-6+6-U<9Y"9M8K3P7Z.7# MA8&"QL!SPB,#CY\4N,5DR9;3)*Y9L0/HBXG5C*JXIK@X^H_87A>:$Y1*IV=! M$)5'O`.C-Q=W-3`[I;4_GE7TO8@ZB70=M<(+`]\5K('.BIN#=:!IBG1E1/$V6 M9$+&&;)77I4=IL_]MC3BF!7^4$8H;2WV^!VLN)JIF10JO"XQPBRGYX<#WIK$ M+DH:9_>Q&:K0*DC9Q7-5Q61M086)>4D+(JI"UII!-0R*5-D4H@^ MCTED41S=R@P[(V@%0$F884'L+&C3&#C729AE0FVH5L4"JPIEJ>EO4ZCQ+!+NWSR;@F`5 MI]#HTLR&O^F1S7W>J4+9VCH)4&]6KW894MGQW'U3*\K2#J0^)/8;@%.&?1-J M`'-!G0#'V24HGZ/(8V>5)7"O;`Z;_5FML)`MR9KEMPF-$&_)CZ,;3/=4TWPQ M^3J9?9F,4#B(LFH'@355G4U6AM-0)3`6\D]E&(:<0\?)?,T56$:!/.8];@D\ M4RZK*4Y38EZIA;=!K)')V7"CMO/E"LVO4(9=L56H&PZ5J_\R?EO4?IK>HFV5`F2137;BW-&^+\L96Q#U: M)MQ.%N/5=/8937Z]G;81.&>G-N(&LS!IC=CO#./0NZ40PB+8L#,L4 MDV!?+@=0JW\ M]("!"@[I>!A0SHR]C1_Z;"QD%Y(VH[9)$C:@:31#F)ZG$MSO'%UF:8=Z1N/?>.2BY;0$"IVM/9Q?QF@JX6\QN4K6G, M9TOC!.Q%9R,$%#%=2\$*0,.1 M6;$:V<:J^>KGR0)E_'B;K4R^,[PRJ8RT,E'4808X=K&R\K6*R88QN2#LB-9D MA(`K?K.`E#,&![IVUJ0W81A-Z^BD.7J;33W?U=@`.OPIT4(8"=4X`9EOF&#Z MM9,C/>096+4BP!F'M8J+.7MI4X'!AM.QVIA@(1.:("2F'C;@!W`)U/%#-AN= MAY>8^(]\;68:TJ&6WV?)TK)N"4ZD5V8I=P&[**INF+`$1T6S4`[-0W201X4. M.'-&*.W$X&II>S,O'NB_V.U0:.WX^2'4:(V>'$*<,/FPI2H_.#']V99=:[JO MH-]K[?]/J;4AOF>G0U^'M:#+KIK\%-9?=:;A?$0\/W3(RS3!FY@:1-]50E]:P$U*YTC2:?AP3S5P=FBHUU=S@">;X+`G MHL,CT>&9*'UH[K/X8T?HZ,&(/WF$CI^-\H>;/LX$]D;3Q;?SR=5\,6%9KU^G MR^E\AN@_\X6YU?C7B>'E:@"25I^Q&I:AT%Z.:IDYVG,<8GF.>YV$`>]2I7:- M9Z!-\\UD]#9K;7"FHJZ_#O-@)BC#Z`[O-6I!7\WX>L0#AAJVNX`OHV(FSN4>32*DJ9I'+VIJG+IHN()]G%Y!G#ZEQ M9%9LP@_XKOA6/67R[6+R\V2VG'Z=9,PV?9"H7]94[OGU2!GS[N2*!BW^?9A> MR.&^K(@3QE1#9D#H\7\%/+X9>_^]BQ.VU*I@9PNG,XP>5KBFH5YQ"P>6J8)R M75!!&9ZH75`''?31\7SVN3NH]Y^_7#=_N4GA93K[SHWF:[S&UV/#^#&HFU0= M98;UD:`%_\JFY8I*1@Z9%'2Y/XGZ%777U":4MKE333,KYH(&BWKVKCEP[;LF M?E24OFLD!QS!)PYA51+CO#SVN1/[+CO0ZP>[!'L*L:EJ#Z#$5S>KC+%<\E#K M?82X='J`/I6W(F;L8.-X,9O./B_1+0T-ES^/%Z9C04T4EBFE"T'#]-(EDP74 MT2&*98RH4#WEL^K=!S`CH9;N%K)5BYL6,#'S#1I M_7QDM9N5C?K;QQ6T]81 M2A<>"UV^AIFLQFOX93+]_/-J+\><)FGVY.:>3W/D5VP*YF<_2Z:[I M(FH=X:XY_VW$.AS/?\'^_0.;DE-D./=XMMO<83)?"S7@F^;)>OV`X6%T,(.[V)OC%6>I0FLBGZE$:F`9:.S*_DF*\O MG/CA*HB>5((,J1AL64FY`4+IQOU-*M0=,`'$):R(!EJ;$BF;`EJ74@%:0I5* M%5R!IC4S-6Y)].A[V#M_^1)C;QKN"PR-W<1_]!-?*3!OT1ET@K2^L559R!R+ M>3?H_`6]93VA:?@.[3M#A]ZLX%XOQE^,ES^CJ^OY+\NCVEFSSVA\L9I^G:ZF MQ@/P]HBN2#YN"V6)DIA<>P M/)+]@Y!X"H/^^C4Z%`,O,HD0V;_(<'\ MSLP[^X<:=E1#,K?LR@:E+9RSN\1;^OU]GE\G<5)'S4"=2TE!(?(K_-H<<;=J)]!5,]2-JRBDP870VUS\'0T-"Y%AUH4586$G2P]E M]0H!6QQC&ONQ9)>\BIYO^K($?:Q65+;0!:I)*N9^@<:.V']DIV.T2%@A;IA^ ME08I$B^710=AF_BF9-K>!C*(#7J%.(>TP:Q;J.=-LT.0D,:D*YB&CW0>'1%? M>M>17,XP^8]-4&1]0<@FMC?9,J32JD6K;%"YJT?JH+19%U3!UV;?4T56DT[G MEN"MXWO-)7T;10V['L$01>^3R9F_4+&%29=X&\4^*W*^S:S(KSSCL_JTB.YA M#+>*]@#&F74/U]6&VI#<]$81-KP^(QJBN"W#(+8;A4^?% M@&:S4OVWS@LOPL!O+G5=LL/>(+<[=G40`QED>#6CADD*JQAU-+)A]>(V_02M MEBYR64O6+0ZFZ"Y:9)(V.85FH_;:;P?3OF4PTX?N=JQ1E-BAOD!1IH9)JE_L MXB3:8#+V'AWZ/O3F`(*P8;)7&*/(]EP2Y:(VT5W!K'Q6C1B`D9L)6#=.UJ&M MF3NU4#,\3K)I":^C&^?/IL.OLZ6;Z*TV<*B%8D MK@J<`7-9G9?L4,G8_,4>H,_7*9I5<42-2^;7<.>RZFBL M.(VG!46#`RK/\:'ZTEE7\G)+OU`R#KT)_=5V([]W3K,@%N&Q["MHY#-8!M1@=R-5HVCNN*G(3W/U<1 MN8C"."$[[AI9"C)UF=+;N!M%C7@8B2&U+H6=G2\*I6<"N)AY]]'&(&J"6Y`Y M\<.3+8GNR3`&*>TMO@)SVKG`5V/0RJK/9,*;-SFY.O?=Z.%LW-7M93?7UEW< M?G9O7\.6K2S3XI!=466IM1`FBGG1O4W3>F[?$]5W[HA&Y/&26RSFSP M17)C-7W2OK-7DE&B9WPYH^1J.AO/+EY#1HD"HA6)JP)G,VNZRX>()&Q#Z1+? M29>5:F6,K=N659>OU/+6)WS;F;6W8VE6V01^1"/F)O"-3+XN:RR&&]`"4ZO) ME3R0K1]7DZ!+/DBA\\5^^+IT`.RQ3LRK#`8OH;AV2O-1FC'3L%C"GI/,+ MD'N`MX=.T7S]3CBMR1KD7;]+"XKSWA'OWE2"2N\OY7*'TR+?J7$#;/>J^)(! MC7O+F/X.QD:UW)S>S639._MJ['[(DW@B@J)=DN;S,+CSG)V<`&Q-O9#6LW$\ MS-9I6!NG='06O24%&I3>X@MZ>L"$R>+LWZX3(OR,B>O'F*W[)/2],%UB_S[T MU[[+5O29ACM,?3***.:I,E%V6I]V\/]9@?E@Y_$`;KWV`Y\^+!ZAZ"G$).96 MT9^Z[._,""KH$^1O-MAC#=':V5`1)L!.^;-%VX3L8E8JA+6.=^X#RVY*'BKR MEN#R??KQ[,<903VY=1O#QE["15O#Q'["P]<0$\J6O+L\DJW"^KTYB'3=QQZ[`^VS_KH!#5IUJVZ@;WV6L]` MX:YK+L[2E?(.$.L!S_#R>?9Z@ MQ7@U0>G?EV@^0VQ]RI2[,64=Z&W=+?@H7-'=AHQP+H<[0YX>7SZ!+G$P$B%0 M=R)57EC,I8U'*&V.*BHZF',46F9,9Q>+R7@Y05.S_.]9:4A:-V.^3&(%P,-2 M5O0=8SJO(>2%3F&^.C1B;6!OLSPXD55,JN)TY:@_0F,6F*32B(N;Y72*YLE7.M=D#Q)FO)K.9X8S##0!*MQHKHE.R`)W":8`26X=WY/0ZZ@9<+FZ(P7% MJG3IKQ'[O+LK!EY428BM7C*C`*N#]"+:%O M[I#C%WK[!=5I@C=*V73*?<#NCFB8)BRJI[*%Q%TV!S[LB7!Y*P:SCE:>9)NY M13,MW#S01:FP=Z`-T0XY-6*UA!5QPGB-"6$'(81L?GY(H2Z3IEUGO9E.7ER.3.TJC&A%G&C'&$'$0HV*F0#C88TQ@AK9`"K98L478`I*M%F M$X6)A!EB6]C4DPI5Q;DE:Y-Z6_1;VLP@YG55-KQK7X<%88>^%@AP MP!U[GL\F?$[`ME*FX86S]6D@TPABN1PHH)M,$(O?^-X)NQ,N;64SQ>,O"1,*.K7F-7%`0!B6$DC%E3.5" M*)<:H:*$C:92*6\"RX8TT/`'4Q:
%[:0[?8!N''O]7D":%>_^]BQ.VGCG#R7R]30K;G!Z'_/"U$Z-_!J7@?DF`3MYLM#';B/!QQ!R;T3^K]S-5DB M2A3XGI-9<$M1GB<4S==9!KH3[/<`54Y;]-,_[-C7TRL1!K9"OR-TU#,?M(I] MLU%JWSLZ=&]%1HD5+RAJ\8)`?5:?Q!(<4J^L>B7>YM*/W2"*=P2O\'-R3M7\ M-I3CJ7K4Z_%!U2]J$'=T>!3ZC3T,\:>]5M\TP(NK"SHI1TI!YH.O86K`4%K?U,`F8 MYN''WV(Z3'ZA+X&P;7/%.X3DO&3`--B=='8IB MFKH&#CN<%L^O0SC<@W!XD&1D49>%._VM:$I-=!"C@]P1G`P.-(;,`CM-JP.^ MHU.S6L@;B!VRT41#V`Y^R-QM$Y*,#B6OV#*E,_MM36.'\VG?/C7#.UC$ZLWM MKS,ZW&)4;.+M"`OJV,5'!&\CPD.\-.O)Y,%[+28J^PJ3P1PK\!6R(Q%*`ZZ* M%'#92)GZ8A7)K+4M0RN0&;`E'!L!)59T;$:344:HA&Q2,=.+6+]'E7$M6"6 M`/5.TH-D-DP5^K>X?O+`ZW\'_B/V1FC[\!+[KA,@)XXQG4_@/4"*Y6#1$P.) M'Z)#3=@'A_H[VN&.W=Q-?\.F%"&[HR=@DAZ58RFS=[O8#WE[7C>6_ABC^RCR MTCD*JQ[CN]F$)8P2?G]*R.Z29FK2YS@!-GR7?1^^J7R7?2^.J?>JXNI+%K"=UUND,T8*F<"M;7D+5V`T*:TEO/I=?06+R/1&+K5A$U>XZ0VJ%5=VV37 MB&W$,H-WZZ@.U'H('(HGC4.THK0E3)%Y]69`F1^97ZUQ+>_NZF5`1J4KO*P= M7/68J.XM3*[G?XXB[\D/`AK&3^GG#^_]NP"/^8Q(*P=,KQ_0=7Y=$\OHS>7Y MZLZA!Y1V8UD/L"K2!\PNYSX((RYM MB\,W;R%@)KLF.$M9[+K('))'"@=JE'NPB$GRXR4J0#,?1+UZ(Q7/SW2P4G9X M)K/__F#_/;??TC!+GZEZ7L5HV+778KYFE?EQ&*=UDC"_S^HBBI.8WU!SY\38 MN\TV`57"LVX=PX9Q75^"0/$#XN=K5.P297TBWND(\6Y/SEF_*._8CNAPP'<2 MJ;R3._5W`AIT]D(8(3CMART6^HWSHL(JT6[7GNWT'+6OH6_7846X/>AK:>4] MK`GC>R).:P?2P!K`9;"$/O][6X#I0`U2. M%GV:<-(?8AN7B6O;&\.L=-U0`*WYY=XNZA^TUU1>0XG6R[[JB[9^>G-PPLUC M.=9I<:/TWT\/OOO`#R%NG9?&A)G"VXG1QGEA?0<[#Z,0)X?%8=HS"GSGS@_8 M:,>*[;($3):4$]V'_N_I64FXC?,L8> MX3Y0DX]4?,$.R8].\MMET:,3[+*;R((@>J+]X!%RMEL2/?L;^@RN'EZO<5IG M`3O4?O89V3^H!M1BA[S0=TA;L"M-,7]EKD/("WV93P[QTG.;]_XC?0=,>5:A MP4%QX5H8_M;2F\\J7XJ??8BC7Z:'0D=HE]`FO^^O3G/X+_GS[QSWVX@+LA_M MCF[/\,,U*R'!I$RNMS9H34:T$X>$%%+Q+28\U%:(96M%0*?@$L7+'B)O MBFC;=*G%BLAU.`L@9\Y-`"I/E!O18P[[*@%IO8Q1],N&]RKP6!%?#FJ$20XT M1HO-*((\F,%76V\=DA1O,5<[I=$@"GQDH]$0\21$N@S/95!1R(H1`LXBV*,> M:H`3SWTHHLT\=_06.75ZL8)1:F&E!(K6A,KV6&H#`S76.]M@%O(6P,W&3])\ M@]"[B/@5GC2F]1673=OU`WPOH)Z)8G6JO3R/K(]ZL&4!UBIC8>\.;`%@\1+! M-NBUC*4J`ZAF1_;Q5%Y&3A6[5HRDMMAK'5L;A]26*(;U!]ZHKU99W*[.VHU0WI*.!;2M\7UIR2L7]Z!E[QL0)]GCOX3Q%KO^ MVL?>9;1Q?"%IOVAHK0PL7B2J"YC)VHY0H37Z+6UO&C=-GT#`3N/[A\//G&W3 M%:H\S'!RL2.$`EL"((D0*(*DRI;N%LS2]>=HEHY]:XR8GYS,UW=3&:K)1K/+M'% M?+::SCY/9A?3R=+:^72+R;.1JYNR!`>>%OC5"79"BLS1;3MB:^#KF:K4%>]# MR;,V>+,1X@U':!K'.^R9O(9)3_LXU?X/I^]/3\_0UB$\8@(R]RA`W.$EIBP&/3-^(W8X#WZX<>]>-[PO+)AH:=#`Y^_Q31- M:9?$"?T+1;"ID;0/1(S0BCUJ`!/2I"P:[I`$QI!S?.^';,<6G3L!2ZP:S*A) MZ,&8-.'XJK<']KJQ6G)Q,_+I&"C7*GZ0IR; M^JHQ*D$*_9:*F`YUF[^%$.PJ?(@.R<[3T"78B?$E3O^K&.)V/[^HWK[CRK)JV8)S&E2=G07^/=.NF?. MWLO^8EK:XX[[G+M=PB]\>\$)8I>UFLSV;4+-Q"!3(#J`Z:!2D#BY`!68^4S(IK*O97^G?Z M!SL83W_S/U!+`P04````"`#L@J]``*;T);X8``!TC0$`%0`<`'-K8FDM,C`Q M,C`S,S%?<')E+GAM;%54"0`#/+NR3SR[LD]U>`L``00E#@``!#D!``#M75MW MVSB2?IX]9_^#-O,ZCB,K?7%.>N?(EISHC&-I)"4]\\1#4Y#,#05H0,JV^M=!X1C3T"?[M3?/MNS<-A#TR M\?'LMS=?QW<7O[[Y^__^]W]]_)^+BW_=#.\;'>(MYPA'C2^LS=1'D\:+'STU MNG]7MZR,-WA(ZN[QZ]ZYUN6GX)FGYX37T]UJ_M#9M MFY?_^G(_\I[0W+WP<1BYV-M1\6Y$=,WKZ^O+^+^RIJ'_(8SI[XGG1C$2N7PU MI"WXORXVS2[X3Q?-JXM6\^UK.'G#=/"7CY0$:(BFC?C['Z+5`OWV)O3GBX#S M'?_V1-&4_?;]T;_@BGS72LC_NL&FC2=='/G1JH>GA,YCIM\T>+]?A[T][L/O M*Z82^NB3B\63RYIZ:!GYGAN\]F?=]^ MN.V./G>[XU%A=N4]'HW7@4N9?IY0S$GUC.]W7Z44HS'[_R_=A_&H?]=[N.U_ MZ;8?.NR/P;#[N?LPZGWK)K]6(I/VQXXEX6U[]/GNOO][-6-+W/.Q>!]];C,U M]>\[W>&H^\^OO?&_*Q="\(FRTO3IS,7^'^7FG[U.RG(T6L[G+EWUIR-_AMGR MY;EL8O,\LF0S&YX-2.![/@H+\ZK9?>E10M@BAB,:ZR1D$_,M11,_&OKA]^+# M0M%G67[7*@B'R$/^L_L8H`<4%>94W%M9'GOXF8E/:!GXTWV4Y:>#%B3T(X[$ M@**%ZT^ZKPN$PQ+L*;HLR^T@<),=PG^6_H+O%LH`+.RL`IL)([KT^/#NX0$E M,XK"XKJ4=%>6RWN"9V-$YS$^*RY[<19%?96W$K:!GOG,YMIAB$HPE^FHO.9< MG)H22FAMOY_2*\X3H1&'(>ZX^,JRWTWYV66**)O@/Q%VNL1\;'RBS.A*3"WB M_DI;K;OP(S<8L\Y"-S:V$B8KZ*LTNA$[VK(9?S5$(:+/9;8.F9[*\C9V7TOP MDU"7Y:'K4LQV/N$`T1'[4'&SS'14EK,A"MP(3=CA*EJEAP1;=]J4_7N&RLV^ MNOV77]?F`[17\RSL>$ M3>"%>$Y1GHQ;MFTMQ.N6[G1Z131$Q?2ZHZR4VRC+J;$R][2X8/MS-J'%Q]M[ MQL8>@^@U0GB")AL6>0>5^DDY"W_Y&!!O[[,!=R@3FC?%\U\<5??M1W868>O+ MIJ.`RQUW[VC3.N\216ERN=9-K/>I&S[&RE^&%S/773`0FLU+%$3AYA';WKB=7"<[-DS[(L;.LT-KVE4VW2?;Y=ZFQ[97S.0[KOEURTN M%[&S]<)[\H/M:)A2,C?7YH87DB-)@]`)HK^]813+D+%(%KPC[DAFPB6[ZOM$ M(5+F8\[9QON1[-DB#)0C#V&7+1#M5S_4033=WKD"`E:.3@Z*!]Q7!68`A>): MG*\X7"`OCN]UR-SUL0I)&8W3J@N:ARA)0%4(E^2SW.>';&_];^12=CKN,&$DZI.KG6Q]3E>5VCU?R1!!)][[5QKL]$TX=<;W3\'FIJ M)_,YP:.(>-]C7W+87T8\,8PSJ9[G%81.\]V9P*$GRP:DGTX.TN9\/6;=2N!( M-W&:4-X`4\4?V=9FT.OYHH"$78 M('$-C`3?Y>KCL&WM-,_E/*L08'>P$H/P\?(P3'&:V(4\:1K.4=6?WOG8Q9[/ M1C)/6U/'.4S(?X0ZBHQZM4+_K-&.@N[4VNRFS-VIU04Y@#%,$@\UYI3]AO6) M:NQA(L8OP[HEV-VZX1/_'T\1?G:#=:;2-DF2)V*'T3J!2XJK?B?@X8\LCF*\ MC42R9"P([P.L':LJJU:0@<=.=/'.$:)>@:_B$&\N5JSB:P522-/-P(,PNA`> M,"UW^Y\79/LW3/+-4=@>/(ZC"Z*,>WDXX;S0?"`1XBO)P>T(K8DVEQ8\9*2+ MLHXD\N#&>2'>CYX0W"C\)IGT/50LBC0N>%<**.!X*]9*[1=B9E2>!C?6:SJU@">9#I MO(#=W\_O9-4^P.Q(X,.'2L!TSC/[PH"[C22KJ>"^^QVA;8\M,4FX0C3K:E+" M1Q\-0#20R1X'T7XY`;:=Z+YZP9)G,WTB9/+B!Z*<.A-RIUD/CY*1'>L*9HO7 MZ5!%!@NQTZR'L\D(7Y$0E?F<"AYVJD0R%S^G>2[.HQV_BBR0!J(&[XFXS_?#; M/H%S!>UC,@)/'93+BE;7K7/L>EFSRPN4>!Y=HE3!,?&V64WE7$$[HTI`J2F? M+=:[31"X(922%UYH1Y7/E&WM7$%[IBJP6XE1J\6P)XJ84E8]XMK%S!>W/J@!IL5C0X=[*\36*,"GIG"MH+U>U MJ(LEM"6"O"FK.D3/""_1MBJWGH=3@]JY@G:?Y6,IF>/UA`,_<5!DM*Y@O:L%1\`N8+9QD7I=U7@]3IW7& MGC6)/)5E!(%"J2S&+'>SR*F=8%0^'2Q MA-E8WF]NL%3=\!:T=EK0GK8W)Q$\8'[C^I(?7SX&D1%9%JW.)G1:T.ZT0XGJ"P8?`)(%KP?LKXEAUIJ'3 M@G:$&>$E%\*6:-401:Z/T63STDO;\Y;S9>S#[Z"I[_FJ;50^L=."]G05LD\] MP6P)9J6DBY,OV#3$^']"./2?40][9([N2 MYE+:$OW*ZLOHE.6\A_:&%0)<+(AU\2[A<;-$'JGSWBZ/F53([6:]]&[]<"C4 MKC3=_K/8Y;>2MX2QBD,TN7$#GA$T>D*(YW"FOJ(J%F7D$$E@";%JRW$=XLHWK4Z=.!)'$_R22PA(X M1XB_"][>=YE^0?-'8:T'#2KPHG1BM"3VJI3C[%]7BJ6[*82MD`J\`)TYMC(Y M*O,?@X%;RN MQ?QK#2(S%7E^@X"\\,/=':$=LGR,ILL@6]Q4XUJI23_@1>G$D$I\O8:26;)M MWM]5L$-_G\9:F\0!Z@&B\>M%VMD6L@[@B]N9C`5]F6R)WN]+G+Q8U5Y&3X3Z M?^P'#+[D7BF,#R0Y8E'C.B1?C,;L M_[]T'\:C_EWOX;;_I=M^Z+`_!L/NY^[#J/>MF_QZ^B<#DT2W+90:MVXD%#]2 M,@Q,1Z[#/VL"1D'_GWR+^_P2E1(! M+$'SEH11?QK+-2*!>O.YUQ(\I<($PRSOMCA[XW MM<`*A)5TX"D42N3$8.<)9,GZ.4)!L-.+,H,MW1`\DZ(`HAD)K%E#$6;*"'C= MXLG5 M4P?.7>M:IC?D;Z7V!:@L_`F*Y0/!9%^^]7C5V"GGTM8ROT&*LY8XMH0]XWO9 M4HE5YJPDA$]RT$-18NFYLEFRD^[A"#%XHCWY\AZQ%Y/`)S>405PEE35;;M?' M?-'JXUUMTE[\#FI<^XY).Z`H4I:MT.T"/O>AS&`PD=*6C7F1)4`Q0T*[R,K` MKQ3+CIW[;@=[QU27E+Q<,G'76UR"PQLT)71=HR5^HJ+[RO3&A/>Q2U?Q#HH7 MNV643)H@UE0R@^:&M8_RU5JF:BA6FZ,JPI9DK:WX:_N[01BI8RX2"OA7&,U' MAU`(6Y*UV!*JY3/8:W=>KRQF6+>CA+1.':\!H3$P443]QV7$TS;&)*F'HA-W MJ^8+\$\U&OF6JA/:EGK5,I7A0_X5RFK'(EF8_UH"K7$62-0F4:E2045_*N89OE$2D$L>;5Z M4TAU<\7FQ@U]C\?S_6`9H8G&^JG9`_PKF2;@&PA578U!8'L7RFP*//P;F2;0 M&8"??B33,J#7FC&`>DT!_SIF]6"G1+/%$9^CI'A_U/%#+R#ADFKE*A;L$?Z- MS0K7`)60VY%S[F[ZW]D.^8D;$N/#G:&'):]BUI]F+GSEK15&_<`_RED&>O%@ M,E:`)6N-1.ZU(DUN3AKV!/^4Y\D&D4H%1US#ZG8+\[8]^GQWW_]]=/HKE]ME MI3^]=<.GNX"\Z"RC*K(?ER^++.MB14K,Z<<-S!\W,.N*X0.*^$@>4/+LL_GR M9O4U1),>WN:$MKW(?TX>/]!(F#3N[*QN;Q82SYYQ4B"R">VC*8:83N"S.B=- MA"CDZWR;F$,X)D/D$>SY`=H3=4RJFR".\3GP2ZA5#K(C*<@6#U,',78]/T98 M,=D2H]&#+O!`K M*F2<"XHT*X:(B@S\5NUI1TF.*FQ)!S_E70'HK+[3#B`#M93/-;].!A-&,UZ[ M$S"/ER(W1!V4_)G2W/H]9[V::)J=P%\3/NV(,M.,+=5ZLU)G7QLP&DY9*?S=YB,-A:R8%N]`>+1W-_^9S0N'Q/!WGX\T(D2"EJ]\4-4G/`[2LF3V9+QO&:=5UOR/+I$$T4MHD+]P%]_+@5^ M89DMNG=Z(/LM.\ZQ@QMM3Y[Y$V=FJ\4A,?Q=Y2/-#2)!;;FQ*IP)N0'$M[,+ MKAB']/#WE(^W:HAD/>*3!#5-#JDD*03^(G3%^0(&^7P7%H9(';?+HX6_;EP07$EP3D=> M^/.KY+BRX;X_O2=X-D9T'CMDDA]E9Q,E$?P%WTK@U1/4%O=U9A#?$Q?K!37R M2.'O_![7W`7BVN+/9AKS$)JL"T8%`8H+(W!CT!X<>CW`7QBN=HSH2VW+.*QTI9H)7 MYC>MHY_CSLY?O3@Q#S;I/.(:& MS"[ZF*N!G?KX'_SD]^P&$N]LD6Z<5DW]M<5&C:GHMCA@8@TBZI/)821<,4[D M1$X+VFMK5*93*8<=4X-X"+>9Z5"Z8E;RS0V6>5CGTCLM:$>L*>Q:(E5FY(MX MD#$>:63Y.(#VJAYA'%28-9J,@RX& M#TX+VG5J,A(,A++E,;W-(RP#UU=5;TTWZ&-$)2X&,J+#?X+"$9%6*.]X0RB:67[M-Y#^Z0+#M&RHK_)RJ: M.OK<'G8_]^\[W>&H^\^OO?&_0:NGCB+B?7\B`5-_R"&)5F9E5.7T/^JI%JNG MJM2H;"MN>V'51!'\A1B"X_/FJZ]58U5$=W[E5B526`(RDVM.<#SLOR!>8%OE M4#EL6Y^ZJ3*0)&X4@2!5X1F`%:>;^`G'_*#8P^L+9;F@*NG`2Z<6!#A/J,JV M/%!H#U'DLH/D9%-UO[U8L"T>]7ET.1?R?&+P:J8%<=>2K+(H25W`_XK=,O"+ MR,'KE58T`"2R518F`9OM/6\Y7\;))+(''_-G?MT^P$N5%ET%#`2L+&`"-2(. M5-,A*;527?(\@8IT?O3=?J` M&VQAU$FFJJ1_D+AS*]OHX7>(6: M5T;+^=REJ_YTQ/:T_I3]1QRM+Q&RZ73`=.;QFW,03N8#'G0>UY,2P>2DJ%2J M8_%Z'8#;L5+MLI5;5S3[3([-11[[`(V_$/(K%4P&/QKZX??3VQG_*N?A*^.) M\OB59LD&)1V(M>VIE;-GMKKJD(-;6I[6I3DG6K+99VK9YW#8`=[$R"29Q-E^ M=QI5&(\VK:$!%>!291+ZQ&`&8:+)`Z,PDLX^DTB_F`1PC2KY^$K+7#2H0%8: M`3\Z*XR*#'QE4>M8LJ[D2&2?\730@H1^%"8GR-232D:V))FNY9WK+RXF?52S MR.A\,7>Q,>H$=M$QU+!H\3&5UCX[RMP%,MR6559W3'PS26--RJ6MQKHVGSG0 M5??5"Y;^&DO+^UJN36EW`+M^&6A59$$F4MIG*Z+G&XYQ6]W`2K2(JS$1Y:=R[4./ M&M8X=)4IL@QM^>PSB\S#-2??RGTB9/+B!P%;V`^9,7(U&/4#Y'R0L:7G@\BE M!M_:'D@D M4TT(5,=-Q)*9DT.[#W!#S05`ME,UD-`^DQN[KY4D7,3]Z&],)=)Z[ MZ92UA]UBRE4DVE`J9#A"132HT;HI!S1`-%X;3[\^''*@L3+(2$#6A$-F=-8` M*0WXG*]0K62V5\EBW^R>?JWFA3$K&1, MF6VV#'H!-ST-&"0F:":E?4;)JY;Z47),Q.R@%U_70ACF;J""&2.7NU$_0'>: M-#C4N]UDTA&XH9HB([%:8ZE/;+@?+SG;W`G#_O'_4$L#!!0````(`.R"KT#B M[$BB#`H``.90```1`!P`[LW%&P[&B"P5>()+Y__1X)\`<(C.-TQMWAI<'H?/^DPY$X].K7E[FO M/&$:D3"X;G5.3EL*#KQP0H+9=>O6[:N?6[]^^?O?KOZAJM^^VD.E%WKQ'`=, M&0'-E.")\DS8@Z+_I=X1_(RI?Y9&6=*(N\! MSY'"$)UA9J(YCA;(P]>M!\86E^WV\_/S2?2XC&#\GH3JX@'1.8S'C'C(/_'" M>9O+/3T_[T"#A[JBG'745\(Q%18R5L\$@)?&)"0XQ?O04[/1R0,)'C"$9.S M)&,2I@`1+Y+SB"$)2T0\.0,,R-%ARP6.I-"($9D.MJ`E2F!$PD#QM'2B?6K# MZ!J%!<7>CHF)J"?FYA1Y3,4O"Q\%B(5TV8??J\B%01#/Y4(FC+:Y:VT@4H$* M4^*MEP7;O2366G:K2,5#IGQWA8(@9(A!IOURA18+$DQ#?O_=NRN^,B^Y=!>8 M%'YQ:QM[9#EA6);FM6"B!XRPI0$*@)(K;"D$0EI)D9B2VC+!4Q(082ID1T5= M/T/@TNK>CG33532SI\!?P_VN&&;?LD>::UCF53LO85-P'.&)%7P1UX!U!"*% M>I[V4LZ4I(QK+;@^#\3)B_TJ1>FM#(.WQ*5KF8XU-'J:J_>^:D/-[.K.C:Z[ M3@)*^7`Y(F<`@P.!PRDD(*.GFX[>4S:E*:DX)9'7`%,7F#&"QP1[P()^!TK; MM.60G;\&,N4_6^+_VT!8`:'CPK\\,3E6WS"[UDB'!`5_QK9^`Y$V[O3D;A'0 MVISE\'ZH!^]:DV+UE42JR*-;VM*!!NV::'L M",D-9#4A#^.DU(&YJ^*>2Z&C@S,%IT1D* MR%\;->76G7)(?N&%(XD\/XQBBN&'90\TT_AW4S+*PNS$\SFB2VOJD%E`IC`( M1;LGMKTDF(U#GWB$[Y4Y`#5IRZ'YG(?&N1V--/N[6!3&P#3Z1E?CY7ZW:]U" MN6\.E#&LH:ZA-^FND.["P`,WJ5`?P3ZK2_&$,)M$CVE^JR`HA^@B#Q'DL2XD M+ELL'R>I(&R]9[B*;3B_-;#D8$G70V1C#Y,G=.]CD^_B.2#RH5(H.J=Y*-)E MX2BVWM6-.^WK4'^OF+K;@)`#P0B>P,N0KC+7YHWR@'?R`3?,.YCZEMWD'\D9 M$%Z$$6$\L8PI7B`RT5\6.(BRD%>,ER-PED>@IX\MQW"=]PKL6<::T5/T;V-> M8"69R')O='MC.30PY6$:^R@YA?LS)@M>I*[2D72D')KS/#3CH9:=S$$%.^;5 M;9.-2I[4$:.QQ[4;P9B&,_`[6CVD96/E,'R0/)\=U[[M\L>S:ICJV+8&MNXT M*R$/PS`,9BZFW/.Z?B@]G5S,'!F1]17.H;R4`I`F>%'6]7&QNN-E1QKPMP09W MZ=/JM*YPNSSPA9TO/["^A9WO=TCWCF[?-3NK0MA=])*%.KDL#V]A6^MJWYJ( M%B*J(QJ08!:-,76`)"U8"G?+XUS8H^J:;1KFP%'&NIV\=FF"G@NZC7W>!35& ME"TWT[063#0*OV=X8ZM4E[@C-IDI^ MLC"?$R9"SL_W0_$>!@?K-S95!.48%;:X76LT,MSD_6720B!>SNCF_^6;&?X/ M;[BU\501G:R7O,'NNA61^8+OHI)[#Z+5D/<(JUGG[Q_@X,G+W,](N/"*GEH! M83XFJ>),1-J!6-UI"T+"!:8,4&UGQK?:;^,21']?E[8!.S:'?'2_KT/`@OUC M](4G@SU]R:V,-_;HJIUUF\+5N@<5AJ[`&=@(*X&T;[^LV3QI^1^&GI!3P<)_ MJ1F?RF^IG3/UO'/R$DT2V_8Q8.75G@9D?'L:(&_AKZDZ8^`Z/];15ME)7Z)4 M*)0RMK'/HNR.NA95V^^*UO0J8R1LZ?4A1LC:_>M8L%#XZJ16(/->5+GB6_O+N$>[,T,AN=\/])24$IUW6(TYE6@H(*ZBX035_!- M8IIV1P;$]_G+G(PVBH&9L)B/#F@8+S(E!,1+W1LG)=TRUP]@L0=,-]RJ)MMT M9Q["ZD-T*7-HBOQ(ZE%2P+%LZ![YO)P#3_$]86_AIN15;S^DF@>^1&3CV%HX M6X?X^%T6V(S1DDOAQS2>!X)RO3K"W5V$/\Q53_0EOH6O)2?APCW)V$_@43<, M)CS^DZ^);.V6[-,`,3]!G(K=U^LC;DD&K4=^/)FSREX7O["O M?N@]UO1O@SYQ,/G&_9)E]U\)[>%>EC<55X*Y']OQ@%K';AFX>_(=&<@EFPS] MQ?-C_I_;B%0%TGX/Z>-&JI+$X6!)1Q89>9*NG/KU68YGVN^R60;U'CQ'!JJD M@JU$M";]\O+5YCF?"[C1:_LRM MSW1DP!H!;&M1A'LX^6L$M0^-]F?]";8*HIVO`Q0````(`.R"KT#ZN*JYI(H` M`/N`Q0````(`.R"KT"GV2_XO0@``*1M M```5`!@```````$```"D@>^*``!S:V)I+3(P,3(P,S,Q7V-A;"YX;6Q55`4` M`SR[LD]U>`L``00E#@``!#D!``!02P$"'@,4````"`#L@J]`87DIB.42``!\ M%@$`%0`8```````!````I('[DP``&UL550% M``,\N[)/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[(*O0)PSO^P+,``` M^*L"`!4`&````````0```*2!+Z<``'-K8FDM,C`Q,C`S,S%?;&%B+GAM;%54 M!0`#/+NR3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.R"KT``IO0EOA@` M`'2-`0`5`!@```````$```"D@8G7``!S:V)I+3(P,3(P,S,Q7W!R92YX;6Q5 M5`4``SR[LD]U>`L``00E#@``!#D!``!02P$"'@,4````"`#L@J]`XNQ(H@P* M``#F4```$0`8```````!````I(&6\````L``00E#@``!#D!``!02P4&``````8`!@`:`@``[?H````` ` end XML 39 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended

Mar. 31, 2012

Mar. 31, 2011

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income $ 1,904,754 $ 1,931,832

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

Depreciation 343,129 332,428

Amortization 100,373 230,922

Provision for doubtful accounts 38,869 0

Change in fair value of warrant/purchase option liability (5,600) (735,494)

Change in operating assets and liabilities

Accounts receivable (2,415,647) (757,356)

Inventories 985,908 (6,826,437)

Deposits, prepaid expenses and other receivables (2,144,356) (2,603,343)

Accounts payable 980,926 197,277

Other payable and accrued expenses 606,331 360,449

Deposits from customers 199,329 14,989

Taxes payable 1,427,655 1,566,418

Net cash provided by (used in) operating activities 2,021,671 (6,288,315)

CASH FLOWS FROM INVESTING ACTIVITIES:

Payments of long-term prepayments 0 (451,722)

Loans receivables (11,515) 0

Collection of loans receivables 0 7,609,000

Purchases of plant and equipment (54,965) (22,275)

Purchases of intangible assets 0 (38,045)

Payments on construction-in-progress (44,940) (634,222)

Net cash (used in) provided by investing activities (111,420) 6,462,736

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from short-term loans 63,520 1,257,007

Due to related parties 326,061 62,834

Net cash provided by financing activities 389,581 1,319,841

EFFECT OF EXCHANGE RATE CHANGES ON CASH 37,784 21,296

INCREASE IN CASH 2,337,616 1,515,558

CASH, beginning of period 7,048,968 5,887,831

CASH, end of period 9,386,584 7,403,389

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Cash paid for interest 152,583 54,409

Non-cash investing and financing activities

Long-term prepayment transferred to construction-in-progress 333,480 421,843

Construction-in-progress transferred to property, plant and equipment $ 3,633 $ 0

X

- Definition

The construction-in-progress transferred to property, plant and equipment in non cash investing and financing activities.

+ References

No definition available.

+ Details

Name: skbi_ConstructionInProgressTransferredToPropertyPlantAndEquipment

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The long-term prepayment transferred to construction-in-progress in non cash investing and financing activities.

+ References

No definition available.

+ Details

Name: skbi_LongTermPrepaymentTransferredToConstructionInProgress

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cashflow for long-term prepayments during the period.

+ References

No definition available.

+ Details

Name: skbi_PaymentsOfLongTermPrepayments

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from the proceeds and repayments made on the accounts payable (receivable) to related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and such forth.

+ References

No definition available.

+ Details

Name: skbi_ProceedsFromRepaymentsOfAccountsPayableReceivableToRelatedParty

Namespace Prefix: skbi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) in cash, excluding cash equivalents, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet. For example, an entity that aggregates cash equivalents with investments discloses the balance of cash excluding cash equivalents on the balance sheet and the change in cash excluding cash equivalents on the statement of cash flows. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

No definition available.

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The effect of exchange rate changes on cash balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInCustomerAdvances

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsForConstructionInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for the purchase of loan receivable arising from the financing of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireLoansReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for acquisition of or capital improvements of property, plant and equipment, used to produce goods or deliver services, and not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireOtherPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the collection, including prepayments, of loans receivable issued for financing of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromCollectionOfLoansReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

ACCOUNTS RECEIVABLE, NET
3 Months Ended

Mar. 31, 2012

Accounts Receivable Disclosure [Abstract]

Accounts Receivable Disclosure [Text Block]
Note 4 - ACCOUNTS RECEIVABLE, NET

Accounts receivable consisted of the following:

March 31,
2012 December 31,
2011

Account receivable $ 6,264,068 $ 3,830,171

Allowance for doubtful accounts (480,237 ) (438,678 )

Account receivable, net $ 5,783,831 $ 3,391,493

The following table presents the movement of allowance for doubtful accounts:

Allowance for doubtful accounts, January 1, 2012 438,678

Addition 38,869

Recovery —

Translation adjustment 2,690

Allowance for doubtful accounts, March 31, 2012 $ 480,237

X

- Details

Name: skbi_AccountsReceivableDisclosureAbstract

Namespace Prefix: skbi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for accounts receivable disclosure during the reporting period.

+ References

No definition available.

+ Details

Name: skbi_AccountsReceivableDisclosureTextBlock

Namespace Prefix: skbi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 24 122 1 false 6 0 false 3 false false R1.htm 001 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://www.skystarbio-pharmaceutical.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION true false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.skystarbio-pharmaceutical.com/role/CONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Sheet http://www.skystarbio-pharmaceutical.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] false false R4.htm 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Sheet http://www.skystarbio-pharmaceutical.com/role/CONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME false false R5.htm 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.skystarbio-pharmaceutical.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://www.skystarbio-pharmaceutical.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY false false R7.htm 007 - Disclosure - ORGANIZATION Sheet http://www.skystarbio-pharmaceutical.com/role/Organization ORGANIZATION false false R8.htm 008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.skystarbio-pharmaceutical.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES false false R9.htm 009 - Disclosure - CONCENTRATIONS AND CREDIT RISK Sheet http://www.skystarbio-pharmaceutical.com/role/ConcentrationsAndCreditRisk CONCENTRATIONS AND CREDIT RISK false false R10.htm 010 - Disclosure - ACCOUNTS RECEIVABLE, NET Sheet http://www.skystarbio-pharmaceutical.com/role/AccountsReceivableNet ACCOUNTS RECEIVABLE, NET false false R11.htm 011 - Disclosure - INVENTORIES Sheet http://www.skystarbio-pharmaceutical.com/role/Inventories INVENTORIES false false R12.htm 012 - Disclosure - DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES Sheet http://www.skystarbio-pharmaceutical.com/role/DepositsAndPrepaidExpenses DEPOSITS, PREPAID EXPENSES AND OTHER RECEIVABLES false false R13.htm 013 - Disclosure - PLANT AND EQUIPMENT, NET Sheet http://www.skystarbio-pharmaceutical.com/role/PlantAndEquipmentNet PLANT AND EQUIPMENT, NET false false R14.htm 014 - Disclosure - CONSTRUCTION-IN-PROGRESS Sheet http://www.skystarbio-pharmaceutical.com/role/ConstructionInProgress CONSTRUCTION-IN-PROGRESS false false R15.htm 015 - Disclosure - LONG-TERM PREPAYMENTS Sheet http://www.skystarbio-pharmaceutical.com/role/LongTermPrepayments LONG-TERM PREPAYMENTS false false R16.htm 016 - Disclosure - INTANGIBLE ASSETS Sheet http://www.skystarbio-pharmaceutical.com/role/IntangibleAssets INTANGIBLE ASSETS false false R17.htm 017 - Disclosure - LOANS RECEIVABLE Sheet http://www.skystarbio-pharmaceutical.com/role/LoansReceivable LOANS RECEIVABLE false false R18.htm 018 - Disclosure - SHORT-TERM LOANS Sheet http://www.skystarbio-pharmaceutical.com/role/ShortTermLoans SHORT-TERM LOANS false false R19.htm 019 - Disclosure - DEFERRED GOVERNMENT GRANT Sheet http://www.skystarbio-pharmaceutical.com/role/DeferredGovernmentGrant DEFERRED GOVERNMENT GRANT false false R20.htm 020 - Disclosure - CAPITAL TRANSACTIONS Sheet http://www.skystarbio-pharmaceutical.com/role/CapitalTransactions CAPITAL TRANSACTIONS false false R21.htm 021 - Disclosure - STATUTORY RESERVES Sheet http://www.skystarbio-pharmaceutical.com/role/StatutoryReserves STATUTORY RESERVES false false R22.htm 022 - Disclosure - TAXES Sheet http://www.skystarbio-pharmaceutical.com/role/Taxes TAXES false false R23.htm 023 - Disclosure - EARNINGS PER SHARE Sheet http://www.skystarbio-pharmaceutical.com/role/EarningsPerShare EARNINGS PER SHARE false false R24.htm 024 - Disclosure - RELATED PARTY TRANSACTIONS AND ARRANGEMENTS Sheet http://www.skystarbio-pharmaceutical.com/role/RelatedPartyTransactionsAndArrangements RELATED PARTY TRANSACTIONS AND ARRANGEMENTS false false R25.htm 025 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.skystarbio-pharmaceutical.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES false false All Reports Book All Reports Element us-gaap_PaymentsToAcquireLoansReceivable had a mix of decimals attribute values: -3 0. Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Process Flow-Through: 005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS skbi-20120331.xml skbi-20120331.xsd skbi-20120331_cal.xml skbi-20120331_def.xml skbi-20120331_lab.xml skbi-20120331_pre.xml true true XML 42 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

CAPITAL TRANSACTIONS
3 Months Ended

Mar. 31, 2012

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Note 14 - CAPITAL TRANSACTIONS

Stock-based compensation

On March 30, 2010, the Company agreed to issue 2,500 shares of common stock to a non-executive director in exchange for services unrelated to his services as a director at the fair market value of $11.74 per share based on the closing price on March 30, 2010. On April 16, 2010, the Company entered into another agreement to grant 10,000 shares of common stock to that director for his one year service from April 1, 2010. The closing price per share on the grant date was $10.61. The common stock compensation vests in four equal quarterly installments of 2,500 shares. Shares owed were accrued at the end of each quarter at the fair market value on the grant date of $10.61 per share. On August 31, 2011, the Company entered into another agreement to grant 36,000 shares of common stock to that director for his one year service from April 1, 2011. The closing price per share on the grant date was $2.58. The common stock compensation vests in four equal quarterly installments of 9,000 shares. Shares owed were accrued at the end of each quarter at the fair market value of the grant date at $2.58 per share. A total of $23,220 and $26,525 was charged to general and administrative expense for the three months ended on March 31, 2012 and 2011, respectively. On October 25, 2010, 5,000 shares were issued to the director for the shares vested in the first two quarters of 2010. As of March 31, 2012, 43,500 shares were accrued for the shares vested and pending to be issued.

On May 26, 2009, the Company agreed to issue 5,556 shares of common stock to a director at the beginning of each term of his directorship. The trading value of the common stock on May 26, 2009 was $4.50 per share. The Company issued 5,556 shares on February 26, 2010. As of March 31, 2012, 11,112 shares were accrued for the shares vested and pending to be issued. In accordance with the agreement between the Company and this director, this director must continue to serve as a member of the Board until his successor is duly elected and qualified in order to receive the shares. This director has continued in his position, and the Company is in the process of finalizing its agreement with this director and expects to complete this process shortly.

On July 29, 2011, the Company entered into a one-year employment agreement with its CFO. Under the agreement, he is entitled to receive an aggregate 8,000 shares of common stock, 4,000 shares of which shall be issuable on the 6 month anniversary and the remainder 4,000 shares of which shall be issuable on the 12 month anniversary. The closing price per share on the grant date was $4.20. A total of $22,584 was charged to general and administrative expense for the three months ended on March 31, 2012. As of March 31, 2012, 4,000 shares were accrued for the shares vested and pending to be issued.

Warrants and Purchase Options

On February 28, 2007, in connection with a financing the Company issued 195,000 warrants to four investors with an exercise price of $6.00 per share for a term of three years (number of warrants and exercise price adjusted for 1-for-10 reverse stock split on May 12, 2009 and 2-for-1 forward stock split on November 16, 2009). On the same date, the Company also issued warrants to the placement agent, exercisable for 114,100 shares of the Company’s common stock at a price of $5.00 per share for a five-year term (number of warrants and exercise price adjusted for 1-for-10 reverse stock split on May 12, 2009 and 2-for-1 forward stock split on November 16, 2009). For the year ended December 31, 2009, 56,846 warrants were exercised. For the year ended December 31, 2010, there was a cashless exercise of 218,024 warrants. For the year ended December 31, 2011, no warrants were exercised. As of March 31, 2012, the remaining 34,230 warrants expired.

In connection with the 2009 equity offering discussed below, the Company granted 140,000 common stock purchase options to five designees of the Underwriters with a vesting date of June 30, 2010. The options are exercisable from June 30, 2010 to June 30, 2014, and each option is exercisable for one share of the Company’s common stock at an exercise price at $8.11 per share. All options were provided for services performed. On June 30, 2010, the purchase options were reclassified from equity to warrant/purchase option liabilities, and the Company reclassified $779,674 from additional paid in capital to warrant/purchase option liability. As of March 31, 2012, 140,000 common stock purchase options were outstanding.

The fair value of each warrant and purchase option is estimated on the date of grant using the Black-Scholes option-pricing model that uses the assumptions noted in the following table. Expected volatilities are based on historical volatility of the Company’s stock, and reflect the assumption that the historical volatilities are indicative of future trends, which may not necessarily be the actual outcome. Expected term of each warrant and purchase option award represents the period of time that options granted are expected to be outstanding and is estimated based on the historical exercise behavior of separate groups of employees or officers. The risk-free rate reflects the interest rate for United States Treasury Notes with similar time-to-maturity to that of the options.

March 31,
2012 March 31,
2011

Expected term (year) 2.25 0.92 – 3.25

Expected volatility 65 % 53% - 147 %

Expected dividend yield 0 % 0 %

Risk-free rate 0.33 % 0.3% - 1.30 %

Following is an activity summary of the Company’s outstanding warrants and purchase options:

Number of
warrants/purchase
options
Weighted –

average

exercise price

Weighted-

average

remaining

contractual term

(Year)

Outstanding at January 1, 2011 174,230 $ 7.50

Granted -

Forfeited -

Exercised -

Outstanding at December 31, 2011 174,230 $ 7.50

Granted - -

Forfeited (34,230 ) -

Exercised -

Outstanding at March 31, 2012 140,000 $ 8.11 2.25

Vested and expected to vest at March 31, 2012 140,000 $ 8.11 2.25

Exercisable at March 31, 2012 140,000 $ 8.11 2.25

Equity Compensation Plan

On December 8, 2009, the Company’s board of directors approved a stock incentive plan for officers, directors, employees and consultants entitled the “Skystar Bio-Pharmaceutical Company 2010 Stock Incentive Plan” (the “2010 Plan”). The maximum number of shares that may be issued under the 2010 Plan is 700,000 shares of common stock. The 2010 Plan was approved by the Company’s stockholders on December 31, 2009, and awards may be granted thereunder until December 7, 2019. As of March 31, 2012, there are 690,000 shares of the Company’s common stock remaining available for future issuance under the Plan. On May 4, 2012, the Board approved common stock grants in the total amount of 442,881 shares to the Company’s employees and members of the Board of Directors, all of which grants were made pursuant to the terms and provisions of the Plan.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2012	Dec. 31, 2011
ASSETS
Cash	$ 9,386,584	$ 7,048,968
Accounts receivable, net of allowance for doubtful accounts of $480,237 (Unaudited) and $438,678 as of March 31, 2012 and December 31, 2011, respectively	5,783,831	3,391,493
Inventories	13,962,087	14,851,159
Deposits, prepaid expenses and other receivables	34,914,476	32,648,448
Loans receivable	981,699	964,088
Total current assets	65,028,677	58,904,156
PLANT AND EQUIPMENT, NET	28,273,028	28,376,559
CONSTRUCTION-IN-PROGRESS	9,434,227	8,839,055
OTHER ASSETS:
Long-term prepayments	1,189,788	1,512,817
Long-term prepayments for acquisitions	652,609	569,788
Intangible assets, net	5,610,135	5,674,206
Total other assets	7,452,532	7,756,811
Total assets	110,188,464	103,876,581
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable	2,046,341	1,047,067
Other payable and accrued expenses	6,059,237	5,274,598
Short-term loans	7,476,480	7,366,320
Deposits from customers	1,640,457	1,432,529
Taxes payable	1,585,156	160,081
Due to related parties	380,669	56,273
Total current liabilities	19,188,340	15,336,868
OTHER LIABILITIES:
Deferred government grant	396,000	393,500
Warrant/purchase option liability	37,800	43,400
Total other liabilities	433,800	436,900
Total liabilities	19,622,140	15,773,768
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred stock, $0.001 par value, 50,000,000 shares authorized, No Series "A" shares authorized. 48,000,000 Series "B" shares authorized. No Series "B" shares issued and outstanding
Common stock, $0.001 par value, 40,000,000 shares authorized, 7,161,919 shares issued and outstanding as of March 31, 2012 (Unaudited) and December 31, 2011	7,162	7,162
Paid-in capital	35,784,378	35,784,378
Statutory reserves	5,708,135	5,708,135
Retained earnings	40,396,785	38,492,031
Accumulated other comprehensive income	8,669,864	8,111,107
Total shareholders' equity	90,566,324	88,102,813
Total liabilities and shareholders' equity	$ 110,188,464	$ 103,876,581

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (USD $)	Common Stock [Member]	Paid-In Capital [Member]	Retained Earnings, Appropriated [Member]	Retained Earnings, Unappropriated [Member]	Accumulated Other Comprehensive Income [Member]	Total
BALANCE at Dec. 31, 2011	$ 7,162	$ 35,784,378	$ 5,708,135	$ 38,492,031	$ 8,111,107	$ 88,102,813
BALANCE (in shares) at Dec. 31, 2011	7,161,919
Foreign currency translation	0	0	0	0	558,757	558,757
Net income	0	0	0	1,904,754	0	1,904,754
BALANCE at Mar. 31, 2012	$ 7,162	$ 35,784,378	$ 5,708,135	$ 40,396,785	$ 8,669,864	$ 90,566,324
BALANCE (in shares) at Mar. 31, 2012	7,161,919

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2012	Dec. 31, 2011
Allowance for doubtful accounts (in dollars)	$ 480,237	$ 438,678
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	7,161,919	7,161,919
Common stock, shares outstanding	7,161,919	7,161,919
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	48,000,000	48,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

DOCUMENT AND ENTITY INFORMATION	3 Months Ended
DOCUMENT AND ENTITY INFORMATION	Mar. 31, 2012	May 10, 2012
Entity Registrant Name	SKYSTAR BIO-PHARMACEUTICAL CO
Entity Central Index Key	0001076939
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	skbi
Entity Common Stock, Shares Outstanding		7,604,800
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2012
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2012

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (USD $)	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
REVENUE, net	$ 7,926,337	$ 7,086,954
COST OF REVENUE	3,643,658	3,491,346
GROSS PROFIT	4,282,679	3,595,608
OPERATING EXPENSES:
Research and development costs	3,654	287,472
Selling expenses	705,616	369,404
General and administrative expenses	1,105,435	1,294,798
Total operating expenses	1,814,705	1,951,674
INCOME FROM OPERATIONS	2,467,974	1,643,934
OTHER INCOME (EXPENSE):
Other income, net	53,760	182
Interest income (expense), net	(153,612)	29,672
Change in fair value of warrant/purchase option liability	5,600	735,494
Total other income (expense), net	(94,252)	765,348
INCOME BEFORE PROVISION FOR INCOME TAXES	2,373,722	2,409,282
PROVISION FOR INCOME TAXES	468,968	477,450
NET INCOME	1,904,754	1,931,832
OTHER COMPREHENSIVE INCOME:
Foreign currency translation adjustment	558,757	465,593
COMPREHENSIVE INCOME	$ 2,463,511	$ 2,397,425
EARNINGS PER SHARE:
Basic (in dollars per share)	$ 0.26	$ 0.27
Diluted (in dollars per share)	$ 0.26	$ 0.27
WEIGHTED AVERAGE NUMBER OF COMMON SHARES:
Basic (in shares)	7,210,256	7,166,919
Diluted (in shares)	7,210,256	7,179,309

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Mar. 31, 2012	Mar. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 1,904,754	$ 1,931,832
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	343,129	332,428
Amortization	100,373	230,922
Provision for doubtful accounts	38,869	0
Change in fair value of warrant/purchase option liability	(5,600)	(735,494)
Change in operating assets and liabilities
Accounts receivable	(2,415,647)	(757,356)
Inventories	985,908	(6,826,437)
Deposits, prepaid expenses and other receivables	(2,144,356)	(2,603,343)
Accounts payable	980,926	197,277
Other payable and accrued expenses	606,331	360,449
Deposits from customers	199,329	14,989
Taxes payable	1,427,655	1,566,418
Net cash provided by (used in) operating activities	2,021,671	(6,288,315)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments of long-term prepayments	0	(451,722)
Loans receivables	(11,515)	0
Collection of loans receivables	0	7,609,000
Purchases of plant and equipment	(54,965)	(22,275)
Purchases of intangible assets	0	(38,045)
Payments on construction-in-progress	(44,940)	(634,222)
Net cash (used in) provided by investing activities	(111,420)	6,462,736
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term loans	63,520	1,257,007
Due to related parties	326,061	62,834
Net cash provided by financing activities	389,581	1,319,841
EFFECT OF EXCHANGE RATE CHANGES ON CASH	37,784	21,296
INCREASE IN CASH	2,337,616	1,515,558
CASH, beginning of period	7,048,968	5,887,831
CASH, end of period	9,386,584	7,403,389
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	152,583	54,409
Non-cash investing and financing activities
Long-term prepayment transferred to construction-in-progress	333,480	421,843
Construction-in-progress transferred to property, plant and equipment	$ 3,633	$ 0